Secreted proteins and polynucleotides encoding them

Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.

Description

[0001] This application is a continuation-in-part of the following applications:

(1) provisional application Ser. No. 60/096,622 (GI 6075), filed Aug. 14, 1998; (2) provisional application Ser. No. 60/096,815 (GI 6076), filed Aug. 17, 1998; (3) provisional application Ser. No. 60/099,229 (GI 6077), filed Sep. 4, 1998; (4) provisional application Ser. No. 60/105,368 (GI 6078), filed Oct. 23, 1998; (5) provisional application Ser. No. 60/115,234 (GI 6079), filed Jan. 8, 1999; (6) provisional application Ser. No. 60/119,931 (GI 6080), filed Feb. 12, 1999; (7) provisional application Ser. No. 60/120,575 (GI 6081), filed Feb. 18, 1999; (8) provisional application Ser. No. 60/132,020 (GI 6082), filed Apr. 30, 1999; (9) provisional application Ser. No. ______ (GI 6083), filed Aug. 11, 1999; all of which are incorporated by reference herein.

FIELD OF THE INVENTION

[0002] The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

[0003] Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino add sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

[0004] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0005] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1; [0006] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821; [0007] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821; [0008] (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625; [0009] (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone co62.sub.--12 deposited under accession number ATCC 98825; [0010] (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone co62.sub.--12 deposited under accession number ATCC 98825; [0011] (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone co62.sub.--12 deposited under accession number ATCC 98825; [0012] (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone co62.sub.--12 deposited under accession number ATCC 98825; [0013] (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2; [0014] (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; [0015] (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; [0016] (l) a polynucleotide which encodes a species-homologue of the protein of (i) or (j) above; [0017] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and [0018] (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:1.

[0019] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821; the nucleotide sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821; the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625; the nucleotide sequence of the full-length protein coding sequence of clone co62.sub.--12 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone co62.sub.--12 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone co62.sub.--12 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.

[0020] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

[0021] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0022] (a) a process comprising the steps of: [0023] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0024] (aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and [0025] (ab) the nucleotide sequence of the cDNA insert of clone co62.sub.--12 deposited under accession number ATCC 98825; [0026] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0027] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0028] and [0029] (b) a process comprising the steps of: [0030] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0031] (ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and [0032] (bb) the nucleotide sequence of the cDNA insert of clone co62.sub.--12 deposited under accession number ATCC 98825; [0033] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0034] (iii) amplifying human DNA sequences; and [0035] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 87 to nucleotide 821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 120 to nucleotide 821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 1625.

[0036] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0037] (a) the amino acid sequence of SEQ ID NO:2; [0038] (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and [0039] (c) the amino acid sequence encoded by the cDNA insert of clone co62.sub.--12 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.

[0040] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0041] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3; [0042] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013; [0043] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013; [0044] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone lo311.sub.--8 deposited under accession number ATCC 98825; [0045] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone lo311.sub.--8 deposited under accession number ATCC 98825; [0046] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone lo311.sub.--8 deposited under accession number ATCC 98825; [0047] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone lo311.sub.--8 deposited under accession number ATCC 98825; [0048] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4; [0049] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; [0050] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0051] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0052] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0053] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.

[0054] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013; the nucleotide sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013; the nucleotide sequence of the full-length protein coding sequence of clone lo311.sub.--8 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone lo311.sub.--8 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone lo311.sub.--8 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.

[0055] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

[0056] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0057] (a) a process comprising the steps of: [0058] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0059] (aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and [0060] (ab) the nucleotide sequence of the cDNA insert of clone lo311.sub.--8 deposited under accession number ATCC 98825; [0061] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0062] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0063] and [0064] (b) a process comprising the steps of: [0065] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0066] (ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and [0067] (bb) the nucleotide sequence of the cDNA insert of clone lo311.sub.--8 deposited under accession number ATCC 98825; [0068] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0069] (iii) amplifying human DNA sequences; and [0070] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013.

[0071] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0072] (a) the amino acid sequence of SEQ ID NO:4; [0073] (b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and [0074] (c) the amino acid sequence encoded by the cDNA insert of clone lo311.sub.--8 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.

[0075] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0076] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5; [0077] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825; [0078] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ns197.sub.--1 deposited under accession number ATCC 98825; [0079] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ns197.sub.--1 deposited under accession number ATCC 98825; [0080] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ns197.sub.--1 deposited under accession number ATCC 98825; [0081] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ns197.sub.--1 deposited under accession number ATCC 98825; [0082] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6; [0083] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; [0084] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0085] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0086] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0087] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:5.

[0088] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825; the nucleotide sequence of the full-length protein coding sequence of clone ns197.sub.--1 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone ns197.sub.--1 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ns197.sub.--1 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.

[0089] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

[0090] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0091] (a) a process comprising the steps of: [0092] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0093] (aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and [0094] (ab) the nucleotide sequence of the cDNA insert of clone ns197.sub.--1 deposited under accession number ATCC 98825; [0095] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0096] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0097] and [0098] (b) a process comprising the steps of: [0099] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0100] (ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and [0101] (bb) the nucleotide sequence of the cDNA insert of clone ns197.sub.--1 deposited under accession number ATCC 98825; [0102] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0103] (iii) amplifying human DNA sequences; and [0104] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID. NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825.

[0105] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0106] (a) the amino acid sequence of SEQ ID NO:6; [0107] (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and [0108] (c) the amino acid sequence encoded by the cDNA insert of clone ns197.sub.--1 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.

[0109] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0110] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7; [0111] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829; [0112] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829; [0113] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pj193.sub.--5 deposited under accession number ATCC 98825; [0114] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pj193.sub.--5 deposited under accession number ATCC 98825; [0115] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pj193.sub.--5 deposited under accession number ATCC 98825; [0116] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pj193.sub.--5 deposited under accession number ATCC 98825; [0117] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8; [0118] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; [0119] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0120] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0121] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0122] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7.

[0123] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829; the nucleotide sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829; the nucleotide sequence of the full-length protein coding sequence of clone pj193.sub.--5 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pj193.sub.--5 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pj193.sub.--5 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.

[0124] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

[0125] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0126] (a) a process comprising the steps of: [0127] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0128] (aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and [0129] (ab) the nucleotide sequence of the cDNA insert of clone pj193.sub.--5 deposited under accession number ATCC 98825; [0130] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0131] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0132] and [0133] (b) a process comprising the steps of: [0134] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0135] (ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and [0136] (bb) the nucleotide sequence of the cDNA insert of clone pj193.sub.--5 deposited under accession number ATCC 98825; [0137] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0138] (iii) amplifying human DNA sequences; and [0139] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829.

[0140] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0141] (a) the amino acid sequence of SEQ ID NO:8; [0142] (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and [0143] (c) the amino acid sequence encoded by the cDNA insert of clone pj193.sub.--5 deposited under accession number ATCC 98825;

[0144] the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.

[0145] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0146] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9; [0147] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292; [0148] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pj3172 deposited under accession number ATCC 98825; [0149] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pj317.sub.--2 deposited under accession number ATCC 98825; [0150] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pj317.sub.--2 deposited under accession number ATCC 98825; [0151] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pj317.sub.--2 deposited under accession number ATCC 98825; [0152] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10; [0153] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; [0154] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0155] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0156] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0157] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:9.

[0158] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292; the nucleotide sequence of the full-length protein coding sequence of clone pj317.sub.--2 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pj317.sub.--2 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pj317.sub.--2 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.

[0159] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

[0160] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0161] (a) a process comprising the steps of: [0162] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0163] (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and [0164] (ab) the nucleotide sequence of the cDNA insert of clone pj317.sub.--2 deposited under accession number ATCC 98825; [0165] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0166] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0167] and [0168] (b) a process comprising the steps of: [0169] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0170] (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and [0171] (bb) the nucleotide sequence of the cDNA insert of clone pj317.sub.--2 deposited under accession number ATCC 98825; [0172] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0173] (iii) amplifying human DNA sequences; and [0174] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292.

[0175] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0176] (a) the amino acid sequence of SEQ ID NO:10; [0177] (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and [0178] (c) the amino acid sequence encoded by the cDNA insert of clone pj317.sub.--2 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.

[0179] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0180] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11; [0181] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517; [0182] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517; [0183] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt332.sub.--1 deposited under accession number ATCC 98825; [0184] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pt332.sub.--1 deposited under accession number ATCC 98825; [0185] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pt332.sub.--1 deposited under accession number ATCC 98825; [0186] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pt332.sub.--1 deposited under accession number ATCC 98825; [0187] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12; [0188] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; [0189] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0190] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0191] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0192] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:11.

[0193] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517; the nucleotide sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517; the nucleotide sequence of the full-length protein coding sequence of clone pt332.sub.--1 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pt332.sub.--1 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pt332.sub.--1 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.

[0194] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

[0195] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0196] (a) a process comprising the steps of: [0197] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0198] (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and [0199] (ab) the nucleotide sequence of the cDNA insert of clone pt332.sub.--1 deposited under accession number ATCC 98825; [0200] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0201] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0202] and [0203] (b) a process comprising the steps of: [0204] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0205] (ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and [0206] (bb) the nucleotide sequence of the cDNA insert of clone pt332.sub.--1 deposited under accession number ATCC 98825; [0207] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0208] (iii) amplifying human DNA sequences; and [0209] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 7 to nucleotide 2517. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 904 to nucleotide 2517.

[0210] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0211] (a) the amino acid sequence of SEQ ID NO:12; [0212] (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and [0213] (c) the amino acid sequence encoded by the cDNA insert of clone pt332.sub.--1 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.

[0214] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0215] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13; [0216] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257; [0217] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qc297.sub.--15 deposited under accession number ATCC 98825; [0218] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qc297.sub.--15 deposited under accession number ATCC 98825; [0219] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qc297.sub.--15 deposited under accession number ATCC 98825; [0220] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qc297.sub.--15 deposited under accession number ATCC 98825; [0221] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14; [0222] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; [0223] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0224] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0225] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0226] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:13.

[0227] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257; the nucleotide sequence of the full-length protein coding sequence of clone qc297.sub.--15 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qc297.sub.--15 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qc297.sub.--15 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:14.

[0228] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

[0229] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0230] (a) a process comprising the steps of: [0231] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0232] (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and [0233] (ab) the nucleotide sequence of the cDNA insert of clone qc297.sub.--15 deposited under accession number ATCC 98825; [0234] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0235] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0236] and [0237] (b) a process comprising the steps of: [0238] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0239] (ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and [0240] (bb) the nucleotide sequence of the cDNA insert of clone qc297.sub.--15 deposited under accession number ATCC 98825; [0241] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0242] (iii) amplifying human DNA sequences; and [0243] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257.

[0244] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0245] (a) the amino acid sequence of SEQ ID NO:14; [0246] (b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and [0247] (c) the amino acid sequence encoded by the cDNA insert of clone qc297.sub.--15 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:14.

[0248] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0249] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15; [0250] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432; [0251] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qg596.sub.--12 deposited under accession number ATCC 98825; [0252] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qg596.sub.--12 deposited under accession number ATCC 98825; [0253] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qg596.sub.--12 deposited under accession number ATCC 98825; [0254] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qg596.sub.--12 deposited under accession number ATCC 98825; [0255] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16; [0256] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino adds of SEQ ID NO:16; [0257] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0258] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0259] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0260] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:15.

[0261] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432; the nucleotide sequence of the full-length protein coding sequence of clone qg596.sub.--12 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qg59612 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qg596.sub.--12 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.

[0262] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

[0263] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0264] (a) a process comprising the steps of: [0265] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0266] (aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and [0267] (ab) the nucleotide sequence of the cDNA insert of clone qg596.sub.--12 deposited under accession number ATCC 98825; [0268] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0269] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0270] and [0271] (b) a process comprising the steps of: [0272] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0273] (ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and [0274] (bb) the nucleotide sequence of the cDNA insert of clone qg596.sub.--12 deposited under accession number ATCC 98825; [0275] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0276] (iii) amplifying human DNA sequences; and [0277] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432.

[0278] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0279] (a) the amino acid sequence of SEQ ID NO:16; [0280] (b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and [0281] (c) the amino acid sequence encoded by the cDNA insert of clone qg596.sub.--12 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.

[0282] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0283] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17; [0284] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105; [0285] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105; [0286] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rb649.sub.--3 deposited under accession number ATCC 98825; [0287] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rb649.sub.--3 deposited under accession number ATCC 98825; [0288] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rb649.sub.--3 deposited under accession number ATCC 98825; [0289] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rb649.sub.--3 deposited under accession number ATCC 98825; [0290] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18; [0291] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; [0292] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0293] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0294] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0295] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:17.

[0296] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105; the nucleotide sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105; the nucleotide sequence of the full-length protein coding sequence of clone rb649.sub.--3 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone rb649.sub.--3 deposited under accession number ATCC 98825. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rb649.sub.--3 deposited under accession number ATCC 98825. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.

[0297] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

[0298] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0299] (a) a process comprising the steps of: [0300] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0301] (aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and [0302] (ab) the nucleotide sequence of the cDNA insert of clone rb649.sub.--3 deposited under accession number ATCC 98825; [0303] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0304] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0305] and [0306] (b) a process comprising the steps of: [0307] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0308] (ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and [0309] (bb) the nucleotide sequence of the cDNA insert of clone rb649.sub.--3 deposited under accession number ATCC 98825; [0310] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0311] (iii) amplifying human DNA sequences; and [0312] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105.

[0313] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0314] (a) the amino acid sequence of SEQ ID NO:18; [0315] (b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and [0316] (c) the amino acid sequence encoded by the cDNA insert of clone rb649.sub.--3 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins. Preferably, such protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.

[0317] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0318] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19; [0319] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467; [0320] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ca106.sub.--19x deposited under accession number ATCC 98835; [0321] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ca106.sub.--19x deposited under accession number ATCC 98835; [0322] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ca106.sub.--19x deposited under accession number ATCC 98835; [0323] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ca106.sub.--19x deposited under accession number ATCC 98835; [0324] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20; [0325] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; [0326] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0327] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0328] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0329] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:19.

[0330] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467; the nucleotide sequence of the full-length protein coding sequence of clone ca106.sub.--19x deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone ca106.sub.--19x deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ca106.sub.--19x deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.

[0331] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.

[0332] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0333] (a) a process comprising the steps of: [0334] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0335] (aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and [0336] (ab) the nucleotide sequence of the cDNA insert of clone ca106.sub.--19x deposited under accession number ATCC 98835; [0337] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0338] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0339] and [0340] (b) a process comprising the steps of: [0341] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0342] (ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and [0343] (bb) the nucleotide sequence of the cDNA insert of clone ca106.sub.--19x deposited under accession number ATCC 98835; [0344] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0345] (iii) amplifying human DNA sequences; and [0346] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467.

[0347] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0348] (a) the amino acid sequence of SEQ ID NO:20; [0349] (b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and [0350] (c) the amino acid sequence encoded by the cDNA insert of clone ca106.sub.--19x deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.

[0351] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0352] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21; [0353] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802; [0354] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802; [0355] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ci52.sub.--2 deposited under accession number ATCC 98835; [0356] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ci52.sub.--2 deposited under accession number ATCC 98835; [0357] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ci52.sub.--2 deposited under accession number ATCC 98835; [0358] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ci52.sub.--2 deposited under accession number ATCC 98835; [0359] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:22; [0360] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; [0361] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0362] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0363] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0364] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.

[0365] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802; the nucleotide sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802; the nucleotide sequence of the full-length protein coding sequence of clone ci52.sub.--2 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone ci52.sub.--2 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ci52.sub.--2 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.

[0366] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:21.

[0367] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0368] (a) a process comprising the steps of: [0369] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0370] (aa) SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21; and [0371] (ab) the nucleotide sequence of the cDNA insert of clone ci52.sub.--2 deposited under accession number ATCC 98835; [0372] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0373] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0374] and [0375] (b) a process comprising the steps of: [0376] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0377] (ba) SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21; and [0378] (bb) the nucleotide sequence of the cDNA insert of clone ci52.sub.--2 deposited under accession number ATCC 98835; [0379] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0380] (iii) amplifying human DNA sequences; and [0381] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802.

[0382] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0383] (a) the amino acid sequence of SEQ ID NO:22; [0384] (b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and [0385] (c) the amino acid sequence encoded by the cDNA insert of clone ci52.sub.--2 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:22. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.

[0386] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0387] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23; [0388] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714; [0389] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714; [0390] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone md124.sub.--16 deposited under accession number ATCC 98835; [0391] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone md124.sub.--16 deposited under accession number ATCC 98835; [0392] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone md124.sub.--16 deposited under accession number ATCC 98835; [0393] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone md124.sub.--16 deposited under accession number ATCC 98835; [0394] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24; [0395] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; [0396] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0397] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0398] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0399] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:23.

[0400] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714; the nucleotide sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714; the nucleotide sequence of the full-length protein coding sequence of clone md124.sub.--16 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone md124.sub.--16 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone md124.sub.--16 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.

[0401] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:23.

[0402] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0403] (a) a process comprising the steps of: [0404] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0405] (aa) SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23; and [0406] (ab) the nucleotide sequence of the cDNA insert of clone md124.sub.--16 deposited under accession number ATCC 98835; [0407] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0408] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0409] and [0410] (b) a process comprising the steps of: [0411] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0412] (ba) SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23; and [0413] (bb) the nucleotide sequence of the cDNA insert of clone md124.sub.--16 deposited under accession number ATCC 98835; [0414] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0415] (iii) amplifying human DNA sequences; and [0416] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714.

[0417] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0418] (a) the amino acid sequence of SEQ ID NO:24; [0419] (b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and [0420] (c) the amino acid sequence encoded by the cDNA insert of clone md124.sub.--16 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:24. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.

[0421] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0422] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25; [0423] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726; [0424] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726; [0425] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pk366.sub.--7 deposited under accession number ATCC 98835; [0426] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pk366.sub.--7 deposited under accession number ATCC 98835; [0427] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pk366.sub.--7 deposited under accession number ATCC 98835; [0428] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pk366.sub.--7 deposited under accession number ATCC 98835; [0429] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:26; [0430] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; [0431] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0432] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0433] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0434] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:25.

[0435] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726; the nucleotide sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726; the nucleotide sequence of the full-length protein coding sequence of clone pk366.sub.--7 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pk366.sub.--7 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pk366.sub.--7 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 267 to amino acid 276 of SEQ ID NO:26.

[0436] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:25.

[0437] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0438] (a) a process comprising the steps of: [0439] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0440] (aa) SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25; and [0441] (ab) the nucleotide sequence of the cDNA insert of clone pk366.sub.--7 deposited under accession number ATCC 98835; [0442] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0443] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0444] and [0445] (b) a process comprising the steps of: [0446] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0447] (ba) SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25; and [0448] (bb) the nucleotide sequence of the cDNA insert of clone pk366.sub.--7 deposited under accession number ATCC 98835; [0449] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0450] (iii) amplifying human DNA sequences; and [0451] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726.

[0452] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0453] (a) the amino acid sequence of SEQ ID NO:26; [0454] (b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and [0455] (c) the amino acid sequence encoded by the cDNA insert of clone pk366.sub.--7 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 267 to amino acid 276 of SEQ ID NO:26.

[0456] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0457] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27; [0458] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788; [0459] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788; [0460] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pl741.sub.--5 deposited under accession number ATCC 98835; [0461] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pl741.sub.--5 deposited under accession number ATCC 98835; [0462] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pl741.sub.--5 deposited under accession number ATCC 98835; [0463] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pl741.sub.--5 deposited under accession number ATCC 98835; [0464] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28; [0465] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; [0466] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0467] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0468] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0469] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.

[0470] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788; the nucleotide sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788; the nucleotide sequence of the full-length protein coding sequence of clone pl741.sub.--5 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pl741.sub.--5 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pl741.sub.--5 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.

[0471] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.

[0472] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0473] (a) a process comprising the steps of: [0474] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0475] (aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and [0476] (ab) the nucleotide sequence of the cDNA insert of clone pl741.sub.--5 deposited under accession number ATCC 98835; [0477] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0478] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0479] and [0480] (b) a process comprising the steps of: [0481] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0482] (ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and [0483] (bb) the nucleotide sequence of the cDNA insert of clone pl741.sub.--5 deposited under accession number ATCC 98835; [0484] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0485] (iii) amplifying human DNA sequences; and [0486] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788.

[0487] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0488] (a) the amino acid sequence of SEQ ID NO:28; [0489] (b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and [0490] (c) the amino acid sequence encoded by the cDNA insert of clone pl741.sub.--5 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.

[0491] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0492] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29; [0493] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338; [0494] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pp314.sub.--19 deposited under accession number ATCC 98835; [0495] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pp314.sub.--19 deposited under accession number ATCC 98835; [0496] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pp314.sub.--19 deposited under accession number ATCC 98835; [0497] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pp314.sub.--19 deposited under accession number ATCC 98835; [0498] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30; [0499] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; [0500] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0501] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0502] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0503] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:29.

[0504] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338; the nucleotide sequence of the full-length protein coding sequence of clone pp314.sub.--19 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pp314.sub.--19 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pp314.sub.--19 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.

[0505] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29.

[0506] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0507] (a) a process comprising the steps of: [0508] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0509] (aa) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and [0510] (ab) the nucleotide sequence of the cDNA insert of clone pp314.sub.--19 deposited under accession number ATCC 98835; [0511] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0512] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0513] and [0514] (b) a process comprising the steps of: [0515] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0516] (ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and [0517] (bb) the nucleotide sequence of the cDNA insert of clone pp314.sub.--19 deposited under accession number ATCC 98835; [0518] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0519] (iii) amplifying human DNA sequences; and [0520] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338.

[0521] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0522] (a) the amino acid sequence of SEQ ID NO:30; [0523] (b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and [0524] (c) the amino acid sequence encoded by the cDNA insert of clone pp314.sub.--19 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.

[0525] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0526] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31; [0527] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102; [0528] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pv35.sub.--1 deposited under accession number ATCC 98835; [0529] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pv35.sub.--1 deposited under accession number ATCC 98835; [0530] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pv35.sub.--1 deposited under accession number ATCC 98835; [0531] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pv35.sub.--1 deposited under accession number ATCC 98835; [0532] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32; [0533] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; [0534] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0535] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0536] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0537] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-h) and that has a length that is at least 25% of the length of SEQ ID NO:31.

[0538] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102; the nucleotide sequence of the full-length protein coding sequence of clone pv35.sub.--1 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pv35.sub.--1 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv35.sub.--1 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.

[0539] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:31.

[0540] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0541] (a) a process comprising the steps of: [0542] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0543] (aa) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and [0544] (ab) the nucleotide sequence of the cDNA insert of clone pv35.sub.--1 deposited under accession number ATCC 98835; [0545] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0546] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0547] and [0548] (b) a process comprising the steps of: [0549] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0550] (ba) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and [0551] (bb) the nucleotide sequence of the cDNA insert of clone pv35.sub.--1 deposited under accession number ATCC 98835; [0552] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0553] (iii) amplifying human DNA sequences; and [0554] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102.

[0555] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0556] (a) the amino acid sequence of SEQ ID NO:32; [0557] (b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and [0558] (c) the amino acid sequence encoded by the cDNA insert of clone pv35.sub.--1 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:32. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.

[0559] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0560] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33; [0561] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733; [0562] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pw337.sub.--6 deposited under accession number ATCC 98835; [0563] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pw337.sub.--6 deposited under accession number ATCC 98835; [0564] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pw337.sub.--6 deposited under accession number ATCC 98835; [0565] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pw337.sub.--6 deposited under accession number ATCC 98835; [0566] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:34; [0567] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; [0568] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0569] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0570] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0571] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:33.

[0572] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733; the nucleotide sequence of the full-length protein coding sequence of clone pw337.sub.--6 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pw337.sub.--6 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pw337.sub.--6 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.

[0573] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:33.

[0574] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0575] (a) a process comprising the steps of: [0576] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0577] (aa) SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33; and [0578] (ab) the nucleotide sequence of the cDNA insert of clone pw337.sub.--6 deposited under accession number ATCC 98835; [0579] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0580] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0581] and [0582] (b) a process comprising the steps of: [0583] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0584] (ba) SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33; and [0585] (bb) the nucleotide sequence of the cDNA insert of clone pw337.sub.--6 deposited under accession number ATCC 98835; [0586] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0587] (iii) amplifying human DNA sequences; and [0588] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733.

[0589] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0590] (a) the amino acid sequence of SEQ ID NO:34; [0591] (b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and [0592] (c) the amino acid sequence encoded by the cDNA insert of clone pw337.sub.--6 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:34. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.

[0593] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0594] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35; [0595] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938; [0596] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd610.sub.--1 deposited under accession number ATCC 98835; [0597] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd610.sub.--1 deposited under accession number ATCC 98835; [0598] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd610.sub.--1 deposited under accession number ATCC 98835; [0599] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd610.sub.--1 deposited under accession number ATCC 98835; [0600] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36; [0601] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; [0602] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0603] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0604] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0605] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:35.

[0606] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938; the nucleotide sequence of the full-length protein coding sequence of clone rd610.sub.--1 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone rd610.sub.--1 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd610.sub.--1 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.

[0607] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:35.

[0608] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0609] (a) a process comprising the steps of: [0610] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0611] (aa) SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35; and [0612] (ab) the nucleotide sequence of the cDNA insert of clone rd610.sub.--1 deposited under accession number ATCC 98835; [0613] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0614] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0615] and [0616] (b) a process comprising the steps of: [0617] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0618] (ba) SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35; and [0619] (bb) the nucleotide sequence of the cDNA insert of clone rd610.sub.--1 deposited under accession number ATCC 98835; [0620] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0621] (iii) amplifying human DNA sequences; and [0622] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938.

[0623] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0624] (a) the amino acid sequence of SEQ ID NO:36; [0625] (b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and [0626] (c) the amino acid sequence encoded by the cDNA insert of clone rd610.sub.--1 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:36. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.

[0627] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0628] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37; [0629] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494; [0630] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494; [0631] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd810.sub.--6 deposited under accession number ATCC 98835; [0632] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd810.sub.--6 deposited under accession number ATCC 98835; [0633] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd810.sub.--6 deposited under accession number ATCC 98835; [0634] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd810.sub.--6 deposited under accession number ATCC 98835; [0635] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:38; [0636] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; [0637] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0638] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0639] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0640] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:37.

[0641] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494; the nucleotide sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494; the nucleotide sequence of the full-length protein coding sequence of clone rd8106 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone rd810.sub.--6 deposited under accession number ATCC 98835. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd810.sub.--6 deposited under accession number ATCC 98835. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.

[0642] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:37.

[0643] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0644] (a) a process comprising the steps of: [0645] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0646] (aa) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and [0647] (ab) the nucleotide sequence of the cDNA insert of clone rd810.sub.--6 deposited under accession number ATCC 98835; [0648] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0649] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0650] and [0651] (b) a process comprising the steps of: [0652] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0653] (ba) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and [0654] (bb) the nucleotide sequence of the cDNA insert of clone rd810.sub.--6 deposited under accession number ATCC 98835; [0655] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0656] (iii) amplifying human DNA sequences; and [0657] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494.

[0658] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0659] (a) the amino acid sequence of SEQ ID NO:38; [0660] (b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and [0661] (c) the amino acid sequence encoded by the cDNA insert of clone rd8106 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:38. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.

[0662] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0663] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39; [0664] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080; [0665] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cf85.sub.--1 deposited under accession number ATCC 98850; [0666] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cf85.sub.--1 deposited under accession number ATCC 98850; [0667] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cf85.sub.--1 deposited under accession number ATCC 98850; [0668] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cf85.sub.--1 deposited under accession number ATCC 98850; [0669] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40; [0670] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; [0671] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0672] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0673] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0674] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:39.

[0675] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080; the nucleotide sequence of the full-length protein coding sequence of clone cf85.sub.--1 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone cf85.sub.--1 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cf85.sub.--1 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.

[0676] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:39.

[0677] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0678] (a) a process comprising the steps of: [0679] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0680] (aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and [0681] (ab) the nucleotide sequence of the cDNA insert of clone cf85.sub.--1 deposited under accession number ATCC 98850; [0682] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0683] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0684] and [0685] (b) a process comprising the steps of: [0686] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0687] (ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and [0688] (bb) the nucleotide sequence of the cDNA insert of clone cf85.sub.--1 deposited under accession number ATCC 98850; [0689] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0690] (iii) amplifying human DNA sequences; and [0691] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080.

[0692] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0693] (a) the amino acid sequence of SEQ ID NO:40; [0694] (b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and [0695] (c) the amino acid sequence encoded by the cDNA insert of clone cf85.sub.--1 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.

[0696] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0697] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41; [0698] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348; [0699] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348; [0700] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd504.sub.--18 deposited under accession number ATCC 98850; [0701] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd504.sub.--18 deposited under accession number ATCC 98850; [0702] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd504.sub.--18 deposited under accession number ATCC 98850; [0703] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dd504.sub.--18 deposited under accession number ATCC 98850; [0704] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42; [0705] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; [0706] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0707] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0708] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0709] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:41.

[0710] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348; the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348; the nucleotide sequence of the full-length protein coding sequence of clone dd504.sub.--18 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone dd504.sub.--18 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dd504.sub.--18 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.

[0711] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

[0712] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0713] (a) a process comprising the steps of: [0714] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0715] (aa) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and [0716] (ab) the nucleotide sequence of the cDNA insert of clone dd504.sub.--18 deposited under accession number ATCC 98850; [0717] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0718] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0719] and [0720] (b) a process comprising the steps of: [0721] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0722] (ba) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and [0723] (bb) the nucleotide sequence of the cDNA insert of clone dd504.sub.--18 deposited under accession number ATCC 98850; [0724] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0725] (iii) amplifying human DNA sequences; and [0726] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348.

[0727] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0728] (a) the amino acid sequence of SEQ ID NO:42; [0729] (b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino adds of SEQ ID NO:42; and [0730] (c) the amino acid sequence encoded by the cDNA insert of clone dd504.sub.--18 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.

[0731] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0732] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43; [0733] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386; [0734] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone np26.sub.--3 deposited under accession number ATCC 98850; [0735] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone np26.sub.--3 deposited under accession number ATCC 98850; [0736] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone np26.sub.--3 deposited under accession number ATCC 98850; [0737] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone np26.sub.--3 deposited under accession number ATCC 98850; [0738] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44; [0739] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; [0740] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0741] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0742] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0743] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:43.

[0744] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386; the nucleotide sequence of the full-length protein coding sequence of clone np26.sub.--3 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone np26.sub.--3 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone np26.sub.--3 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.

[0745] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:43.

[0746] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0747] (a) a process comprising the steps of: [0748] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0749] (aa) SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43; and [0750] (ab) the nucleotide sequence of the cDNA insert of clone np26.sub.--3 deposited under accession number ATCC 98850; [0751] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0752] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0753] and [0754] (b) a process comprising the steps of: [0755] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0756] (ba) SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43; and [0757] (bb) the nucleotide sequence of the cDNA insert of clone np26.sub.--3 deposited under accession number ATCC 98850; [0758] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0759] (iii) amplifying human DNA sequences; and [0760] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386.

[0761] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0762] (a) the amino acid sequence of SEQ ID NO:44; [0763] (b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and [0764] (c) the amino acid sequence encoded by the cDNA insert of clone np26.sub.--3 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.

[0765] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0766] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45; [0767] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515; [0768] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm412.sub.--12 deposited under accession number ATCC 98850; [0769] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm412.sub.--12 deposited under accession number ATCC 98850; [0770] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pm412.sub.--12 deposited under accession number ATCC 98850; [0771] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm412.sub.--12 deposited under accession number ATCC 98850; [0772] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:46; [0773] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; [0774] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0775] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0776] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0777] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:45.

[0778] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515; the nucleotide sequence of the full-length protein coding sequence of clone pm412.sub.--12 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pm412.sub.--12 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm412.sub.--12 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 571 to amino acid 580 of SEQ ID NO:46.

[0779] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:45.

[0780] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0781] (a) a process comprising the steps of: [0782] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0783] (aa) SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45; and [0784] (ab) the nucleotide sequence of the cDNA insert of clone pm412.sub.--12 deposited under accession number ATCC 98850; [0785] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0786] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0787] and [0788] (b) a process comprising the steps of: [0789] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0790] (ba) SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45; and [0791] (bb) the nucleotide sequence of the cDNA insert of clone pm412.sub.--12 deposited under accession number ATCC 98850; [0792] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0793] (iii) amplifying human DNA sequences; and [0794] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515.

[0795] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0796] (a) the amino acid sequence of SEQ ID NO:46; [0797] (b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and [0798] (c) the amino acid sequence encoded by the cDNA insert of clone pm412.sub.--12 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 571 to amino acid 580 of SEQ ID NO:46.

[0799] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0800] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47; [0801] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780; [0802] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780; [0803] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm421.sub.--3 deposited under accession number ATCC 98850; [0804] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm421.sub.--3 deposited under accession number ATCC 98850; [0805] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pm421.sub.--3 deposited under accession number ATCC 98850; [0806] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm421.sub.--3 deposited under accession number ATCC 98850; [0807] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48; [0808] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; [0809] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0810] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0811] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0812] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:47.

[0813] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780; the nucleotide sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780; the nucleotide sequence of the full-length protein coding sequence of clone pm421.sub.--3 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pm421.sub.--3 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm421.sub.--3 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.

[0814] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:47.

[0815] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0816] (a) a process comprising the steps of: [0817] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0818] (aa) SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47; and [0819] (ab) the nucleotide sequence of the cDNA insert of clone pm421.sub.--3 deposited under accession number ATCC 98850; [0820] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0821] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0822] and [0823] (b) a process comprising the steps of: [0824] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0825] (ba) SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47; and [0826] (bb) the nucleotide sequence of the cDNA insert of clone pm421.sub.--3 deposited under accession number ATCC 98850; [0827] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0828] (iii) amplifying human DNA sequences; and [0829] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780.

[0830] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0831] (a) the amino acid sequence of SEQ ID NO:48; [0832] (b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and [0833] (c) the amino acid sequence encoded by the cDNA insert of clone pm421.sub.--3 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.

[0834] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0835] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49; [0836] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486;

[0837] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486; [0838] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pv6.sub.--1 deposited under accession number ATCC 98850; [0839] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pv6.sub.--1 deposited under accession number ATCC 98850; [0840] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pv6.sub.--1 deposited under accession number ATCC 98850; [0841] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pv6.sub.--1 deposited under accession number ATCC 98850; [0842] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:50; [0843] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; [0844] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0845] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0846] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0847] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:49.

[0848] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486; the nucleotide sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486; the nucleotide sequence of the full-length protein coding sequence of clone pv6.sub.--1 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pv6.sub.--1 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv6.sub.--1 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:50.

[0849] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:49.

[0850] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0851] (a) a process comprising the steps of: [0852] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0853] (aa) SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49; and [0854] (ab) the nucleotide sequence of the cDNA insert of clone pv6.sub.--1 deposited under accession number ATCC 98850; [0855] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0856] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0857] and [0858] (b) a process comprising the steps of: [0859] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0860] (ba) SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49; and [0861] (bb) the nucleotide sequence of the cDNA insert of clone pv6.sub.--1 deposited under accession number ATCC 98850; [0862] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0863] (iii) amplifying human DNA sequences; and [0864] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486.

[0865] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0866] (a) the amino acid sequence of SEQ ID NO:50; [0867] (b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and [0868] (c) the amino acid sequence encoded by the cDNA insert of clone pv6.sub.--1 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:50. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:50.

[0869] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0870] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51; [0871] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783; [0872] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783; [0873] (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938; [0874] (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qs14.sub.--3 deposited under accession number ATCC 98850; [0875] (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qs14.sub.--3 deposited under accession number ATCC 98850; [0876] (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qs14.sub.--3 deposited under accession number ATCC 98850; [0877] (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qs14.sub.--3 deposited under accession number ATCC 98850; [0878] (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52; [0879] (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; [0880] (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

[0881] (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above; [0882] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and [0883] (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:51.

[0884] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783; the nucleotide sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783; the nucleotide sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938; the nucleotide sequence of the full-length protein coding sequence of clone qs14.sub.--3 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone qs14.sub.--3 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qs14.sub.--3 deposited under accession number ATCC 98850. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.

[0885] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:51.

[0886] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0887] (a) a process comprising the steps of: [0888] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0889] (aa) SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and [0890] (ab) the nucleotide sequence of the cDNA insert of clone qs14.sub.--3 deposited under accession number ATCC 98850; [0891] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0892] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0893] and [0894] (b) a process comprising the steps of: [0895] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0896] (ba) SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and [0897] (bb) the nucleotide sequence of the cDNA insert of clone qs14.sub.--3 deposited under accession number ATCC 98850; [0898] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0899] (iii) amplifying human DNA sequences; and [0900] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide 3783. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938.

[0901] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0902] (a) the amino acid sequence of SEQ ID NO:52; [0903] (b) the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135; [0904] (c) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and [0905] (d) the amino acid sequence encoded by the cDNA insert of clone qs14.sub.--3 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:52 or the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.

[0906] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0907] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53; [0908] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843; [0909] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843; [0910] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qy338.sub.--9 deposited under accession number ATCC 98850; [0911] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy338.sub.--9 deposited under accession number ATCC 98850; [0912] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qy338.sub.--9 deposited under accession number ATCC 98850; [0913] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qy338.sub.--9 deposited under accession number ATCC 98850; [0914] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54; [0915] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; [0916] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0917] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0918] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0919] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:53.

[0920] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843; the nucleotide sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843; the nucleotide sequence of the full-length protein coding sequence of clone qy338.sub.--9 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone qy338.sub.--9 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy338.sub.--9 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.

[0921] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:53.

[0922] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0923] (a) a process comprising the steps of: [0924] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0925] (aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and [0926] (ab) the nucleotide sequence of the cDNA insert of clone qy338.sub.--9 deposited under accession number ATCC 98850; [0927] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0928] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0929] and [0930] (b) a process comprising the steps of: [0931] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0932] (ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and [0933] (bb) the nucleotide sequence of the cDNA insert of clone qy338.sub.--9 deposited under accession number ATCC 98850; [0934] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0935] (iii) amplifying human DNA sequences; and [0936] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide 843. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843.

[0937] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0938] (a) the amino acid sequence of SEQ ID NO:54; [0939] (b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and [0940] (c) the amino acid sequence encoded by the cDNA insert of clone qy338.sub.--9 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.

[0941] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0942] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55; [0943] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906; [0944] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906; [0945] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rc58.sub.--1 deposited under accession number ATCC 98850; [0946] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rc58.sub.--1 deposited under accession number ATCC 98850; [0947] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rc58.sub.--1 deposited under accession number ATCC 98850; [0948] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rc58.sub.--1 deposited under accession number ATCC 98850; [0949] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:56; [0950] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; [0951] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [0952] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [0953] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [0954] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.

[0955] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906; the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906; the nucleotide sequence of the full-length protein coding sequence of clone rc58.sub.--1 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rc58.sub.--1 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rc58.sub.--1 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:56.

[0956] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:55.

[0957] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0958] (a) a process comprising the steps of: [0959] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0960] (aa) SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and [0961] (ab) the nucleotide sequence of the cDNA insert of clone rc58.sub.--1 deposited under accession number ATCC 98850; [0962] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0963] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0964] and [0965] (b) a process comprising the steps of: [0966] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0967] (ba) SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and [0968] (bb) the nucleotide sequence of the cDNA insert of clone rc58.sub.--1 deposited under accession number ATCC 98850; [0969] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [0970] (iii) amplifying human DNA sequences; and [0971] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906.

[0972] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [0973] (a) the amino acid sequence of SEQ ID NO:56; [0974] (b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and [0975] (c) the amino acid sequence encoded by the cDNA insert of clone rc58.sub.--1 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:56.

[0976] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [0977] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57; [0978] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973; [0979] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd232.sub.--5 deposited under accession number ATCC 98850; [0980] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd232.sub.--5 deposited under accession number ATCC 98850; [0981] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd232.sub.--5 deposited under accession number ATCC 98850; [0982] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd232.sub.--5 deposited under accession number ATCC 98850; [0983] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:58; [0984] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; [0985] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [0986] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [0987] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [0988] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:57.

[0989] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973; the nucleotide sequence of the full-length protein coding sequence of clone rd232.sub.--5 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rd232.sub.--5 deposited under accession number ATCC 98850. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd232.sub.--5 deposited under accession number ATCC 98850. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.

[0990] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:57.

[0991] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [0992] (a) a process comprising the steps of: [0993] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [0994] (aa) SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57; and [0995] (ab) the nucleotide sequence of the cDNA insert of clone rd232.sub.--5 deposited under accession number ATCC 98850; [0996] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [0997] (iii) isolating the DNA polynucleotides detected with the probe(s);

[0998] and [0999] (b) a process comprising the steps of: [1000] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1001] (ba) SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57; and [1002] (bb) the nucleotide sequence of the cDNA insert of clone rd232.sub.--5 deposited under accession number ATCC 98850; [1003] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1004] (iii) amplifying human DNA sequences; and [1005] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973.

[1006] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1007] (a) the amino acid sequence of SEQ ID NO:58; [1008] (b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and [1009] (c) the amino acid sequence encoded by the cDNA insert of clone rd232.sub.--5 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:58. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.

[1010] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1011] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59; [1012] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596; [1013] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ck213.sub.--12 deposited under accession number ATCC 98918; [1014] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ck213.sub.--12 deposited under accession number ATCC 98918; [1015] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ck213.sub.--12 deposited under accession number ATCC 98918; [1016] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ck213.sub.--12 deposited under accession number ATCC 98918; [1017] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:60; [1018] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; [1019] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1020] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1021] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1022] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:59.

[1023] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596; the nucleotide sequence of the full-length protein coding sequence of clone ck21312 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone ck213.sub.--12 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ck213.sub.--12 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.

[1024] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:59.

[1025] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1026] (a) a process comprising the steps of: [1027] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1028] (aa) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and [1029] (ab) the nucleotide sequence of the cDNA insert of clone ck213.sub.--12 deposited under accession number ATCC 98918; [1030] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1031] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1032] and [1033] (b) a process comprising the steps of: [1034] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1035] (ba) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and [1036] (bb) the nucleotide sequence of the cDNA insert of clone ck213.sub.--12 deposited under accession number ATCC 98918; [1037] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1038] (iii) amplifying human DNA sequences; and [1039] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596.

[1040] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1041] (a) the amino acid sequence of SEQ ID NO:60; [1042] (b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and [1043] (c) the amino acid sequence encoded by the cDNA insert of clone ck213.sub.--12 deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.

[1044] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1045] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61; [1046] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750; [1047] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pg195.sub.--1 deposited under accession number ATCC 98918; [1048] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pg195.sub.--1 deposited under accession number ATCC 98918; [1049] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pg195.sub.--1 deposited under accession number ATCC 98918; [1050] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pg195.sub.--1 deposited under accession number ATCC 98918; [1051] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:62; [1052] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; [1053] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1054] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1055] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1056] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:61.

[1057] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750; the nucleotide sequence of the full-length protein coding sequence of clone pg195.sub.--1 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone pg195.sub.--1 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pg195.sub.--1 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.

[1058] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:61.

[1059] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1060] (a) a process comprising the steps of: [1061] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1062] (aa) SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61; and [1063] (ab) the nucleotide sequence of the cDNA insert of clone pg195.sub.--1 deposited under accession number ATCC 98918; [1064] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1065] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1066] and [1067] (b) a process comprising the steps of: [1068] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1069] (ba) SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61; and [1070] (bb) the nucleotide sequence of the cDNA insert of clone pg195.sub.--1 deposited under accession number ATCC 98918; [1071] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1072] (iii) amplifying human DNA sequences; and [1073] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750.

[1074] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1075] (a) the amino acid sequence of SEQ ID NO:62; [1076] (b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and [1077] (c) the amino acid sequence encoded by the cDNA insert of clone pg195.sub.--1 deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:62. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.

[1078] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1079] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63; [1080] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440; [1081] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440; [1082] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pw460.sub.--5 deposited under accession number ATCC 98918; [1083] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pw460.sub.--5 deposited under accession number ATCC 98918; [1084] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pw460.sub.--5 deposited under accession number ATCC 98918; [1085] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pw460.sub.--5 deposited under accession number ATCC 98918; [1086] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:64; [1087] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; [1088] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1089] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1090] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1091] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:63.

[1092] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440; the nucleotide sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440; the nucleotide sequence of the full-length protein coding sequence of clone pw460.sub.--5 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone pw460.sub.--5 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pw460.sub.--5 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.

[1093] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:63.

[1094] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1095] (a) a process comprising the steps of: [1096] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1097] (aa) SEQ ID NO:63, but excluding the poly(A) tail at the 3' end of SEQ ID NO:63; and [1098] (ab) the nucleotide sequence of the cDNA insert of clone pw460.sub.--5 deposited under accession number ATCC 98918; [1099] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1100] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1101] and [1102] (b) a process comprising the steps of: [1103] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1104] (ba) SEQ ID NO:63, but excluding the poly(A) tail at the 3' end of SEQ ID NO:63; and [1105] (bb) the nucleotide sequence of the cDNA insert of clone pw460.sub.--5 deposited under accession number ATCC 98918; [1106] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1107] (iii) amplifying human DNA sequences; and [1108] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:63, but excluding the poly(A) tail at the 3' end of SEQ ID NO:63. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440.

[1109] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1110] (a) the amino acid sequence of SEQ ID NO:64; [1111] (b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and [1112] (c) the amino acid sequence encoded by the cDNA insert of clone pw460.sub.--5 deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:64. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.

[1113] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1114] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65; [1115] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356; [1116] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356; [1117] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qa136.sub.--1 deposited under accession number ATCC 98918; [1118] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qa136.sub.--1 deposited under accession number ATCC 98918; [1119] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qa136.sub.--1 deposited under accession number ATCC 98918; [1120] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qa136.sub.--1 deposited under accession number ATCC 98918; [1121] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:66; [1122] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; [1123] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1124] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1125] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1126] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:65.

[1127] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356; the nucleotide sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356; the nucleotide sequence of the full-length protein coding sequence of clone qa136.sub.--1 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone qa136.sub.--1 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qa136.sub.--1 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 213 to amino acid 222 of SEQ ID NO:66.

[1128] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:65.

[1129] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1130] (a) a process comprising the steps of: [1131] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1132] (aa) SEQ ID NO:65; and [1133] (ab) the nucleotide sequence of the cDNA insert of clone qa136.sub.--1 deposited under accession number ATCC 98918; [1134] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1135] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1136] and [1137] (b) a process comprising the steps of: [1138] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1139] (ba) SEQ ID NO:65; and [1140] (bb) the nucleotide sequence of the cDNA insert of clone qa136.sub.--1 deposited under accession number ATCC 98918; [1141] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1142] (iii) amplifying human DNA sequences; and [1143] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:65 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:65. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356.

[1144] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1145] (a) the amino acid sequence of SEQ ID NO:66; [1146] (b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and [1147] (c) the amino acid sequence encoded by the cDNA insert of clone qa136.sub.--1 deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:66. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 213 to amino acid 222 of SEQ ID NO:66.

[1148] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1149] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67; [1150] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624; [1151] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624; [1152] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qy1261.sub.--2 deposited under accession number ATCC 98918; [1153] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy1261.sub.--2 deposited under accession number ATCC 98918; [1154] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qy1261.sub.--2 deposited under accession number ATCC 98918; [1155] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qy1261.sub.--2 deposited under accession number ATCC 98918; [1156] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:68; [1157] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:68; [1158] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1159] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1160] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1161] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:67.

[1162] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624; the nucleotide sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624; the nucleotide sequence of the full-length protein coding sequence of clone qy1261.sub.--2 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone qy1261.sub.--2 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy1261.sub.--2 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 231 to amino acid 240 of SEQ ID NO:68.

[1163] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:67.

[1164] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1165] (a) a process comprising the steps of: [1166] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1167] (aa) SEQ ID NO:67, but excluding the poly(A) tail at the 3' end of SEQ ID NO:67; and [1168] (ab) the nucleotide sequence of the cDNA insert of clone qy1261.sub.--2 deposited under accession number ATCC 98918; [1169] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4>(SSC at 50 degrees C.; and [1170] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1171] and [1172] (b) a process comprising the steps of: [1173] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1174] (ba) SEQ ID NO:67, but excluding the poly(A) tail at the 3' end of SEQ ID NO:67; and [1175] (bb) the nucleotide sequence of the cDNA insert of clone qy1261.sub.--2 deposited under accession number ATCC 98918; [1176] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1177] (iii) amplifying human DNA sequences; and [1178] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:67 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:67, but excluding the poly(A) tail at the 3' end of SEQ ID NO:67. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624.

[1179] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1180] (a) the amino acid sequence of SEQ ID NO:68; [1181] (b) a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68; and [1182] (c) the amino acid sequence encoded by the cDNA insert of clone qy1261.sub.--2 deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:68. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 231 to amino acid 240 of SEQ ID NO:68.

[1183] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1184] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69; [1185] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817; [1186] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rd432.sub.--4 deposited under accession number ATCC 98918; [1187] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rd432.sub.--4 deposited under accession number ATCC 98918; [1188] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rd432.sub.--4 deposited under accession number ATCC 98918; [1189] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rd432.sub.--4 deposited under accession number ATCC 98918; [1190] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:70; [1191] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:70; [1192] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1193] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1194] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1195] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:69.

[1196] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817; the nucleotide sequence of the full-length protein coding sequence of clone rd432.sub.--4 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone rd432.sub.--4 deposited under accession number ATCC 98918. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd432.sub.--4 deposited under accession number ATCC 98918. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:70.

[1197] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:69.

[1198] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1199] (a) a process comprising the steps of: [1200] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1201] (aa) SEQ ID NO:69, but excluding the poly(A) tail at the 3' end of SEQ ID NO:69; and [1202] (ab) the nucleotide sequence of the cDNA insert of clone rd432.sub.--4 deposited under accession number ATCC 98918; [1203] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1204] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1205] and [1206] (b) a process comprising the steps of: [1207] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1208] (ba) SEQ ID NO:69, but excluding the poly(A) tail at the 3' end of SEQ ID NO:69; and [1209] (bb) the nucleotide sequence of the cDNA insert of clone rd432.sub.--4 deposited under accession number ATCC 98918; [1210] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1211] (iii) amplifying human DNA sequences; and [1212] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:69 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:69, but excluding the poly(A) tail at the 3' end of SEQ ID NO:69. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:69 from nucleotide 1359 to nucleotide 1817.

[1213] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1214] (a) the amino acid sequence of SEQ ID NO:70; [1215] (b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70; and [1216] (c) the amino acid sequence encoded by the cDNA insert of clone rd432.sub.--4 deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:70. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:70.

[1217] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1218] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71; [1219] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195; [1220] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195; [1221] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rb789.sub.--14 deposited under accession number ATCC 207004; [1222] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rb789.sub.--14 deposited under accession number ATCC 207004; [1223] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rb789.sub.--14 deposited under accession number ATCC 207004; [1224] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rb789.sub.--14 deposited under accession number ATCC 207004; [1225] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:72; [1226] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; [1227] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1228] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1229] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1230] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:71.

[1231] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195; the nucleotide sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195; the nucleotide sequence of the full-length protein coding sequence of clone rb789.sub.--14 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone rb789.sub.--14 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rb789.sub.--14 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:72.

[1232] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:71.

[1233] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1234] (a) a process comprising the steps of: [1235] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1236] (aa) SEQ ID NO:71, but excluding the poly(A) tail at the 3' end of SEQ ID NO:71; and [1237] (ab) the nucleotide sequence of the cDNA insert of clone rb789.sub.--14 deposited under accession number ATCC 207004; [1238] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1239] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1240] and [1241] (b) a process comprising the steps of: [1242] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1243] (ba) SEQ ID NO:71, but excluding the poly(A) tail at the 3' end of SEQ ID NO:71; and [1244] (bb) the nucleotide sequence of the cDNA insert of clone rb789.sub.--14 deposited under accession number ATCC 207004; [1245] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1246] (iii) amplifying human DNA sequences; and [1247] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:71 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:71, but excluding the poly(A) tail at the 3' end of SEQ ID NO:71. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:71 from nucleotide 884 to nucleotide 1195. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:71 from nucleotide 947 to nucleotide 1195.

[1248] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1249] (a) the amino acid sequence of SEQ ID NO:72; [1250] (b) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; and [1251] (c) the amino acid sequence encoded by the cDNA insert of clone rb789.sub.--14 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:72. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:72.

[1252] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1253] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73; [1254] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374; [1255] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374; [1256] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yd137.sub.--1 deposited under accession number ATCC 207004; [1257] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yd137.sub.--1 deposited under accession number ATCC 207004; [1258] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yd137.sub.--1 deposited under accession number ATCC 207004; [1259] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yd137.sub.--1 deposited under accession number ATCC 207004; [1260] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:74; [1261] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; [1262] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1263] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1264] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1265] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:73.

[1266] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374; the nucleotide sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374; the nucleotide sequence of the full-length protein coding sequence of clone yd137.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yd137.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yd137.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:74.

[1267] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:73.

[1268] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1269] (a) a process comprising the steps of: [1270] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1271] (aa) SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73; and [1272] (ab) the nucleotide sequence of the cDNA insert of clone yd137.sub.--1 deposited under accession number ATCC 207004; [1273] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1274] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1275] and [1276] (b) a process comprising the steps of: [1277] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1278] (ba) SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73; and [1279] (bb) the nucleotide sequence of the cDNA insert of clone yd137.sub.--1 deposited under accession number ATCC 207004; [1280] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1281] (iii) amplifying human DNA sequences; and [1282] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:73 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:73 from nucleotide 69 to nucleotide 374. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:73 from nucleotide 186 to nucleotide 374.

[1283] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1284] (a) the amino acid sequence of SEQ ID NO:74; [1285] (b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; and [1286] (c) the amino acid sequence encoded by the cDNA insert of clone yd137.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:74. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:74.

[1287] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1288] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75; [1289] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343; [1290] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343; [1291] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yd218.sub.--1 deposited under accession number ATCC 207004; [1292] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yd218.sub.--1 deposited under accession number ATCC 207004; [1293] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yd218.sub.--1 deposited under accession number ATCC 207004; [1294] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yd218.sub.--1 deposited under accession number ATCC 207004; [1295] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:76; [1296] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; [1297] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1298] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1299] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1300] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:75.

[1301] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343; the nucleotide sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343; the nucleotide sequence of the full-length protein coding sequence of clone yd218.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yd218.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yd218.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:76.

[1302] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:75.

[1303] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1304] (a) a process comprising the steps of: [1305] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1306] (aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and [1307] (ab) the nucleotide sequence of the cDNA insert of clone yd218.sub.--1 deposited under accession number ATCC 207004; [1308] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1309] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1310] and [1311] (b) a process comprising the steps of: [1312] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1313] (ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and [1314] (bb) the nucleotide sequence of the cDNA insert of clone yd218.sub.--1 deposited under accession number ATCC 207004; [1315] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1316] (iii) amplifying human DNA sequences; and [1317] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:75 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 8 to nucleotide 343. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 50 to nucleotide 343.

[1318] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1319] (a) the amino acid sequence of SEQ ID NO:76; [1320] (b) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and [1321] (c) the amino acid sequence encoded by the cDNA insert of clone yd218.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:76. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:76.

[1322] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1323] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77; [1324] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679; [1325] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye11.sub.--1 deposited under accession number ATCC 207004; [1326] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye11.sub.--1 deposited under accession number ATCC 207004; [1327] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye11.sub.--1 deposited under accession number ATCC 207004; [1328] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye11.sub.--1 deposited under accession number ATCC 207004; [1329] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78; [1330] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; [1331] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1332] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1333] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1334] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:77.

[1335] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679; the nucleotide sequence of the full-length protein coding sequence of clone ye11.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye11.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye11.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 261 to amino acid 270 of SEQ ID NO:78.

[1336] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:77.

[1337] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1338] (a) a process comprising the steps of: [1339] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1340] (aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77; and [1341] (ab) the nucleotide sequence of the cDNA insert of clone ye11.sub.--1 deposited under accession number ATCC 207004; [1342] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1343] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1344] and [1345] (b) a process comprising the steps of: [1346] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1347] (ba) SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77; and [1348] (bb) the nucleotide sequence of the cDNA insert of clone ye11.sub.--1 deposited under accession number ATCC 207004; [1349] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1350] (iii) amplifying human DNA sequences; and [1351] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:77 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 84 to nucleotide 1679.

[1352] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1353] (a) the amino acid sequence of SEQ ID NO:78; [1354] (b) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino adds of SEQ ID NO:78; and [1355] (c) the amino acid sequence encoded by the cDNA insert of clone ye11.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:78. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 261 to amino acid 270 of SEQ ID NO:78.

[1356] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1357] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79; [1358] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646; [1359] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646; [1360] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye72.sub.--1 deposited under accession number ATCC 207004; [1361] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye72.sub.--1 deposited under accession number ATCC 207004; [1362] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye72.sub.--1 deposited under accession number ATCC 207004; [1363] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye72.sub.--1 deposited under accession number ATCC 207004; [1364] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:80; [1365] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; [1366] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1367] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1368] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1369] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:79.

[1370] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646; the nucleotide sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646; the nucleotide sequence of the full-length protein coding sequence of clone ye72.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye72.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye72.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 257 to amino acid 266 of SEQ ID NO:80.

[1371] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:79.

[1372] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1373] (a) a process comprising the steps of: [1374] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1375] (aa) SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79; and [1376] (ab) the nucleotide sequence of the cDNA insert of clone ye72.sub.--1 deposited under accession number ATCC 207004; [1377] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1378] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1379] and [1380] (b) a process comprising the steps of: [1381] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1382] (ba) SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79; and [1383] (bb) the nucleotide sequence of the cDNA insert of clone ye72.sub.--1 deposited under accession number ATCC 207004; [1384] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1385] (iii) amplifying human DNA sequences; and [1386] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide 72 to nucleotide 1646. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide 180 to nucleotide 1646.

[1387] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1388] (a) the amino acid sequence of SEQ ID NO:80; [1389] (b) a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; and [1390] (c) the amino acid sequence encoded by the cDNA insert of clone ye72.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 257 to amino acid 266 of SEQ ID NO:80.

[1391] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1392] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81; [1393] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423; [1394] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423; [1395] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye78.sub.--1 deposited under accession number ATCC 207004; [1396] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye78.sub.--1 deposited under accession number ATCC 207004; [1397] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye78.sub.--1 deposited under accession number ATCC 207004; [1398] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye78.sub.--1 deposited under accession number ATCC 207004; [1399] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:82; [1400] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:82; [1401] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1402] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1403] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1404] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:81.

[1405] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423; the nucleotide sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423; the nucleotide sequence of the full-length protein coding sequence of clone ye78.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye78.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye78.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:82.

[1406] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:81.

[1407] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1408] (a) a process comprising the steps of: [1409] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1410] (aa) SEQ ID NO:81, but excluding the poly(A) tail at the 3' end of SEQ ID NO:81; and [1411] (ab) the nucleotide sequence of the cDNA insert of clone ye78.sub.--1 deposited under accession number ATCC 207004; [1412] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1413] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1414] and [1415] (b) a process comprising the steps of: [1416] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1417] (ba) SEQ ID NO:81, but excluding the poly(A) tail at the 3' end of SEQ ID NO:81; and [1418] (bb) the nucleotide sequence of the cDNA insert of clone ye78.sub.--1 deposited under accession number ATCC 207004; [1419] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1420] (iii) amplifying human DNA sequences; and [1421] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:81 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:81, but excluding the poly(A) tail at the 3' end of SEQ ID NO:81. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:81 from nucleotide 954 to nucleotide 2423. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:81 from nucleotide 1224 to nucleotide 2423.

[1422] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1423] (a) the amino acid sequence of SEQ ID NO:82; [1424] (b) a fragment of the amino acid sequence of SEQ ID NO:82, the fragment comprising eight contiguous amino acids of SEQ ID NO:82; and [1425] (c) the amino acid sequence encoded by the cDNA insert of clone ye78.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:82. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:82, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:82 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:82.

[1426] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1427] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83; [1428] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321; [1429] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321; [1430] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ye90.sub.--1 deposited under accession number ATCC 207004; [1431] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ye90.sub.--1 deposited under accession number ATCC 207004; [1432] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ye90.sub.--1 deposited under accession number ATCC 207004; [1433] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ye90.sub.--1 deposited under accession number ATCC 207004; [1434] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:84; [1435] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:84; [1436] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1437] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1438] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1439] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:83.

[1440] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321; the nucleotide sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321; the nucleotide sequence of the full-length protein coding sequence of clone ye90.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone ye90.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ye90.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID. NO:84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising the amino acid sequence from amino acid 186 to amino acid 195 of SEQ ID NO:84.

[1441] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:83.

[1442] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1443] (a) a process comprising the steps of: [1444] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1445] (aa) SEQ ID NO:83, but excluding the poly(A) tail at the 3' end of SEQ ID NO:83; and [1446] (ab) the nucleotide sequence of the cDNA insert of clone ye90.sub.--1 deposited under accession number ATCC 207004; [1447] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1448] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1449] and [1450] (b) a process comprising the steps of: [1451] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1452] (ba) SEQ ID NO:83, but excluding the poly(A) tail at the 3' end of SEQ ID NO:83; and [1453] (bb) the nucleotide sequence of the cDNA insert of clone ye90.sub.--1 deposited under accession number ATCC 207004; [1454] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1455] (iii) amplifying human DNA sequences; and [1456] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:83 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:83, but excluding the poly(A) tail at the 3' end of SEQ ID NO:83. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:83 from nucleotide 176 to nucleotide 1321. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:83 from nucleotide 233 to nucleotide 1321.

[1457] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1458] (a) the amino acid sequence of SEQ ID NO:84; [1459] (b) a fragment of the amino acid sequence of SEQ ID NO:84, the fragment comprising eight contiguous amino acids of SEQ ID NO:84; and [1460] (c) the amino acid sequence encoded by the cDNA insert of clone ye90.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:84. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:84, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:84 having biological activity, the fragment comprising the amino acid sequence from amino acid 186 to amino acid 195 of SEQ ID NO:84.

[1461] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1462] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85; [1463] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605; [1464] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yi62.sub.--1 deposited under accession number ATCC 207004; [1465] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yi62.sub.--1 deposited under accession number ATCC 207004; [1466] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yi62.sub.--1 deposited under accession number ATCC 207004; [1467] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yi62.sub.--1 deposited under accession number ATCC 207004; [1468] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:86; [1469] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:86; [1470] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1471] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1472] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1473] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:85.

[1474] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605; the nucleotide sequence of the full-length protein coding sequence of clone yi62.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yi62.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yi62.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:86, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:86.

[1475] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:85.

[1476] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1477] (a) a process comprising the steps of: [1478] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1479] (aa) SEQ ID NO:85, but excluding the poly(A) tail at the 3' end of SEQ ID NO:85; and [1480] (ab) the nucleotide sequence of the cDNA insert of clone yi62.sub.--1 deposited under accession number ATCC 207004; [1481] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1482] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1483] and [1484] (b) a process comprising the steps of: [1485] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1486] (ba) SEQ ID NO:85, but excluding the poly(A) tail at the 3' end of SEQ ID NO:85; and [1487] (bb) the nucleotide sequence of the cDNA insert of clone yi62.sub.--1 deposited under accession number ATCC 207004; [1488] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1489] (iii) amplifying human DNA sequences; and [1490] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:85 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:85, but excluding the poly(A) tail at the 3' end of SEQ ID NO:85. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:85 from nucleotide 105 to nucleotide 605.

[1491] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1492] (a) the amino acid sequence of SEQ ID NO:86; [1493] (b) a fragment of the amino acid sequence of SEQ ID NO:86, the fragment comprising eight contiguous amino acids of SEQ ID NO:86; and [1494] (c) the amino acid sequence encoded by the cDNA insert of clone yi62.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:86. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:86, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:86 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:86.

[1495] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1496] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87; [1497] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798; [1498] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798; [1499] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yk78.sub.--1 deposited under accession number ATCC 207004; [1500] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yk78.sub.--1 deposited under accession number ATCC 207004; [1501] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yk78.sub.--1 deposited under accession number ATCC 207004; [1502] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yk78.sub.--1 deposited under accession number ATCC 207004; [1503] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:88; [1504] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:88; [1505] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1506] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1507] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1508] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:87.

[1509] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798; the nucleotide sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798; the nucleotide sequence of the full-length protein coding sequence of clone yk78.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yk78.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yk78.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 91 to amino acid 100 of SEQ ID NO:88.

[1510] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:87.

[1511] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1512] (a) a process comprising the steps of: [1513] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1514] (aa) SEQ ID NO:87, but excluding the poly(A) tail at the 3' end of SEQ ID NO:87; and [1515] (ab) the nucleotide sequence of the cDNA insert of clone yk78.sub.--1 deposited under accession number ATCC 207004; [1516] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1517] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1518] and [1519] (b) a process comprising the steps of: [1520] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1521] (ba) SEQ ID NO:87, but excluding the poly(A) tail at the 3' end of SEQ ID NO:87; and [1522] (bb) the nucleotide sequence of the cDNA insert of clone yk78.sub.--1 deposited under accession number ATCC 207004; [1523] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1524] (iii) amplifying human DNA sequences; and [1525] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:87 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:87, but excluding the poly(A) tail at the 3' end of SEQ ID NO:87. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:87 from nucleotide 223 to nucleotide 798. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798, and extending contiguously from a nucleotide sequence corresponding to the 5 end of said sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:87 from nucleotide 430 to nucleotide 798.

[1526] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1527] (a) the amino acid sequence of SEQ ID NO:88; [1528] (b) a fragment of the amino acid sequence of SEQ ID NO:88, the fragment comprising eight contiguous amino acids of SEQ ID NO:88; and [1529] (c) the amino acid sequence encoded by the cDNA insert of clone yk78.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:88. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 91 to amino acid 100 of SEQ ID NO:88.

[1530] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1531] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89; [1532] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942; [1533] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942; [1534] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yk251.sub.--1 deposited under accession number ATCC 207004; [1535] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yk251.sub.--1 deposited under accession number ATCC 207004; [1536] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yk251.sub.--1 deposited under accession number ATCC 207004; [1537] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yk251.sub.--1 deposited under accession number ATCC 207004; [1538] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:90; [1539] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:90; [1540] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1541] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1542] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1543] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:89.

[1544] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942; the nucleotide sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942; the nucleotide sequence of the full-length protein coding sequence of clone yk251.sub.--1 deposited under accession number ATCC 207004; or the nucleotide sequence of a mature protein coding sequence of clone yk251.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yk251.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:90.

[1545] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:89.

[1546] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1547] (a) a process comprising the steps of: [1548] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1549] (aa) SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO:89; and [1550] (ab) the nucleotide sequence of the cDNA insert of clone yk251.sub.--1 deposited under accession number ATCC 207004; [1551] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1552] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1553] and [1554] (b) a process comprising the steps of: [1555] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1556] (ba) SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO:89; and [1557] (bb) the nucleotide sequence of the cDNA insert of clone yk251.sub.--1 deposited under accession number ATCC 207004; [1558] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1559] (iii) amplifying human DNA sequences; and [1560] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:89 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO:89. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:89 from nucleotide 211 to nucleotide 942. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:89 from nucleotide 298 to nucleotide 942.

[1561] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1562] (a) the amino acid sequence of SEQ ID NO:90; [1563] (b) a fragment of the amino acid sequence of SEQ ID NO:90, the fragment comprising eight contiguous amino acids of SEQ ID NO:90; and [1564] (c) the amino acid sequence encoded by the cDNA insert of clone yk251.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:90. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:90, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:90 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:90.

[1565] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1566] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91; [1567] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784; [1568] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yt14.sub.--1 deposited under accession number ATCC 207004; [1569] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yt14.sub.--1 deposited under accession number ATCC 207004; [1570] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yt14.sub.--1 deposited under accession number ATCC 207004; [1571] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yt14.sub.--1 deposited under accession number ATCC 207004; [1572] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:92; [1573] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:92; [1574] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1575] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1576] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1577] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:91.

[1578] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784; the nucleotide sequence of the full-length protein coding sequence of clone yt14.sub.--1 deposited under accession number ATCC 207004;

[1579] or the nucleotide sequence of a mature protein coding sequence of clone yt14.sub.--1 deposited under accession number ATCC 207004. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yt14.sub.--1 deposited under accession number ATCC 207004. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:92.

[1580] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:91.

[1581] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1582] (a) a process comprising the steps of: [1583] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1584] (aa) SEQ ID NO:91, but excluding the poly(A) tail at the 3' end of SEQ ID NO:91; and [1585] (ab) the nucleotide sequence of the cDNA insert of clone yt14.sub.--1 deposited under accession number ATCC 207004; [1586] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1587] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1588] and [1589] (b) a process comprising the steps of: [1590] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1591] (ba) SEQ ID NO:91, but excluding the poly(A) tail at the 3' end of SEQ ID NO:91; and [1592] (bb) the nucleotide sequence of the cDNA insert of clone yt14.sub.--1 deposited under accession number ATCC 207004; [1593] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1594] (iii) amplifying human DNA sequences; and [1595] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:91 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:91, but excluding the poly(A) tail at the 3' end of SEQ ID NO:91. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:91 from nucleotide 149 to nucleotide 784.

[1596] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1597] (a) the amino acid sequence of SEQ ID NO:92; [1598] (b) a fragment of the amino acid sequence of SEQ ID NO:92, the fragment comprising eight contiguous amino acids of SEQ ID NO:92; and [1599] (c) the amino acid sequence encoded by the cDNA insert of clone yt14.sub.--1 deposited under accession number ATCC 207004; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:92. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:92, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:92 having biological activity, the fragment comprising the amino acid sequence from amino acid 101 to amino acid 110 of SEQ ID NO:92.

[1600] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1601] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93; [1602] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441; [1603] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bf157.sub.--16 deposited under accession number ATCC 207088; [1604] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bf157.sub.--16 deposited under accession number ATCC 207088; [1605] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bf157.sub.--16 deposited under accession number ATCC 207088; [1606] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bf157.sub.--16 deposited under accession number ATCC 207088; [1607] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:94; [1608] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; [1609] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1610] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1611] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1612] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:93.

[1613] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441; the nucleotide sequence of the full-length protein coding sequence of clone bf157.sub.--16 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone bf157.sub.--16 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bf157.sub.--16 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID. NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 220 to amino acid 229 of SEQ ID NO:94.

[1614] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:93.

[1615] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1616] (a) a process comprising the steps of: [1617] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1618] (aa) SEQ ID NO:93, but excluding the poly(A) tail at the 3' end of SEQ ID NO:93; and [1619] (ab) the nucleotide sequence of the cDNA insert of clone bf157.sub.--16 deposited under accession number ATCC 207088; [1620] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1621] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1622] and [1623] (b) a process comprising the steps of: [1624] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1625] (ba) SEQ ID NO:93, but excluding the poly(A) tail at the 3' end of SEQ ID NO:93; and [1626] (bb) the nucleotide sequence of the cDNA insert of clone bf157.sub.--16 deposited under accession number ATCC 207088; [1627] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1628] (iii) amplifying human DNA sequences; and [1629] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:93 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:93, but excluding the poly(A) tail at the 3' end of SEQ ID NO:93. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 89 to nucleotide 1441.

[1630] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1631] (a) the amino acid sequence of SEQ ID. NO:94; [1632] (b) a fragment of the amino acid sequence of SEQ ID NO:94, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; and [1633] (c) the amino acid sequence encoded by the cDNA insert of clone bf157.sub.--16 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:94. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 220 to amino acid 229 of SEQ ID NO:94.

[1634] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1635] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95; [1636] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629; [1637] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bk343.sub.--2 deposited under accession number ATCC 207088; [1638] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bk343.sub.--2 deposited under accession number ATCC 207088; [1639] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bk343.sub.--2 deposited under accession number ATCC 207088; [1640] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bk343.sub.--2 deposited under accession number ATCC 207088; [1641] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:96; [1642] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; [1643] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1644] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1645] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1646] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:95.

[1647] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629; the nucleotide sequence of the full-length protein coding sequence of clone bk343.sub.--2 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone bk343.sub.--2 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bk343.sub.--2 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 63 to amino acid 72 of SEQ ID NO:96.

[1648] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:95.

[1649] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1650] (a) a process comprising the steps of: [1651] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1652] (aa) SEQ ID NO:95, but excluding the poly(A) tail at the 3' end of SEQ ID NO:95; and [1653] (ab) the nucleotide sequence of the cDNA insert of clone bk343.sub.--2 deposited under accession number ATCC 207088; [1654] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4>(SSC at 50 degrees C.; and [1655] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1656] and [1657] (b) a process comprising the steps of: [1658] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1659] (ba) SEQ ID NO:95, but excluding the poly(A) tail at the 3' end of SEQ ID NO:95; and [1660] (bb) the nucleotide sequence of the cDNA insert of clone bk343.sub.--2 deposited under accession number ATCC 207088; [1661] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1662] (iii) amplifying human DNA sequences; and [1663] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:95 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:95, but excluding the poly(A) tail at the 3' end of SEQ ID NO:95. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:95 from nucleotide 219 to nucleotide 629.

[1664] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1665] (a) the amino acid sequence of SEQ ID NO:96; [1666] (b) a fragment of the amino acid sequence of SEQ ID NO:96, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; and [1667] (c) the amino acid sequence encoded by the cDNA insert of clone bk343.sub.--2 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:96. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 63 to amino acid 72 of SEQ ID NO:96.

[1668] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1669] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97; [1670] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951; [1671] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951; [1672] (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295; [1673] (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cd205.sub.--2 deposited under accession number ATCC 207088; [1674] (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cd205.sub.--2 deposited under accession number ATCC 207088; [1675] (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cd205.sub.--2 deposited under accession number ATCC 207088; [1676] (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cd205.sub.--2 deposited under accession number ATCC 207088; [1677] (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:98; [1678] (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:98; [1679] (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; [1680] (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above; [1681] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and [1682] (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:97.

[1683] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951; the nucleotide sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951; the nucleotide sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295; the nucleotide sequence of the full-length protein coding sequence of clone cd205.sub.--2 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cd205.sub.--2 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cd205.sub.--2 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:98.

[1684] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:97.

[1685] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1686] (a) a process comprising the steps of: [1687] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1688] (aa) SEQ ID NO:97, but excluding the poly(A) tail at the 3' end of SEQ ID NO:97; and [1689] (ab) the nucleotide sequence of the cDNA insert of clone cd205.sub.--2 deposited under accession number ATCC 207088; [1690] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1691] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1692] and [1693] (b) a process comprising the steps of: [1694] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1695] (ba) SEQ ID NO:97, but excluding the poly(A) tail at the 3' end of SEQ ID NO:97; and [1696] (bb) the nucleotide sequence of the cDNA insert of clone cd205.sub.--2 deposited under accession number ATCC 207088; [1697] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1698] (iii) amplifying human DNA sequences; and [1699] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:97 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:97, but excluding the poly(A) tail at the 3' end of SEQ ID NO:97. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:97 from nucleotide 556 to nucleotide 951. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:97 from nucleotide 868 to nucleotide 951. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:97 from nucleotide 9 to nucleotide 1295.

[1700] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1701] (a) the amino acid sequence of SEQ ID NO:98; [1702] (b) a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ID NO:98; and [1703] (c) the amino acid sequence encoded by the cDNA insert of clone cd205.sub.--2 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:98. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:98.

[1704] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1705] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99; [1706] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443; [1707] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443; [1708] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cw1292.sub.--8 deposited under accession number ATCC 207088; [1709] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cw1292.sub.--8 deposited under accession number ATCC 207088; [1710] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cw1292.sub.--8 deposited under accession number ATCC 207088; [1711] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cw1292.sub.--8 deposited under accession number ATCC 207088; [1712] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:100; [1713] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:100; [1714] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1715] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1716] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1717] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:99.

[1718] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443; the nucleotide sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443; the nucleotide sequence of the full-length protein coding sequence of clone cw1292.sub.--8 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cw1292.sub.--8 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cw1292.sub.--8 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:100, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:100.

[1719] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:99.

[1720] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1721] (a) a process comprising the steps of: [1722] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1723] (aa) SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99; and [1724] (ab) the nucleotide sequence of the cDNA insert of clone cw1292.sub.--8 deposited under accession number ATCC 207088; [1725] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1726] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1727] and [1728] (b) a process comprising the steps of: [1729] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1730] (ba) SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99; and [1731] (bb) the nucleotide sequence of the cDNA insert of clone cw1292.sub.--8 deposited under accession number ATCC 207088; [1732] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1733] (iii) amplifying human DNA sequences; and [1734] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:99 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:99 from nucleotide 216 to nucleotide 443. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:99 from nucleotide 306 to nucleotide 443.

[1735] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1736] (a) the amino acid sequence of SEQ ID NO:100; [1737] (b) a fragment of the amino acid sequence of SEQ ID NO:100, the fragment comprising eight contiguous amino acids of SEQ ID NO:100; and [1738] (c) the amino acid sequence encoded by the cDNA insert of clone cw1292.sub.--8 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:100. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:100, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:100 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:100.

[1739] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1740] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101; [1741] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447; [1742] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cw1475.sub.--2 deposited under accession number ATCC 207088; [1743] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cw1475.sub.--2 deposited under accession number ATCC 207088; [1744] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cw1475.sub.--2 deposited under accession number ATCC 207088; [1745] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cw1475.sub.--2 deposited under accession number ATCC 207088; [1746] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:102; [1747] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:102; [1748] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1749] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1750] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1751] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:101.

[1752] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447; the nucleotide sequence of the full-length protein coding sequence of clone cw1475.sub.--2 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone cw1475.sub.--2 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cw1475.sub.--2 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:102, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:102. Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:101.

[1753] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1754] (a) a process comprising the steps of: [1755] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1756] (aa) SEQ ID NO:101, but excluding the poly(A) tail at the 3' end of SEQ ID NO:101; and [1757] (ab) the nucleotide sequence of the cDNA insert of clone cw1475.sub.--2 deposited under accession number ATCC 207088; [1758] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1759] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1760] and [1761] (b) a process comprising the steps of: [1762] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1763] (ba) SEQ ID NO:101, but excluding the poly(A) tail at the 3' end of SEQ ID NO:101; and [1764] (bb) the nucleotide sequence of the cDNA insert of clone cw1475.sub.--2 deposited under accession number ATCC 207088; [1765] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1766] (iii) amplifying human DNA sequences; and [1767] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:101 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:101, but excluding the poly(A) tail at the 3' end of SEQ ID NO:101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:101 from nucleotide 2136 to nucleotide 2447.

[1768] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1769] (a) the amino acid sequence of SEQ ID NO:102; [1770] (b) a fragment of the amino acid sequence of SEQ ID NO:102, the fragment comprising eight contiguous amino acids of SEQ ID NO:102; and [1771] (c) the amino acid sequence encoded by the cDNA insert of clone cw1475.sub.--2 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:102. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:102, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:102.

[1772] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1773] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103; [1774] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954; [1775] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd428.sub.--4 deposited under accession number ATCC 207088; [1776] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd428.sub.--4 deposited under accession number ATCC 207088; [1777] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd428.sub.--4 deposited under accession number ATCC 207088; [1778] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dd428.sub.--4 deposited under accession number ATCC 207088; [1779] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:104; [1780] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:104; [1781] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1782] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1783] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1784] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:103.

[1785] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954; the nucleotide sequence of the full-length protein coding sequence of clone dd428.sub.--4 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dd428.sub.--4 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dd428.sub.--4 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 102 to amino acid 111 of SEQ ID NO:104.

[1786] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:103.

[1787] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1788] (a) a process comprising the steps of: [1789] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1790] (aa) SEQ ID NO:103, but excluding the poly(A) tail at the 3' end of SEQ ID NO:103; and [1791] (ab) the nucleotide sequence of the cDNA insert of clone dd428.sub.--4 deposited under accession number ATCC 207088; [1792] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1793] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1794] and [1795] (b) a process comprising the steps of: [1796] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1797] (ba) SEQ ID NO:103, but excluding the poly(A) tail at the 3' end of SEQ ID NO:103; and [1798] (bb) the nucleotide sequence of the cDNA insert of clone dd428.sub.--4 deposited under accession number ATCC 207088; [1799] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1800] (iii) amplifying human DNA sequences; and [1801] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:103 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:103, but excluding the poly(A) tail at the 3' end of SEQ ID NO:103. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:103 from nucleotide 310 to nucleotide 954.

[1802] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1803] (a) the amino acid sequence of SEQ ID NO:104; [1804] (b) a fragment of the amino acid sequence of SEQ ID NO:104, the fragment comprising eight contiguous amino acids of SEQ ID NO:104; and [1805] (c) the amino acid sequence encoded by the cDNA insert of clone dd428.sub.--4 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:104. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 102 to amino acid 111 of SEQ ID NO:104.

[1806] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1807] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105; [1808] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895; [1809] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dh1073.sub.--12 deposited under accession number ATCC 207088; [1810] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dh1073.sub.--12 deposited under accession number ATCC 207088; [1811] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dh1073.sub.--12 deposited under accession number ATCC 207088; [1812] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dh1073.sub.--12 deposited under accession number ATCC 207088; [1813] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:106; [1814] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising eight contiguous amino adds of SEQ ID NO:106; [1815] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1816] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1817] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1818] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:105.

[1819] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895; the nucleotide sequence of the full-length protein coding sequence of clone dh1073.sub.--12 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dh1073.sub.--12 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dh1073.sub.--12 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:106.

[1820] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:105.

[1821] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1822] (a) a process comprising the steps of: [1823] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1824] (aa) SEQ ID NO:105, but excluding the poly(A) tail at the 3' end of SEQ ID NO:105; and [1825] (ab) the nucleotide sequence of the cDNA insert of clone dh1073.sub.--12 deposited under accession number ATCC 207088; [1826] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1827] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1828] and [1829] (b) a process comprising the steps of: [1830] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1831] (ba) SEQ ID NO:105, but excluding the poly(A) tail at the 3' end of SEQ ID NO:105; and [1832] (bb) the nucleotide sequence of the cDNA insert of clone dh1073.sub.--12 deposited under accession number ATCC 207088; [1833] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1834] (iii) amplifying human DNA sequences; and [1835] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:105 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:105, but excluding the poly(A) tail at the 3' end of SEQ ID NO:105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:105 from nucleotide 1698 to nucleotide 1895.

[1836] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1837] (a) the amino acid sequence of SEQ ID NO:106; [1838] (b) a fragment of the amino acid sequence of SEQ ID NO:106, the fragment comprising eight contiguous amino acids of SEQ ID NO:106; and [1839] (c) the amino acid sequence encoded by the cDNA insert of clone dh1073.sub.--12 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:106. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 28 to amino acid 37 of SEQ ID NO:106.

[1840] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1841] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:107; [1842] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791; [1843] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dw78.sub.--1 deposited under accession number ATCC 207088; [1844] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dw78.sub.--1 deposited under accession number ATCC 207088; [1845] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dw78.sub.--1 deposited under accession number ATCC 207088; [1846] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dw78.sub.--1 deposited under accession number ATCC 207088; [1847] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:108; [1848] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:108; [1849] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1850] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1851] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1852] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:107.

[1853] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791; the nucleotide sequence of the full-length protein coding sequence of clone dw78.sub.--1 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone dw78.sub.--1 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dw78.sub.--1 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:108, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:108.

[1854] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:107.

[1855] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1856] (a) a process comprising the steps of: [1857] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1858] (aa) SEQ ID NO:107, but excluding the poly(A) tail at the 3' end of SEQ ID NO:107; and [1859] (ab) the nucleotide sequence of the cDNA insert of clone dw78.sub.--1 deposited under accession number ATCC 207088; [1860] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1861] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1862] and [1863] (b) a process comprising the steps of: [1864] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1865] (ba) SEQ ID NO:107, but excluding the poly(A) tail at the 3' end of SEQ ID NO:107; and [1866] (bb) the nucleotide sequence of the cDNA insert of clone dw78.sub.--1 deposited under accession number ATCC 207088; [1867] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1868] (iii) amplifying human DNA sequences; and [1869] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:107 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:107, but excluding the poly(A) tail at the 3' end of SEQ ID NO:107. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:107 from nucleotide 423 to nucleotide 791.

[1870] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1871] (a) the amino acid sequence of SEQ ID NO:108; [1872] (b) a fragment of the amino acid sequence of SEQ ID NO:108, the fragment comprising eight contiguous amino acids of SEQ ID NO:108; and [1873] (c) the amino acid sequence encoded by the cDNA insert of clone dw78.sub.--1 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:108. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:108, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:108 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:108.

[1874] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1875] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:109; [1876] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944; [1877] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fh116.sub.--11 deposited under accession number ATCC 207088; [1878] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fh116.sub.--11 deposited under accession number ATCC 207088; [1879] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fh116.sub.--11 deposited under accession number ATCC 207088; [1880] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fh116.sub.--11 deposited under accession number ATCC 207088; [1881] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:110; [1882] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:110; [1883] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1884] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1885] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1886] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:109.

[1887] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944; the nucleotide sequence of the full-length protein coding sequence of clone fh116.sub.--11 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone fh116.sub.--11 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fh116.sub.--11 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:110, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising the amino acid sequence from amino acid 136 to amino acid 145 of SEQ ID NO:110.

[1888] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:109.

[1889] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1890] (a) a process comprising the steps of: [1891] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1892] (aa) SEQ ID NO:109, but excluding the poly(A) tail at the 3' end of SEQ ID NO:109; and [1893] (ab) the nucleotide sequence of the cDNA insert of clone fh116.sub.--11 deposited under accession number ATCC 207088; [1894] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1895] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1896] and [1897] (b) a process comprising the steps of: [1898] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1899] (ba) SEQ ID NO:109, but excluding the poly(A) tail at the 3' end of SEQ ID NO:109; and [1900] (bb) the nucleotide sequence of the cDNA insert of clone fh116.sub.--11 deposited under accession number ATCC 207088; [1901] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1902] (iii) amplifying human DNA sequences; and [1903] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:109 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:109, but excluding the poly(A) tail at the 3' end of SEQ ID NO:109. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:109 from nucleotide 96 to nucleotide 944.

[1904] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1905] (a) the amino acid sequence of SEQ ID NO:110; [1906] (b) a fragment of the amino acid sequence of SEQ ID NO:110, the fragment comprising eight contiguous amino acids of SEQ ID NO:110; and [1907] (c) the amino acid sequence encoded by the cDNA insert of clone fh116.sub.--11 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:110. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:110, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:110 having biological activity, the fragment comprising the amino acid sequence from amino acid 136 to amino acid 145 of SEQ ID NO:110.

[1908] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1909] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111; [1910] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610; [1911] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fy356.sub.--14 deposited under accession number ATCC 207088; [1912] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fy356.sub.--14 deposited under accession number ATCC 207088; [1913] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fy356.sub.--14 deposited under accession number ATCC 207088; [1914] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fy356.sub.--14 deposited under accession number ATCC 207088; [1915] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:112; [1916] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:112; [1917] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1918] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1919] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1920] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:111.

[1921] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610; the nucleotide sequence of the full-length protein coding sequence of clone fy356.sub.--14 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone fy35614 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fy356.sub.--14 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:112.

[1922] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:111.

[1923] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1924] (a) a process comprising the steps of: [1925] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1926] (aa) SEQ ID NO:111, but excluding the poly(A) tail at the 3' end of SEQ ID NO:111; and [1927] (ab) the nucleotide sequence of the cDNA insert of clone fy356.sub.--14 deposited under accession number ATCC 207088; [1928] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1929] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1930] and [1931] (b) a process comprising the steps of: [1932] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1933] (ba) SEQ ID NO:111, but excluding the poly(A) tail at the 3' end of SEQ ID NO:111; and [1934] (bb) the nucleotide sequence of the cDNA insert of clone fy356.sub.--14 deposited under accession number ATCC 207088; [1935] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1936] (iii) amplifying human DNA sequences; and [1937] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:111 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:111 but excluding the poly(A) tail at the 3' end of SEQ ID NO:111. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:111 from nucleotide 150 to nucleotide 1610.

[1938] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1939] (a) the amino acid sequence of SEQ ID NO:112; [1940] (b) a fragment of the amino acid sequence of SEQ ID NO:112, the fragment comprising eight contiguous amino acids of SEQ ID NO:112; and [1941] (c) the amino acid sequence encoded by the cDNA insert of clone fy356.sub.--14 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:112. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:112.

[1942] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1943] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113; [1944] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669; [1945] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669; [1946] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone iw66.sub.--1 deposited under accession number ATCC 207088; [1947] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone iw66.sub.--1 deposited under accession number ATCC 207088; [1948] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone iw66.sub.--1 deposited under accession number ATCC 207088; [1949] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone iw66.sub.--1 deposited under accession number ATCC 207088; [1950] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:114; [1951] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:114; [1952] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [1953] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [1954] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [1955] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:113.

[1956] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669; the nucleotide sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669; the nucleotide sequence of the full-length protein coding sequence of clone iw66.sub.--1 deposited under accession number ATCC 207088; or the nucleotide sequence of a mature protein coding sequence of clone iw66.sub.--1 deposited under accession number ATCC 207088. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone iw66.sub.--1 deposited under accession number ATCC 207088. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:114, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:114.

[1957] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:113.

[1958] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1959] (a) a process comprising the steps of: [1960] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1961] (aa) SEQ ID NO:113, but excluding the poly(A) tail at the 3' end of SEQ ID NO:113; and [1962] (ab) the nucleotide sequence of the cDNA insert of clone iw66.sub.--1 deposited under accession number ATCC 207088; [1963] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1964] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1965] and [1966] (b) a process comprising the steps of: [1967] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1968] (ba) SEQ ID NO:113, but excluding the poly(A) tail at the 3' end of SEQ ID NO:113; and [1969] (bb) the nucleotide sequence of the cDNA insert of clone iw66.sub.--1 deposited under accession number ATCC 207088; [1970] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [1971] (iii) amplifying human DNA sequences; and [1972] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:113 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:113, but excluding the poly(A) tail at the 3' end of SEQ ID NO:113. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:113 from nucleotide 49 to nucleotide 669. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:113 from nucleotide 112 to nucleotide 669.

[1973] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [1974] (a) the amino acid sequence of SEQ ID NO:114; [1975] (b) a fragment of the amino acid sequence of SEQ ID NO:114, the fragment comprising eight contiguous amino acids of SEQ ID NO:114; and [1976] (c) the amino acid sequence encoded by the cDNA insert of clone iw66.sub.--1 deposited under accession number ATCC 207088; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:114. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:114, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:114 having biological activity, the fragment comprising the amino acid sequence from amino acid 98 to amino acid 107 of SEQ ID NO:114.

[1977] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [1978] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:115; [1979] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416; [1980] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone kh13.sub.--4 deposited under accession number ATCC 207089; [1981] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone kh13.sub.--4 deposited under accession number ATCC 207089; [1982] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone kh13.sub.--4 deposited under accession number ATCC 207089; [1983] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone kh13.sub.--4 deposited under accession number ATCC 207089; [1984] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:116; [1985] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:116; [1986] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [1987] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [1988] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [1989] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:115.

[1990] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416; the nucleotide sequence of the full-length protein coding sequence of clone kh13.sub.--4 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone kh13.sub.--4 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone kh13.sub.--4 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:116, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:116.

[1991] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:115.

[1992] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [1993] (a) a process comprising the steps of: [1994] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [1995] (aa) SEQ ID NO:115, but excluding the poly(A) tail at the 3' end of SEQ ID NO:115; and [1996] (ab) the nucleotide sequence of the cDNA insert of clone kh13.sub.--4 deposited under accession number ATCC 207089; [1997] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [1998] (iii) isolating the DNA polynucleotides detected with the probe(s);

[1999] and [2000] (b) a process comprising the steps of: [2001] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2002] (ba) SEQ ID NO:115, but excluding the poly(A) tail at the 3' end of SEQ ID NO:115; and [2003] (bb) the nucleotide sequence of the cDNA insert of clone kh13.sub.--4 deposited under accession number ATCC 207089; [2004] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2005] (iii) amplifying human DNA sequences; and [2006] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:115, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:115 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:115, but excluding the poly(A) tail at the 3' end of SEQ ID NO:115. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:115 from nucleotide 165 to nucleotide 416.

[2007] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2008] (a) the amino acid sequence of SEQ ID NO:116; [2009] (b) a fragment of the amino acid sequence of SEQ ID NO:116, the fragment comprising eight contiguous amino acids of SEQ ID NO:116; and [2010] (c) the amino acid sequence encoded by the cDNA insert of clone kh13.sub.--4 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:116. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:116, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:116 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:116.

[2011] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2012] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:117; [2013] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602; [2014] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ko258.sub.--4 deposited under accession number ATCC 207089; [2015] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ko258.sub.--4 deposited under accession number ATCC 207089; [2016] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ko258.sub.--4 deposited under accession number ATCC 207089; [2017] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ko258.sub.--4 deposited under accession number ATCC 207089; [2018] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:118; [2019] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:118; [2020] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2021] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2022] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2023] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:117.

[2024] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602; the nucleotide sequence of the full-length protein coding sequence of clone ko258.sub.--4 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone ko258.sub.--4 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ko258.sub.--4 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:118, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:118.

[2025] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:117.

[2026] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2027] (a) a process comprising the steps of: [2028] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2029] (aa) SEQ ID NO:117, but excluding the poly(A) tail at the 3' end of SEQ ID NO:117; and [2030] (ab) the nucleotide sequence of the cDNA insert of clone ko258.sub.--4 deposited under accession number ATCC 207089; [2031] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and (iii) isolating the DNA polynucleotides detected with the probe(s);

[2032] and [2033] (b) a process comprising the steps of: [2034] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2035] (ba) SEQ ID NO:117, but excluding the poly(A) tail at the 3' end of SEQ ID NO:117; and [2036] (bb) the nucleotide sequence of the cDNA insert of clone ko258.sub.--4 deposited under accession number ATCC 207089; [2037] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2038] (iii) amplifying human DNA sequences; and [2039] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:117, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:117 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:117, but excluding the poly(A) tail at the 3' end of SEQ ID NO:117. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:117 from nucleotide 204 to nucleotide 602.

[2040] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2041] (a) the amino acid sequence of SEQ ID NO:118; [2042] (b) a fragment of the amino acid sequence of SEQ ID NO:118, the fragment comprising eight contiguous amino acids of SEQ ID NO:118; and [2043] (c) the amino acid sequence encoded by the cDNA insert of clone ko258.sub.--4 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:118. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:118, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:118 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:118.

[2044] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2045] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119; [2046] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739; [2047] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone kv10.sub.--8 deposited under accession number ATCC 207089; [2048] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone kv10.sub.--8 deposited under accession number ATCC 207089; [2049] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone kv10.sub.--8 deposited under accession number ATCC 207089; [2050] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone kv10.sub.--8 deposited under accession number ATCC 207089; [2051] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:120; [2052] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:120; [2053] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2054] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2055] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2056] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:119.

[2057] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739; the nucleotide sequence of the full-length protein coding sequence of clone kv10.sub.--8 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone kv10.sub.--8 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone kv108 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:120.

[2058] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1119.

[2059] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2060] (a) a process comprising the steps of: [2061] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2062] (aa) SEQ ID NO:119, but excluding the poly(A) tail at the 3' end of SEQ ID NO:119; and [2063] (ab) the nucleotide sequence of the cDNA insert of clone kv10.sub.--8 deposited under accession number ATCC 207089; [2064] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2065] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2066] and [2067] (b) a process comprising the steps of: [2068] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2069] (ba) SEQ ID NO:119, but excluding the poly(A) tail at the 3' end of SEQ ID NO:119; and [2070] (bb) the nucleotide sequence of the cDNA insert of clone kv10.sub.--8 deposited under accession number ATCC 207089; [2071] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2072] (iii) amplifying human DNA sequences; and [2073] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:119 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:119, but excluding the poly(A) tail at the 3' end of SEQ ID NO:119. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:119 from nucleotide 434 to nucleotide 739.

[2074] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2075] (a) the amino acid sequence of SEQ ID NO:120; [2076] (b) a fragment of the amino acid sequence of SEQ ID NO:120, the fragment comprising eight contiguous amino acids of SEQ ID NO:120; and [2077] (c) the amino acid sequence encoded by the cDNA insert of clone kv10.sub.--8 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:120. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:120.

[2078] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2079] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121; [2080] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310; [2081] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone LL89.sub.--3 deposited under accession number ATCC 207089; [2082] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone LL89.sub.--3 deposited under accession number ATCC 207089; [2083] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone LL89.sub.--3 deposited under accession number ATCC 207089; [2084] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone LL89.sub.--3 deposited under accession number ATCC 207089; [2085] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:122; [2086] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:122; [2087] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2088] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2089] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2090] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:121.

[2091] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310; the nucleotide sequence of the full-length protein coding sequence of clone LL89.sub.--3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone LL89.sub.--3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone LL89.sub.--3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty contiguous amino acids of SEQ ID NO:122, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:122.

[2092] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:121.

[2093] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2094] (a) a process comprising the steps of: [2095] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2096] (aa) SEQ ID NO:121, but excluding the poly(A) tail at the 3' end of SEQ ID NO:121; and [2097] (ab) the nucleotide sequence of the cDNA insert of clone LL89.sub.--3 deposited under accession number ATCC 207089; [2098] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2099] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2100] and [2101] (b) a process comprising the steps of: [2102] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2103] (ba) SEQ ID NO:121, but excluding the poly(A) tail at the 3' end of SEQ ID NO:121; and [2104] (bb) the nucleotide sequence of the cDNA insert of clone LL89.sub.--3 deposited under accession number ATCC 207089; [2105] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2106] (iii) amplifying human DNA sequences; and [2107] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:121, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:121 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:121, but excluding the poly(A) tail at the 3' end of SEQ ID NO:121. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:121 from nucleotide 149 to nucleotide 310.

[2108] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2109] (a) the amino acid sequence of SEQ ID NO:122; [2110] (b) a fragment of the amino acid sequence of SEQ ID NO:122, the fragment comprising eight contiguous amino acids of SEQ ID NO:122; and [2111] (c) the amino acid sequence encoded by the cDNA insert of clone LL89.sub.--3 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:122. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:122, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 22 to amino acid 31 of SEQ ID NO:122.

[2112] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2113] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123; [2114] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288; [2115] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mc300.sub.--1 deposited under accession number ATCC 207089; [2116] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mc300.sub.--1 deposited under accession number ATCC 207089; [2117] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mc300.sub.--1 deposited under accession number ATCC 207089; [2118] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mc300.sub.--1 deposited under accession number ATCC 207089; [2119] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:124; [2120] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:124; [2121] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2122] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2123] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2124] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:123.

[2125] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288; the nucleotide sequence of the full-length protein coding sequence of clone mc300.sub.--1 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mc300.sub.--1 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mc300.sub.--1 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:124.

[2126] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:123.

[2127] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2128] (a) a process comprising the steps of: [2129] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2130] (aa) SEQ ID NO:123, but excluding the poly(A) tail at the 3' end of SEQ ID NO:123; and [2131] (ab) the nucleotide sequence of the cDNA insert of clone mc300.sub.--1 deposited under accession number ATCC 207089; [2132] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2133] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2134] and [2135] (b) a process comprising the steps of: [2136] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2137] (ba) SEQ ID NO:123, but excluding the poly(A) tail at the 3' end of SEQ ID NO:123; and [2138] (bb) the nucleotide sequence of the cDNA insert of clone mc300.sub.--1 deposited under accession number ATCC 207089; [2139] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2140] (iii) amplifying human DNA sequences; and [2141] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:123 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:123, but excluding the poly(A) tail at the 3' end of SEQ ID NO:123. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:123 from nucleotide 22 to nucleotide 288.

[2142] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2143] (a) the amino acid sequence of SEQ ID NO:124; [2144] (b) a fragment of the amino acid sequence of SEQ ID NO:124, the fragment comprising eight contiguous amino acids of SEQ ID NO:124; and [2145] (c) the amino acid sequence encoded by the cDNA insert of clone mc300.sub.--1 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:124. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:124.

[2146] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2147] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125;

[2148] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449; [2149] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ml227.sub.--1 deposited under accession number ATCC 207089; [2150] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ml227.sub.--1 deposited under accession number ATCC 207089; [2151] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ml227.sub.--1 deposited under accession number ATCC 207089; [2152] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ml227.sub.--1 deposited under accession number ATCC 207089; [2153] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:126; [2154] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:126; [2155] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2156] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2157] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2158] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-h) and that has a length that is at least 25% of the length of SEQ ID NO:125.

[2159] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449; the nucleotide sequence of the full-length protein coding sequence of clone ml227.sub.--1 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone ml227.sub.--1 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ml227.sub.--1 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:126, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 370 to amino acid 379 of SEQ ID NO:126.

[2160] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:125.

[2161] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2162] (a) a process comprising the steps of: [2163] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2164] (aa) SEQ ID NO:125, but excluding the poly(A) tail at the 3' end of SEQ ID NO:125; and [2165] (ab) the nucleotide sequence of the cDNA insert of clone ml227.sub.--1 deposited under accession number ATCC 207089; [2166] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2167] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2168] and [2169] (b) a process comprising the steps of: [2170] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2171] (ba) SEQ ID NO:125, but excluding the poly(A) tail at the 3' end of SEQ ID NO:125; and [2172] (bb) the nucleotide sequence of the cDNA insert of clone ml227.sub.--1 deposited under accession number ATCC 207089; [2173] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2174] (iii) amplifying human DNA sequences; and [2175] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:125 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:125, but excluding the poly(A) tail at the 3' end of SEQ ID NO:125. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:125 from nucleotide 200 to nucleotide 2449.

[2176] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2177] (a) the amino acid sequence of SEQ ID NO:126; [2178] (b) a fragment of the amino acid sequence of SEQ ID NO:126, the fragment comprising eight contiguous amino acids of SEQ ID NO:126; and [2179] (c) the amino acid sequence encoded by the cDNA insert of clone ml227_deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:126. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:126, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 370 to amino acid 379 of SEQ ID NO:126.

[2180] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2181] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127; [2182] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980; [2183] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mm367.sub.--6 deposited under accession number ATCC 207089; [2184] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mm367.sub.--6 deposited under accession number ATCC 207089; [2185] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mm367.sub.--6 deposited under accession number ATCC 207089; [2186] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mm367.sub.--6 deposited under accession number ATCC 207089; [2187] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:128; [2188] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:128; [2189] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2190] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2191] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2192] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:127.

[2193] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980; the nucleotide sequence of the full-length protein coding sequence of clone mm367.sub.--6 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mm367.sub.--6 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mm367.sub.--6 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 311 to amino acid 320 of SEQ ID NO:128.

[2194] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:127.

[2195] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2196] (a) a process comprising the steps of: [2197] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2198] (aa) SEQ ID NO:127, but excluding the poly(A) tail at the 3' end of SEQ ID NO:127; and [2199] (ab) the nucleotide sequence of the cDNA insert of clone mm367.sub.--6 deposited under accession number ATCC 207089; [2200] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2201] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2202] and [2203] (b) a process comprising the steps of: [2204] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2205] (ba) SEQ ID NO:127, but excluding the poly(A) tail at the 3' end of SEQ ID NO:127; and [2206] (bb) the nucleotide sequence of the cDNA insert of clone mm367.sub.--6 deposited under accession number ATCC 207089; [2207] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2208] (iii) amplifying human DNA sequences; and [2209] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:127 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:127, but excluding the poly(A) tail at the 3' end of SEQ ID NO:127. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:127 from nucleotide 82 to nucleotide 1980.

[2210] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2211] (a) the amino acid sequence of SEQ ID NO:128; [2212] (b) a fragment of the amino acid sequence of SEQ ID NO:128, the fragment comprising eight contiguous amino acids of SEQ ID NO:128; and [2213] (c) the amino acid sequence encoded by the cDNA insert of clone mm367.sub.--6 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:128. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 311 to amino acid 320 of SEQ ID NO:128.

[2214] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2215] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129; [2216] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856; [2217] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone mt124.sub.--3 deposited under accession number ATCC 207089; [2218] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone mt124.sub.--3 deposited under accession number ATCC 207089; [2219] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone mt124.sub.--3 deposited under accession number ATCC 207089; [2220] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone mt124.sub.--3 deposited under accession number ATCC 207089; [2221] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:130; [2222] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:130; [2223] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2224] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2225] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2226] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:129.

[2227] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856; the nucleotide sequence of the full-length protein coding sequence of clone mt124.sub.--3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone mt124.sub.--3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mt124.sub.--3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:130, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:130.

[2228] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:129.

[2229] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2230] (a) a process comprising the steps of: [2231] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2232] (aa) SEQ ID NO:129, but excluding the poly(A) tail at the 3' end of SEQ ID NO:129; and [2233] (ab) the nucleotide sequence of the cDNA insert of clone mt124.sub.--3 deposited under accession number ATCC 207089; [2234] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2235] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2236] and [2237] (b) a process comprising the steps of: [2238] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2239] (ba) SEQ ID NO:129, but excluding the poly(A) tail at the 3' end of SEQ ID NO:129; and [2240] (bb) the nucleotide sequence of the cDNA insert of clone mt124.sub.--3 deposited under accession number ATCC 207089; [2241] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2242] (iii) amplifying human DNA sequences; and [2243] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:129 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:129, but excluding the poly(A) tail at the 3' end of SEQ ID NO:129. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:129 from nucleotide 125 to nucleotide 856.

[2244] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2245] (a) the amino acid sequence of SEQ ID NO:130; [2246] (b) a fragment of the amino acid sequence of SEQ ID NO:130, the fragment comprising eight contiguous amino acids of SEQ ID NO:130; and [2247] (c) the amino acid sequence encoded by the cDNA insert of clone mt124.sub.--3 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:130. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:130, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:130.

[2248] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2249] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131; [2250] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940; [2251] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940; [2252] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nf56.sub.--3 deposited under accession number ATCC 207089; [2253] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nf56.sub.--3 deposited under accession number ATCC 207089; [2254] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nf56.sub.--3 deposited under accession number ATCC 207089; [2255] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nf56.sub.--3 deposited under accession number ATCC 207089; [2256] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:132; [2257] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:132; [2258] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2259] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2260] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2261] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:131.

[2262] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940; the nucleotide sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940; the nucleotide sequence of the full-length protein coding sequence of clone nf56.sub.--3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone nf56.sub.--3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nf56.sub.--3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 342 to amino acid 351 of SEQ ID NO:132.

[2263] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:131.

[2264] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2265] (a) a process comprising the steps of: [2266] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2267] (aa) SEQ ID NO:131, but excluding the poly(A) tail at the 3' end of SEQ ID NO:131; and [2268] (ab) the nucleotide sequence of the cDNA insert of clone nf56.sub.--3 deposited under accession number ATCC 207089; [2269] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2270] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2271] and [2272] (b) a process comprising the steps of: [2273] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2274] (ba) SEQ ID NO:131, but excluding the poly(A) tail at the 3' end of SEQ ID NO:131; and [2275] (bb) the nucleotide sequence of the cDNA insert of clone nf56.sub.--3 deposited under accession number ATCC 207089; [2276] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2277] (iii) amplifying human DNA sequences; and [2278] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:131 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:131, but excluding the poly(A) tail at the 3' end of SEQ ID NO:131. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:131 from nucleotide 856 to nucleotide 2940. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:131 from nucleotide 901 to nucleotide 2940.

[2279] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2280] (a) the amino acid sequence of SEQ ID NO:132; [2281] (b) a fragment of the amino acid sequence of SEQ ID NO:132, the fragment comprising eight contiguous amino acids of SEQ ID NO:132; and [2282] (c) the amino acid sequence encoded by the cDNA insert of clone nf56.sub.--3 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:132. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 342 to amino acid 351 of SEQ ID NO:132.

[2283] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2284] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133; [2285] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448; [2286] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448; [2287] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qy442.sub.--2 deposited under accession number ATCC 207089; [2288] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qy442.sub.--2 deposited under accession number ATCC 207089; [2289] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qy442.sub.--2 deposited under accession number ATCC 207089; [2290] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qy442.sub.--2 deposited under accession number ATCC 207089; [2291] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:134; [2292] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:134; [2293] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2294] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2295] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2296] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:133.

[2297] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448; the nucleotide sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448; the nucleotide sequence of the full-length protein coding sequence of clone qy442.sub.--2 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone qy442.sub.--2 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy442_deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:134.

[2298] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:133.

[2299] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2300] (a) a process comprising the steps of: [2301] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2302] (aa) SEQ ID NO:133, but excluding the poly(A) tail at the 3' end of SEQ ID NO:133; and [2303] (ab) the nucleotide sequence of the cDNA insert of clone qy442.sub.--2 deposited under accession number ATCC 207089; [2304] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2305] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2306] and [2307] (b) a process comprising the steps of: [2308] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2309] (ba) SEQ ID NO:133, but excluding the poly(A) tail at the 3' end of SEQ ID NO:133; and [2310] (bb) the nucleotide sequence of the cDNA insert of clone qy442.sub.--2 deposited under accession number ATCC 207089; [2311] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4>(SSC at 50 degrees C.; [2312] (iii) amplifying human DNA sequences; and [2313] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:133 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:133, but excluding the poly(A) tail at the 3' end of SEQ ID NO:133. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:133 from nucleotide 122 to nucleotide 448. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:133 from nucleotide 167 to nucleotide 448.

[2314] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2315] (a) the amino acid sequence of SEQ ID NO:134; [2316] (b) a fragment of the amino acid sequence of SEQ ID NO:134, the fragment comprising eight contiguous amino acids of SEQ ID NO:134; and [2317] (c) the amino acid sequence encoded by the cDNA insert of clone qy442.sub.--2 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:134. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:134.

[2318] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2319] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135; [2320] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777; [2321] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777; [2322] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rj214.sub.--14 deposited under accession number ATCC 207089; [2323] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rj214.sub.--14 deposited under accession number ATCC 207089; [2324] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rj214.sub.--14 deposited under accession number ATCC 207089; [2325] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rj214.sub.--14 deposited under accession number ATCC 207089; [2326] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:136; [2327] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:136; [2328] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2329] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2330] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2331] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:135.

[2332] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777; the nucleotide sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777; the nucleotide sequence of the full-length protein coding sequence of clone rj214.sub.--14 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone rj214.sub.--14 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rj214.sub.--14 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:136, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:136.

[2333] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:135.

[2334] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2335] (a) a process comprising the steps of: [2336] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2337] (aa) SEQ ID NO:135, but excluding the poly(A) tail at the 3' end of SEQ ID NO:135; and [2338] (ab) the nucleotide sequence of the cDNA insert of clone rj214.sub.--14 deposited under accession number ATCC 207089; [2339] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2340] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2341] and [2342] (b) a process comprising the steps of: [2343] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2344] (ba) SEQ ID NO:135, but excluding the poly(A) tail at the 3' end of SEQ ID NO:135; and [2345] (bb) the nucleotide sequence of the cDNA insert of clone rj214.sub.--14 deposited under accession number ATCC 207089; [2346] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2347] (iii) amplifying human DNA sequences; and [2348] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:135 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:135, but excluding the poly(A) tail at the 3' end of SEQ ID NO:135. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:135 from nucleotide 28 to nucleotide 777. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:135 from nucleotide 73 to nucleotide 777.

[2349] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2350] (a) the amino acid sequence of SEQ ID NO:136; [2351] (b) a fragment of the amino acid sequence of SEQ ID NO:136, the fragment comprising eight contiguous amino acids of SEQ ID NO:136; and [2352] (c) the amino acid sequence encoded by the cDNA insert of clone rj214.sub.--14 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:136. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:136, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:136 having biological activity, the fragment comprising the amino acid sequence from amino acid 120 to amino acid 129 of SEQ ID NO:136.

[2353] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2354] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137; [2355] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745; [2356] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745; [2357] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone rk80.sub.--3 deposited under accession number ATCC 207089; [2358] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone rk80.sub.--3 deposited under accession number ATCC 207089; [2359] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rk80.sub.--3 deposited under accession number ATCC 207089; [2360] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone rk80.sub.--3 deposited under accession number ATCC 207089; [2361] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:138; [2362] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:138; [2363] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2364] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2365] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2366] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:137.

[2367] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745; the nucleotide sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745; the nucleotide sequence of the full-length protein coding sequence of clone rk80.sub.--3 deposited under accession number ATCC 207089; or the nucleotide sequence of a mature protein coding sequence of clone rk80.sub.--3 deposited under accession number ATCC 207089. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rk80.sub.--3 deposited under accession number ATCC 207089. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:138, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:138.

[2368] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:137.

[2369] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2370] (a) a process comprising the steps of: [2371] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2372] (aa) SEQ ID NO:137, but excluding the poly(A) tail at the 3' end of SEQ ID NO:137; and [2373] (ab) the nucleotide sequence of the cDNA insert of clone rk80.sub.--3 deposited under accession number ATCC 207089; [2374] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2375] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2376] and [2377] (b) a process comprising the steps of: [2378] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2379] (ba) SEQ ID NO:137, but excluding the poly(A) tail at the 3' end of SEQ ID NO:137; and [2380] (bb) the nucleotide sequence of the cDNA insert of clone rk80.sub.--3 deposited under accession number ATCC 207089; [2381] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2382] (iii) amplifying human DNA sequences; and [2383] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:137 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:137, but excluding the poly(A) tail at the 3' end of SEQ ID NO:137. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:137 from nucleotide 179 to nucleotide 745. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:137 from nucleotide 233 to nucleotide 745.

[2384] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2385] (a) the amino acid sequence of SEQ ID NO:138; [2386] (b) a fragment of the amino acid sequence of SEQ ID NO:138, the fragment comprising eight contiguous amino acids of SEQ ID NO:138; and [2387] (c) the amino acid sequence encoded by the cDNA insert of clone rk80.sub.--3 deposited under accession number ATCC 207089; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:138. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:138, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:138 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:138.

[2388] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2389] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:139; [2390] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274; [2391] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone au36.sub.--42 deposited under accession number ATCC 207187; [2392] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone au36.sub.--42 deposited under accession number ATCC 207187; [2393] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone au36.sub.--42 deposited under accession number ATCC 207187; [2394] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone au36.sub.--42 deposited under accession number ATCC 207187; [2395] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:140; [2396] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:140; [2397] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2398] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2399] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2400] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:139.

[2401] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274; the nucleotide sequence of the full-length protein coding sequence of clone au36.sub.--42 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone au36.sub.--42 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone au36.sub.--42 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:140, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:140.

[2402] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:139.

[2403] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2404] (a) a process comprising the steps of: [2405] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2406] (aa) SEQ ID NO:139, but excluding the poly(A) tail at the 3' end of SEQ ID NO:139; and [2407] (ab) the nucleotide sequence of the cDNA insert of clone au36.sub.--42 deposited under accession number ATCC 207187; [2408] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2409] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2410] and [2411] (b) a process comprising the steps of: [2412] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2413] (ba) SEQ ID NO:139, but excluding the poly(A) tail at the 3' end of SEQ ID NO:139; and [2414] (bb) the nucleotide sequence of the cDNA insert of clone au36.sub.--42 deposited under accession number ATCC 207187; [2415] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2416] (iii) amplifying human DNA sequences; and [2417] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:139 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:139, but excluding the poly(A) tail at the 3' end of SEQ ID NO:139. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:139 from nucleotide 1017 to nucleotide 1274.

[2418] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2419] (a) the amino acid sequence of SEQ ID NO:140; [2420] (b) a fragment of the amino acid sequence of SEQ ID NO:140, the fragment comprising eight contiguous amino acids of SEQ ID NO:140; and [2421] (c) the amino acid sequence encoded by the cDNA insert of clone au36.sub.--42 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:140. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:140, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:140 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:140.

[2422] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2423] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:141; [2424] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774; [2425] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bo549.sub.--13 deposited under accession number ATCC 207187; [2426] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bo549.sub.--13 deposited under accession number ATCC 207187; [2427] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bo549.sub.--13 deposited under accession number ATCC 207187; [2428] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bo549.sub.--13 deposited under accession number ATCC 207187; [2429] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:142; [2430] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:142; [2431] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2432] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2433] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2434] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a) h) and that has a length that is at least 25% of the length of SEQ ID NO:141.

[2435] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774; the nucleotide sequence of the full-length protein coding sequence of clone bo549.sub.--13 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone bo549.sub.--13 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bo549.sub.--13 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:142, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:142.

[2436] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:141.

[2437] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2438] (a) a process comprising the steps of: [2439] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2440] (aa) SEQ ID NO:141, but excluding the poly(A) tail at the 3' end of SEQ ID NO:141; and [2441] (ab) the nucleotide sequence of the cDNA insert of clone bo549.sub.--13 deposited under accession number ATCC 207187; [2442] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2443] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2444] and [2445] (b) a process comprising the steps of: [2446] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2447] (ba) SEQ ID NO:141, but excluding the poly(A) tail at the 3' end of SEQ ID NO:141; and [2448] (bb) the nucleotide sequence of the cDNA insert of clone bo549.sub.--13 deposited under accession number ATCC 207187; [2449] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2450] (iii) amplifying human DNA sequences; and [2451] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:141 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:141, but excluding the poly(A) tail at the 3' end of SEQ ID NO:141. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:141 from nucleotide 580 to nucleotide 774.

[2452] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2453] (a) the amino acid sequence of SEQ ID NO:142; [2454] (b) a fragment of the amino acid sequence of SEQ ID NO:142, the fragment comprising eight contiguous amino acids of SEQ ID NO:142; and [2455] (c) the amino acid sequence encoded by the cDNA insert of clone bo549.sub.--13 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:142. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:142, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:142 having biological activity, the fragment comprising the amino acid sequence from amino acid 27 to amino acid 36 of SEQ ID NO:142.

[2456] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2457] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143; [2458] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969; [2459] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969; [2460] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone da529.sub.--3 deposited under accession number ATCC 207187; [2461] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone da529.sub.--3 deposited under accession number ATCC 207187; [2462] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone da529.sub.--3 deposited under accession number ATCC 207187; [2463] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone da529.sub.--3 deposited under accession number ATCC 207187; [2464] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:144; [2465] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:144; [2466] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2467] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2468] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2469] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:143.

[2470] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969; the nucleotide sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969; the nucleotide sequence of the full-length protein coding sequence of clone da529.sub.--3 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone da529.sub.--3 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone da529.sub.--3 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:144, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:144.

[2471] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:143.

[2472] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2473] (a) a process comprising the steps of: [2474] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2475] (aa) SEQ ID NO:143, but excluding the poly(A) tail at the 3' end of SEQ ID NO:143; and [2476] (ab) the nucleotide sequence of the cDNA insert of clone da529.sub.--3 deposited under accession number ATCC 207187; [2477] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2478] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2479] and [2480] (b) a process comprising the steps of: [2481] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2482] (ba) SEQ ID NO:143, but excluding the poly(A) tail at the 3' end of SEQ ID NO:143; and [2483] (bb) the nucleotide sequence of the cDNA insert of clone da529.sub.--3 deposited under accession number ATCC 207187; [2484] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2485] (iii) amplifying human DNA sequences; and [2486] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:143 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:143, but excluding the poly(A) tail at the 3' end of SEQ ID NO:143. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:143 from nucleotide 172 to nucleotide 969. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:143 from nucleotide 385 to nucleotide 969.

[2487] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2488] (a) the amino acid sequence of SEQ ID NO:144; [2489] (b) a fragment of the amino acid sequence of SEQ ID NO:144, the fragment comprising eight contiguous amino acids of SEQ ID NO:144; and [2490] (c) the amino acid sequence encoded by the cDNA insert of clone da529.sub.--3 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:144. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:144, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:144 having biological activity, the fragment comprising the amino acid sequence from amino acid 128 to amino acid 137 of SEQ ID NO:144.

[2491] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2492] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145; [2493] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667; [2494] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667; [2495] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dm365.sub.--3 deposited under accession number ATCC 207187; [2496] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dm365.sub.--3 deposited under accession number ATCC 207187; [2497] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dm365.sub.--3 deposited under accession number ATCC 207187; [2498] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone dm365.sub.--3 deposited under accession number ATCC 207187; [2499] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:146; [2500] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:146; [2501] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2502] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2503] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2504] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:145.

[2505] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667; the nucleotide sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667; the nucleotide sequence of the full-length protein coding sequence of clone dm365.sub.--3 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone dm365.sub.--3 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dm365.sub.--3 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:146, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:146.

[2506] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:145.

[2507] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2508] (a) a process comprising the steps of: [2509] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2510] (aa) SEQ ID NO:145, but excluding the poly(A) tail at the 3' end of SEQ ID NO:145; and [2511] (ab) the nucleotide sequence of the cDNA insert of clone dm365.sub.--3 deposited under accession number ATCC 207187; [2512] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2513] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2514] and [2515] (b) a process comprising the steps of: [2516] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2517] (ba) SEQ ID NO:145, but excluding the poly(A) tail at the 3' end of SEQ ID NO:145; and [2518] (bb) the nucleotide sequence of the cDNA insert of clone dm365.sub.--3 deposited under accession number ATCC 207187; [2519] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2520] (iii) amplifying human DNA sequences; and [2521] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:145 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:145, but excluding the poly(A) tail at the 3' end of SEQ ID NO:145. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:145 from nucleotide 329 to nucleotide 667. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:145 from nucleotide 368 to nucleotide 667.

[2522] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2523] (a) the amino acid sequence of SEQ ID NO:146; [2524] (b) a fragment of the amino acid sequence of SEQ ID NO:146, the fragment comprising eight contiguous amino acids of SEQ ID NO:146; and [2525] (c) the amino acid sequence encoded by the cDNA insert of clone dm365.sub.--3 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:146. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:146, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:146 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:146.

[2526] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2527] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:147; [2528] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368; [2529] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fa171.sub.--1 deposited under accession number ATCC 207187; [2530] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fa171.sub.--1 deposited under accession number ATCC 207187; [2531] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fa171.sub.--1 deposited under accession number ATCC 207187; [2532] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fa171.sub.--1 deposited under accession number ATCC 207187; [2533] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:148; [2534] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:148; [2535] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2536] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2537] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2538] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:147.

[2539] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368; the nucleotide sequence of the full-length protein coding sequence of clone fa171.sub.--1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone fa171.sub.--1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fa171.sub.--1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:148, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:148.

[2540] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:147.

[2541] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2542] (a) a process comprising the steps of: [2543] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2544] (aa) SEQ ID NO:147, but excluding the poly(A) tail at the 3' end of SEQ ID NO:147; and [2545] (ab) the nucleotide sequence of the cDNA insert of clone fa171.sub.--1 deposited under accession number ATCC 207187; [2546] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2547] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2548] and [2549] (b) a process comprising the steps of: [2550] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2551] (ba) SEQ ID NO:147, but excluding the poly(A) tail at the 3' end of SEQ ID NO:147; and [2552] (bb) the nucleotide sequence of the cDNA insert of clone fa171.sub.--1 deposited under accession number ATCC 207187; [2553] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2554] (iii) amplifying human DNA sequences; and [2555] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:147 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:147, but excluding the poly(A) tail at the 3' end of SEQ ID NO:147. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:147 from nucleotide 103 to nucleotide 1368.

[2556] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2557] (a) the amino acid sequence of SEQ ID NO:148; [2558] (b) a fragment of the amino acid sequence of SEQ ID NO:148, the fragment comprising eight contiguous amino acids of SEQ ID NO:148; and [2559] (c) the amino acid sequence encoded by the cDNA insert of clone fa1711 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:148. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:148, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:148 having biological activity, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:148.

[2560] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2561] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149; [2562] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407; [2563] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407; [2564] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone lp572.sub.--2 deposited under accession number ATCC 207187; [2565] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone lp572.sub.--2 deposited under accession number ATCC 207187; [2566] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone lp572.sub.--2 deposited under accession number ATCC 207187; [2567] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone lp572.sub.--2 deposited under accession number ATCC 207187; [2568] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:150; [2569] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:150; [2570] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2571] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2572] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2573] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:149.

[2574] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407; the nucleotide sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407; the nucleotide sequence of the full-length protein coding sequence of clone lp572.sub.--2 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone lp572.sub.--2 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone lp572.sub.--2 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:150, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO:150.

[2575] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:149.

[2576] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2577] (a) a process comprising the steps of: [2578] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2579] (aa) SEQ ID NO:149, but excluding the poly(A) tail at the 3' end of SEQ ID NO:149; and [2580] (ab) the nucleotide sequence of the cDNA insert of clone lp572.sub.--2 deposited under accession number ATCC 207187; [2581] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2582] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2583] and [2584] (b) a process comprising the steps of: [2585] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2586] (ba) SEQ ID NO:149, but excluding the poly(A) tail at the 3' end of SEQ ID NO:149; and [2587] (bb) the nucleotide sequence of the cDNA insert of clone lp572.sub.--2 deposited under accession number ATCC 207187; [2588] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2589] (iii) amplifying human DNA sequences; and [2590] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:149 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:149, but excluding the poly(A) tail at the 3' end of SEQ ID NO:149. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:149 from nucleotide 190 to nucleotide 1407. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:149 from nucleotide 463 to nucleotide 1407.

[2591] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2592] (a) the amino acid sequence of SEQ ID NO:150; [2593] (b) a fragment of the amino acid sequence of SEQ ID NO:150, the fragment comprising eight contiguous amino acids of SEQ ID NO:150; and [2594] (c) the amino acid sequence encoded by the cDNA insert of clone lp572.sub.--2 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:150. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:150, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:150 having biological activity, the fragment comprising the amino acid sequence from amino acid 198 to amino acid 207 of SEQ ID NO:150.

[2595] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2596] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151; [2597] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035; [2598] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035; [2599] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pe246.sub.--1 deposited under accession number ATCC 207187; [2600] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pe246.sub.--1 deposited under accession number ATCC 207187; [2601] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pe246.sub.--1 deposited under accession number ATCC 207187; [2602] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pe246.sub.--1 deposited under accession number ATCC 207187; [2603] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:152; [2604] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:152; [2605] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2606] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2607] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2608] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:151.

[2609] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035; the nucleotide sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035; the nucleotide sequence of the full-length protein coding sequence of clone pe246.sub.--1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone pe246.sub.--1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pe246.sub.--1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:152, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:152.

[2610] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:151.

[2611] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2612] (a) a process comprising the steps of: [2613] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2614] (aa) SEQ ID NO:151, but excluding the poly(A) tail at the 3' end of SEQ ID NO:151; and [2615] (ab) the nucleotide sequence of the cDNA insert of clone pe246.sub.--1 deposited under accession number ATCC 207187; [2616] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2617] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2618] and [2619] (b) a process comprising the steps of: [2620] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2621] (ba) SEQ ID NO:151, but excluding the poly(A) tail at the 3' end of SEQ ID NO:151; and [2622] (bb) the nucleotide sequence of the cDNA insert of clone pe246.sub.--1 deposited under accession number ATCC 207187; [2623] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2624] (iii) amplifying human DNA sequences; and [2625] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:151 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:151, but excluding the poly(A) tail at the 3' end of SEQ ID NO:151. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:151 from nucleotide 301 to nucleotide 1035. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:151 from nucleotide 916 to nucleotide 1035.

[2626] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2627] (a) the amino acid sequence of SEQ ID NO:152; [2628] (b) a fragment of the amino acid sequence of SEQ ID NO:152, the fragment comprising eight contiguous amino acids of SEQ ID NO:152; and [2629] (c) the amino acid sequence encoded by the cDNA insert of clone pe246.sub.--1 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:152. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:152, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:152 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:152.

[2630] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2631] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:153; [2632] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281; [2633] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qf122.sub.--3 deposited under accession number ATCC 207187; [2634] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qf122.sub.--3 deposited under accession number ATCC 207187; [2635] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qf122.sub.--3 deposited under accession number ATCC 207187; [2636] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qf122.sub.--3 deposited under accession number ATCC 207187; [2637] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:154; [2638] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:154; [2639] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2640] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2641] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2642] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:153.

[2643] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281; the nucleotide sequence of the full-length protein coding sequence of clone qf122.sub.--3 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone qf122.sub.--3 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qf122.sub.--3 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:154, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:154.

[2644] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:153.

[2645] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2646] (a) a process comprising the steps of: [2647] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2648] (aa) SEQ ID NO:153; and [2649] (ab) the nucleotide sequence of the cDNA insert of clone qf122.sub.--3 deposited under accession number ATCC 207187; [2650] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2651] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2652] and [2653] (b) a process comprising the steps of: [2654] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2655] (ba) SEQ ID NO:153; and [2656] (bb) the nucleotide sequence of the cDNA insert of clone qf122.sub.--3 deposited under accession number ATCC 207187; [2657] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2658] (iii) amplifying human DNA sequences; and [2659] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:153, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:153 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:153. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:153 from nucleotide 94 to nucleotide 1281.

[2660] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2661] (a) the amino acid sequence of SEQ ID NO:154; [2662] (b) a fragment of the amino acid sequence of SEQ ID NO:154, the fragment comprising eight contiguous amino acids of SEQ ID NO:154; and [2663] (c) the amino acid sequence encoded by the cDNA insert of clone qf122.sub.--3 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:154. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:154, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:154 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:154.

[2664] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2665] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155; [2666] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742; [2667] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742; [2668] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone qv538.sub.--1 deposited under accession number ATCC 207187; [2669] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone qv538.sub.--1 deposited under accession number ATCC 207187; [2670] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qv538.sub.--1 deposited under accession number ATCC 207187; [2671] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone qv538.sub.--1 deposited under accession number ATCC 207187; [2672] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:156; [2673] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:156; [2674] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2675] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2676] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2677] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:155.

[2678] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742; the nucleotide sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742; the nucleotide sequence of the full-length protein coding sequence of clone qv538.sub.--1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone qv538.sub.--1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qv538.sub.--1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:156, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:156.

[2679] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:155.

[2680] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2681] (a) a process comprising the steps of: [2682] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2683] (aa) SEQ ID NO:155, but excluding the poly(A) tail at the 3' end of SEQ ID NO:155; and [2684] (ab) the nucleotide sequence of the cDNA insert of clone qv538.sub.--1 deposited under accession number ATCC 207187; [2685] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2686] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2687] and [2688] (b) a process comprising the steps of: [2689] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2690] (ba) SEQ ID NO:155, but excluding the poly(A) tail at the 3' end of SEQ ID NO:155; and [2691] (bb) the nucleotide sequence of the cDNA insert of clone qv538.sub.--1 deposited under accession number ATCC 207187; [2692] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2693] (iii) amplifying human DNA sequences; and [2694] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:155 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:155, but excluding the poly(A) tail at the 3' end of SEQ ID NO:155. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742.

[2695] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2696] (a) the amino acid sequence of SEQ ID NO:156; [2697] (b) a fragment of the amino acid sequence of SEQ ID NO:156, the fragment comprising eight contiguous amino acids of SEQ ID NO:156; and [2698] (c) the amino acid sequence encoded by the cDNA insert of clone qv538.sub.--1 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:156. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:156, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:156.

[2699] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2700] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:157; [2701] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757; [2702] (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ys20.sub.--1 deposited under accession number ATCC 207187; [2703] (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ys20.sub.--1 deposited under accession number ATCC 207187; [2704] (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ys20.sub.--1 deposited under accession number ATCC 207187; [2705] (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ys20.sub.--1 deposited under accession number ATCC 207187; [2706] (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:158; [2707] (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:158; [2708] (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; [2709] (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; [2710] (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and [2711] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:157.

[2712] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757; the nucleotide sequence of the full-length protein coding sequence of clone ys20.sub.--1 deposited under accession number ATCC 207187; or the nucleotide sequence of a mature protein coding sequence of clone ys20.sub.--1 deposited under accession number ATCC 207187. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ys20.sub.--1 deposited under accession number ATCC 207187. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:158, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:158.

[2713] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:157.

[2714] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2715] (a) a process comprising the steps of: [2716] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2717] (aa) SEQ ID NO:157, but excluding the poly(A) tail at the 3' end of SEQ ID NO:157; and [2718] (ab) the nucleotide sequence of the cDNA insert of clone ys20.sub.--1 deposited under accession number ATCC 207187; [2719] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2720] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2721] and [2722] (b) a process comprising the steps of: [2723] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2724] (ba) SEQ ID NO:157, but excluding the poly(A) tail at the 3' end of SEQ ID NO:157; and [2725] (bb) the nucleotide sequence of the cDNA insert of clone ys201 deposited under accession number ATCC 207187; [2726] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2727] (iii) amplifying human DNA sequences; and [2728] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:157 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:157, but excluding the poly(A) tail at the 3' end of SEQ ID NO:157. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:157 from nucleotide 41 to nucleotide 757.

[2729] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2730] (a) the amino acid sequence of SEQ ID NO:158; [2731] (b) a fragment of the amino acid sequence of SEQ ID NO:158, the fragment comprising eight contiguous amino acids of SEQ ID NO:158; and [2732] (c) the amino acid sequence encoded by the cDNA insert of clone ys20.sub.--1 deposited under accession number ATCC 207187; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:158. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:158, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:158 having biological activity, the fragment comprising the amino acid sequence from amino acid 114 to amino acid 123 of SEQ ID NO:158.

[2733] In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: [2734] (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159; [2735] (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253; [2736] (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253; [2737] (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone as180.sub.--1 deposited under accession number ATCC XXXXXX; [2738] (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone as180.sub.--1 deposited under accession number ATCC XXXXXX; [2739] (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone as180.sub.--1 deposited under accession number ATCC XXXXXX; [2740] (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone as1801 deposited under accession number ATCC XXXXXX; [2741] (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:160; [2742] (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:160; [2743] (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; [2744] (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; [2745] (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and [2746] (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:159.

[2747] Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253; the nucleotide sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253; the nucleotide sequence of the full-length protein coding sequence of clone as180.sub.--1 deposited under accession number ATCC XXXXXX; or the nucleotide sequence of a mature protein coding sequence of clone as180.sub.--1 deposited under accession number ATCC XXXXXX. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone as180.sub.--1 deposited under accession number ATCC XXXXXX. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:160, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising the amino acid sequence from amino acid 366 to amino acid 375 of SEQ ID NO:160.

[2748] Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:159.

[2749] Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: [2750] (a) a process comprising the steps of: [2751] (i) preparing one or more polynucleotide probes that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2752] (aa) SEQ ID NO:159; and [2753] (ab) the nucleotide sequence of the cDNA insert of clone as180.sub.--1 deposited under accession number ATCC XXXXXX; [2754] (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; and [2755] (iii) isolating the DNA polynucleotides detected with the probe(s);

[2756] and [2757] (b) a process comprising the steps of: [2758] (i) preparing one or more polynucleotide primers that hybridize in 6.times.SSC at 65 degrees C. to a nucleotide sequence selected from the group consisting of: [2759] (ba) SEQ ID NO:159; and [2760] (bb) the nucleotide sequence of the cDNA insert of clone as1801 deposited under accession number ATCC XXXXXX; [2761] (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4.times.SSC at 50 degrees C.; [2762] (iii) amplifying human DNA sequences; and [2763] (iv) isolating the polynucleotide products of step (b)(iii). Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:159 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:159. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:159 from nucleotide 28 to nucleotide 2253. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:159 from nucleotide 568 to nucleotide 2253.

[2764] In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: [2765] (a) the amino acid sequence of SEQ ID NO:160; [2766] (b) a fragment of the amino acid sequence of SEQ ID NO:160, the fragment comprising eight contiguous amino acids of SEQ ID NO:160; and [2767] (c) the amino acid sequence encoded by the cDNA insert of clone as180.sub.--1 deposited under accession number ATCC XXXXXX; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:160. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:160, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:160 having biological activity, the fragment comprising the amino acid sequence from amino acid 366 to amino acid 375 of SEQ ID NO:160.

[2768] In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

[2769] Processes are also provided for producing a protein, which comprise: [2770] (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and [2771] (b) purifying the protein from the culture. The protein produced according to such methods is also provided by the present invention.

[2772] Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

[2773] Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

[2774] FIGS. 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

[2775] FIG. 2 is a schematic representation of the pCMVSport2 vector used for deposit of clone qs14.sub.--3 disclosed herein.

DETAILED DESCRIPTION

Isolated Proteins and Polynucleotides

[2776] Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

[2777] As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

[2778] Clone "co62.sub.--12"

[2779] A polynucleotide of the present invention has been identified as clone "co62.sub.--12". co62.sub.--12 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. co62.sub.--12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "co62.sub.--12 protein").

[2780] The nucleotide sequence of co62.sub.--12 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the co62.sub.--12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 1 to 11 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 12. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the co62.sub.--12 protein.

[2781] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone co62.sub.--12 should be approximately 2200 bp.

[2782] The nucleotide sequence disclosed herein for co62.sub.--12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. co62.sub.--12 demonstrated at least some similarity with sequences identified as AA019597 (ze60f10.s1 Soares retina N2b4HR Homo sapiens cDNA), AA021678 (mh82c02.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus), AA057573 (zf62d10.s1 Soares retina N2b4HR Homo sapiens cDNA clone 381523 3' similar to WP T12G3.4 CE06440 STRICTOSIDINE SYNTHASE LIKE, mRNA sequence), AA130982, AA287697 (zs53g02.r1 Soares NbHTGBC Homo sapiens cDNA clone 701234 5'), AI042188 (oy37d10.x1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE:1668019 3' similar to WP:F57C2.5 CE16156, mRNA sequence), R63905 (yi19b03.s1 Homo sapiens cDNA clone 139661 3'), T03538 (IB43 Infant brain, Bento Soares Homo sapiens cDNA clone IB43 3' end), T20257 (Human gene signature HUMGS01405), and T23663 (seq294 Homo sapiens cDNA clone b4HB3MA-Cot109+103-Bio-24 3'). The predicted amino acid sequence disclosed herein for co62.sub.--12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted co62.sub.--12 protein demonstrated at least some similarity to sequences identified as R88502 (Protein sequence for mediating male fertility in plants) and Z83110 (F57C2.5 [Caenorhabditis elegans]). Based upon sequence similarity, co62.sub.--12 proteins and each similar protein or peptide may share at least some activity.

[2783] Clone "lo311.sub.--8"

[2784] A polynucleotide of the present invention has been identified as clone "lo311.sub.--8". lo311.sub.--8 was isolated from a human adult thyroid cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. lo311.sub.--8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "lo311.sub.--8 protein").

[2785] The nucleotide sequence of lo311.sub.--8 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the lo311.sub.--8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 17 to 29 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the lo311.sub.--8 protein.

[2786] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone lo311.sub.--8 should be approximately 3850 bp.

[2787] The nucleotide sequence disclosed herein for lo311.sub.--8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. lo311.sub.--8 demonstrated at least some similarity with sequences identified as AA046836 (zf14b10.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 376891 5' similar to WP:ZK686.3 CE00457), AA297716 (EST113273 Infant adrenal gland, subtracted (total cDNA) I Homo sapiens cDNA 5' end similar to similar to C. elegans hypothetical protein, cosmid ZK686.sub.--3), AF008554 (Rattus norvegicus implantation-associated protein (IAG2) mRNA, partial cds), T68050 (yc39h10.r1 Homo sapiens cDNA clone 83107 5' similar to SP ZK686.3 CE00457), and U42349 (Human N33 mRNA, complete cds). The predicted amino acid sequence disclosed herein for lo311.sub.--8 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted lo311.sub.--8 protein demonstrated at least some similarity to sequences identified as AF008554 (implantation-associated protein [Rattus norvegicus]), R85333 (Human prostate/colon tumour suppressor protein form 1) and U42349 (39 kDa encoded by N33 [Homo sapiens]). Based upon sequence similarity, lo311.sub.--8 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the lo311.sub.--8 protein sequence, centered around amino acids 10, 190, 220, 275, and 310 of SEQ ID NO:4, respectively.

[2788] Clone "ns197.sub.--1"

[2789] A polynucleotide of the present invention has been identified as clone "ns197.sub.--1". ns197.sub.--1 was isolated from a human adult retina (retinoblastoma WERI-Rb1) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ns197.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ns197.sub.--1 protein").

[2790] The nucleotide sequence of ns197.sub.--1 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ns197.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.

[2791] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ns197.sub.--1 should be approximately 3650 bp.

[2792] The nucleotide sequence disclosed herein for ns197.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ns197.sub.--1 demonstrated at least some similarity with sequences identified as AA495135 (fa03c11.r1 Zebrafish ICRFzfls Danio rerio cDNA clone 3K8 5' similar to WP:ZC518.3 CE06603 ALCOHOL DEHYDROGENASE TRANSCRIPTION EFFECTOR LIE; mRNA sequence). The predicted amino acid sequence disclosed herein for ns197.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ns197.sub.--1 protein demon-strated at least some similarity to the sequence identified as Z68753 (ZC518.3 [Caenorhabditis elegans]). Based upon sequence similarity, ns197.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ns197.sub.--1 protein sequence centered around amino acid 135 of SEQ ID NO:6. The nucleotide sequence of ns197.sub.--1 indicates that it may contain one or more repeat sequences, including primate simple repeat GCC, Alu, and other repetitive elements.

[2793] Clone "pj193.sub.--5"

[2794] A polynucleotide of the present invention has been identified as clone "pj193.sub.--5". pj193.sub.--5 was isolated from a human fetal carcinoma (NTD2 cells, treated with retinoic acid for 23 days) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the ammo acid sequence of the encoded protein. pj193.sub.--5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pj193.sub.--5 protein").

[2795] The nucleotide sequence of pj193.sub.--5 as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pj193.sub.--5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 9 to 21 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pj193.sub.--5 protein.

[2796] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pj193.sub.--5 should be approximately 1500 bp.

[2797] The nucleotide sequence disclosed herein for pj193.sub.--5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pj193.sub.--5 demonstrated at least some similarity with sequences identified as AA296889 (EST112653 Cerebellum II Homo sapiens cDNA 5' end), AA296961 (EST112514 Adrenal gland tumor Homo sapiens cDNA 5' end), AA661635 (nv02g06.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1219066), and U80744 (Homo sapiens CTG4a mRNA, complete cds). The predicted amino acid sequence disclosed herein for pj193.sub.--5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pj193.sub.--5 protein demon-strated at least some similarity to the sequence identified as U80744 (CTG4a [Homo sapiens]). Based upon sequence similarity, pj193.sub.--5 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of pj193.sub.--5 indicates that it may contain CAG nucleotide repeats; these repeats may create a "hotspot" for certain types of mutations. "Twelve diseases, most with neuropsychiatric features, arise from trinucleotide repeat expansion mutations. Expansion mutations may also cause a number of other disorders, including several additional forms of spinocerebellar ataxia, bipolar affective disorder, schizophrenia, and autism." (Margolis et al., 1997, Human Genetics 100(1): 114-122, which is incorporated by reference herein.) It is possible that the gene corresponding to pj193.sub.--5 undergoes a similar etiology.

[2798] pj193.sub.--5 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 31 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[2799] Clone "pj317.sub.--2"

[2800] A polynucleotide of the present invention has been identified as clone "pj317.sub.--2". pj317.sub.--2 was isolated from a human fetal carcinoma (NTD2 cells, treated with retinoic acid for 23 days) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pj317.sub.--2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pj317.sub.--2 protein").

[2801] The nucleotide sequence of pj317.sub.--2 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pj317.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.

[2802] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pj317.sub.--2 should be approximately 2300 bp.

[2803] The nucleotide sequence disclosed herein for pj317.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pj317.sub.--2 demonstrated at least some similarity with sequences identified as AA305508 (EST176494 Colon carcinoma (Caco-2) cell line II Homo sapiens cDNA 5' end, mRNA sequence), AA471379 (PMY1151 KG1a Lambda Zap Express cDNA Library Homo sapiens cDNA 5', mRNA sequence), and AA906311 (ok03f08.s1 Soares NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1506759 3', mRNA sequence). The predicted amino acid sequence disclosed herein for pj317.sub.--2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.

[2804] The predicted pj317.sub.--2 protein demonstrated at least some similarity to the sequences identified as U37763 (Per9p [Pichia angusta]) and U56965 (Caenorhabditis elegans cosmid C.sub.15H.sub.9). Per9p is a peroxisomal membrane protein, and the predicted pj317.sub.--2 protein demonstrated at least some similarity to peroxisomal proteins from other species as well. Based upon sequence similarity, pj317.sub.--2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pj317.sub.--2 protein sequence centered around amino acid 25 of SEQ ID NO:10. The nucleotide sequence of pj317.sub.--2 indicates that it may contain a simple AT and MER repeat region.

[2805] Clone "pt332.sub.--1"

[2806] A polynucleotide of the present invention has been identified as clone "pt332.sub.--1". pt332.sub.--1 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pt332.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pt332.sub.--1 protein").

[2807] The nucleotide sequence of pt332.sub.--1 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pt332.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 287 to 299 of SEQ ID NO:12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 300. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pt332.sub.--1 protein.

[2808] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pt332.sub.--1 should be approximately 3450 bp.

[2809] The nucleotide sequence disclosed herein for pt332.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pt332.sub.--1 demonstrated at least some similarity with sequences identified as AA167221 (zp13c09.s1 Stratagene fetal retina 937202 Homo sapiens cDNA clone 609328 3'), AA437109 (zv53c07.s1 Soares testis NHT Homo sapiens cDNA clone 757356 3'), H14107 (ym62a06.r1 Homo sapiens cDNA clone 163474 5'), and U41264 (C. elegans cDNA). Based upon sequence similarity, pt332.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pt332.sub.--1 protein sequence centered around amino acid 270 of SEQ ID NO:12.

[2810] pt332.sub.--1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 100 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2811] Clone "qc297.sub.--15"

[2812] A polynucleotide of the present invention has been identified as clone "qc297.sub.--15". qc297.sub.--15 was isolated from a human adult neural (neuroepithelioma HTB-10 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qc297.sub.--15 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qc297.sub.--15 protein").

[2813] The nucleotide sequence of qc297.sub.--15 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qc297.sub.--15 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14.

[2814] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qc297.sub.--15 should be approximately 1400 bp.

[2815] The nucleotide sequence disclosed herein for qc297.sub.--15 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qc297.sub.--15 demonstrated at least some similarity with sequences identified as AA625537 (af72g07.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 1047612 5') and T24537 (EST112 Homo sapiens cDNA clone 4H3). Based upon sequence similarity, qc297.sub.--15 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the qc297.sub.--15 protein sequence, around amino acid 20 of SEQ ID NO:14. The nucleotide/amino acid sequence of qc297.sub.--15 indicates that it may contain an Alu/SVA/MER repeat region.

[2816] qc297.sub.--15 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[2817] Clone "qg596.sub.--12"

[2818] A polynucleotide of the present invention has been identified as clone "qg596.sub.--12". qg596.sub.--12 was isolated from a human adult neural (neuroepithelioma HTB-10 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qg596.sub.--12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qg596.sub.--12 protein").

[2819] The nucleotide sequence of qg596.sub.--12 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qg596.sub.--12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16.

[2820] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qg596.sub.--12 should be approximately 2750 bp.

[2821] The nucleotide sequence disclosed herein for qg596.sub.--12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qg59612 demonstrated at least some similarity with sequences identified as AA332939 (EST37132 Embryo, 8 week I Homo sapiens cDNA 5' end), AA334678 (EST39190 Embryo, 9 week Homo sapiens cDNA 5' end), AA362653 (EST72375 Namalwa B cells I Homo sapiens cDNA 5' end), and AA829841 (od40d01.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1370401 3' similar to WP:F10G7.1 CE02624). The predicted amino acid sequence disclosed herein for qg596.sub.--12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qg596.sub.13 12 protein demonstrated at least some similarity to the sequence identified as U40029 (coded for by C. elegans cDNA yk16b1.3; coded for by C. elegans cDNA yk8g6.5; coded for by C. elegans cDNA yk8g6.3; coded for by C. elegans cDNA yk6d3.5). Based upon sequence similarity, qg596.sub.--12 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the qg596.sub.--12 protein sequence, one centered around amino acid 180 and another around amino acid 660 of SEQ ID NO:16.

[2822] qg596.sub.--12 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 33 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2823] Clone "rb649.sub.--3"

[2824] A polynucleotide of the present invention has been identified as clone "rb649.sub.--3". rb649.sub.--3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rb649.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rb649.sub.--3 protein").

[2825] The nucleotide sequence of rb649.sub.--3 as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rb649.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 42 to 54 of SEQ ID NO:18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 55. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rb649.sub.--3 protein.

[2826] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rb649.sub.--3 should be approximately 2500 bp.

[2827] The nucleotide sequence disclosed herein for rb649.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rb649.sub.--3 demonstrated at least some similarity with sequences identified as AA177001 (nc01h02.s1 NCI_CGAP_Pr1 Homo sapiens cDNA clone IMAGE 182). The predicted amino acid sequence disclosed herein for rb649.sub.--3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rb649.sub.--3 protein demonstrated at least some similarity to sequences identified as AB002405 (LAK-4p [Homo sapiens]), R89470 (Collagen/TGF-beta-1 fusion protein), and U23516 (Undefined [Caenorhabditis elegans]). Based upon sequence similarity, rb649.sub.--3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts eight additional potential transmembrane domains within the rb649.sub.--3 protein sequence, centered around amino acids 140, 240, 280, 325, 370, 425, 475, and 540 of SEQ ID NO:18, respectively. The nucleotide sequence of rb649.sub.--3 indicates that it may contain a simple GGA repeat region.

[2828] Clone "ca106.sub.--19x"

[2829] A polynucleotide of the present invention has been identified as clone "ca106.sub.--19x". A cDNA clone was first isolated from a mouse embryonic (ES cell embryoid bodies harvested 2-12 days after LIF removed) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate ca106.sub.--19.times. from a mixture of human fetal brain and human adult brain cDNA libraries. ca106.sub.--19.times. is a full-length human clone, including the entire coding sequence of a secreted protein (also referred to herein as "ca106.sub.--19.times. protein").

[2830] The nucleotide sequence of ca106.sub.--19.times. as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ca106.sub.--19.times. protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20.

[2831] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ca106.sub.--19.times. should be approximately 4050 bp.

[2832] The nucleotide sequence disclosed herein for ca106.sub.--19x was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ca106.sub.--19x demonstrated at least some similarity with sequences identified as AA886998 (oj30g03.s1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1499860 3'), F08279 (H. sapiens partial cDNA sequence; clone c-zpe11), F13022 (H. sapiens partial cDNA sequence; clone c-3hf07), H38128 (yp46c12.s1 Homo sapiens cDNA clone 190486 3'), T77601 (yc91e07.r1 Homo sapiens cDNA clone 23192 5'), U93720 (Homo sapiens TEX28 mRNA, complete cds), W55512 (ma28h03.r1 Life Tech mouse brain Mus musculus cDNA clone 312053 5'), and Z22333 (H.sapiens DNA sequence). The predicted amino acid sequence disclosed herein for ca106.sub.--19x was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ca106.sub.--19.times. protein demonstrated at least some similarity to sequences identified as U56965 (C15H.sub.9.4 gene product [Caenorhabditis elegans]) and U93720 (TEX28 [Homo sapiens]). Based upon sequence similarity, ca106.sub.--19.times. proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the ca106.sub.--19.times. protein sequence, centered around amino acids 170, 430, 590, and 625 of SEQ ID NO:20, respectively. The nucleotide sequence of ca106.sub.--19.times. indicates that it contains at least one repetitive element.

[2833] Clone "ci52.sub.--2"

[2834] A polynucleotide of the present invention has been identified as clone "ci52.sub.--2". A cDNA clone was first isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate ci52.sub.--2 from a human fetal brain cDNA library. ci52.sub.--2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ci52.sub.--2 protein").

[2835] The nucleotide sequence of ci52.sub.--2 as presently determined is reported in SEQ ID NO:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ci52.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:22. Amino acids 9 to 21 of SEQ ID NO:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ci52.sub.--2 protein.

[2836] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ci52.sub.--2 should be approximately 1775 bp.

[2837] The nucleotide sequence disclosed herein for ci52.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ci52.sub.--2 demonstrated at least some similarity with sequences identified as AA083339 (zn31d10.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 549043 5'), AA514339 (nf56c10.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 923922), AA628942 (af28f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032985 3', mRNA sequence), M78692 (EST00840 Homo sapiens cDNA clone HHCMC16), N67265 (yz49d04.s1 Homo sapiens cDNA clone 286375 3'), N95514 (yy62d10.r1 Homo sapiens cDNA clone 278131 5'), Q60715 (Human brain Expressed Sequence Tag EST00840; standard; cDNA), and R46588 (yg51a12.s1 Homo sapiens cDNA clone 35984 3'). The predicted amino acid sequence disclosed herein for ci52.sub.--2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ci52.sub.--2 protein demonstrated at least some similarity to the sequence identified as M68866 (stranded at second [Drosophila melanogaster]). Based upon sequence similarity, ci52.sub.--2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the ci52.sub.--2 protein sequence, one around amino acid 146 and another around amino acid 177 of SEQ ID NO:22.

[2838] Clone "md124.sub.--16"

[2839] A polynucleotide of the present invention has been identified as clone "md124.sub.--16". A cDNA clone was first isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate md124.sub.--16 from a human adult kidney cDNA library. md124.sub.--16 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "md124.sub.--16 protein").

[2840] The nucleotide sequence of md124.sub.--16 as presently determined is reported in SEQ ID NO:23, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the md124.sub.--16 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 152 to 164 of SEQ ID NO:24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 165. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the md124.sub.--16 protein.

[2841] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone md124.sub.--16 should be approximately 2300 bp.

[2842] The nucleotide sequence disclosed herein for md124.sub.--16 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. md124.sub.--16 demonstrated at least some similarity with sequences identified as AA215643 (zr98d05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:683721 3'), AA489121 (aa56b07.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824917 5'), W72865 (zd59e07.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344964 3'), and W76100 (zd59e07.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344964 5'). Based upon sequence similarity, md124.sub.--16 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of md124.sub.--16 indicates that it may contain at least one MER repeat sequence.

[2843] Clone "pk366.sub.--7"

[2844] A polynucleotide of the present invention has been identified as clone "pk366.sub.--7". pk366.sub.--7 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pk366.sub.--7 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pk366.sub.--7 protein").

[2845] The nucleotide sequence of pk366.sub.--7 as presently determined is reported in SEQ ID NO:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pk366.sub.--7 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:26. Amino acids 361 to 373 of SEQ ID NO:26 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 374. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pk366.sub.--7 protein.

[2846] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pk366.sub.--7 should be approximately 3300 bp.

[2847] The nucleotide sequence disclosed herein for pk366.sub.--7 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pk366.sub.--7 demonstrated at least some similarity with sequences identified as AA057428 (zf57c11.s1 Soares retina N2b4HR Homo sapiens cDNA clone 381044 3'), AA457625 (aa89e09.r1 Stratagene fetal retina 937202 Homo sapiens cDNA clone 838504 5'), AA601545 (nn87h11.s1 NCI_CGAP_Br2 Homo sapiens cDNA clone IMAGE:1098213), T19564 (Human gene signature HUMGS00629; standard; cDNA to mRNA), and U94831 (Homo sapiens multispanning membrane protein mRNA, complete cds). The predicted amino acid sequence disclosed herein for pk366.sub.--7 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pk366.sub.--7 protein demonstrated at least some similarity to sequences identified as D87444 (endomembrane protein EMP70 precursor isolog [Arabidopsis thaliana]), U94831 (multispanning membrane protein [Homo sapiens]), and U95973 (endomembrane protein EMP70 precursor isolog [Arabidopsis thaliana]). Based upon sequence similarity, pk366.sub.--7 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts nine additional potential transmembrane domains within the pk366.sub.--7 protein sequence, centered around amino acids 191, 260, 288, 325, 355, 412, 447, 481, and 517 of SEQ ID NO:26, respectively.

[2848] Clone "pl741.sub.--5"

[2849] A polynucleotide of the present invention has been identified as clone "pl741.sub.--5". pl741.sub.--5 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pl741.sub.--5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pl741.sub.--5 protein").

[2850] The nucleotide sequence of pl741.sub.--5 as presently determined is reported in SEQ ID NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pl741.sub.--5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28. Amino acids 3 to 15 of SEQ ID NO:28 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pl741.sub.--5 protein.

[2851] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pl741.sub.--5 should be approximately 3000 bp.

[2852] The nucleotide sequence disclosed herein. for pl741.sub.--5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pl741.sub.--5 demonstrated at least some similarity with sequences identified as AA283176 (zt17a04.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 713358 3'), AA204801 (zq61d12.r1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 646103 5'), and H59410 (yr19g04.r1 Homo sapiens cDNA clone 205782 5'). The predicted amino acid sequence disclosed herein for pl741.sub.--5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pl741.sub.--5 protein demonstrated at least some similarity to sequences identified as U00027 (Cdc23p cell cycle protein [Saccharomyces cerevisiae]) and U58763 (F10C5.1 [Caenorhabditis elegans]). Based upon sequence similarity, pl741.sub.--5 proteins and each similar protein or peptide may share at least some activity. Analysis of the amino acid sequence of the predicted pl741.sub.--5 protein reveals the presence of four TPR (tetratricopeptide) domains. TPR domains are found in a wide variety of proteins with varying functions and localizations--from the nucleus to the extracellular milieu--and are thought to function as protein-protein interaction domains. The TPR domains are found at amino acid residues 166-194, 328-356, 362-390, and 396424 of SEQ ID NO:28.

[2853] Clone "pp314.sub.--19"

[2854] A polynucleotide of the present invention has been identified as clone "pp314.sub.--19". pp314.sub.--9 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pp314.sub.--19 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pp314.sub.--19 protein").

[2855] The nucleotide sequence of pp314.sub.--19 as presently determined is reported in SEQ ID NO:29, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pp314.sub.--19 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 147 to 159 of SEQ ID NO:30 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 160; amino acids 238 to 250 of SEQ ID NO:30 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 251. Due to the hydrophobic nature of these possible leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the pp314.sub.--19 protein.

[2856] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pp314.sub.--19 should be approximately 2300 bp.

[2857] The nucleotide sequence disclosed herein for pp314.sub.--19 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pp314.sub.--19 demonstrated at least some similarity with sequences identified as AA044042 (zk58g05.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487064 5', mRNA sequence), AA127902 (zl12d01.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 501697 5'), AA609481 (af14a12.s1 Soares testis NHT Homo sapiens cDNA clone 1031614 3', mRNA sequence), T26699 (Human gene signature HUMGS08949; standard; cDNA to mRNA), and W93399 (zd95b06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 357203 3'). The predicted amino acid sequence disclosed herein for pp314.sub.--19 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pp314.sub.--19 protein demonstrated at least some similarity to sequences identified as AE000857 (chaperonin [Methanobacterium thermoautotrophicum]), AJ006549 (ThsA [Pyrodictium occultum]), and L34691 (thermophilic factor 56 [Sulfolobus shibatae]). Based upon sequence similarity, pp314.sub.--19 proteins and each similar protein or peptide may share at least some activity. Analysis of the amino acid sequence of the predicted pp314.sub.--19 protein revealed the cpn60_TCP1 signature (at amino acids 29-570 of SEQ ID NO:30) which has some ATPase activity and is indicative of chaperoning. A P-loop motif--a common motif in ATP- and GTP-binding proteins--is found around amino acid 200 of SEQ ID NO:30. The presence of the P-loop is interesting when taken in conjunction with the potential ATPase activity associated with the cpn60_TCP1 signature. The TopPredII computer program predicts three additional potential transmembrane domains within the pp31419 protein sequence, centered around amino acids 55, 90, and 330 of SEQ ID NO:30, respectively.

[2858] pp314.sub.--19 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 6 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2859] Clone "pv35.sub.--1"

[2860] A polynucleotide of the present invention has been identified as clone "pv35.sub.--1". pv35.sub.--1 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pv35.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pv35.sub.--1 protein").

[2861] The nucleotide sequence of pv35.sub.--1 as presently determined is reported in SEQ ID NO:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pv35.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:32.

[2862] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pv35.sub.--1 should be approximately 2300 bp.

[2863] The nucleotide sequence disclosed herein for pv35.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pv35.sub.--1 demonstrated at least some similarity with sequences identified as AA335869 (EST40348 Epididymus Homo sapiens cDNA 5' end), AA599418 (ag23c03.s1 Jia bone marrow stroma Homo sapiens cDNA clone 1071172 3'), and H03595 (yj42e06.r1 Homo sapiens cDNA clone 151426 5'). The predicted amino acid sequence disclosed herein for pv35.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pv35.sub.--1 protein demonstrated at least some similarity to sequences identified as Z99277 (Y53C12A.3 [Caenorhabditis elegans]). Based upon sequence similarity, pv35.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the pv35.sub.--1 protein sequence, centered around amino acids 127, 161, 192, and 250 of SEQ ID NO:32, respectively.

[2864] Clone "pw337.sub.--6"

[2865] A polynucleotide of the present invention has been identified as clone "pw337.sub.--6". pw337.sub.--6 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pw337.sub.--6 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pw337.sub.--6 protein").

[2866] The nucleotide sequence of pw337.sub.--6 as presently determined is reported in SEQ ID NO:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pw337.sub.--6 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:34.

[2867] Another potential pw337.sub.--6 reading frame and predicted amino acid sequence is encoded by basepairs 648 to 908 of SEQ ID NO:33 and is reported in SEQ ID NO:238. The overlapping reading frames of SEQ ID NO:34 and SEQ ID NO:238 could be joined if a frameshift were introduced into the nucleotide sequence of SEQ ID NO:33 between position 645 and position 736.

[2868] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pw337.sub.--6 should be approximately 1000 bp.

[2869] The nucleotide sequence disclosed herein for pw337.sub.--6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pw337.sub.--6 demonstrated at least some similarity with sequences identified as AA682471 (zj18c02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 450626 3', mRNA sequence), T20708 (Human gene signature HUMGS01925; standard; cDNA to mRNA), W24658 (zb63b05.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 308241 5'), and Z82192 (Homo sapiens DNA sequence from PAC 18601 on chromosome 22). The predicted amino acid sequence disclosed herein for pw337.sub.--6 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pw337.sub.--6 protein demonstrated at least some similarity to the sequence identified as Z82192 (dJ186O1.1 [Homo sapiens]). Based upon sequence similarity, pw337.sub.--6 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pw337.sub.--6 protein sequence centered around amino acid 75 of SEQ ID NO:34. The nucleotide sequence of pw337.sub.--6 indicates that it may contain one or more repetitive elements.

[2870] pw337.sub.--6 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 22 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2871] Clone "rd610.sub.--1"

[2872] A polynucleotide of the present invention has been identified as clone "rd610.sub.--1". rd610.sub.--1 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd610.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rd610.sub.--1 protein").

[2873] The nucleotide sequence of rd610.sub.--1 as presently determined is reported in SEQ ID NO:35, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd610.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:36.

[2874] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd610_should be approximately 1800 bp.

[2875] The nucleotide sequence disclosed herein for rd610.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd610.sub.--1 demonstrated at least some similarity with sequences identified as AA442056 (zw56f08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 774087 5'), AA992905 (ot92b06.s1 Soares_total_fetus_Nb2HF8.sub.--9w Homo sapiens cDNA clone IMAGE 1624211 3', mRNA sequence), D31767 (Human mRNA for KIAA0058 gene, complete cds), and T40090 (Human Serrate-1 (HJ1) cDNA; standard; cDNA). Based upon sequence similarity, rd610.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rd610.sub.--1 protein sequence centered around amino acid 30 of SEQ ID NO:36; amino acids 23 to 35 of SEQ ID NO:36 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 36.

[2876] rd610.sub.--1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

[2877] Clone "rd810.sub.--6"

[2878] A polynucleotide of the present invention has been identified as clone "rd810.sub.--6". rd810.sub.--6 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd810.sub.--6 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rd8106 protein").

[2879] The nucleotide sequence of rd8106 as presently determined is reported in SEQ ID NO:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd810.sub.--6 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:38. Amino acids 112 to 124 of SEQ ID NO:38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 125. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rd8106 protein.

[2880] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd810.sub.--6 should be approximately 850 bp.

[2881] The nucleotide sequence disclosed herein for rd810.sub.--6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd810.sub.--6 demonstrated at least some similarity with sequences identified as AA452718 (zx39d04.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 788839 5', mRNA sequence), AA292888 (zt66c01.r1 Soares testis NHT Homo sapiens cDNA clone 727296 5'), and T23348 (Human gene signature HUMGS05169; standard; cDNA to mRNA). Based upon sequence similarity, rd810.sub.--6 proteins and each similar protein or peptide may share at least some activity.

[2882] rd810.sub.--6 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 23 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[2883] Clone "cf85.sub.--1"

[2884] A polynucleotide of the present invention has been identified as clone "cf85.sub.--1". A cDNA clone was first isolated from a human adult placenta library cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate cf85.sub.--1 from a human adult brain cDNA library. cf85.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "cf85.sub.--1 protein").

[2885] The nucleotide sequence of cf85.sub.--1 as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cf85.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:40.

[2886] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cf85.sub.--1 should be approximately 2000 bp.

[2887] The nucleotide sequence disclosed herein for cf85.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cf85.sub.--1 demonstrated at least some similarity with sequences identified as H50932 (yo35f03.r1 Homo sapiens cDNA clone 179933 5'), H51595 (yo35f03.s1 Homo sapiens cDNA clone 179933 3'), and T24664 (Human gene signature HUMGS06728; standard; cDNA to mRNA). Based upon sequence similarity, cf85.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the cf85.sub.--1 protein sequence, centered around amino acids 150, 195, and 220 of SEQ ID NO:40, respectively. The nucleotide sequence of cf85.sub.--1 indicates that it may contain an Alu repetitive element.

[2888] Clone "dd504.sub.--18"

[2889] A polynucleotide of the present invention has been identified as clone "dd504.sub.--18". dd504.sub.--18 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dd504.sub.--18 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dd504.sub.--18 protein").

[2890] The nucleotide sequence of dd504.sub.--18 as presently determined is reported in SEQ ID NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dd504.sub.--18 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 134 to 146 of SEQ ID NO:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence be ginning at amino acid 147. Amino acids 7 to 19 of SEQ ID NO:42 are also a possible leader/signal sequence, with a predicted mature amino acid sequence beginning in that case at amino acid 20. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the dd504.sub.--18 protein.

[2891] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dd504.sub.--18 should be approximately 2000 bp.

[2892] The nucleotide sequence disclosed herein for dd504.sub.--18 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dd504.sub.--18 demonstrated at least some similarity with sequences identified as AA393779 (zt77f07.r1 Soares testis NHT Homo sapiens cDNA clone 728389 5' similar to WP:F41E7.1 CE03301; mRNA sequence), AA429-420 (zw51f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773595 5' similar to WP W02B12.7 CE03767 KINENSIN-LIKE PROTEIN), AC002038 (*** SEQUENCING IN PROGRESS *** Human chromosome 16p12 BAC clone CIT987SK-101B6; HTGS phase 1, 1 unordered pieces; Homo sapiens chromosome 2 clone 101B6 from 2p11, complete sequence), H10672 (yl99g09.r1 Homo sapiens cDNA clone 46448 5'), and R59895 (yh07f12.r1 Homo sapiens cDNA clone 42477 5'). The predicted amino acid sequence disclosed herein for dd504.sub.--18 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted dd504.sub.--18 protein demonstrated at least some similarity to sequences identified as AE000854 (Na+/H+-exchanging protein Na+/H+ antiporter [Methanobacterium thermoautotrophicum]) and Z68106 (F41E7.1 [Caeno-rhabditis elegans]). Based upon sequence similarity, dd504.sub.--18 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts eight potential transmembrane domains within the dd504.sub.--18 protein sequence, centered around amino acids 20, 48, 118, 144, 191, 220, 268, and 326 of SEQ ID NO:42, respectively.

[2893] dd504.sub.--18 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 36 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2894] Clone "np26.sub.--3"

[2895] A polynucleotide of the present invention has been identified as clone "np26.sub.--3". np26.sub.--3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. np26.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "np26.sub.--3 protein").

[2896] The nucleotide sequence of np26.sub.--3 as presently determined is reported in SEQ ID NO:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the np26.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:44.

[2897] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone np26.sub.--3 should be approximately 3800 bp.

[2898] The nucleotide sequence disclosed herein for np26.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. np26.sub.--3 demonstrated at least some similarity with sequences identified as AA118527 (mo99d08.r1 Stratagene mouse heart (#937316) Mus musculus cDNA clone 567855 5'), AA284633 (zt15d04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:713191 3', mRNA sequence), AA427620 (zw30d02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 770787 3' similar to contains MER17.b1 MER17 repetitive element; mRNA sequence), and AA496955 (aa42f01.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 823609 3', mRNA sequence). The predicted amino acid sequence disclosed herein for np26.sub.--3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted np26.sub.--3 protein demonstrated at least some similarity to the sequence identified as M86752 (transformation-sensitive protein [Homo sapiens]). Based upon sequence similarity, np26.sub.--3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the np26.sub.--3 protein sequence centered around amino acid 146 of SEQ ID NO:44.

[2899] np26.sub.--3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 63 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

[2900] Clone "pm412.sub.--12"

[2901] A polynucleotide of the present invention has been identified as clone "pm412.sub.--12". pm412.sub.--12 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pm412.sub.--12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pm412.sub.--12 protein").

[2902] The nucleotide sequence of pm412.sub.--12 as presently determined is reported in SEQ ID NO:45, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pm412.sub.--12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:46. Amino acids 607 to 619 of SEQ ID NO:46 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 620. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should it not be separated from the remainder of the pm412.sub.--12 protein.

[2903] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm412.sub.--12 should be approximately 4000 bp.

[2904] The nucleotide sequence disclosed herein for pm412.sub.--12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm412.sub.--12 demonstrated at least some similarity with sequences identified as AA176820 (zp34a12.s1 Stratagene muscle 937209 Homo sapiens cDNA clone 611326 3'), AA425762 (zw47f10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773227 3' similar to TR:G285999 G285999 ORF, COMPLETE CDS), AA568580 (nm21a10.s1 NCI_CGAP_Co10 Homo sapiens cDNA clone IMAGE:1060794 similar to TR:G642306 G642306 HYPOTHETICAL 153.8 KD PROTEIN), AA610863 (np98h01.s1 NCI_CGAP_Lu1 Homo sapiens cDNA clone IMAGE 1142449 similar to TR G285999 G285999 ORF, COMPLETE CDS), AA769312 (nz39f06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1290179 similar to TR Q15393 Q15393 ORF, COMPLETE CDS; mRNA sequence), D13642 (Human mRNA for KIAA0017 gene, complete cds), and T92977 (ye22e09.r1 Homo sapiens cDNA clone 118504 5'). The predicted amino acid sequence disclosed herein for pm412.sub.--12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pm412.sub.--12 protein demonstrated at least some similarity to sequences identified as AF043699 (ORF; similar to human UV-damaged DNA binding factor [C. elegans]), D13642 (KIAA0017 [Homo sapiens]), R72386 (XAP-1, part of the DNA repair complex), and X54413 (alpha1(IX) collagen precursor [Homo sapiens]). Based upon sequence similarity, pm412.sub.--12 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the pm412.sub.--12 protein sequence, centered around amino acids 277, 415, and 1060 of SEQ ID NO:46, respectively.

[2905] pm412.sub.--12 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 119 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[2906] Clone "pm421.sub.--3"

[2907] A polynucleotide of the present invention has been identified as clone "pm421.sub.--3". pm421.sub.--3 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pm421.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pm421.sub.--3 protein").

[2908] The nucleotide sequence of pm421.sub.--3 as presently determined is reported in SEQ ID NO:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pm421.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Amino acids 10 to 22 of SEQ ID NO:48 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pm421.sub.--3 protein.

[2909] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm421.sub.--3 should be approximately 2800 bp.

[2910] The nucleotide sequence disclosed herein for pm421.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm421.sub.--3 demonstrated at least some similarity with sequences identified as AA196485 (zq59a06.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 645874 3'), AA421712 (zu26g11.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 739172 5', mRNA sequence), AC005026 (Homo sapiens clone GS489L14; HTGS phase 1, 3 unordered pieces), AC005028 (Homo sapiens clone GS539F22; HTGS phase 1, 1 unordered pieces), Q60534 (Human brain Expressed Sequence Tag EST02540; standard; cDNA), and R13985 (yf68h04.r1 Homo sapiens cDNA clone 27722 5'). Based upon sequence similarity, pm421.sub.--3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the pm421.sub.--3 protein sequence centered around amino acid 36 of SEQ ID NO:48.

[2911] Clone "pv6.sub.--1"

[2912] A polynucleotide of the present invention has been identified as clone "pv6.sub.--1". pv6.sub.--1 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pv6.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pv6.sub.--1 protein").

[2913] The nucleotide sequence of pv6.sub.--1 as presently determined is reported in SEQ ID NO:49, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pv6.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:50. Amino acids 39 to 51 of SEQ ID NO:50 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 52. Amino acids 8 to 20 of SEQ ID NO:50 are also a possible leader/signal sequence, with a predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of these predicted leader/signal sequences, each is likely to act as a transmembrane domain should it not be separated from the remainder of the pv6.sub.--1 protein.

[2914] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pv6.sub.--1 should be approximately 1800 bp.

[2915] The nucleotide sequence disclosed herein for pv6.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pv6.sub.--1 demonstrated at least some similarity with sequences identified as B53192 (CIT-HSP-2009D9.TR CIT-HSP Homo sapiens genomic clone 2009D9, genomic survey sequence), R18429 (yg02g05.r1 Homo sapiens cDNA clone 31056 5'), T77089 (yc93b02.r1 Homo sapiens cDNA clone 23653 5'), and X89480 (S.scrofa mRNA for membrane protein). The predicted amino acid sequence disclosed herein for pv6.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pv6.sub.--1 protein demonstrated at least some similarity to the sequence identified as X89480 (transmembrane protein [Sus scrofa]). Based upon sequence similarity, pv6.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the pv6.sub.--1 protein sequence centered around amino acid 21 of SEQ ID NO:50.

[2916] Clone "qs14.sub.--3"

[2917] A polynucleotide of the present invention has been identified as clone "qs14.sub.--3". A cDNA clone was isolated from a human whole embryo cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate qs14.sub.--3 from a human fetal heart cDNA library. qs14.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qs14.sub.--3 protein").

[2918] The nucleotide sequence of qs14.sub.--3 as presently determined is reported in SEQ ID NO:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qs14.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:52. Amino acids 15 to 27 of SEQ ID NO:52 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qs14.sub.--3 protein.

[2919] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qs14.sub.--3 should be approximately 5000 bp.

[2920] The nucleotide sequence disclosed herein for qs14.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qs14.sub.--3 demonstrated at least some similarity with sequences identified as AA558554 (nl69g02.s1 NCI_CGAP_Pr4.1 Homo sapiens cDNA clone IMAGE 1045970 similar to TR G307329 G307329 PROTOCADHERIN 43), AB002343 (Human mRNA for KIAA0345 gene), and L43592 (Rattus norvegicus protocadherin-3 (pcdh3) mRNA, and translated products). The predicted amino acid sequence disclosed herein for qs14.sub.--3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qs14.sub.--3 protein demonstrated at least some similarity to sequences identified as AF029343 (protocadherin [Homo sapiens]), AF042192 (protocadherin [Xenopus]), AF052685 (protocadherin 43 [Homo sapiens]), L11373 (protocadherin 43 [Homo sapiens]), R49144 (Product of alternative splicing of human protocadherin-43 mRNA), and Y08715 (protocadherin [Mus musculus]). The cadherins are a family of calcium-binding membrane glycoproteins. Most cadherins are capable of acting as cell adhesion molecules (CAMs). Motif analysis of the predicted qs14.sub.--3 protein also detects the `cadherins extracellular repeated domain signature`. Based upon sequence similarity, qs14.sub.--3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the qs14.sub.--3 protein sequence, one centered around amino acid 510 and another around amino acid 721 of SEQ ID NO:52.

[2921] qs14.sub.--3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 132 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2922] Clone "qy338.sub.--9"

[2923] A polynucleotide of the present invention has been identified as clone "qy338.sub.--9". qy338.sub.--9 was isolated from a human adult blood (promyelocytic leukemia HL-60) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qy338.sub.--9 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qy338.sub.--9 protein").

[2924] The nucleotide sequence of qy338.sub.--9 as presently determined is reported in SEQ ID NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qy338.sub.--9 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:54. Amino acids 144 to 156 of SEQ ID NO:54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 157. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qy338.sub.--9 protein.

[2925] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qy338.sub.--9 should be approximately 1300 bp.

[2926] The nucleotide sequence disclosed herein for qy338.sub.--9 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qy338.sub.--9 demonstrated at least some similarity with sequences identified as AA205412 (zq66a09.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 646552 3' similar to contains Alu repetitive element; contains element LTR1 repetitive element; mRNA), AA595068 (no40h10.s1 NCI_CGAP_Pr23 Homo sapiens cDNA clone IMAGE 1103203 similar to WP C27F2.4 CE01171 METHYLTRANSERASE), AJ224442 (Homo sapiens mRNA for putative methyltransferase), and H40834 (yo05g09.r1 Homo sapiens cDNA clone 177088 5'). The predicted amino acid sequence disclosed herein for qy338.sub.--9 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qy338.sub.--9 protein demonstrated at least some similarity to sequences identified as AJ224442 (methyl-transferase [Homo sapiens]), U40419 (similar to S. cerevisiae gene YCR47c, putative 30.7 kd methyltransferase (SP YCT7_YEAST, P25627) [Caenorhabditis elegans]), and Z69240 (putative methyltransferase [S. cerevisiae]). Based upon sequence similarity, qy338.sub.--9 proteins and each similar protein or peptide may share at least some activity.

[2927] qy338.sub.--9 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 34 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2928] Clone "rc58.sub.--1"

[2929] A polynucleotide of the present invention has been identified as clone "rc58.sub.--1". rc58.sub.--1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rc58.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rc58.sub.--1 protein").

[2930] The nucleotide sequence of rc58.sub.--1 as presently determined is reported in SEQ ID NO:55, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rc58.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:56. Amino acids 2 to 14 of SEQ ID NO:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rc58.sub.--1 protein.

[2931] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rc58.sub.--1 should be approximately 1500 bp.

[2932] The nucleotide sequence disclosed herein for rc58.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rc58.sub.--1 demonstrated at least some similarity with sequences identified as AA203670 (zx52d04.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 446119 5' similar to gb X07868_rna1 PUTATIVE INSULIN-LIKE GROWTH FACTOR II ASSOCIATED (HUMAN); mRNA sequence), AA878778 (oe80h01.s1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1417969 3', mRNA sequence), and U96448 (Bos taurus cleavage and polyadenylation specificity factor 30 kDa subunit mRNA, complete cds). The predicted amino acid sequence disclosed herein for rc58.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rc58.sub.--1 protein demonstrated at least some similarity to sequences identified as AF033201 (cleavage and polyadenylation specificity factor [Mus musculus]) and U96448 (cleavage and polyadenylation specificity factor 30 kDa subunit [Bos taurus]). Based upon sequence similarity, rc58.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the rc58.sub.--1 protein sequence centered around amino acid 53 of SEQ ID NO:56.

[2933] Clone "rd232.sub.--5"

[2934] A polynucleotide of the present invention has been identified as clone "rd232.sub.--5". rd232.sub.--5 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd232.sub.--5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rd232.sub.--5 protein").

[2935] The nucleotide sequence of rd232.sub.--5 as presently determined is reported in SEQ ID NO:57, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd232.sub.--5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:58.

[2936] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd232.sub.--5 should be approximately 3800 bp.

[2937] The nucleotide sequence disclosed herein for rd232.sub.--5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd232.sub.--5 demonstrated at least some similarity with sequences identified as AA768103 (oc16g01.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1341072), AA831487 (oc61a11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1354172 3', mRNA sequence), and R57296 (F2616 Fetal heart Homo sapiens cDNA clone F2616 5' end). The predicted amino acid sequence disclosed herein for rd232.sub.--5 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rd232.sub.--5 protein demonstrated at least some similarity to the sequence identified as Z79755 (F43G9.2 [Caenorhabditis elegans]). Based upon sequence similarity, rd232.sub.--5 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rd232.sub.--5 protein sequence centered around amino acid 225 of SEQ ID NO:58. The nucleotide sequence of rd232.sub.--5 indicates that it may contain a simple AC repeat region.

[2938] Clone "ck213.sub.--12"

[2939] A polynucleotide of the present invention has been identified as clone "ck213.sub.--12". ck213.sub.--12 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ck213.sub.--12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ck213.sub.--12 protein").

[2940] The nucleotide sequence of ck213.sub.--12 as presently determined is reported in SEQ ID NO:59, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ck213.sub.--12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:60.

[2941] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ck213.sub.--12 should be approximately 3500 bp.

[2942] The nucleotide sequence disclosed herein for ck213.sub.--12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ck213.sub.--12 demonstrated at least some similarity with sequences identified as AA062731 (zm01h03.s1 Stratagene corneal stroma (#937222) Homo sapiens cDNA clone 512885 3' similar to TR:G1136390 G1136390 KIAA0164 PROTEIN, mRNA sequence), AA173803 (zp30f05.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 610977 3', mRNA sequence), D79986 (Human mRNA for KIAA0164 protein gene, complete cds), and R01411 (ye77c11.s1 Homo sapiens cDNA clone 123764 3'). The predicted amino acid sequence disclosed herein for ck213.sub.--12 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ck213.sub.--12 protein demonstrated at least some similarity to the sequence identified as D79986 (similar to human DNA-binding protein 5 [Homo sapiens], KIAA0164 protein [Homo sapiens], HUMKIAA04.sub.--1). Based upon sequence similarity, ck213.sub.--12 proteins and each similar protein or peptide may share at least some activity.

[2943] Clone "pg195.sub.--1"

[2944] A polynucleotide of the present invention has been identified as clone "pg195.sub.--1". pg195.sub.--1 was isolated from a human adult thyroid cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pg195.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pg195.sub.--1 protein").

[2945] The nucleotide sequence of pg195.sub.--1 as presently determined is reported in SEQ ID NO:61, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pg195.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:62.

[2946] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pg195.sub.--1 should be approximately 3300 bp.

[2947] The nucleotide sequence disclosed herein for pg195.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pg195.sub.--1 demonstrated at least some similarity with sequences identified as H72617 (yu02g10.r1 Homo sapiens cDNA clone 232674 5') and W37280 (zc11a07.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 321972 5', mRNA sequence). The predicted amino acid sequence disclosed herein for pg195.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pg195.sub.--1 protein demonstrated at least some similarity to the sequence identified as AF007270 (contains similarity to myosin heavy chain [Arabidopsis thaliana]). Based upon sequence similarity, pg195.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the pg195.sub.--1 protein sequence, one centered around amino acid 480 and another around amino acid 520 of SEQ ID NO:62. The nucleotide sequence of pg195.sub.--1 indicates that it may contain one or more repetitive sequences.

[2948] Clone "pw460.sub.--5"

[2949] A polynucleotide of the present invention has been identified as clone "pw460.sub.--5". pw460.sub.--5 was isolated from a human adult brain (cerebellum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pw460.sub.--5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pw460.sub.--5 protein").

[2950] The nucleotide sequence of pw460.sub.--5 as presently determined is reported in SEQ ID NO:63, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pw460.sub.--5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:64. Amino acids 17 to 29 of SEQ ID NO:64 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pw460.sub.--5 protein.

[2951] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pw460.sub.--5 should be approximately 1800 bp.

[2952] The nucleotide sequence disclosed herein for pw460.sub.--5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pw460.sub.--5 demonstrated at least some similarity with sequences identified as AA447258 (zw93e03.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 784540 5', mRNA sequence), AA617801 (nq04f05.s1 NCI_CGAP_Lu1 Homo sapiens cDNA clone IMAGE 1142913), AC002486 (Human BAC clone RG367017 from 7p15-p21, complete sequence), AC004837 (human genomic DNA fragments), and H45347 (yo65h03.r1 Homo sapiens cDNA clone 182837 5'). Based upon sequence similarity, pw460.sub.--5 proteins and each similar protein or peptide may share at least some activity.

[2953] Clone "qa136.sub.--1"

[2954] A polynucleotide of the present invention has been identified as clone "qa136.sub.--1". qa136.sub.--1 was isolated from a human adult cartilage (chondrosarcoma HTB-94 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qa136.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qa136.sub.--1 protein").

[2955] The nucleotide sequence of qa136.sub.--1 as presently determined is reported in SEQ ID NO:65. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qa136.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:66. Amino acids 15 to 27 of SEQ ID NO:66 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qa136.sub.--1 protein.

[2956] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qa136.sub.--1 should be approximately 1600 bp.

[2957] The nucleotide sequence disclosed herein for qa136.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qa136.sub.--1 demonstrated at least some similarity with sequences identified as AA758023 (ah67g02.s1 Soares testis NHT Homo sapiens cDNA clone 1320722 3', mRNA sequence), R69911 (yi47c02.r1 Homo sapiens cDNA clone 142370 5'), and T21835 (Human gene signature HUMGS03376; standard; cDNA to mRNA). Based upon sequence similarity, qa136.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the qa136.sub.--1 protein sequence, centered around amino acids 59, 136, 171, 201, and 268 of SEQ ID NO:66, respectively.

[2958] qa136.sub.--1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[2959] Clone "qy1261.sub.--2"

[2960] A polynucleotide of the present invention has been identified as clone "qy1261.sub.--2". qy1261.sub.--2 was isolated from a human adult blood (promyelocytic Leukemia HL-60) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qy1261.sub.--2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qy1261.sub.--2 protein").

[2961] The nucleotide sequence of qy1261.sub.--2 as presently determined is reported in SEQ ID NO:67, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qy1261.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:68. Amino acids 100 to 112 of SEQ ID NO:68 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 113. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qy1261.sub.--2 protein.

[2962] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qy1261.sub.--2 should be approximately 2500 bp.

[2963] The nucleotide sequence disclosed herein for qy1261.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qy1261.sub.--2 demonstrated at least some similarity with sequences identified as AA076472 (zm91b06.r1 Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 545267 5'), AA115700 (zl87g10.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 511650 5', mRNA sequence), and AA190522 (zp85e07.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 627012 5'). The predicted amino acid sequence disclosed herein for qy1261.sub.--2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qy1261.sub.--2 protein demonstrated at least some similarity to the sequence identified as U49082 (transporter protein [Homo sapiens]). Based upon sequence similarity, qy1261.sub.--2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts ten additional potential transmembrane domains within the qy1261.sub.--2 protein sequence, centered around amino acids 80, 157, 203, 227, 286, 322, 365, 403, 426, and 462 of SEQ ID NO:68. The nucleotide sequence of qy1261.sub.--2 indicates that it may contain one or more Alu repeat sequences.

[2964] Clone "rd432.sub.--4"

[2965] A polynucleotide of the present invention has been identified as clone "rd432.sub.--4". rd432.sub.--4 was isolated from a human kidney (293 embryonal carcinoma cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rd432.sub.--4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rd432.sub.--4 protein").

[2966] The nucleotide sequence of rd432.sub.--4 as presently determined is reported in SEQ ID NO:69, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rd432.sub.--4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:70.

[2967] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rd432.sub.--4 should be approximately 2200 bp.

[2968] The nucleotide sequence disclosed herein for rd432.sub.--4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rd432.sub.--4 demonstrated at least some similarity with sequences identified as AA662913 (nu92b03.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:1218125, mRNA sequence). Based upon sequence similarity, rd432.sub.--4 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rd432.sub.--4 protein sequence, which includes amino acids 102-122 of SEQ ID NO:70. The nucleotide sequence of rd432.sub.--4 indicates that it may contain one or more Alu repetitive elements.

[2969] rd432.sub.--4 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 18 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2970] Clone "rb789.sub.--14"

[2971] A polynucleotide of the present invention has been identified as clone "rb789.sub.--14". rb789.sub.--14 was isolated from a human kidney (293 embryonal carcinoma line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rb789.sub.--14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rb789.sub.--14 protein").

[2972] The nucleotide sequence of rb789.sub.--14 as presently determined is reported in SEQ ID NO:71, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rb789.sub.--14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:72. Amino acids 9 to 21 of SEQ ID NO:72 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rb789.sub.--14 protein.

[2973] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rb789.sub.--14 should be approximately 2300 bp.

[2974] The nucleotide sequence disclosed herein for rb789.sub.--14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rb789.sub.--14 demonstrated at least some similarity with sequences identified as AL008582 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 223H9; HTGS phase 1), AL022393 (Homo sapiens DNA sequence from P1 p373c6 on chromosome 6p21.31-21.33. Contains zinc finger proteins, pseudogenes, ESTs and STS), N28823 (yx71f11.r1 Homo sapiens cDNA clone 267213 5'), and Q60944 (Human brain. Expressed Sequence Tag EST01025; standard; DNA). Based upon sequence similarity, rb789.sub.--14 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the rb789.sub.--14 protein sequence, one centered around amino acid 30 and another around amino acid 75 of SEQ ID NO:72.

[2975] Clone "yd137.sub.--1"

[2976] A polynucleotide of the present invention has been identified as clone "yd137.sub.--1". yd137.sub.--1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yd137.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yd137.sub.--1 protein").

[2977] The nucleotide sequence of yd137.sub.--1 as presently determined is reported in SEQ ID NO:73, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yd137.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:74. Amino acids 27 to 39 of SEQ ID NO:74 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 40. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yd137.sub.--1 protein.

[2978] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yd137.sub.--1 should be approximately 789 bp.

[2979] The nucleotide sequence disclosed herein for yd137.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yd137.sub.--1 demonstrated at least some similarity with sequences identified as AI015619 (ov29g02.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1638770 3' similar to WP:C34B2.10 CE16898; mRNA sequence). The predicted amino acid sequence disclosed herein for yd137.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted yd137.sub.--1 protein demonstrated at least some similarity to the sequence identified as AF043693 (Caenorhabditis elegans cosmid C34B2). Based upon sequence similarity, yd137.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the yd137.sub.--1 protein sequence, one centered around amino acid 30 and another around amino acid 55 of SEQ ID NO:74.

[2980] Clone "yd218.sub.--1"

[2981] A polynucleotide of the present invention has been identified as clone "yd218.sub.--1". yd218.sub.--1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yd218.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yd218.sub.--1 protein").

[2982] The nucleotide sequence of yd128.sub.--1 as presently determined is reported in SEQ ID NO:75, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yd218.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:76. Amino acids 2 to 14 of SEQ ID NO:76 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yd218.sub.--1 protein.

[2983] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yd218.sub.--1 should be approximately 900 bp.

[2984] The nucleotide sequence disclosed herein for yd218.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yd218.sub.--1 demonstrated at least some similarity with sequences identified as AA402818 (zu55f06.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 741923 3', mRNA sequence) and AI150344 (qf35b11.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1751997 3', mRNA sequence). Based upon sequence similarity, yd218.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the yd218.sub.--1 protein sequence, one centered around amino acid 66 and another around amino acid 100 of SEQ ID NO:76.

[2985] yd218.sub.--1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 15 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[2986] Clone "ye11.sub.--1"

[2987] A polynucleotide of the present invention has been identified as clone "ye11.sub.--1". ye11.sub.--1 was isolated from a humna fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye11.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ye11.sub.--1 protein").

[2988] The nucleotide sequence of ye11.sub.--1 as presently determined is reported in SEQ ID NO:77, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ye11.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:78.

[2989] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ye11.sub.--1 should be approximately 2700 bp.

[2990] The nucleotide sequence disclosed herein for ye11.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye11.sub.--1 demonstrated at least some similarity with sequences identified as AC005082 (*** SEQUENCING IN PROGRESS *** Homo sapiens clone RG271G13; HTGS phase 1, 7 unordered pieces). The predicted amino acid sequence disclosed herein for ye11.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ye11.sub.--1 protein demonstrated at least some similarity to sequences identified as AF059569 (actin binding protein MAYVEN [Homo sapiens]) and R94386 (Human neural cell protein marker RR/B). MAYVEN is an actin-binding protein expressed in brain. Hidden markov model analysis reveals the presence of a BTB (BR-c/Ttk) domain in the predicted ye11.sub.--1 protein. BTB domains are characteristic of certain bacterial membrane transport proteins. The MAYVEN protein is thought to contain a similar BTB motif, an indication that ye11.sub.--1 and MAYVEN may share a similar function. Based upon sequence similarity, ye11.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the ye11.sub.--1 protein sequence, one centered around amino acid 20 and another around amino acid 480 of SEQ ID NO:78.

[2991] ye11.sub.--1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 57 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[2992] Clone "ye72.sub.--1"

[2993] A polynucleotide of the present invention has been identified as clone "ye72.sub.--1". ye72.sub.--1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye72.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ye72.sub.--1 protein").

[2994] The nucleotide sequence of ye72.sub.--1 as presently determined is reported in SEQ ID NO:79, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ye72.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:80. Amino acids 24 to 36 of SEQ ID NO:80 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 37. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ye72.sub.--1 protein.

[2995] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ye72.sub.--1 should be approximately 2261 bp.

[2996] The nucleotide sequence disclosed herein for ye72.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye72.sub.--1 demonstrated at least some similarity with sequences identified as AA968450 (op49d06.s1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1580171 3', mRNA sequence). The predicted amino acid sequence disclosed herein for ye72.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ye72.sub.--1 protein demonstrated at least some similarity to sequences identified as U16258 (I kappa BR [Homo sapiens]) and W15483 (Human P28). Based upon sequence similarity, ye72.sub.--1 proteins and each similar protein or peptide may share at least some activity. Hidden markov model analysis reveals the presence of three ankyrin repeats in the predicted ye72.sub.--1 protein at amino acids 273 to 306, 307 to 339, and 341 to 373 of SEQ ID NO:80. The ankyrin 33-residue repeating motif, an L-shaped structure with protruding beta-hairpin tips, mediates specific macromolecular interactions with cytoskeletal, membrane, and regulatory proteins. The TopPredII computer program predicts an additional potential transmembrane domain within the ye72.sub.--1 protein sequence centered around amino acid 140 of SEQ ID NO:80.

[2997] Clone "ye78.sub.--1"

[2998] A polynucleotide of the present invention has been identified as clone "ye78.sub.--1". ye78.sub.--1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye78.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ye78.sub.--1 protein").

[2999] The nucleotide sequence of ye78.sub.--1 as presently determined is reported in SEQ ID NO:81, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ye78.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:82. Amino acids 78 to 90 of SEQ ID NO:82 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 91. Amino acids 42 to 54 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 55. Due to the hydrophobic nature of leader/signal sequences, both of these predicted and possible leader sequences are likely to act as a transmembrane domain should either of them not be separated from the remainder of the ye78.sub.--1 protein.

[3000] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ye78.sub.--1 should be approximately 2654 bp.

[3001] The nucleotide sequence disclosed herein for ye78.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye78.sub.--1 demonstrated at least some similarity with sequences identified as AA522797 (ni40c10.s1 NCI_CGAP_Lu1 Homo sapiens cDNA clone IMAGE:979314, mRNA sequence). Based upon sequence similarity, ye78.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the ye78.sub.--1 protein sequence, centered around amino acids 55, 75, 84, and 480 of SEQ ID NO:12, respectively.

[3002] Clone "ye90.sub.--1"

[3003] A polynucleotide of the present invention has been identified as clone "ye90.sub.--1". ye90.sub.--1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ye90.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ye90.sub.--1 protein").

[3004] The nucleotide sequence of ye90.sub.--1 as presently determined is reported in SEQ ID NO:83, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ye90.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:84. Amino acids 7 to 19 of SEQ ID NO:84 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ye90.sub.--1 protein.

[3005] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ye90.sub.--1 should be approximately 1505 bp.

[3006] The nucleotide sequence disclosed herein for ye90.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ye90.sub.--1 demonstrated at least some similarity with sequences identified as AI1079268 (oz32f06.x1 Soares_total_fetus_Nb2HF8.sub.--9w Homo sapiens cDNA clone IMAGE:1677059 3', mRNA sequence) and T25543 (Human gene signature HUMGS07715, standard; cDNA to mRNA). Based upon sequence similarity, ye90.sub.--1 proteins and each similar protein or peptide may share at least some activity. Motifs analysis reveals the presence of a neutral zinc metallopeptidases, zinc-binding region signature beginning around amino acid residue 236 of SEQ ID NO:84; some known secreted proteins have this motif. The TopPredII computer program predicts two additional potential transmembrane domains within the ye90.sub.--1 protein sequence, one centred around amino acid 195 and another around amino acid 300 of SEQ ID NO:84.

[3007] Clone "yi62.sub.--1"

[3008] A polynucleotide of the present invention has been identified as clone "yi62.sub.--1". yi62.sub.--1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yi62.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yi62.sub.--1 protein").

[3009] The nucleotide sequence of yi62.sub.--1 as presently determined is reported in SEQ ID NO:85, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yi62.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:86. Amino acids 2 to 14 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yi62.sub.--1 protein.

[3010] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yi62.sub.--1 should be approximately 1240 bp.

[3011] The nucleotide sequence disclosed herein for yi62.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yi62.sub.--1 demonstrated at least some similarity with sequences identified as R57572 (F3589 Fetal heart Homo sapiens cDNA clone F3589 5' end, mRNA sequence). Based upon sequence similarity, yi62.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the yi6.sub.--1 protein sequence, centered around amino adds 15, 75, 100, and 125 of SEQ ID NO:86, respectively.

[3012] Clone "yk78.sub.--1"

[3013] A polynucleotide of the present invention has been identified as clone "yk78.sub.--1". yk78.sub.--1 was isolated from a human adult thymus cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yk78.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yk78.sub.--1 protein").

[3014] The nucleotide sequence of yk78.sub.--1 as presently determined is reported in SEQ ID NO:87, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yk78.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:88. Amino acids 57 to 69 of SEQ ID NO:88 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 70. Amino acids 7 to 19 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of leader/signal sequences, both of these predicted and possible leader sequences are likely to act as a transmembrane domain should either of them not be separated from the remainder of the yk78.sub.--1 protein.

[3015] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yk78.sub.--1 should be approximately 1088 bp.

[3016] The nucleotide sequence disclosed herein for yk78.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yk78.sub.--1 demonstrated at least some similarity with sequences identified as AC004921 (*** SEQUENCING IN PROGRESS *** Homo sapiens clone DJ0899E09; HTGS phase 1, 11 unordered pieces). Based upon sequence similarity, yk78.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the yk78.sub.--1 protein sequence, one centered around amino acid 20 and another around amino acids 60 of SEQ ID NO:88.

[3017] Clone "yk251.sub.--1"

[3018] A polynucleotide of the present invention has been identified as clone "yk251.sub.--1". yk251.sub.--1 was isolated from a human adult thymus cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yk251.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yk251.sub.--1 protein").

[3019] The nucleotide sequence of yk251.sub.--1 as presently determined is reported in SEQ ID NO:89, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yk251.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:90. Amino acids 17 to 29 of SEQ ID NO:90 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yk251.sub.--1 protein.

[3020] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yk251.sub.--1 should be approximately 2558 bp.

[3021] The nucleotide sequence disclosed herein for yk251.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the databases. The TopPredII computer program predicts a potential transmembrane domain within the yk251.sub.--1 protein sequence centered, around amino acid 20 of SEQ ID NO:90. The nucleotide sequence of yk251.sub.--1 indicates that it may contain Alu and SVA repetitive elements.

[3022] Clone "yt14.sub.--1"

[3023] A polynucleotide of the present invention has been identified as clone "yt14.sub.--1". yt14.sub.--1 was isolated from a human adult retina (WERI-Rb1 retinoblastoma line) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yt14.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yt14.sub.--1 protein").

[3024] The nucleotide sequence of yt14.sub.--1 as presently determined is reported in SEQ ID NO:91, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yt14.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:92. Amino acids 1 to 9 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 10. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yk2511 protein.

[3025] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yt14.sub.--1 should be approximately 2429 bp.

[3026] The nucleotide sequence disclosed herein for yt14.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yt14.sub.--1 demonstrated at least some similarity with sequences identified as W07167 (za93b12.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 300095 5', mRNA sequence). The predicted amino acid sequence disclosed herein for yt14.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted yt14.sub.--1 protein demonstrated at least some similarity to the sequence identified as AF002196 (weak similarity to Bacillus and Pseudomonas probable glucarate transporters (GI 709999 and PIR S27616) [Caenorhabditis elegans]). Based upon sequence similarity, yt14.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts six potential transmembrane domains within the yt14.sub.--1 protein sequence, centered around amino acids 10, 40, 65, 90, 130, and 160 of SEQ ID NO:92, respectively. The nucleotide sequence of yt14.sub.--1 indicates that it may contain Alu and L1 repetitive elements.

[3027] Clone "bf157.sub.--16"

[3028] A polynucleotide of the present invention has been identified as clone "bf157.sub.--16". bf157.sub.--16 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bf157.sub.--16 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "bf157.sub.--16 protein").

[3029] The nucleotide sequence of bf157.sub.--16 as presently determined is reported in SEQ ID NO:93, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bf157.sub.--16 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:94.

[3030] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bf157.sub.--16 should be approximately 3480 bp.

[3031] The nucleotide sequence disclosed herein for bf157.sub.--16 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bf157.sub.--16 demonstrated at least some similarity with sequences identified as AA186595 (zo71g04.r1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 592374 5' similar to WP C16A3.3 CE04004 HUMAN ALPHA-FETOPROTEIN ENHANCER-BINDING PROTEIN), AA630405 (ac09b05.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 855921 3' similar to WP C16A3.3 CE04004 HUMAN ALPHA-FETOPROTEIN ENHANCER-BINDING PROTEIN; mRNA sequence), AF075104 (Homo sapiens full length insert cDNA YR39H06), H49655 (yq20h07.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 274428 3'), Z28494 (H. sapiens partial cDNA sequence; clone 22G07; version 1; strand(-), single read), Z56794 (H.sapiens CpG island DNA genomic Mse1 fragment, clone), and Z64553 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 139f5, forward read cpg139f5.ft1a). The predicted amino acid sequence disclosed herein for bf157.sub.--16 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bf157.sub.--16 protein demonstrated at least some similarity to sequences identified as R23962 (AFP-1. DNA encoding protein binding to alpha-fetoprotein gene enhancer-useful for prodn. of biological active protein), and U41534 (similar to yeast hypothetical protein (SP:YB9M_YEAST,P38344); similar to human alpha-fetoprotein enhancer-binding protein (PIR:A41948) [Caenorhabditis elegans]). Based upon sequence similarity, bf157.sub.--16 proteins and each similar protein or peptide may share at least some activity. Hidden Markov model and motifs analyses have revealed the presence of the following protein domains in the predicted bf157.sub.--16 protein: four Zinc finger, C2H2 type, domains at amino acids 4 to 28, 67 to 91, 252 to 275, and 303 to 330 of SEQ ID NO:94; and a D-isomer-specific 2-hydroxyacid dehydrogenases signature at residues 119 to 131 of SEQ ID NO:94. A number of NAD-dependent 2-hydroxyacid dehydrogenases, with at least some specificity for the D-isomer of their substrate, have been shown to be functionally and structurally related. Clone bf157.sub.--16 appears to encode a novel protein which may have NAD-dependent 2-hydroxyacid dehydrogenase activity.

[3032] bf157.sub.--16 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 16 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[3033] Clone "bk343.sub.--2"

[3034] A polynucleotide of the present invention has been identified as clone "bk343.sub.--2". bk343.sub.--2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bk343.sub.--2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bk343.sub.--2 protein").

[3035] The nucleotide sequence of bk343.sub.--2 as presently determined is reported in SEQ ID NO:95, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bk343.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:96.

[3036] Another possible reading frame within the bk343.sub.--2 clone extends from nucleotide 45 to nucleotide 188 of SEQ ID NO:95, and encodes the amino acid sequence reported in SEQ ID NO:239. Amino acids 5 to 17 of SEQ ID NO:239 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO:239.

[3037] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bk343.sub.--2 should be approximately 1600 bp.

[3038] The nucleotide sequence disclosed herein for bk343.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bk343.sub.--2 demonstrated at least some similarity with sequences identified as AA156969 (zo51d05.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 590409 5'), AA947938 (oe60c08.s1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1416014 3', mRNA sequence), N31147 (yx52g05.r1 Homo sapiens cDNA clone 265400 5'), N42759 (yy22a09.r1 Homo sapiens cDNA clone 271960 5'), N47537 (yy90h10.s1 Homo sapiens cDNA clone 280867 3'), R68913 (yi43b04.r1 Homo sapiens cDNA clone 141967 5'), T24885 (Human gene signature HUMGS06991; standard; cDNA to mRNA), and T30099 (EST112339 Homo sapiens cDNA 5' end similar to None). The predicted amino acid sequence disclosed herein for bk343.sub.--2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bk343.sub.--2 protein demonstrated at least some similarity to sequences identified as Z72508 (F28H7.4 [Caenorhabditis elegans]) and Z78417 (C35C5.3 [Caenorhabditis elegans]). Based upon sequence similarity, bk343.sub.--2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the bk343.sub.--2 protein sequence centered around amino acid 36 of SEQ ID NO:96.

[3039] Clone "cd205.sub.--2"

[3040] A polynucleotide of the present invention has been identified as clone "cd205.sub.--2". cd205.sub.--2 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cd205.sub.--2 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "cd205.sub.--2 protein").

[3041] The nucleotide sequence of cd205.sub.--2 as presently determined is reported in SEQ ID NO:97, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cd205.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:98. Amino acids 92 to 104 of SEQ ID NO:98 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 105. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the cd205.sub.--2 protein.

[3042] Another possible reading frame within the cd205.sub.--2 clone extends from nucleotide 59 to nucleotide 478 of SEQ ID NO:97, and encodes the amino acid sequence reported in SEQ ID NO:240. The open reading frames encoding the amino acid sequences of SEQ ID NO:98 and SEQ ID NO:240 could be joined if one or more frame shifts were made in the nucleotide sequence of SEQ ID NO:97.

[3043] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cd205.sub.--2 should be approximately 1300 bp.

[3044] The nucleotide sequence disclosed herein for cd205.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cd205.sub.--2 demonstrated at least some similarity with sequences identified as AA053543 (zl71f10.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 510091 5' similar to gb:M77830 DESMOPLAKIN I AND II (HUMAN)), AC005332 (Homo sapiens chromosome 17, clone hRPK.147_L.sub.--13, complete sequence), N84944 (J1677F Homo sapiens cDNA clone J1677 5' similar to CHROMOSOME 4 (CLONE P4-661) STS4-563), N86274 (J7481F Fetal heart, Lambda ZAP Express Homo sapiens cDNA clone J7481 5' similar to CHROMOSOME 4 (CLONE P4-661) STS4-563), W68823 (zd37f04.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 342847 5', mRNA sequence), and Z54387 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 10.sub.g3, reverse read cpg10g3.rt1a). Based upon sequence similarity, cd205.sub.--2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the cd205.sub.--2 protein sequence located around amino acid 105 of SEQ ID NO:98.

[3045] Clone "cw1292.sub.--8"

[3046] A polynucleotide of the present invention has been identified as clone "cw1292.sub.--8". cw1292.sub.--8 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cw1292.sub.--8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "cw1292.sub.--8 protein").

[3047] The nucleotide sequence of cw1292.sub.--8 as presently determined is reported in SEQ ID NO:99, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cw1292.sub.--8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:100. Amino acids 18 to 30 of SEQ ID NO:100 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 31. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the cw1292.sub.--8 protein.

[3048] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cw1292.sub.--8 should be approximately 1100 bp.

[3049] The nucleotide sequence disclosed herein for cw1292.sub.--8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cw1292.sub.--8 demonstrated at least some similarity with sequences identified as AA017976 (mh46h10.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus), AA423855 (zv79c04.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 759846 3'), AA626784 (ad09f08.s1 Soares NbHFB Homo sapiens cDNA clone 877767 3', mRNA sequence), H23387 (ym57f05.r1 Homo sapiens cDNA clone 52337 5'), H78534 (yu13d06.r1 Homo sapiens cDNA clone 233675 5'), H79021 (yu13d06.s1 Homo sapiens cDNA clone 233675 3'), R44807 (yg23g06.s1 Homo sapiens cDNA clone 33217 3'), T24772 (Human gene signature HUMGS06848; standard; cDNA to mRNA), T97424 (ye53h08.r1 Homo sapiens cDNA clone 121503 5'), and Z44597 (H. sapiens partial cDNA sequence; clone c-25a05). The predicted amino acid sequence disclosed herein for cw1292.sub.--8 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted cw1292.sub.--8 protein demonstrated at least some similarity to the sequence identified as M33521 (HLA-B-associated transcript 3 (BAT3) [Homo]). Based upon sequence similarity, cw1292.sub.--8 proteins and each similar protein or peptide may share at least some activity.

[3050] Clone "cw1475.sub.--2"

[3051] A polynucleotide of the present invention has been identified as clone "cw1475.sub.--2". cw1475.sub.--2 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cw1475.sub.--2 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "cw1475.sub.--2 protein").

[3052] The nucleotide sequence of cw1475.sub.--2 as presently determined is reported in SEQ ID NO:101, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cw1475.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:102.

[3053] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cw1475.sub.--2 should be approximately 2800 bp.

[3054] The nucleotide sequence disclosed herein for cw1475.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cw1475.sub.--2 demonstrated at least some similarity with sequences identified as AA527429 (ng41a10.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE:937338, mRNA sequence), AD000092 (Homo sapiens DNA from chromosome 19p13.2 cosmids R31240, R30272 and R28549 containing the EKLF, GCDH, CRTC, and RAD23A genes, genomic sequence), H98508 (yv90f08.r1 Homo sapiens cDNA clone 250023 5'), N25554 (yx76f08.s1 Homo sapiens cDNA clone 267687 3'), N50970 (yy94b06.s1 Homo sapiens cDNA clone 281171 3'), N81188 (yw36g06.r1 Homo sapiens cDNA clone 254362 5'), R32569 (yh54g03.r1 Homo sapiens cDNA clone 133588 5'), R81017 (yi94g02.r1 Homo sapiens cDNA clone 146930 5' similar to contains Alu repetitive element contains MER30 repetitive element), T06537 (EST04426 Homo sapiens cDNA clone HFBDU83 similar to EST containing Alu repeat), T31594 (Probe (BLUR11) for Alu repeat sequence), and W30895 (zb78e12.r1 Soares senescent fibroblasts NbHSF Homo). Based upon sequence similarity, cw1475.sub.--2 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of cw1475.sub.--2 indicates that it may contain noe or more of the following repetitive elements: Alu, SVA.

[3055] Clone "dd428.sub.--4"

[3056] A polynucleotide of the present invention has been identified as clone "dd428.sub.--4". dd428.sub.--4 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dd428.sub.--4 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "dd428.sub.--4 protein").

[3057] The nucleotide sequence of dd428.sub.--4 as presently determined is reported in SEQ ID NO:103, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dd428.sub.--4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:104.

[3058] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dd428.sub.--4 should be approximately 1500 bp.

[3059] The nucleotide sequence disclosed herein for dd428.sub.--4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dd428.sub.--4 demonstrated at least some similarity with sequences identified as AC000057 (Human BAC clone RG067M09 from 7q21-7q22; HTGS phase 3, complete sequence), AC005500 (complete sequence), L27428 (Human L1 putative reverse transcriptase gene insertion in hamster, 3' end), T86176 (yd78c11.s1 Homo sapiens cDNA clone 114356 3' similar to gb L25879 EPOXIDE HYDROLASE (HUMAN); contains L1 repetitive element), X61307 (Staphylococcus aureus spa gene for protein A), and Z69647 (Human DNA sequence from cosmid E118G4, maps to 10cen and 11q13-q14). Based upon sequence similarity, dd428.sub.--4 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of dd428.sub.--4 indicates that it may contain L1 repeat sequences.

[3060] Clone "dh1073.sub.--12"

[3061] A polynucleotide of the present invention has been identified as clone "dh1073.sub.--12". dh1073.sub.--12 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dh1073.sub.--12 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "dh1073.sub.--12 protein").

[3062] The nucleotide sequence of dh1073.sub.--12 as presently determined is reported in SEQ ID NO:105, and includes a poly(A) tail What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dh1073.sub.--12 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:106.

[3063] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dh1073.sub.--12 should be approximately 2400 bp.

[3064] The nucleotide sequence disclosed herein for dh1073.sub.--12 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dh1073.sub.--12 demonstrated at least some similarity with sequences identified as AA257983 (zs35h03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 687221 3' similar to TR G666014 G666014 SA SA GENE PRODUCT, COMPLETE CDS PRECURSOR; mRNA sequence), AA526325 (ni59g06.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone 981178 similar to contains Alu repetitive element), AF001549 (Human Chromosome 16 BAC clone CIT987SK-A-270G1, complete sequence), N57823 (yv59e04.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 247038 3'), and N68408 (za13c05.s1 Homo sapiens cDNA clone 292424 3'). The predicted amino acid sequence disclosed herein for cw1292.sub.--8 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted dh1073.sub.--12 protein demonstrated at least some similarity to the sequence identified as AC003034 (Gene with similarity to rat kidney-specific (KS) gene [Homo sapiens]). Based upon sequence similarity, dh1073.sub.--12 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of dh1073.sub.--12 indicates that it may contain an Alu repetitive element.

[3065] Clone "dw78.sub.--1"

[3066] A polynucleotide of the present invention has been identified as clone "dw78.sub.--1". dw78.sub.--1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dw78.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dw78.sub.--1 protein").

[3067] The nucleotide sequence of dw78.sub.--1 as presently determined is reported in SEQ ID NO:107, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dw78.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:108.

[3068] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dw78.sub.--1 should be approximately 1400 bp.

[3069] The nucleotide sequence disclosed herein for dw78.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dw78.sub.--1 demonstrated at least some similarity with sequences identified as AA807622 (nv65g11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1234724, mRNA sequence), AF086326 (Homo sapiens full length insert cDNA clone ZD54A02), D37980 (Dictyostelium discoidium DDCOF1 gene for cofilin, complete cds (exon1-2)), H26207 (yl53c04.r1 Homo sapiens cDNA clone 161958 5'), N72717 (za47h03.s1 Homo sapiens cDNA clone 295733 3' similar to contains Alu repetitive element; contains element L1 repetitive element), T23963 (Human gene signature HUMGS05917; standard; cDNA to mRNA), U14567 (*** ALU WARNING Human Alu-J subfamily consensus sequence), U-43572 (Human alpha-N-acetylglucosaminidase (NAGLU) gene, complete cds), W42787 (zc25a04.s1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 323310 3'), and W73472 (zd54a02.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344426 3', mRNA sequence). The predicted amino acid sequence disclosed herein for dw78.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted dw78.sub.--1 protein demonstrated at least some similarity to the sequence identified as D32202 (alpha 1C adrenergic receptor isoform 2 [Homo sapiens]). Based upon sequence similarity, dw78.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the dw78.sub.--1 protein sequence, one centered around amino acid 45 and another around amino acid 93 of SEQ ID NO:108. The nucleotide sequence of dw78.sub.--1 indicates that it may contain an Alu repetitive element.

[3070] Clone "fh116.sub.--11"

[3071] A polynucleotide of the present invention has been identified as clone "ffh116.sub.--11". fh116.sub.--11 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fh116.sub.--11 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fh116.sub.--11 protein").

[3072] The nucleotide sequence of fh11611 as presently determined is reported in SEQ ID NO:109, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fh116.sub.--11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:110.

[3073] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fh116.sub.--1 should be approximately 1200 bp.

[3074] The nucleotide sequence disclosed herein for fh116.sub.--11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fh116.sub.--11 demonstrated at least some similarity with sequences identified as AA054185 (zf51c06.r1 Soares retina N2b4HR Homo sapiens cDNA clone 380458 5'), AA057975 (mj57b02.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 480171 5' similar to WP:F57A8.2 CE05983), AA128902 (zn90a05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565424 3'), AA426021 (zw49h09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773441 3'), AA505926 (nh98g03.s1 NCI_CGAP_Br2 Homo sapiens cDNA clone 966580), AI079540 (oz04e08.x1 Soares_fetal_liver_spleen.sub.--1NFLS--S1 Homo sapiens cDNA clone IMAGE:1674374 3' similar to WP:F57A8.2 CE05983; mRNA sequence), H68794 (yr91h09.s1 Homo sapiens cDNA clone 2127053'), H86659 (yt02c04.r1 Homo sapiens cDNA clone 223110 5'), T24554 (Human gene signature HUMGS06604; standard; cDNA to mRNA), U96490 (Rattus norvegicus liver mRNA, complete cds), and W00635 (yy71d12.r1 Homo sapiens cDNA clone 278999 5' similar to contains element PTR5 repetitive element). The predicted amino acid sequence disclosed herein for fh116.sub.--11 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fh116.sub.--11 protein demonstrated at least some similarity to sequences identified as AF004876 (54TMp [Homo sapiens]), U96490 (unknown [Rattus norvegicus]), and Z70781 (F57A8.2 [Caenorhabditis elegans]). Based upon sequence similarity, fh116.sub.--11 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five potential transmembrane domains within the fh116.sub.--11 protein sequence, centered around amino acids 35 to 49, 136, 171, 215, and 270 of SEQ ID NO:110, respectively.

[3075] fh116.sub.--11 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 28 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[3076] Clone "fy356.sub.--14"

[3077] A polynucleotide of the present invention has been identified as clone "fy356.sub.--14". fy356.sub.--14 was isolated from a human fetal placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fy356.sub.--14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "fy356.sub.--14 protein").

[3078] The nucleotide sequence of fy356.sub.--14 as presently determined is reported in SEQ ID NO:111, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fy356.sub.--14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:112. Amino acids 385 to 397 of SEQ ID NO:112 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 398. Due to the hydrophobic nature of this possible leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the fy356.sub.--14 protein.

[3079] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fy356.sub.--14 should be approximately 3700 bp.

[3080] The nucleotide sequence disclosed herein for fy356.sub.--14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fy356.sub.--14 demonstrated at least some similarity with sequences identified as AA017639 (ze38c05.r1 Soares retina N2b4HR Homo sapiens cDNA clone 361256 5' similar to PIR S55385 S55385 PEA-15 protein--mouse), AA181529 (zp51f07.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 612997 3'), AA687129 (nv63d03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1234469), AA811277 (ob68e06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:1336546, mRNA sequence), N53623 (yz04e01.r1 Homo sapiens cDNA clone 282072 5'), T25935 (Human gene signature HUMGS08167; standard; cDNA to mRNA), T24538 (Human gene signature HUMGS06585; standard; cDNA to mRNA), and X86809 (H.sapiens mRNA for major astrocytic phosphoprotein PEA-15). The predicted amino acid sequence disclosed herein for fy356.sub.--14 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fy356.sub.--14 protein demonstrated at least some similarity to the sequence identified as X86809 (PEA-15 gene product [Homo sapiens]). Based upon sequence similarity, fy356.sub.--14 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the fy356.sub.--14 protein sequence, centered around amino acid 398 of SEQ ID NO:112.

[3081] Clone "iw66.sub.--1"

[3082] A polynucleotide of the present invention has been identified as clone "iw66.sub.--1". iw66.sub.--1 was isolated from a human adult retina (WERI-Rb1 retinoblastoma line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. iw66.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "iw66.sub.--1 protein").

[3083] The nucleotide sequence of iw66.sub.--1 as presently determined is reported in SEQ ID NO:113, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the iw66.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:114. Amino acids 9 to 21 of SEQ ID NO:114 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the iw66.sub.--1 protein.

[3084] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone iw66.sub.--1 should be approximately 1450 bp.

[3085] The nucleotide sequence disclosed herein for iw66.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. iw66.sub.--1 demonstrated at least some similarity with sequences identified as AA216917 (mv75h11.r1 Soares mouse 3NME12 5 Mus musculus cDNA clone 660933 5'), AA339406 (EST44484 Fetal brain I Homo sapiens cDNA 5' end), AI275861 (ql68b12.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:1877471 3', mRNA sequence), Q61257 (Human brain Expressed Sequence Tag EST01278; standard; DNA), R89651 (ym97c08.r1 Homo sapiens cDNA clone 166862 5'), W53584 (md55f06.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 372323 5'), and Z60886 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 38a8, reverse read cpg38a8.rt1a). The predicted amino acid sequence disclosed herein for iw66.sub.--1 was searched against the GenPept and GeneSeq ammo acid sequence databases using the BLASTX search protocol. The predicted iw66.sub.--1 protein demonstrated at least some similarity to sequences identified as AF004874 (latent TGF-beta binding protein-2 [Mus musculus]), L29029 (amino acid feature Rod protein domain, aa 266 468; amino acid feature globular protein domain, aa 32 . . . 265 [Chlamydomonas reinhardtii]), R27150 (PspA fragment), and R79478 (Mouse LTBP-2). Based upon sequence similarity, iw66.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three additional potential transmembrane domains within the iw66.sub.--1 protein sequence, centered around amino acids 45, 74, and 158 of SEQ ID NO:114, respectively. The nucleotide sequence of iw66.sub.--1 indicates that it may contain one or more of the following repetitive elements: MIR.

[3086] Clone "kh13.sub.--4"

[3087] A polynucleotide of the present invention has been identified as clone "kh13.sub.--4". kh13.sub.--4 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. kh13.sub.--4 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "kh13.sub.--4 protein").

[3088] The nucleotide sequence of kh13.sub.--4 as presently determined is reported in SEQ ID NO:115, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the kh13.sub.--4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:116.

[3089] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone kh13.sub.--4 should be approximately 950 bp.

[3090] The nucleotide sequence disclosed herein for kh13.sub.--4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. kh13.sub.--4 demonstrated at least some similarity with sequences identified as AA435981 (zu01f08.s1 Soares testis NHT Homo sapiens cDNA clone 730599 3'), AA436078 (zu01f08.r1 Soares testis NHT Homo sapiens cDNA clone 730599 5'), AA778636 (af87c04.s1 Soares testis NHT Homo sapiens cDNA clone 1048998 3' similar to gb:M94856 PSORIASIS-ASSOCIATED FATTY ACID BINDING PROTEIN HOMOLOG (HUMAN); mRNA sequence), M94856 (Human fatty acid binding protein homologue (PA-FABP) mRNA, complete cds), and Q66842 (Melanogenic inhibitor; standard; DNA). The predicted amino acid sequence disclosed herein for kh13.sub.--4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted kh13.sub.--4 protein demonstrated at least some similarity to sequences identified as M94856 (fatty acid binding protein homologue [Homo sapiens]) and R55866 (Melanogenic inhibitor). Fatty acid binding protein homologue (M94856) is described as "a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins." Based upon sequence similarity, kh13.sub.--4 proteins and each similar protein or peptide may share at least some activity.

[3091] Clone "ko258.sub.--4"

[3092] A polynucleotide of the present invention has been identified as clone "ko258.sub.--4". ko258.sub.--4 was isolated from a human adult uterus cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ko258.sub.--4 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "ko258.sub.--4 protein").

[3093] The nucleotide sequence of ko258.sub.--4 as presently determined is reported in SEQ ID NO:117, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ko258.sub.--4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:118.

[3094] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ko258.sub.--4 should be approximately 2500 bp.

[3095] The nucleotide sequence disclosed herein for ko258.sub.--4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ko258.sub.--4 demonstrated at least some similarity with sequences identified as AC002401 (*** SEQUENCING IN PROGRESS *** Homo sapiens chromosome 17, clone RPC875H18; HTGS phase 1, 4 unordered pieces), AC002401 (Homo sapiens chromosome 17, clone RPC875H18, complete sequence), C15329 (Human fetal brain cDNA 5'-end GEN-133H10, mRNA sequence), AF035306 (Homo sapiens clone 23771 mRNA sequence), and R28382 (IMAGE 3p clone). Based upon sequence similarity, ko258.sub.--4 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ko258.sub.--4 protein sequence, centered around amino acid 28 of SEQ ID NO:118.

[3096] Clone "kv10.sub.--8"

[3097] A polynucleotide of the present invention has been identified as clone "kv10.sub.--8". kv10.sub.--8 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. kv10.sub.--8 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "kv10.sub.--8 protein").

[3098] The nucleotide sequence of kv10.sub.--8 as presently determined is reported in SEQ ID NO:119, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the kv10.sub.--8 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:120.

[3099] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone kv10.sub.--8 should be approximately 4300 bp.

[3100] The nucleotide sequence disclosed herein for kv10.sub.--8 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. kv10.sub.--8 demonstrated at least some similarity with sequences identified as AA418842 (zw01e12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 768046 3'), AC004228 (*** SEQUENCING IN PROGRESS *** Homo sapiens Chromosome 11q12 pac pDJ519o3; HTGS phase 1, 18 unordered pieces), AF052108 (Homo sapiens clone 23687 mRNA sequence), R00761 (ye78b11.s1 Homo sapiens cDNA clone 123837 3'), T83434 (yd46b04.r1 Homo sapiens cDNA clone 111247 5'), T84080 (yd46b04.s1 Homo sapiens cDNA clone 111247 3'), and U00594 (Mustela vison unknown mRNA down regulated by TGF-beta, partial sequence). Based upon sequence similarity, kv10.sub.--8 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the kv10.sub.--8 protein sequence, centered around amino acids 35 to 45 of SEQ ID NO:120. The nucleotide sequence of kv10.sub.--8 indicates that it may contain one or more of the following repetitive elements: Alu, SVA.

[3101] Clone "LL89.sub.--3"

[3102] A polynucleotide of the present invention has been identified as clone "LL89.sub.--3". LL89.sub.--3 was isolated from a human adult thyroid cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. LL89.sub.--3 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "LL89.sub.--3 protein").

[3103] The nucleotide sequence of LL89.sub.--3 as presently determined is reported in SEQ ID NO:121, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the LL89.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:122.

[3104] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone LL89.sub.--3 should be approximately 900 bp.

[3105] The nucleotide sequence disclosed herein for LL89.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. LL89.sub.--3 demonstrated at least some similarity with sequences identified as AL031010 (Human DNA sequence *** SEQUENCING IN PROGRESS from clone 422F24, complete sequence), H78002 (yu82h09.r1 Homo sapiens cDNA clone 240353 5'), and W90018 (zh72c08.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 417614 3'). Based upon sequence similarity, LL89.sub.--3 proteins and each similar protein or peptide may share at least some activity.

[3106] Clone "mc300.sub.--1"

[3107] A polynucleotide of the present invention has been identified as clone "mc300.sub.--1". mc300.sub.--1 was isolated from a human adult thyroid cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. mc300.sub.--1 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "mc300.sub.--1 protein").

[3108] The nucleotide sequence of mc300.sub.--1 as presently determined is reported in SEQ ID NO:123, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the mc300.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:124.

[3109] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone mc300.sub.--1 should be approximately 2600 bp.

[3110] The nucleotide sequence disclosed herein for mc300.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. mc300.sub.--1 demonstrated at least some similarity with sequences identified as AA142942 (IMAGE 3p clone), AA315299 (EST187017 Colon carcinoma (HCC) cell line Homo sapiens cDNA 5' end), AA142942 (zl43c04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 504678 3'), AI246503 (qn64a06.x1 NCI_CGAP_HN4 Homo sapiens cDNA clone IMAGE:1902994 3', mRNA sequence), D61461 (Human fetal brain cDNA 5'-end GEN-404B08), D79662 (Human aorta cDNA 5'-end GEN-300D05, mRNA sequence), H93575 (yv14h11.s1 Homo sapiens cDNA clone 242757 3'), T25928 (Human gene signature HUMGS08160; standard; cDNA to mRNA), and W93059 (zd93h06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 357083 3'). Based upon sequence similarity, mc300.sub.--1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of mc300.sub.--1 indicates that it may contain one or more Alu repetitive elements.

[3111] Clone "ml227.sub.--1"

[3112] A polynucleotide of the present invention has been identified as clone "ml227.sub.--1". ml227.sub.--1 was isolated from a human adult brain (caudate nucleus) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ml227.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ml227.sub.--1 protein").

[3113] The nucleotide sequence of ml227.sub.--1 as presently determined is reported in SEQ ID NO:125, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ml227.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:126.

[3114] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ml227.sub.--1 should be approximately 2700 bp.

[3115] The nucleotide sequence disclosed herein for ml227.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ml227.sub.--1 demonstrated at least some similarity with sequences identified as AA857826 (oe88e05.s1 NCI_CGAP_Col2 Homo sapiens cDNA clone IMAGE:1418720 3', mRNA sequence), F18464 (H.sapiens EST sequence (017-T4-16) from skeletal muscle), H30845 (yo78d11.r1 Homo sapiens cDNA clone 184053 5'), T06839 (EST04728 Homo sapiens cDNA clone HFBDZ66), T19759 (Human gene signature HUMGS00834), T26021 (Human gene signature HUMGS08257; standard; cDNA to mRNA), and Z69043 (H.sapiens mRNA translocon-associated protein delta subunit precursor). The predicted amino acid sequence disclosed herein for ml227.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ml227.sub.--1 protein demonstrated at least some similarity to the sequence identified as Z69664 (K04D7.5 [Caenorhabditis elegans]). Based upon sequence similarity, ml227.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts six potential transmembrane domains within the ml227.sub.--1 protein sequence, centered around amino acids 465, 510, 560, 572, 595, and 615 of SEQ ID NO:126, respectively.

[3116] Clone "mm367.sub.--6"

[3117] A polynucleotide of the present invention has been identified as clone "mm367.sub.--6". mm367.sub.--6 was isolated from a human adult retina (WERI-Rb1 retinoblastoma line) cDNA library and was identified as encoding a protein. mm367.sub.--6 is a full-length clone, including the entire coding sequence of a protein (also referred to herein as "mm367.sub.--6 protein").

[3118] The nucleotide sequence of mm367.sub.--6 as presently determined is reported in SEQ ID NO:127, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the mm367.sub.--6 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:128.

[3119] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone mm367.sub.--6 should be approximately 2600 bp.

[3120] The nucleotide sequence disclosed herein for mm367.sub.--6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. mm367.sub.--6 demonstrated at least some similarity with sequences identified as AA114127 (zn65f02.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 563067 5'), AA127284 (zn91c12.r1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 565558 5'), AA173842 (zp30d01.r1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 610945 5'), AF000364 (Homo sapiens heterogeneous nuclear ribonucleoprotein R mRNA, complete CDs), N31934 (yy22d10.s1 Homo sapiens cDNA clone 271987 3'), T24354 (Human gene signature HUMGS06385; standard; cDNA to mRNA), U48271 (Dictyostelium discoideum UbpA deubiquitinase mRNA, complete CDs), W16579 (zb13g11.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 301988 5'), and W72461 (zd67f06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 345731 3'). The predicted amino acid sequence disclosed herein for mm367.sub.--6 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted mm367.sub.--6 protein demonstrated at least some similarity to sequences identified as AF000364 (heterogeneous nuclear ribonucleoprotein R [Homo sapiens]) and W26553 (Human heterogeneous nuclear ribonucleoprotein (hnRNP) A2). Based upon sequence similarity, mm367.sub.--6 proteins and each similar protein or peptide may share at least some activity.

[3121] mm367.sub.--6 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 79 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[3122] Clone "mt124.sub.--3"

[3123] A polynucleotide of the present invention has been identified as clone "mt124.sub.--3". mt124.sub.--3 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. mt124.sub.--3 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "mt124.sub.--3 protein").

[3124] The nucleotide sequence of mt124.sub.--3 as presently determined is reported in SEQ ID NO:129, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the mt124.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:130.

[3125] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone mt124.sub.--3 should be approximately 1100 bp.

[3126] The nucleotide sequence disclosed herein for mt124.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. mt124.sub.--3 demonstrated at least some similarity with sequences identified as AA435386 (ve15h01.r1 Soares mouse NbMH Mus musculus cDNA clone 818257 5' similar to TR:E198756 E198756 PUTATIVE ORF), AI185116 (qe51g07.x1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone IMAGE 1742556 3' similar to TR Q92564 Q92564 MYELOBLAST KIAA0276; mRNA sequence), C03847 (Human Heart cDNA, clone 3NHC2256), N74186 (za76h03.s1 Homo sapiens cDNA clone 298517 3'), T24234 (Human gene signature HUMGS06248; standard; cDNA to mRNA), W87997 (mf65b06.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 419123 5'), and Z86062 (Human DNA sequence from PAC 121G13 on chromosome 6 contains flow sorted chromosome 6 HindIII fragment ESTs, polymorphic CA repeat, CpG island, CpG island genomic fragments). The predicted amino acid sequence disclosed herein for mt124.sub.--3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted mt124.sub.--3 protein demonstrated at least some similarity to sequences identified as AL024499 (H38K22.2 [Caenorhabditis elegans]) and D87466 (Similar to S.cerevisiae hypothetical protein L3111 (S59316) [Homo sapiens]). Based upon sequence similarity, mt124.sub.--3 proteins and each similar protein or peptide may share at least some activity.

[3127] Clone "nf56.sub.--3"

[3128] A polynucleotide of the present invention has been identified as clone "nf56.sub.--3". nf56.sub.--3 was isolated from a human adult brain (substantia nigra) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. nf56.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "nf56.sub.--3 protein").

[3129] The nucleotide sequence of nf56.sub.--3 as presently determined is reported in SEQ ID NO:131, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the nf56.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:132. Amino acids 3 to 15 of SEQ ID NO:132 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the nf56.sub.--3 protein.

[3130] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone nf56.sub.--3 should be approximately 5000 bp.

[3131] The nucleotide sequence disclosed herein for nf56.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. nf56.sub.--3 demonstrated at least some similarity with sequences identified as H08054 (yl86a09.s1 Homo sapiens cDNA clone 44915 3'), Q60495 (Human brain Expressed Sequence Tag EST02500; standard; cDNA), T25509 (Human gene signature HUMGS07678), W34534 (mc58h01.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 352753 5'), and Z64987 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 186b1, reverse read cpg186b1.rt1b). The predicted amino acid sequence disclosed herein for nf56.sub.--3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted nf56.sub.--3 protein demonstrated at least some similarity to sequences identified as D86983 (similar to D.melanogaster peroxidasin (U11052) [Homo sapiens]), R25079 (Drosophila SLIT protein involved in axon pathway development), and X53959 (slit protein [Drosophila melanogaster]). Based upon sequence similarity, nf56.sub.--3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the nf56.sub.--3 protein sequence, one centered around amino acid 514 and another around amino acid 628 of SEQ ID NO:132.

[3132] Clone "qy442.sub.--2"

[3133] A polynucleotide of the present invention has been identified as clone "qy442.sub.--2". qy442.sub.--2 was isolated from a human adult blood (promyelocytic leukemia HL-60 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qy442.sub.--2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qy442.sub.--2 protein").

[3134] The nucleotide sequence of qy442.sub.--2 as presently determined is reported in SEQ ID NO:133, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qy442.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:134. Amino acids 3 to 15 of SEQ ID NO:134 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qy442.sub.--2 protein.

[3135] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qy442.sub.--2 should be approximately 1800 bp.

[3136] The nucleotide sequence disclosed herein for qy442.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qy442.sub.--2 demonstrated at least some similarity with sequences identified as AI081522 (on04e12.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1555726 3' similar to contains Alu repetitive element; mRNA sequence) and AA449854 (zx37a06.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 788626 5'). Based upon sequence similarity, qy442.sub.--2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the qy442.sub.--2 protein sequence, centered around amino acid 68 of SEQ ID NO:20. The nucleotide sequence of qy442.sub.--2 indicates that it may contain one or more Alu repetitive elements.

[3137] Clone "rj214.sub.--14"

[3138] A polynucleotide of the present invention has been identified as clone "rj214.sub.--14". rj214.sub.--14 was isolated from a human adult neural (neuroepithelioma HTB-10 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rj214.sub.--14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rj214.sub.--14 protein").

[3139] The nucleotide sequence of rj214.sub.--14 as presently determined is reported in SEQ ID NO:135, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rj214.sub.--14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:136. Amino acids 3 to 15 of SEQ ID NO:136 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rj214.sub.--14 protein.

[3140] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rj214.sub.--14 should be approximately 900 bp.

[3141] The nucleotide sequence disclosed herein for rj214.sub.--14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rj214.sub.--14 demonstrated at least some similarity with sequences identified as AA167035 (zp05c10.s1 Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 595506 3' similar to TR:G563357 G563357 GENES RAS1, RLB1 AND RLC1; mRNA sequence), AA491109 (aa52d09.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 824561 5' similar to TR G563357 G563357 GENES RAS1, RLB1 AND RLC1), and AI189156 (qd04c02.x1 Soares_placenta.sub.--8 to 9 weeks.sub.--2NbHP8 to 9W Homo sapiens cDNA clone IMAGE:1722722 3' similar to TR:O01437 O01437 SIMILAR TO DROSOPHILA RLC1 GENE PRODUCT; mRNA sequence). The predicted amino acid sequence disclosed herein for rj214.sub.--14 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted rj214.sub.--14 protein demonstrated at least some similarity to sequences identified as U97016 (similar to drosophila Rlc1 gene product (NID g563361) and S. cerevisiae mitochondrial 60S ribosomal protein L4 (YML4) (NID g459259) [Caenorhabditis elegans]), and X73219 (Rlc1). Drosophila Rlc1 is a basic protein that is bound to the inner face of the cell membrane. Transcription mapping and nucleotide sequence analysis reveal that Rlc1 lies in the same genomic region as Drosophila Ras1 and shows expression patterns that are similar to those of Ras1. It has been demonstrated (Ezer et al., 1994, Dev. Dyn. 201(2): 179-190, which is incorporated by reference herein) that during embryogenesis Ras1 transcripts are restricted mainly to the embryonic central nervous system, suggesting that the Rlc1 gene product also may have a role in these nerve cells. Based upon sequence similarity, rj214.sub.--14 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the rj214.sub.--14 protein sequence, centered around amino acid 32 of SEQ ID NO:136.

[3142] rj214.sub.--14 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 22 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[3143] Clone "rk80.sub.--3"

[3144] A polynucleotide of the present invention has been identified as clone "rk80.sub.--3". rk80.sub.--3 was isolated from a human adult tumor (colorectal adenocarcinoma SW480 line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. rk80.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "rk80.sub.--3 protein").

[3145] The nucleotide sequence of rk80.sub.--3 as presently determined is reported in SEQ ID NO:137, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the rk80.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:138. Amino acids 6 to 18 of SEQ ID NO:138 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the rk80.sub.--3 protein.

[3146] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone rk80.sub.--3 should be approximately 1096 bp.

[3147] The nucleotide sequence disclosed herein for rk80.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. rk80.sub.--3 demonstrated at least some similarity with sequences identified as AA418955 (zw01c10.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 768018 5', mRNA sequence), AB004061 (domestic pig mRNA for STAT2, complete CDs, a signal transducer and activator of transcription), C06368 (similar to none), and U38443 (Human clone JkA3 mRNA induced upon T-cell activation, 3' end). The predicted rk80.sub.--3 protein demonstrated at least some similarity to granulocyte-colony stimulating factor (G-CSF) and interleukin-6 (IL-6). Hidden Markov model analysis has revealed the presence of an IL-6/G-CSF/mast cell growth factor (MGF) family signature at amino acids 69 to 181 of SEQ ID NO:138. This family of cytokines are glycoproteins of about 170 to 180 amino acid residues in size that contain four conserved cysteine residues involved in two disulfide bonds. rk80.sub.--3 appears to encode a novel cytokine in the IL-6/G-CSF family. Based upon sequence similarity, rk80.sub.--3 proteins and each similar protein or peptide may share at least some activity.

[3148] rk80.sub.--3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

[3149] Clone "au36.sub.--42"

[3150] A polynucleotide of the present invention has been identified as clone "au36.sub.--42". au36.sub.--42 was isolated from a human adult testes cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. au36.sub.--42 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "au36.sub.--42 protein").

[3151] The nucleotide sequence of au36.sub.--42 as presently determined is reported in SEQ ID NO:139, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the au36.sub.--42 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:140.

[3152] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone au36.sub.--42 should be approximately 1400 bp.

[3153] The nucleotide sequence disclosed herein for au36.sub.--42 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No significant hits were found in the database. The nucleotide sequence of au36.sub.--42 indicates that it may contain a L1ME repetitive element.

[3154] Clone "bo549.sub.--13"

[3155] A polynucleotide of the present invention has been identified as clone "bo549.sub.--13". bo549.sub.--13 was isolated from a human adult retina cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bo549.sub.--13 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "bo549.sub.--13 protein").

[3156] The nucleotide sequence of bo549.sub.--13 as presently determined is reported in SEQ ID NO:141, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bo549.sub.--13 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:142. The region of SEQ ID NO:141 at nucleotides 518 and 519 may represent the border of an alternatively spliced exon.

[3157] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bo549.sub.--13 should be approximately 1200 bp.

[3158] The nucleotide sequence disclosed herein for bo549.sub.--13 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bo549.sub.--13 demonstrated at least some similarity with sequences identified as AI261562 (qz30c06.x1 NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE 2028394 3' similar to TR Q63061 Q63061 HYPOTHETICAL 4.7 KD PROTEIN; mRNA sequence) and J02649 (Rat stomach (H+,K+)-ATPase mRNA, complete cds). The predicted amino acid sequence disclosed herein for bo549.sub.--13 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bo549.sub.--13 protein demonstrated at least some similarity to sequences identified as J02649 (unknown protein [Rattus norvegicus]). Based upon sequence similarity, bo549.sub.--13 proteins and each similar protein or peptide may share at least some activity.

[3159] Clone "da529.sub.--3"

[3160] A polynucleotide of the present invention has been identified as clone "da529.sub.--3". da529.sub.--3 was isolated from a human fetal placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. da529.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "da529.sub.--3 protein").

[3161] The nucleotide sequence of da529.sub.--3 as presently determined is reported in SEQ ID NO:143, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the da529.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:144. Amino acids 59 to 71 of SEQ ID NO:144 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 72. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the da529.sub.--3 protein.

[3162] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone da529.sub.--3 should be approximately 1150 bp.

[3163] The nucleotide sequence disclosed herein for da529.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. da529.sub.--3 demonstrated at least some similarity with sequences identified as AI189911 (qd33e06.x1 Soares_placenta.sub.--8 to 9 weeks.sub.--2NbHP8 to 9W Homo sapiens cDNA clone IMAGE 1725538 3' similar to TR O42204 O42204 PUTATIVE TRANSMEMBRANE PROTEIN E3-16; mRNA sequence), T35254 (EST82005 Homo sapiens cDNA 5' end similar to None), U76253 (Mus musculus E25B protein mRNA, complete cds), V43619 (Human secreted protein 19 encoding DNA), W28608 (49b1 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA), and W41628 (mc47c10.r1 Soares mouse p3NMF19). The predicted amino acid sequence disclosed herein for da529.sub.--3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted da529.sub.--3 protein demonstrated at least some similarity to sequences identified as AF03895 (E25 protein [Homo sapiens]) and W63699 (Human secreted protein 19). Based upon sequence similarity, da529.sub.--3 proteins and each similar protein or peptide may share at least some activity.

[3164] Clone "dm365.sub.--3"

[3165] A polynucleotide of the present invention has been identified as clone "dm365.sub.--3". A cDNA clone was first isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. This cDNA clone was then used to isolate dm365.sub.--3 from a human fetal brain cDNA library. dm365.sub.--3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dm365.sub.--3 protein").

[3166] The nucleotide sequence of dm365.sub.--3 as presently determined is reported in SEQ ID NO:145, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dm365.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:146. Amino acids 1 to 13 of SEQ ID NO:146 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 14. Amino acids 40 to 52 of SEQ ID NO:146 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 53. Due to the hydrophobic nature of each of these predicted leader/signal sequences, each predicted leader/signal sequence is likely to act as a transmembrane domain should it not be separated from the remainder of the dm365.sub.--3 protein.

[3167] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone dm365.sub.--3 should be approximately 1300 bp.

[3168] The nucleotide sequence disclosed herein for dm365.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dm365.sub.--3 demonstrated at least some similarity with sequences identified as AC005533 (*** SEQUENCING IN PROGRESS *** Homo sapiens clone DJ0794K21; HTGS phase 1, 22 unordered pieces), AI125562 (qd94d09.x1 Soares testis NHT Homo sapiens cDNA clone IMAGE 1737137 3', mRNA sequence), R02268 (ye85c10.r1 Homo sapiens cDNA clone 124530 5' similar to contains LTR5 repetitive element), and V90427 (EST clone DM365). Based upon sequence similarity, dm365.sub.--3 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of dm365.sub.--3 indicates that it may contain repetitive sequences.

[3169] dm365.sub.--3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 23 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[3170] Clone "fa171.sub.--1"

[3171] A polynucleotide of the present invention has been identified as clone "fa171.sub.--1". fa171.sub.--1 was isolated from a human fetal brain cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fa171.sub.--1 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "fa171.sub.--1 protein"). The nucleotide sequence of fa171.sub.--1 as presently determined is reported in SEQ ID NO:147, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fa171.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:148.

[3172] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fa171.sub.--1 should be approximately 2500 bp.

[3173] The nucleotide sequence disclosed herein for fa171.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fa171.sub.--1 demonstrated at least some similarity with sequences identified as AA446057 (zw66d04.r1 Soares testis NHT Homo sapiens cDNA clone 781159 5', mRNA sequence), AC002099 (*** SEQUENCING IN PROGRESS *** Genomic sequence from Human 9q34; HTGS phase 1, 2 unordered pieces), AC002355 (*** SEQUENCING IN PROGRESS *** Genomic sequence from Human 9q34; HTGS phase 1, 7 unordered pieces), and U10185 (Xenopus laevis XPMC2 protein mRNA, complete cds). The predicted amino acid sequence disclosed herein for fa171.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fa171.sub.--1 protein demonstrated at least some similarity to sequences identified as R67549 (Fruiting body inducing polypeptide) and U10185 (XPMC2 protein [Xenopus laevis]). XPMC2 is a Xenopus cDNA clone that can rescue several different yeast mitotic catastrophe mutants defective in Wee1 kinase function, and is a nuclear protein. Based upon sequence similarity, fa171.sub.--1 proteins and each similar protein or peptide may share at least some activity.

[3174] Clone "lp572.sub.--2"

[3175] A polynucleotide of the present invention has been identified as clone "lp572.sub.--2". lp572.sub.--2 was isolated from a human adult blood (peripheral blood mononuclear cells treated with granulocyte-colony stimulating factor in vivo) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. lp572.sub.--2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "lp572.sub.--2 protein").

[3176] The nucleotide sequence of lp572.sub.--2 as presently determined is reported in SEQ ID NO:149, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the lp572.sub.--2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:150. Amino acids 79 to 91 of SEQ ID NO:150 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 92. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the lp572.sub.--2 protein.

[3177] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone lp572.sub.--2 should be approximately 2100 bp.

[3178] The nucleotide sequence disclosed herein for lp572.sub.--2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. lp572.sub.--2 demonstrated at least some similarity with sequences identified as AA489012 (aa56a03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone 824908 3'), AA533633 (nf73b09.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone IMAGE 925529, mRNA sequence), AC004686 (Homo sapiens chromosome 17, clone hRPC.1073_F.sub.--15, complete sequence), T18977 (g07030t Testis 1 Homo sapiens cDNA clone g07030 5' end), T21490 (Human gene signature HUMGS02862), and W73324 (zd01h01.r1 Pancreatic Islet Homo sapiens cDNA clone 339409 5'). The predicted amino acid sequence disclosed herein for lp572.sub.--2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted lp572.sub.--2 protein demonstrated at least some similarity to sequences identified as AL03262 (predicted using Genefinder [Caenorhabditis elegans]). Based upon sequence similarity, lp572.sub.--2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five additional potential transmembrane domains within the lp572.sub.--2 protein sequence, centered around amino acids 129, 263, 286, 326, and 378 of SEQ ID NO:150, respectively.

[3179] Clone "pe246.sub.--1"

[3180] A polynucleotide of the present invention has been identified as clone "pe246.sub.--1". pe246.sub.--1 was isolated from a human adult blood (chronic myelogenous leukemia line K562) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pe246.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pe246.sub.--1 protein").

[3181] The nucleotide sequence of pe246.sub.--1 as presently determined is reported in SEQ ID NO:151, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pe246.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:152. Amino acids 193 to 205 of SEQ ID NO:152 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 206. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pe246.sub.--1 protein.

[3182] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pe246.sub.--1 should be approximately 1500 bp.

[3183] The nucleotide sequence disclosed herein for pe246.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pe246.sub.--1 demonstrated at least some similarity with sequences identified as AA234138 (zr51b06.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 666899 5' similar to SW FCEB_HUMAN Q01362 HIGH AFFINITY IMMUNOGLOBULIN EPSILON RECEPTOR BETA-SUBUNIT), AA418443 (zv92e05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 767264 5' similar to SW FCEB_RAT P13386 HIGH AFFINITY IMMUNOGLOBULIN EPSILON RECEPTOR BETA-SUBUNIT; mRNA sequence), AC004584 (Homo sapiens chromosome 17, clone hRPC1107_A.sub.--17, complete sequence), M74509 (Human endogenous retrovirus type C oncovirus sequence), and V57903 (Hereditary haemochromatosis subregion from an HH affected individual). The predicted amino acid sequence disclosed herein for pe246.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pe246.sub.--1 protein demonstrated at least some similarity to sequences identified as L35848 (IgE receptor beta subunit [Homo sapiens]), R05026 (Beta subunit of rat high affinity IgE receptor Fc(epsilon)RI), and R42341 (Subunit of the human IgE receptor). The first 359 nucleotides of SEQ ID NO:13 is similar in sequence to that of M74509 (Human endogenous retrovirus type C oncovirus sequence) and also to several genomic sequences as a result. It appears that this region may be retroviral DNA that has been incorporated into the genome. Based upon sequence similarity, pe246.sub.--1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three additional potential transmembrane domains within the pe246.sub.--1 protein sequence, centered around amino acids 86, 115, and 154 of SEQ ID NO:152, respectively.

[3184] Clone "qf122.sub.--3"

[3185] A polynucleotide of the present invention has been identified as clone "qf122.sub.--3". qf122.sub.--3 was isolated from a human adult bladder (carcinoma line 5637) cDNA library and was identified as encoding a novel protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qf122.sub.--3 is a full-length clone, including the entire coding sequence of a novel protein (also referred to herein as "qf122.sub.--3 protein").

[3186] The nucleotide sequence of qf122.sub.--3 as presently determined is reported in SEQ ID NO:153. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qf122.sub.--3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:154.

[3187] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qf122.sub.--3 should be approximately 1700 bp.

[3188] The nucleotide sequence disclosed herein for qf122.sub.--3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qf122.sub.--3 demonstrated at least some similarity with sequences identified as AA206909 (zq80d10.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 647923 5' similar to SW YYAF_BACSU P37518 HYPOTHETICAL 40.1 KD GTP-BINDING PROTEIN IN RPSF-SPO0J INTERGENIC REGION; mRNA sequence), AA237053 (zs01c01.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 683904 5' similar to SW YBN5_YEAST P38219 HYPOTHETICAL 44.2 KD PROTEIN IN SCO2-MRF1 INTERGENIC REGION), AA775776 (ad14e03.s1 Soares NbHFB Homo sapiens cDNA clone 8782363' similar to TR P91917 P91917 W08E3.3; mRNA sequence), AL021878 (Homo sapiens DNA sequence from PAC 257120 on chromosome 22q13.1-13.2; contains cytochrome P450 pseudogenes CYP2D7P, CYP2D8P, CYP2D6(D), TCF20, NADH ubiquinone oxidoreductase B14 subunit, ESTs, CA repeat, STS, GSS), and N32932 (yy10a02.s1 Homo sapiens cDNA clone 270794 3' similar to SW:YBN5_YEAST P38219 HYPOTHETICAL 44.2 KD PROTEIN IN SCO2-MRF1 INTERGENIC REGION). The predicted amino acid sequence disclosed herein for qf122.sub.--3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qf122.sub.--3 protein demonstrated at least some similarity to sequences identified as W48670 (Staphylococcus aureus gbpA protein), Z92773 (W08E3.3 [Caenorhabditis elegans]), and Z92773 (predicted using Genefinder; Similarity to Yeast hypothetical 44.2 KD protein, putative GTP-binding protein (SW P38219); cDNA EST EMBL D64516 comes from this gene). Based upon sequence similarity, qf122.sub.--3 proteins and each similar protein or peptide may share at least some activity. Analysis of protein motifs in SEQ ID NO:154 predicts an ATP/GTP-binding site motif A (P-loop) around amino acid 29 of SEQ ID NO:154.

[3189] Clone "qv538.sub.--1"

[3190] A polynucleotide of the present invention has been identified as clone "qv538.sub.--1". qv538.sub.--1 was isolated from a human adult testes (embryonal carcinoma NT2D1 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. qv538.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "qv538.sub.--1 protein").

[3191] The nucleotide sequence of qv538.sub.--1 as presently determined is reported in SEQ ID NO:155, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the qv538.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:156. Amino acids 8 to 20 of SEQ ID NO:156 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the qv538.sub.--1 protein.

[3192] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone qv538.sub.--1 should be approximately 2600 bp.

[3193] The nucleotide sequence disclosed herein for qv538.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. qv538.sub.--1 demonstrated at least some similarity with sequences identified as W44974 (zc22e11.r1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 323084 5' similar to SW:FKB2_YEAST P32472 FK506-BINDING PROTEIN PRECURSOR; mRNA sequence), and Z62799 (H.sapiens CpG island DNA genomic Mse1 fragment, clone 73c8, reverse read cpg73c8.rt1a). The predicted amino acid sequence disclosed herein for qv538.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted qv538.sub.--1 protein demonstrated at least some similarity to sequences identified as AF04025 (FK506-binding protein [Mus musculus]) and W88556 (Secreted protein encoded by gene 23 clone HSQEO84). FK506-binding protein (or "FKBP") is the major high-affinity binding protein, in vertebrates, for the immunosuppressive drug FK506 (used to aid in organ transplantation acceptance among other indications). It exhibits peptidyl-prolyl cis-trans isomerase activity (PPIase or rotamase). PPIase is an enzyme that accelerates protein folding by catalyzing the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Based upon sequence similarity, qv538.sub.--1 proteins and each similar protein or peptide may share at least some activity. Analysis of protein motifs in SEQ ID NO:156 detects an endoplasmic reticulum targeting sequence around amino acid 208. Hidden Markov Model analysis detects an EF-hand calcium-binding domain at amino acids 183 to 211 of SEQ ID NO:156 (also found by motif analysis) and a FKBP-type peptidyl-prolyl cis-trans isomerase signatures/profile at amino acids 38 to 132 of SEQ ID NO:156. The nucleotide sequence of qv538.sub.--1 indicates that it may contain an Alu repetitive element.

[3194] qv538.sub.--1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

[3195] Clone "ys20.sub.--1"

[3196] A polynucleotide of the present invention has been identified as clone "ys20.sub.--1". ys20.sub.--1 was isolated from a human adult thymus cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ys20.sub.--1 is a full-length clone; including the entire coding sequence of a secreted protein (also referred to herein as "ys20.sub.--1 protein").

[3197] The nucleotide sequence of ys20.sub.--1 as presently determined is reported in SEQ ID NO:157, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ys20.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:158. Amino acids 41 to 53 of SEQ ID NO:158 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 54. Amino acids 121 to 133 of SEQ ID NO:158 are also a possible leader/signal sequence, with the predicted mature amino acid sequence beginning in that case at amino acid 134. Due to the hydrophobic nature of each of these predicted leader/signal sequences, each predicted leader/signal sequence is likely to act as a transmembrane domain should it not be separated from the remainder of the ys20.sub.--1 protein.

[3198] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ys201 should be approximately 2229 bp.

[3199] The nucleotide sequence disclosed herein for ys20.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ys20.sub.--1 demonstrated at least some similarity with sequences identified as B76357 (RPCI11-15B19.TV RPCI11 Homo sapiens genomic clone R-15B19, genomic survey sequence). Based upon sequence similarity, ys201 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the ys20.sub.--1 protein sequence, centered around amino acid 205 of SEQ ID NO:158. The nucleotide sequence of ys201 indicates that it may contain one or more mammalian transposon-like long terminal repeat elements, such as MCT1b/c.

[3200] Clone "as180.sub.--1"

[3201] A polynucleotide of the present invention has been identified as clone "as180.sub.--1". as180.sub.--1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. as180.sub.--1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "as180.sub.--1 protein").

[3202] The nucleotide sequence of as1801 as presently determined is reported in SEQ ID NO:159. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the as180.sub.--1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:160. Amino acids 168 to 180 of SEQ ID NO:160 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 181. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the as180.sub.--1 protein.

[3203] The EcoRI/NotI restriction fragment obtainable from the deposit containing clone as180.sub.--1 should be approximately 3580 bp.

[3204] The nucleotide sequence disclosed herein for as180.sub.--1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. as180.sub.--1 demonstrated at least some similarity with sequences identified as AB018279 (Homo sapiens mRNA for KIAA0736 protein, complete cds), S47919 (p87=transporter-like protein [cattle, mRNA]), V89585 (EST clone CR618), and W28902 (53d11 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA, mRNA sequence). The predicted amino acid sequence disclosed herein for as180.sub.--1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted as180.sub.--1 protein demonstrated at least some similarity to sequences identified as AB018279 (KIAA0736 protein [Homo sapiens]), L05435 (synaptic vesicle protein 2 [Rattus norvegicus]), S47919 (p87 [Bos sp.]), and W64538 (Human liver cell clone HP01293 protein). Synaptic vesicle protein 2 (SV2) is a membrane glycoprotein specifically localized to secretory vesicles in neurons and endocrine cells (Bajjalieh, S. M. et al., 1992, Science August 28; 257(5074):1271-1273, which is incorporated by reference herein). Based upon sequence similarity, as 180.sub.--1 proteins and each similar protein or peptide may share at least some activity. Analysis of amino acid motifs detected a sugar-transport protein signature around amino acid 264 of SEQ ID NO:160, and hidden Markov Model analysis detected a sugar-transporter amino acid profile from amino acid 153 to amino acid 741 of SEQ ID NO:160. The TopPredII computer program predicts twelve potential transmembrane domains within the as 180.sub.--1 protein sequence, centered around amino acids 181, 205, 248, 270, 308, 344, 432, 458, 605, 638, 654, and 710 of SEQ ID NO:160, respectively.

[3205] Deposit of Clones

[3206] Clones co62.sub.--12, lo311.sub.--8, ns197.sub.--1, pj193.sub.--5, pj317.sub.--2, pt332.sub.--1, qc297.sub.--15, qg596.sub.--12, and rb649.sub.--3 were deposited on Jul. 29, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98825, from which each clone comprising a particular polynucleotide is obtainable.

[3207] Clones ca106.sub.--19xx, ci52.sub.--2, md124.sub.--16, pk366.sub.--7, pl741.sub.--5, pp314.sub.--19, pv35.sub.--1, pw337.sub.--6, rd610.sub.--1, and rd810.sub.--6 were deposited on Aug. 11, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98835, from which each clone comprising a particular polynucleotide is obtainable.

[3208] Clones cf85.sub.--1, dd504.sub.--18, np26.sub.--3, pm412.sub.--12, pm421.sub.--3, pv6.sub.--1, qs14.sub.--3, qy338.sub.--9, rc58.sub.--1, and rd232.sub.--5 were deposited on Aug. 27, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98850, from which each clone comprising a particular polynucleotide is obtainable.

[3209] Clones ck213.sub.--12, pg195.sub.--1, pw460.sub.--5, qa136.sub.--1, qy1261.sub.--2, and rd432.sub.--4 were deposited on Oct. 8, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98918, from which each clone comprising a particular polynucleotide is obtainable.

[3210] Clones rb789.sub.--14, yd137.sub.--1, yd218.sub.--1, ye11.sub.--1, ye72.sub.--1, ye78.sub.--1, ye90.sub.--1, yi62.sub.--1, yk78.sub.--1, yk251.sub.--1, and yt14.sub.--1 were deposited on Dec. 15, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207004, from which each clone comprising a particular polynucleotide is obtainable.

[3211] Clones bf157.sub.--16, bk343.sub.--2, cd205.sub.--2, cw1292.sub.--8, cw1475.sub.--2, dd428.sub.--4, dh1073.sub.--12, dw78.sub.--1, fh116.sub.--11, fy356.sub.--14, and iw66.sub.--1 were deposited on Feb. 4, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207088, from which each clone comprising a particular polynucleotide is obtainable.

[3212] Clones kh13.sub.--4, ko258.sub.--4, kv108, LL89.sub.--3, mc300.sub.--1, ml227.sub.--1, mm367.sub.--6, mt124.sub.--3, nf56.sub.--3, qy442.sub.--2, rj214.sub.--1, and rk80.sub.--3 were deposited on Feb. 4, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207089, from which each clone comprising a particular polynucleotide is obtainable.

[3213] Clones au36.sub.--42, bo549.sub.--13, da529.sub.--3, dm365.sub.--3, fa1711, lp572.sub.--2, pe246.sub.--1, qf122.sub.--3, qv538.sub.--1, and ys2O.sub.--1 were deposited on Apr. 2, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 207187, from which each clone comprising a particular polynucleotide is obtainable.

[3214] Clone as180.sub.--1 was deposited on Aug. 11, 1999 with the American Type Culture Collection (10801 University Boulevard, Manassas, Va. 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC XXXXXX, from which the as180.sub.--1 clone comprising a particular polynucleotide is obtainable.

[3215] All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. .sctn. 1.808(b), and the term of the deposit will comply with 37 C.F.R. .sctn. 1.806.

[3216] Each clone has been transfected into separate bacterial cells (E. coli) in the above composite deposits. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in FIGS. 1A and 1B, respectively, or in the case of clone qs14.sub.--3, in the pCMVSport2 vector (Life Technologies, Inc., Rockville, Md. 20850, U.S.A.) depicted in FIG. 2. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman et al., 1991, Nucleic Acids Res. 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et al., 1989, Mol. Cell. Biol. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

[3217] Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

[3218] An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

TABLE-US-00001 Clone Probe Sequence co62_12 SEQ ID NO: 161 lo311_8 SEQ ID NO: 162 ns197_1 SEQ ID NO: 163 pj193_5 SEQ ID NO: 164 pj317_2 SEQ ID NO: 165 pt332_1 SEQ ID NO: 166 qc297_15 SEQ ID NO: 167 qg596_12 SEQ ID NO: 168 rb649_3 SEQ ID NO: 169 ca106_19x SEQ ID NO: 170 ci52_2 SEQ ID NO: 171 md124_16 SEQ ID NO: 172 pk366_7 SEQ ID NO: 173 pl741_5 SEQ ID NO: 174 pp314_19 SEQ ID NO: 175 pv35_1 SEQ ID NO: 176 pw337_6 SEQ ID NO: 177 rd610_1 SEQ ID NO: 178 rd810_6 SEQ ID NO: 179 cf85_1 SEQ ID NO: 180 dd504_18 SEQ ID NO: 181 np26_3 SEQ ID NO: 182 pm412_12 SEQ ID NO: 183 pm421_3 SEQ ID NO: 184 pv6_1 SEQ ID NO: 185 qs14_3 SEQ ID NO: 186 qy338_9 SEQ ID NO: 187 rc58_1 SEQ ID NO: 188 rd232_5 SEQ ID NO: 189 ck213_12 SEQ ID NO: 190 pg195_1 SEQ ID NO: 191 pw460_5 SEQ ID NO: 192 qa136_1 SEQ ID NO: 193 qy1261_2 SEQ ID NO: 194 rd432_4 SEQ ID NO: 195 rb789_14 SEQ ID NO: 196 yd137_1 SEQ ID NO: 197 ye11_1 SEQ ID NO: 198 ye72_1 SEQ ID NO: 199 ye78_1 SEQ ID NO: 200 ye90_1 SEQ ID NO: 201 yk251_1 SEQ ID NO: 202 yt14_1 SEQ ID NO: 203 bf157_16 SEQ ID NO: 204 bk343_2 SEQ ID NO: 205 cd205_2 SEQ ID NO: 206 cw1292_8 SEQ ID NO: 207 cw1475_2 SEQ ID NO: 208 dd428_4 SEQ ID NO: 209 dh1073_12 SEQ ID NO: 210 dw78_1 SEQ ID NO: 211 fh116_11 SEQ ID NO: 212 fy356_14 SEQ ID NO: 213 iw66_1 SEQ ID NO: 214 kh13_4 SEQ ID NO: 215 ko258_4 SEQ ID NO: 216 kv10_8 SEQ ID NO: 217 LL89_3 SEQ ID NO: 218 mc300_1 SEQ ID NO: 219 ml227_1 SEQ ID NO: 220 mm367_6 SEQ ID NO: 221 mt124_3 SEQ ID NO: 222 nf56_3 SEQ ID NO: 223 qy442_2 SEQ ID NO: 224 rj214_14 SEQ ID NO: 225 rk80_3 SEQ ID NO: 226 au36_42 SEQ ID NO: 227 bo549_13 SEQ ID NO: 228 da529_3 SEQ ID NO: 229 dm365_3 SEQ ID NO: 230 fa171_1 SEQ ID NO: 231 lp572_2 SEQ ID NO: 232 pe246_1 SEQ ID NO: 233 qf122_3 SEQ ID NO: 234 qv538_1 SEQ ID NO: 235 ys20_1 SEQ ID NO: 236 as180_1 SEQ ID NO: 237

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4aminobutyl)-propyl-3-O-(2-cyanoethyl- )-(N,N-diisopropyl)-phosphoramadite) (Glen Research, cat. no. 10-1953)).

[3219] The design of the oligonucleotide probe should preferably follow these parameters: [3220] (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any; [3221] (b) It should be designed to have a T.sub.m of approx. 80.degree. C. (assuming 2.degree. for each A or T and 4 degrees for each G or C).

[3222] The oligonucleotide should preferably be labeled with .gamma.-.sup.32P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e/6 dpm/pmole.

[3223] The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 .mu.l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 pg/ml. The culture should preferably be grown to saturation at 37.degree. C., and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 pg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37.degree. C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

[3224] Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

[3225] The filter is then preferably incubated at 65.degree. C. for 1 hour with gentle agitation in 6.times.SSC (20.times. stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 .mu.g/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65.degree. C. with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2.times.SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2.times.SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1.times.SSC/0.5% SDS at 65.degree. C. for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

[3226] The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

[3227] Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein--IgM fusion would generate a decavalent form of the protein of the invention.

[3228] The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

[3229] The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

[3230] The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes in situ. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address http://www.ncbi.nlm.nih.gov/UniGene/, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

[3231] Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al., 1997, Biochem. Mol. Med. 62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1-39; all of which are incorporated by reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide molecules having some complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression of the mRNA ("RNA intereference" or "RNAi"; Fire et al., 1998, Nature 391 (6669): 806-811; Montgomery et al., 1998, Proc. Natl. Acad. Sci. USA 95 (26): 15502-15507; and Sharp, 1999, Genes Dev. 13 (2): 139-141; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14(9): 629-633; Zwaal et al., 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431-7435; Clark et al., 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al., 1988, Nature 336: 348-352; U.S. Pat. Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

[3232] Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

[3233] Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

[3234] In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle ed., Methods in Enzymology 266: 460-480; Altschul et al., 1990, Basic local alignment search tool, Journal of Molecular Biology 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, Nature Genetics 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad. Sci. USA 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from ftp://blast.wustl.edu/blast/executables. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite--BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX--the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

[3235] Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, Pan troglodytes, Gorilla gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulatta, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, Aohts trivirgatus, Sanguinus oedipus, Microcebus murinus, Mus musculus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela vison, Canis familiaris, Oryctolagus cuniculus, Bos taurus, Ovis aries, Sus scrofa, and Equus caballus, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuanez, 1988, Ann. Rev. Genet. 22: 323-351; O'Brien et al., 1993, Nature Genetics 3:103-112; Johansson et al., 1995, Genomics 25: 682-690; Lyons et al., 1997, Nature Genetics 15: 47-56; O'Brien et al., 1997, Trends in Genetics 13(10): 393-399; Carver and Stubbs, 1997, Genome Research 7:1123-1137; all of which are incorporated by reference herein).

[3236] The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

[3237] The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

[3238] The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

TABLE-US-00002 Hybrid Wash Stringency Polynucleotide Length Hybridization Temperature and Temperature Condition Hybrid (bp).sup..dagger-dbl. Buffer.sup..dagger. and Buffer.sup..dagger. A DNA:DNA .gtoreq.50 65.degree. C.; 1xSSC -or- 65.degree. C.; 0.3xSSC 42.degree. C.; 1xSSC, 50% formamide B DNA:DNA <50 T.sub.B*; 1xSSC T.sub.B*; 1xSSC C DNA:RNA .gtoreq.50 67.degree. C.; 1xSSC -or- 67.degree. C.; 0.3xSSC 45.degree. C.; 1xSSC, 50% formamide D DNA:RNA <50 T.sub.D*; 1xSSC T.sub.D*; 1xSSC E RNA:RNA .gtoreq.50 70.degree. C.; 1xSSC -or- 70.degree. C.; 0.3xSSC 50.degree. C.; 1xSSC, 50% formamide F RNA:RNA <50 T.sub.F*; 1xSSC T.sub.F*; 1xSSC G DNA:DNA .gtoreq.50 65.degree. C.; 4xSSC -or- 65.degree. C.; 1xSSC 42.degree. C.; 4xSSC, 50% formamide H DNA:DNA <50 T.sub.H*; 4xSSC T.sub.H*; 4xSSC I DNA:RNA .gtoreq.50 67.degree. C.; 4xSSC -or- 67.degree. C.; 1xSSC 45.degree. C.; 4xSSC, 50% formamide J DNA:RNA <50 T.sub.J*; 4xSSC T.sub.J*; 4xSSC K RNA:RNA .gtoreq.50 70.degree. C.; 4xSSC -or- 67.degree. C.; 1xSSC 50.degree. C.; 4xSSC, 50% formamide L RNA:RNA <50 T.sub.L*; 2xSSC T.sub.L*; 2xSSC M DNA:DNA .gtoreq.50 50.degree. C.; 4xSSC -or- 50.degree. C.; 2xSSC 40.degree. C.; 6xSSC, 50% formamide N DNA:DNA <50 T.sub.N*; 6xSSC T.sub.N*; 6xSSC 0 DNA:RNA .gtoreq.50 55.degree. C.; 4xSSC -or- 55.degree. C.; 2xSSC 42.degree. C.; 6xSSC, 50% formamide P DNA:RNA <50 T.sub.P*; 6xSSC T.sub.P*; 6xSSC Q RNA:RNA .gtoreq.50 60.degree. C.; 4xSSC -or- 60.degree. C.; 2xSSC 45.degree. C.; 6xSSC, 50% formamide R RNA:RNA <50 T.sub.R*; 4xSSC T.sub.R*; 4xSSC .sup..dagger-dbl.The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity. .sup..dagger.SSPE (1xSSPE is 0.15M NaCl, 10 mM NaH.sub.2PO.sub.4, and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete. *T.sub.B-T.sub.R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10.degree. C. less than the melting temperature (T.sub.m) of the hybrid, where T.sub.m is determined according to the following equations. For hybrids less than 18 base pairs in length, T.sub.m(.degree. C.) = 2(# of A + T bases)+ 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T.sub.m(.degree. C.) = 81.5 + 16.6(log.sub.10[Na.sup.+]) + 0.41(% G + C) - (600/N), where N is the number of bases in the hybrid, and [Na.sup.+] is the concentration of sodium ions in the hybridization buffer ([Na.sup.+] for 1xSSC = 0.165 M).

[3239] Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

[3240] Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

[3241] The isolated polynucleotide encoding the protein of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

[3242] A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

[3243] Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

[3244] The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBac.RTM. kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

[3245] The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl.RTM. or Cibacrom blue 3GA Sepharose.RTM.; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

[3246] Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and Invitrogen Corporation (Carlsbad, Calif.), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, Conn.).

[3247] Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

[3248] The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

[3249] The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

[3250] The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

[3251] Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

Uses and Biological Activity

[3252] The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

[3253] Research Uses and Utilities

[3254] The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al., 1993, Cell 75: 791-803 and in Rossi et al., 1997, Proc. Natl. Acad. Sci. USA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

[3255] The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

[3256] Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

[3257] Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

[3258] Nutritional Uses

[3259] Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

[3260] Cytokine and Cell Proliferation/Differentiation Activity

[3261] A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

[3262] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3263] Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

[3264] Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. e. a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon .gamma., Schreiber, R. D. In Current Protocols in Immunology. J. E. e. a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

[3265] Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. e. a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6--Nordan, R. In Current Protocols in Immunology. J. E. e. a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11--Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J. E. e. a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9--Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. e. a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

[3266] Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

[3267] Immune Stimulating or Suppressing Activity

[3268] A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

[3269] Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

[3270] Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

[3271] Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

[3272] The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

[3273] Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

[3274] Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

[3275] Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

[3276] In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.

[3277] The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I .alpha. chain protein and .beta..sub.2 microglobulin protein or an MHC class II .alpha. chain protein and an MHC class II .beta. chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

[3278] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3279] Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

[3280] Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e. a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

[3281] Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation,

[3282] those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140: 508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

[3283] Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

[3284] Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

[3285] Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

[3286] Hematopoiesis Regulating Activity

[3287] A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

[3288] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3289] Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

[3290] Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

[3291] Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

[3292] Tissue Growth Activity

[3293] A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

[3294] A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein or the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

[3295] A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

[3296] Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

[3297] The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

[3298] Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

[3299] It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

[3300] A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

[3301] A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

[3302] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3303] Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

[3304] Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, H I and Rovee, D T, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eagistein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

[3305] Activin/Inhibin Activity

[3306] A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease sperm atogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-.beta. group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

[3307] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3308] Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

[3309] Chemotactic/Chemokinetic Activity

[3310] A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

[3311] A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

[3312] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3313] Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

[3314] Hemostatic and Thrombolytic Activity

[3315] A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

[3316] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3317] Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

[3318] Receptor/Ligand Activity

[3319] A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectin, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

[3320] The activity of a protein of the invention may, among other means, be measured by the following methods:

[3321] Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

[3322] Anti-Inflammatory Activity

[3323] Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

[3324] Cadherin/Tumor Invasion Suppressor Activity

[3325] Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

[3326] The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

[3327] E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

[3328] Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

[3329] Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

[3330] Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and poly-nucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

[3331] Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

[3332] Tumor Inhibition Activity

[3333] In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

[3334] Other Activities

[3335] A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitarins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

Administration and Dosing

[3336] A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

[3337] A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

[3338] The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

[3339] The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Pat. No. 4,235,871; U.S. Pat. No. 4,501,728; U.S. Pat. No. 4,837,028; and U.S. Pat. No. 4,737,323, all of which are incorporated herein by reference.

[3340] As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

[3341] In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

[3342] Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

[3343] When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

[3344] When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

[3345] The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 pg to about 100 mg (preferably about 0.1 ng to about 10 mg, more preferably about 0.1 .mu.g to about 1 mg) of protein of the present invention per kg body weight.

[3346] The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

[3347] Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein. Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

[3348] Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Coding, 1983, Monoclonal antibodies: principles and practice, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in Current Protocols in Immunology, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, supra; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in Current Protocols in Immunology, Unit 2.8, Greene Publishing Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, U.S. Pat. Nos. 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S. Pat. Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild et al., 1996, Nature Biotechnology 14: 845-851; Mendez et al., 1997, Nature Genetics 15: 146-156 (erratum Nature Genetics 16: 410); and U.S. Pat. Nos. 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R. P. Merrifield, J. Amer. Chem. Soc. 85, 2149-2154 (1963); J. L. Krstenansky, et al., FEBS Lett. 211, 10 (1987).

[3349] Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

[3350] For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

[3351] The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

[3352] Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

[3353] A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt %, preferably 1-10 wt % based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

[3354] In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-.alpha. and TGF-.beta.), and insulin-like growth factor (IGF).

[3355] The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

[3356] The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

[3357] Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

[3358] Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.

[3359] Patent and literature references cited herein are incorporated by reference as if fully set forth.

Sequence CWU 1

1

24011925DNAHomo sapiens 1aggtcgtcac agacgatgat ggccaggccc cggaggctaa ggacggcagc tcctttagcg 60gcagagtttt ccgagtgacc ttcttgatgc tggctgtttc tctcaccgtt cccctgcttg 120gagccatgat gctgctggaa tctcctatag atccacagcc tctcagcttc aaagaacccc 180cgctcttgct tggtgttctg catccaaata cgaagctgcg acaggcagaa aggctgtttg 240aaaatcaact tgttggaccg gagtccatag cacatattgg ggatgtgatg tttactggga 300cagcagatgg cccggtcgta aaacttgaaa atggtgaaat agagaccatt gcccggtttg 360gttcgggccc ttgcaaaacc cgagatgatg agcctgtgtg tgggagaccc ctgggtatcc 420gtgcagggcc caatgggact ctctttgtgg ccgatgcata caagggacta tttgaagtaa 480atccctggaa acgtgaagtg aaactgctgc tgtcctccga gacacccatt gaggggaaga 540acatgtcctt tgtgaatgat cttacagtca ctcaggatgg gaggaagatt tatttcaccg 600attctagcag caaatggcaa agacgagact acctgcttct ggtgatggag ggcacagatg 660acgggcgcct gctggagtat gatactgtga ccagggaagt aaaagtttta ttggaccagc 720tgcggttccc gaatggagtc cagctgtctc ctgcagaaga ctttgtcctg gtggcagaaa 780caaccatggc caggatacga agctctttag tcaagagacg gtgatgaagt ttgtgccgcg 840gtacagcctc gtcctagaac tcagcgacag cggtgccttc cggagaagcc tgcatgatcc 900cgatgggctg gtggccacct acatcaccga ggtgcacgaa cacgatgggc acctgtacct 960gggctctttc aggtccccct tcctctgcag actcagcctc caggctgttt agccctccca 1020gatagctgcc cctgccacgc aggccaggag tcttcacact caggcaccag gcctggtcca 1080ggaggagctg tggacacagt cgtggttcaa gtgtccacat gcacctgtta gtccctgaga 1140ggtggtggga atggctgctt cattcctcga ggatgcccgg gccccacctg ggcttgtctt 1200tctgtttaga gggaagtgta acatatctgc catgaggaac ataaattcat gtaaagccat 1260tttctcttaa acaaaacaaa actttctaag tacaatcatt ctctaggatt tgggaagctc 1320cttgcacttg gaacagggct caggtgggtg gagcagtaag gcactaccca gagagcttgc 1380tgctgcggcc ctgtcctgcg gcctcaaagt tcttctttac tatatataac gtgcggtcat 1440acctttcttc gttgtggtgg ggatggaaga gcagagggag catggcccag gggtgttgag 1500gccagcggtg agagccgtgt tagccaagac atggaactgt gttctcaagg gttatgtggg 1560gcgtgggctc tccatagtgt gtatgaaaag cttgttgact ctagcggctc agagaggact 1620ttgctgggtt tctttctgtg aatatctccg tgctgaccat gctggaattg gatgattctg 1680caattcggga cctactgcag gggtccgttt agtaacgtct tgtctgtgat ctttgttctt 1740gacctctaga ccccaagatg tgaacagtgc acgtgttaat gtcatctttg ctcatgtgtt 1800ataagcccca agttgctgta tattttcaca agtatgtcta cacactggtc atgattttga 1860taataaataa cgataaatcg acttctgctg attaaccttt aaaaaaaaaa aaaaaaaaaa 1920aaaaa 19252245PRTHomo sapiens 2Met Leu Ala Val Ser Leu Thr Val Pro Leu Leu Gly Ala Met Met Leu 1 5 10 15Leu Glu Ser Pro Ile Asp Pro Gln Pro Leu Ser Phe Lys Glu Pro Pro 20 25 30Leu Leu Leu Gly Val Leu His Pro Asn Thr Lys Leu Arg Gln Ala Glu 35 40 45Arg Leu Phe Glu Asn Gln Leu Val Gly Pro Glu Ser Ile Ala His Ile 50 55 60Gly Asp Val Met Phe Thr Gly Thr Ala Asp Gly Pro Val Val Lys Leu 65 70 75 80Glu Asn Gly Glu Ile Glu Thr Ile Ala Arg Phe Gly Ser Gly Pro Cys 85 90 95Lys Thr Arg Asp Asp Glu Pro Val Cys Gly Arg Pro Leu Gly Ile Arg 100 105 110Ala Gly Pro Asn Gly Thr Leu Phe Val Ala Asp Ala Tyr Lys Gly Leu 115 120 125Phe Glu Val Asn Pro Trp Lys Arg Glu Val Lys Leu Leu Leu Ser Ser 130 135 140Glu Thr Pro Ile Glu Gly Lys Asn Met Ser Phe Val Asn Asp Leu Thr145 150 155 160Val Thr Gln Asp Gly Arg Lys Ile Tyr Phe Thr Asp Ser Ser Ser Lys 165 170 175Trp Gln Arg Arg Asp Tyr Leu Leu Leu Val Met Glu Gly Thr Asp Asp 180 185 190Gly Arg Leu Leu Glu Tyr Asp Thr Val Thr Arg Glu Val Lys Val Leu 195 200 205Leu Asp Gln Leu Arg Phe Pro Asn Gly Val Gln Leu Ser Pro Ala Glu 210 215 220Asp Phe Val Leu Val Ala Glu Thr Thr Met Ala Arg Ile Arg Ser Ser225 230 235 240Leu Val Lys Arg Arg 24533508DNAHomo sapiens 3gagcgaacat ggcagcgcgt tggcggtttt ggtgtgtctc tgtgaccatg gtggtggcgc 60tgctcatcgt ttgcgacgtt ccctcagcct ctgcccaaag aaagaaggag atggtgttat 120ctgaaaaggt tagtcagctg atggaatgga ctaacaaaag acctgtaata agaatgaatg 180gagacaagtt ccgtcgcctt gtgaaagccc caccgagaaa ttactccgtt atcgtcatgt 240tcactgctct ccaactgcat agacagtgtg tcgtttgcaa gcaagctgat gaagaattcc 300agatcctggc aaactcctgg cgatactcca gtgcattcac caacaggata ttttttgcca 360tggtggattt tgatgaaggc tctgatgtat ttcagatgct aaacatgaat tcagctccaa 420ctttcatcaa ctttcctgca aaagggaaac ccaaacgggg tgatacatat gagttacagg 480tgcggggttt ttcagctgag cagattgccc ggtggatcgc cgacagaact gatgtcaata 540ttagagtgat tagaccccca aattatgctg gtccccttat gttgggattg cttttggctg 600ttattggtgg acttgtgtat cttcgaagaa gtaatatgga atttctcttt aataaaactg 660gatgggcttt tgcagctttg tgttttgtgc ttgctatgac atctggtcaa atgtggaacc 720atataagagg accaccatat gcccataaga atccccacac gggacatgtg aattatatcc 780atggaagcag tcaagcccag tttgtagctg aaacacacat tgttcttctg tttaatggtg 840gagttacctt aggaatggtg cttttatgtg aagctgctac ctctgacatg gatattggaa 900agcgaaagat aatgtgtgtg gctggtattg gacttgttgt attattcttc agttggatgc 960tctctatttt tagatctaaa tatcatggct acccatacag ctttctgatg agttaaaaag 1020gtcccagaga tatatagaca ctggagtact ggaaattgaa aaacgaaaat cgtgtgtgtt 1080tgaaaagaag aatgcaactt gtatattttg tattacctct ttttttttca agtgatttaa 1140atagttaatc atttaaccaa agaagatgtg tagtgcctta acaagcaatc ctctgtcaaa 1200atctgaggta tttgaaaata attatcctct taaccttctc ttcccagtga actttatgga 1260acatttaatt tagtacaatt aagtatatta taaaaattgt aaaactacta ctttgtttta 1320gttagaacaa agctcaaaac tactttagtt aacttggtca tctgatttta tattgcctta 1380tccaaagatg gggaaagtaa gtcctgacca ggtgttccca catatgcctg ttacagataa 1440ctacattagg aattcattct tagcttcttc atctttgtgt ggatgtgtat actttacgca 1500tctttccttt tgagtagaga aattatgtgt gtcatgtggt cttctgaaaa tggaacacca 1560ttcttcagag cacacgtcta gccctcagca agacagttgt ttctcctcct ccttgcatat 1620ttcctactga aatacagtgc tgtctatgat tgtttttgtt ttgttgtttt tttgagacgg 1680tctcgctgtg tcacacaggc ggagattgca gtgagccgag atcacgctac tgcgctcagc 1740ctgagtgata gagtgagact ctgtctcaaa aaaaagtatc tctaaataca ggattataat 1800ttctgcttga gtatggtgtt aactaccttg tatttagaaa gatttcagat tcattccatc 1860tccttagttt tcttttaagg tgacccatct gtgataaaaa tatagcttag tgctaaaatc 1920agtgtaactt atacatggcc taaaatgttt ctacaaatta gagtttgtca cttattccat 1980ttgtacctaa gagaaaaata tgctcagtta gaaaaggact ccctggccag gcgcagtgac 2040ttacgcctgt tatctcagca ctttgggagg ccaaggcagg cagatcacga ggtcaggagt 2100tcgagaccat cctggccaac atggtgaaac cccgtctcta ctaaaaatat aaaaattagc 2160tgggtgtggt ggcaggagcc tgtaatccca gctacacagg aggctgaggc acgagaatca 2220cttgaactca gggagatgga ggtttcagtg agccaagatc acaccactgc actccagcct 2280ggcaacagag cgagaattcc atctcaaaaa aaaaaaaaaa agtaagaaaa gaaaaggact 2340cccttagaat gggaaagaaa aatcataaaa tattgagctg aagcctgtat atagaaatta 2400agcgtttctc gaaagctgtt ctatgttctg ccgttattta gtctttattc tcttccttga 2460ggtggagaaa caaagtacca atttgaaggg atttttttta ttttgtcttt tggtttctgt 2520cagtagaaat aaccatatgt gctaaccaaa tttctgtgaa gaatgttttc atggttatca 2580ttatatctaa ctataacctc ccccatagtt atgaagagta acctgaaatg ccactattgt 2640ggaaatagga taattgtaat tgtgaaaaaa taattttaag gaaatcttac aagtattaca 2700ttaaaaagat actatgactg ccacctgcca tttaccttct aataaccctg ccatgtggtt 2760tgcagaaaga gatggatata gtagcctcag aagaaatatt ttatgtgggt tttttgtttt 2820tcgttactag atttcttgga tgaggggtta tggttgacct tttacttttt aatggagcag 2880ccagtttttg ttaattactc acttgtaaat tgtgagattc tgaattcctt acctgctatt 2940cttgtacttg tctcaggcca aatctatgct gtggttctta tgagacttgt atgaagatgc 3000cctgatttgt acagattgac cacgggaata ctactgccat gtaatctgta tagttccaga 3060taatttgtca tgaacattga cagaatgaca attttttgta tttgcttttt ctccctttaa 3120gagcacattc ttctgtaagg agaaaggcag cattctggct aaaatgtgta gaaggtaatt 3180tactacactt ataaaatagt gtgacttttg tgaaaatttt gaattagctt tcatatgaag 3240tgccttaagt agactcttca tttacttttc tggtaatggt ttaaatatca tttgttatgc 3300atttttaaga tacagttcag aatgacacat tgtagtggca aagataacca aatgtctggc 3360tgtttgcttt ttgaccatat caataaactt ttacaatctt aaaaaaaaaa aaaaaaaaaa 3420aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3480aaaaaaaaaa aaaaaaaaaa aaaaaaaa 35084335PRTHomo sapiens 4Met Ala Ala Arg Trp Arg Phe Trp Cys Val Ser Val Thr Met Val Val 1 5 10 15Ala Leu Leu Ile Val Cys Asp Val Pro Ser Ala Ser Ala Gln Arg Lys 20 25 30Lys Glu Met Val Leu Ser Glu Lys Val Ser Gln Leu Met Glu Trp Thr 35 40 45Asn Lys Arg Pro Val Ile Arg Met Asn Gly Asp Lys Phe Arg Arg Leu 50 55 60Val Lys Ala Pro Pro Arg Asn Tyr Ser Val Ile Val Met Phe Thr Ala 65 70 75 80Leu Gln Leu His Arg Gln Cys Val Val Cys Lys Gln Ala Asp Glu Glu 85 90 95Phe Gln Ile Leu Ala Asn Ser Trp Arg Tyr Ser Ser Ala Phe Thr Asn 100 105 110Arg Ile Phe Phe Ala Met Val Asp Phe Asp Glu Gly Ser Asp Val Phe 115 120 125Gln Met Leu Asn Met Asn Ser Ala Pro Thr Phe Ile Asn Phe Pro Ala 130 135 140Lys Gly Lys Pro Lys Arg Gly Asp Thr Tyr Glu Leu Gln Val Arg Gly145 150 155 160Phe Ser Ala Glu Gln Ile Ala Arg Trp Ile Ala Asp Arg Thr Asp Val 165 170 175Asn Ile Arg Val Ile Arg Pro Pro Asn Tyr Ala Gly Pro Leu Met Leu 180 185 190Gly Leu Leu Leu Ala Val Ile Gly Gly Leu Val Tyr Leu Arg Arg Ser 195 200 205Asn Met Glu Phe Leu Phe Asn Lys Thr Gly Trp Ala Phe Ala Ala Leu 210 215 220Cys Phe Val Leu Ala Met Thr Ser Gly Gln Met Trp Asn His Ile Arg225 230 235 240Gly Pro Pro Tyr Ala His Lys Asn Pro His Thr Gly His Val Asn Tyr 245 250 255Ile His Gly Ser Ser Gln Ala Gln Phe Val Ala Glu Thr His Ile Val 260 265 270Leu Leu Phe Asn Gly Gly Val Thr Leu Gly Met Val Leu Leu Cys Glu 275 280 285Ala Ala Thr Ser Asp Met Asp Ile Gly Lys Arg Lys Ile Met Cys Val 290 295 300Ala Gly Ile Gly Leu Val Val Leu Phe Phe Ser Trp Met Leu Ser Ile305 310 315 320Phe Arg Ser Lys Tyr His Gly Tyr Pro Tyr Ser Phe Leu Met Ser 325 330 33551697DNAHomo sapiens 5ttcaatgaaa acgagggggg cgcggaggag gaggcggcgg cgtcggtggc ggcggcgacg 60gcggcgcgga ggcgaaggca gcggcgggcg cagcgaggag ggcgaggccg ggggccgaga 120gggcgggagg gcgtagtggc ggcccgtcgg ggcggctgag gcgggcagcc gaagcagtgg 180ctctcggagg gggaacaaag agcagcgact aaggcggcag aggagcggcg gcggtggcgg 240cgctgcagca gcgggcggga ctggtatggt ggttccacag ggcagacccc gctgcactca 300cagggaggag gaggcggcag cggcggagga aggcggcgca ccccgagagg catgcccaaa 360gaaaaatacg agccccctga ccctcggagg atgtatacaa ttatgtcttc tgaggaagca 420gcaaatggaa agaaatccca ctgggcagag cttgaaataa gtggaaaagt aagaagctta 480agcgcatctt tgtggtcact aactcacctg acagctttgc atttgagtga caattccctg 540tcccgaattc cttcagacat tgccaagctt cacaatctgg tgtatttgga cctgtcatct 600aataaaattc gtagcttacc cgcagaactc ggaaacatgg tatcactcag ggagctccat 660ttaaataaca acctgttacg agttctacct tttgagctgg gaaaactgtt tcagttgcag 720actttaggcc tgaaaggtat gacttccata tttgtacttc ttatggtttg tgtatatgtc 780tttgaatcta aggaagccaa gaagctttct gctaggggat tcttttaaag actcattttc 840ccccagactt catcagtttc ttagctatat cgcaatggtt ttatcttctc tgttcagctg 900tagactatct actagtcttt gttttctttt tttttgctcc ggacccagcc cttcttttct 960agcctctgtt ttaatgaacc ctgtgttctg gtgatacatc cctgaggcta tgctttattt 1020catcatgtta taaacagctg tttttcttag attcaaatct caaaaaacat ggagcctctc 1080atatagtaca gaaaacagga agtcgaaaat gttgaccatt tgaacctgct gatgatcaag 1140atttaagcat atttaaaaaa acttgattta tgaggacttg tgattatagg gccataattg 1200atccagcaag aactattagg aaataaatat tttttaagcc aacaatattg aaagttatat 1260tttgacagta tgtcaatgcc tataaatttt ttatcatgtt aagcagttct tcaccagcct 1320tgggtaggtg tgtctagcct actgtacagt tgcttcttca aaaaagtcac tagatgaagt 1380cgtcaagatt tgcaccctta ggccgggcac agtggctcac acctgtaatc acaaaacttt 1440gggaggctga ggtgggtgga tatcttgagg ccaagagttc aagaccagca tgagcaacat 1500ggcaaaaccc aatctctacc aaaaatacaa aagtcagctt ggcatggtgg ttcccacctg 1560tagtaccacc tacttgggag gctgaggcat gagatttgct tgaacctggg aagcagaggt 1620tgaagtgagg tgacattgtg gcattgcact ccagcctggg tgacagagcg agactctgtc 1680ttaaaaaaaa aaaaaaa 16976158PRTHomo sapiens 6Met Pro Lys Glu Lys Tyr Glu Pro Pro Asp Pro Arg Arg Met Tyr Thr 1 5 10 15Ile Met Ser Ser Glu Glu Ala Ala Asn Gly Lys Lys Ser His Trp Ala 20 25 30Glu Leu Glu Ile Ser Gly Lys Val Arg Ser Leu Ser Ala Ser Leu Trp 35 40 45Ser Leu Thr His Leu Thr Ala Leu His Leu Ser Asp Asn Ser Leu Ser 50 55 60Arg Ile Pro Ser Asp Ile Ala Lys Leu His Asn Leu Val Tyr Leu Asp 65 70 75 80Leu Ser Ser Asn Lys Ile Arg Ser Leu Pro Ala Glu Leu Gly Asn Met 85 90 95Val Ser Leu Arg Glu Leu His Leu Asn Asn Asn Leu Leu Arg Val Leu 100 105 110Pro Phe Glu Leu Gly Lys Leu Phe Gln Leu Gln Thr Leu Gly Leu Lys 115 120 125Gly Met Thr Ser Ile Phe Val Leu Leu Met Val Cys Val Tyr Val Phe 130 135 140Glu Ser Lys Glu Ala Lys Lys Leu Ser Ala Arg Gly Phe Phe145 150 15571462DNAHomo sapiens 7gctagccgcc tgggaattta agggacccac actaccttcc cgaagttgaa ggcaagcggt 60gattgtttgt agacggcgct ttgtcatggg acctgtgcgg ttgggaatat tgcttttcct 120ttttttggcc gtgcacgagg cttgggctgg gatgttgaag gaggaggacg atgacacaga 180acgcttgccc agcaaatgcg aagtgtgtaa gctgctgagc acagagctac aggcggaact 240gagtcgcacc ggtcgatctc gagaggtgct ggagctgggg caggtgctgg atacaggcaa 300gaggaagaga cacgtgcctt acagcgtttc agagacaagg ctggaagagg ccttagagaa 360tttatgtgag cggatcctgg actatagtgt tcacgctgag cgcaagggct cactgagata 420tgccaagggt cagagtcaga ccatggcaac actgaaaggc ctagtgcaga agggggtgaa 480ggtggatctg gggatccctc tggagctttg ggatgagccc agcgtggagg tcacatacct 540caagaagcag tgtgagacca tgttggagga gtttgaagac attgtgggag actggtactt 600ccaccatcag gagcagcccc tacaaaattt tctctgtgaa ggtcatgtgc tcccagctgc 660tgaaactgca tgtctacagg aaacttggac tggaaaggag atcacagatg gggaagagaa 720aacagaaggg gaggaagagc aggaggagga ggaggaagag gaggaagagg aagggggaga 780caagatgacc aagacaggaa gccaccccaa acttgaccga gaagatcttt gacccttgcc 840tttgagcccc caggagggga agggatcatg gagagccctc taaagcctgc actctccctg 900ctccacagct ttcagggtgt gtttatgagt gactccaccc aagcttgtag ctgttctctc 960ccatctaacc tcaggcaaga tcctggtgaa acagcatgac atggcttctg gggtggaggg 1020tgggggtgga ggtcctgctc ctagagatga actctatcca gccccttaat tggcaggtgt 1080atgtgctgac agtactgaaa gctttcctct ttaactgatc ccacccccac ccaaaagtca 1140gcagtggcac tggagctgtg ggctttgggg aagtcactta gctccttaag gtctgttttt 1200agacccttcc aaggaagagg ccagaacgga cattctctgc gatctatata cattgcctgt 1260atccaggagg ctacacacca gcaaaccgtg aaggagaatg ggacactggg tcatggcctg 1320gagttgctga taatttaggt gggatagata cttggtctac ttaagctcaa tgtaacccag 1380agcccaccat atagttttat aggtgctcaa ttttctatat cgctattaaa cttttttctt 1440tttttctaaa aaaaaaaaaa aa 14628248PRTHomo sapiens 8Met Gly Pro Val Arg Leu Gly Ile Leu Leu Phe Leu Phe Leu Ala Val 1 5 10 15His Glu Ala Trp Ala Gly Met Leu Lys Glu Glu Asp Asp Asp Thr Glu 20 25 30Arg Leu Pro Ser Lys Cys Glu Val Cys Lys Leu Leu Ser Thr Glu Leu 35 40 45Gln Ala Glu Leu Ser Arg Thr Gly Arg Ser Arg Glu Val Leu Glu Leu 50 55 60Gly Gln Val Leu Asp Thr Gly Lys Arg Lys Arg His Val Pro Tyr Ser 65 70 75 80Val Ser Glu Thr Arg Leu Glu Glu Ala Leu Glu Asn Leu Cys Glu Arg 85 90 95Ile Leu Asp Tyr Ser Val His Ala Glu Arg Lys Gly Ser Leu Arg Tyr 100 105 110Ala Lys Gly Gln Ser Gln Thr Met Ala Thr Leu Lys Gly Leu Val Gln 115 120 125Lys Gly Val Lys Val Asp Leu Gly Ile Pro Leu Glu Leu Trp Asp Glu 130 135 140Pro Ser Val Glu Val Thr Tyr Leu Lys Lys Gln Cys Glu Thr Met Leu145 150 155 160Glu Glu Phe Glu Asp Ile Val Gly Asp Trp Tyr Phe His His Gln Glu 165 170 175Gln Pro Leu Gln Asn Phe Leu Cys Glu Gly His Val Leu Pro Ala Ala 180 185 190Glu Thr Ala Cys Leu Gln Glu Thr Trp Thr Gly Lys Glu Ile Thr Asp 195 200 205Gly Glu Glu Lys Thr Glu Gly Glu Glu Glu Gln Glu Glu Glu Glu Glu 210 215 220Glu Glu Glu Glu Glu Gly Gly Asp Lys Met Thr Lys Thr Gly Ser His225 230 235 240Pro Lys Leu Asp Arg Glu Asp Leu 24592104DNAHomo sapiens 9ccccttgccg ctccggtgac agtctctgcg gaaagtcacg tktgtgattt cgggagagca 60cagaacggga cgacggcgct cttgctgggt catctgggcc aggtgacgaa gaaacagttt 120cctggtgaag

cagtccctca cccctagtca gcccacaccc ctagggccta aagatgctga 180ggtctgtatg gaattttctg aaacgccaca aaaagaaatg catcttcctg ggcacggtcc 240ttggaggagt atatattctg gggaaatatg gacagaagaa aatcagagaa atacaggaaa 300gggaggctgc agaatacatt gcccaagcac gacgacaata tcattttgaa agtaaccaga 360ggacttgcaa tatgacagtg ctgtccatgc ttccaacact gagagaggcc ttaatgcagc 420aactgaattc cgagagcctc acagctctgc taaaaaacag gccttcaaac aagctagaaa 480tatgggagga tctgaagata ataagtttca caagaagtac tgtggctgta tacagtacct 540gtatgctggt tgttcttttg cgggtccagt taaacataat tggtggatat atttacctgg 600ataatgcagc agttggcaaa aatggcacta caattcttgc tcccccagat gtccaacagc 660agtatttatc aagtattcag cacctacttg gagatggcct gacagaattg atcactgtca 720ttaaacaagc tgtgcagaag gttttaggaa gtgtttctct taaacattct ttgtcccttt 780tggacttgga gcaaaaacta aaagaaatca gaaatctcgt tgagcagcat aagtcttctt 840cttggattaa taaagatgga tccaaacctt tattatgcca ttatatgatg ccagatgaag 900aaactccatt agcagtgcag gcctgtggac tttctcctcg agacattacc actattaaac 960ttctcaatga aactagagac atgttggaaa gcccagattt tagtacagtt ttgaatacct 1020gtttaaaccg aggttttagt agacttctag acaatatggc tgagttcttt cgacctactg 1080aacaggacct gcaacatggt aactctatga atagtctttc cagtgtcagc ctgcctttag 1140ctaagataat tccaatagta aacggacaga tccattcagt ttgcagtgaa acacctagtc 1200attttgttca ggatctgttg acaatggagc aagtgaaaga ctttgctgct aatgtgtatg 1260aagcttttag tacccctcag caactggaga aatgattttt ccttcaagaa aaactacagt 1320gggattcatt tactttttaa aatacactgg gtaaatcacc tatacttaga gtaacagttt 1380gttatcaaaa tgcctgataa aatatattct taataaaagt cttcatttca taatgaaatc 1440aatttatttg gcatcttaat atattttttt agattcatca acagaccagt ttttgtgggc 1500atatatatat acacgtgcaa atatcagaat tgttaataat ttgttacaca tggacatttg 1560ttccaaactg actaaaaatc aatatagata ttttatatac atatatatat ataaaaatac 1620aaaattcagt gtactttacc atattaatac tgaggaaaaa tctgttggag acataggtct 1680aggatgtgtg aagtttggaa aaatatgcta tttaattata atgttcccta gactgctgta 1740aacagaagtg aatcagactt ttctccagct acctttcaaa ataataaatt atttgtctca 1800aatatacctt gatggaggac ttttttattc ttatggaaat agtgaattcc aacaactatg 1860atgaactatg ttctttgcta tttcttcact atatttttta aggttttatt aaaaagcctt 1920agaaagttac atattggttt agaggctaaa attgtgttga tgctgtttac tcacctaatt 1980acatagtttt aatcatttgt acataatttt aaaaacttac tttgtattga ttttgaatac 2040agtgaaaatc ttattgcaat aaactatttt agtaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100aaaa 210410373PRTHomo sapiens 10Met Leu Arg Ser Val Trp Asn Phe Leu Lys Arg His Lys Lys Lys Cys 1 5 10 15Ile Phe Leu Gly Thr Val Leu Gly Gly Val Tyr Ile Leu Gly Lys Tyr 20 25 30Gly Gln Lys Lys Ile Arg Glu Ile Gln Glu Arg Glu Ala Ala Glu Tyr 35 40 45Ile Ala Gln Ala Arg Arg Gln Tyr His Phe Glu Ser Asn Gln Arg Thr 50 55 60Cys Asn Met Thr Val Leu Ser Met Leu Pro Thr Leu Arg Glu Ala Leu 65 70 75 80Met Gln Gln Leu Asn Ser Glu Ser Leu Thr Ala Leu Leu Lys Asn Arg 85 90 95Pro Ser Asn Lys Leu Glu Ile Trp Glu Asp Leu Lys Ile Ile Ser Phe 100 105 110Thr Arg Ser Thr Val Ala Val Tyr Ser Thr Cys Met Leu Val Val Leu 115 120 125Leu Arg Val Gln Leu Asn Ile Ile Gly Gly Tyr Ile Tyr Leu Asp Asn 130 135 140Ala Ala Val Gly Lys Asn Gly Thr Thr Ile Leu Ala Pro Pro Asp Val145 150 155 160Gln Gln Gln Tyr Leu Ser Ser Ile Gln His Leu Leu Gly Asp Gly Leu 165 170 175Thr Glu Leu Ile Thr Val Ile Lys Gln Ala Val Gln Lys Val Leu Gly 180 185 190Ser Val Ser Leu Lys His Ser Leu Ser Leu Leu Asp Leu Glu Gln Lys 195 200 205Leu Lys Glu Ile Arg Asn Leu Val Glu Gln His Lys Ser Ser Ser Trp 210 215 220Ile Asn Lys Asp Gly Ser Lys Pro Leu Leu Cys His Tyr Met Met Pro225 230 235 240Asp Glu Glu Thr Pro Leu Ala Val Gln Ala Cys Gly Leu Ser Pro Arg 245 250 255Asp Ile Thr Thr Ile Lys Leu Leu Asn Glu Thr Arg Asp Met Leu Glu 260 265 270Ser Pro Asp Phe Ser Thr Val Leu Asn Thr Cys Leu Asn Arg Gly Phe 275 280 285Ser Arg Leu Leu Asp Asn Met Ala Glu Phe Phe Arg Pro Thr Glu Gln 290 295 300Asp Leu Gln His Gly Asn Ser Met Asn Ser Leu Ser Ser Val Ser Leu305 310 315 320Pro Leu Ala Lys Ile Ile Pro Ile Val Asn Gly Gln Ile His Ser Val 325 330 335Cys Ser Glu Thr Pro Ser His Phe Val Gln Asp Leu Leu Thr Met Glu 340 345 350Gln Val Lys Asp Phe Ala Ala Asn Val Tyr Glu Ala Phe Ser Thr Pro 355 360 365Gln Gln Leu Glu Lys 370113262DNAHomo sapiens 11gccaagatgg agccggcagt cggcggtccg ggcccactga tcgtgaacaa caaacagccc 60cagcccccgc cacctccgcc gccggcagcc gcacagccac cacccggggc accgcgggcc 120gccgcgggcc tcctgcctgg gggcaaagcc cgcgagttca accgcaacca gcgcaaagac 180tcagagggct attcggagtc accagacctg gagtttgagt atgctgacac agacaagtgg 240gctgcagagc tctcggagct ttacagctac acggaagggc cagaattcct gatgaatcga 300aaatgctttg aggaggactt ccggatccat gtgacagaca agaagtggac tgagctggat 360accaaccagc accggaccca tgccatgagg ctcctggatg gcttggaagt cactgccagg 420gagaagagac tcaaggtggc tcgagcaatt ctctatgttg ctcaaggcac gtttggggag 480tgcagctcgg aggcagaggt gcagtcctgg atgcgctaca acatctttct cctcctggag 540gtgggcacgt tcaatgcttt ggtggagctt ctgaacatgg aaatagacaa cagtgccgcc 600tgcagcagtg ctgtgaggaa gcctgccatc tccctggctg acagcacaga cctcagggtc 660ctgctcaaca tcatgtacct gatagtggag accgttcatc aggagtgtga gggtgacaag 720gctgagtgga ggaccatgcg gcagaccttc agagccgagc tgggctcccc gctgtacaac 780aatgagccat ttgccatcat gctgtttggg atggtgacca aattttgcag tggtcacgcc 840cctcactttc ccatgaagaa agttctcttg ctgctctgga agacagtatt gtgcacgcta 900ggcggctttg aggagctgca gagcatgaag gctgagaagc gcagcatcct gggcctcccc 960ccgcttcctg aggacagcat caaagtgatt cgcaacatga gagcagcctc tccaccagca 1020tctgcttcag acttgattga gcagcagcag aaacggggcc gccgagagca caaggctctg 1080ataaagcagg acaacctaga tgccttcaac gagcgggatc cctacaaggc tgatgactct 1140cgagaagagg aagaggagaa tgatgatgac aacagtctgg agggggagac gtttcccctg 1200gaacgggatg aagtgatgcc tcccccgcta cagcacccac agactgacag gctgacttgc 1260cccaaagggc tcccgtgggc tcccaaggtc agagagaaag acattgagat gttccttgag 1320tccagccgca gcaaatttat aggttacact ctaggcagtg acacgaacac agtggtgggg 1380ctgcccaggc caatccacga aagcatcaag actctgaaac agcacaagta cacgtcgatt 1440gcagaggtcc aggcacagat ggaggaggaa tacctccgct cccctctctc agggggagaa 1500gaagaagttg agcaagtccc tgcagaaacc ctctaccaag gcttgctccc cagcctgcct 1560cagtatatga ttgccctcct gaagatcctg ttggctgcag cacccacctc aaaagccaaa 1620acagactcaa tcaacatcct agcggacgtc ttgcctgagg agatgcccac cacagtgttg 1680cagagcatga agctgggggt ggatgtaaac cgccacaaag aggtcattgt taaggccatt 1740tctgctgtcc tgctgctgct gctcaagcac tttaagttga accatgtcta ccagtttgaa 1800tacatggccc agcacctggt gtttgccaac tgcattcctt tgatcctaaa gttcttcaat 1860caaaacatca tgtcctacat cactgccaag aacagcattt ctgtcctgga ttaccctcac 1920tgcgtggtgc atgagctgcc agagctgacg gcggagagtt tggaagcagg tgacagtaac 1980caattttgct ggaggaacct cttttcttgt atcaatctgc ttcggatctt gaacaagctg 2040acaaagtgga agcattcaag gacaatgatg ctggtggtgt tcaagtcagc ccccatcttg 2100aagcgggccc taaaggtgaa acaagccatg atgcagctct atgtgctgaa gctgctcaag 2160gtacagacca aatacttggg gcggcagtgg cgaaagagca acatgaagac catgtctgcc 2220atctaccaga aggtgcggca tcggctgaac gacgactggg catacggcaa tgatcttgat 2280gcccggcctt gggacttcca ggcagaggag tgtgcccttc gtgccaacat tgaacgcttc 2340aacgcccggc gctatgaccg ggcccacagc aaccctgact tcctgccagt ggacaactgc 2400ctgcagagtg tcctgggcca acgggtggac ctccctgagg actttcagat gaactatgac 2460ctctggttag aaagggaggt cttctccaag cccatttcct gggaagagct gctgcagtga 2520ggctgttggt taggggactg aaatggagag aaaagatgat ctgaaggtac ctgtgggact 2580gtcctagttc attgctgcag tgctcccatc ccccaccagg tggcagcaca gccccactgt 2640gtcttccgca gtctgtcctg ggcttgggtg agcccagctt gacctcccct tggttcccag 2700ggtcctgctc cgaagcagtc atctctgcct gagatccatt cttcctttac ttcccccacc 2760ctcctctctt ggatatggtt ggttttggct catttcacaa tcagcccaag gctgggaaag 2820ctggaatggg atgggaaccc ctccgccgtg catctgaatt tcaggggtca tgctgatgcc 2880tctcgagaca tacaaatcct tgctttgtca gcttgcaaag gaggagagtt taggattagg 2940gccagggcca gaaagtcggt atcttggttg tgctctgggg tgggggtggg gtgtttctga 3000tgttattcca gcctcctgct acattatatc cagaagtaat tgcggaggct ccttcagctg 3060cctcagcact ttgattttgg acagggacaa ggtaggaaga gaagcttccc ttaaccagag 3120gggccatttt tccttttggc tttcgagggc ctgtaaatat ctatatataa ttctgtgtgt 3180attctgtgtc atgttggggt ttttaatgtg attgtgtatt ctgtttacat taaaaagaag 3240caaaaataaa aaaaaaaaaa aa 326212837PRTHomo sapiens 12Met Glu Pro Ala Val Gly Gly Pro Gly Pro Leu Ile Val Asn Asn Lys 1 5 10 15Gln Pro Gln Pro Pro Pro Pro Pro Pro Pro Ala Ala Ala Gln Pro Pro 20 25 30Pro Gly Ala Pro Arg Ala Ala Ala Gly Leu Leu Pro Gly Gly Lys Ala 35 40 45Arg Glu Phe Asn Arg Asn Gln Arg Lys Asp Ser Glu Gly Tyr Ser Glu 50 55 60Ser Pro Asp Leu Glu Phe Glu Tyr Ala Asp Thr Asp Lys Trp Ala Ala 65 70 75 80Glu Leu Ser Glu Leu Tyr Ser Tyr Thr Glu Gly Pro Glu Phe Leu Met 85 90 95Asn Arg Lys Cys Phe Glu Glu Asp Phe Arg Ile His Val Thr Asp Lys 100 105 110Lys Trp Thr Glu Leu Asp Thr Asn Gln His Arg Thr His Ala Met Arg 115 120 125Leu Leu Asp Gly Leu Glu Val Thr Ala Arg Glu Lys Arg Leu Lys Val 130 135 140Ala Arg Ala Ile Leu Tyr Val Ala Gln Gly Thr Phe Gly Glu Cys Ser145 150 155 160Ser Glu Ala Glu Val Gln Ser Trp Met Arg Tyr Asn Ile Phe Leu Leu 165 170 175Leu Glu Val Gly Thr Phe Asn Ala Leu Val Glu Leu Leu Asn Met Glu 180 185 190Ile Asp Asn Ser Ala Ala Cys Ser Ser Ala Val Arg Lys Pro Ala Ile 195 200 205Ser Leu Ala Asp Ser Thr Asp Leu Arg Val Leu Leu Asn Ile Met Tyr 210 215 220Leu Ile Val Glu Thr Val His Gln Glu Cys Glu Gly Asp Lys Ala Glu225 230 235 240Trp Arg Thr Met Arg Gln Thr Phe Arg Ala Glu Leu Gly Ser Pro Leu 245 250 255Tyr Asn Asn Glu Pro Phe Ala Ile Met Leu Phe Gly Met Val Thr Lys 260 265 270Phe Cys Ser Gly His Ala Pro His Phe Pro Met Lys Lys Val Leu Leu 275 280 285Leu Leu Trp Lys Thr Val Leu Cys Thr Leu Gly Gly Phe Glu Glu Leu 290 295 300Gln Ser Met Lys Ala Glu Lys Arg Ser Ile Leu Gly Leu Pro Pro Leu305 310 315 320Pro Glu Asp Ser Ile Lys Val Ile Arg Asn Met Arg Ala Ala Ser Pro 325 330 335Pro Ala Ser Ala Ser Asp Leu Ile Glu Gln Gln Gln Lys Arg Gly Arg 340 345 350Arg Glu His Lys Ala Leu Ile Lys Gln Asp Asn Leu Asp Ala Phe Asn 355 360 365Glu Arg Asp Pro Tyr Lys Ala Asp Asp Ser Arg Glu Glu Glu Glu Glu 370 375 380Asn Asp Asp Asp Asn Ser Leu Glu Gly Glu Thr Phe Pro Leu Glu Arg385 390 395 400Asp Glu Val Met Pro Pro Pro Leu Gln His Pro Gln Thr Asp Arg Leu 405 410 415Thr Cys Pro Lys Gly Leu Pro Trp Ala Pro Lys Val Arg Glu Lys Asp 420 425 430Ile Glu Met Phe Leu Glu Ser Ser Arg Ser Lys Phe Ile Gly Tyr Thr 435 440 445Leu Gly Ser Asp Thr Asn Thr Val Val Gly Leu Pro Arg Pro Ile His 450 455 460Glu Ser Ile Lys Thr Leu Lys Gln His Lys Tyr Thr Ser Ile Ala Glu465 470 475 480Val Gln Ala Gln Met Glu Glu Glu Tyr Leu Arg Ser Pro Leu Ser Gly 485 490 495Gly Glu Glu Glu Val Glu Gln Val Pro Ala Glu Thr Leu Tyr Gln Gly 500 505 510Leu Leu Pro Ser Leu Pro Gln Tyr Met Ile Ala Leu Leu Lys Ile Leu 515 520 525Leu Ala Ala Ala Pro Thr Ser Lys Ala Lys Thr Asp Ser Ile Asn Ile 530 535 540Leu Ala Asp Val Leu Pro Glu Glu Met Pro Thr Thr Val Leu Gln Ser545 550 555 560Met Lys Leu Gly Val Asp Val Asn Arg His Lys Glu Val Ile Val Lys 565 570 575Ala Ile Ser Ala Val Leu Leu Leu Leu Leu Lys His Phe Lys Leu Asn 580 585 590His Val Tyr Gln Phe Glu Tyr Met Ala Gln His Leu Val Phe Ala Asn 595 600 605Cys Ile Pro Leu Ile Leu Lys Phe Phe Asn Gln Asn Ile Met Ser Tyr 610 615 620Ile Thr Ala Lys Asn Ser Ile Ser Val Leu Asp Tyr Pro His Cys Val625 630 635 640Val His Glu Leu Pro Glu Leu Thr Ala Glu Ser Leu Glu Ala Gly Asp 645 650 655Ser Asn Gln Phe Cys Trp Arg Asn Leu Phe Ser Cys Ile Asn Leu Leu 660 665 670Arg Ile Leu Asn Lys Leu Thr Lys Trp Lys His Ser Arg Thr Met Met 675 680 685Leu Val Val Phe Lys Ser Ala Pro Ile Leu Lys Arg Ala Leu Lys Val 690 695 700Lys Gln Ala Met Met Gln Leu Tyr Val Leu Lys Leu Leu Lys Val Gln705 710 715 720Thr Lys Tyr Leu Gly Arg Gln Trp Arg Lys Ser Asn Met Lys Thr Met 725 730 735Ser Ala Ile Tyr Gln Lys Val Arg His Arg Leu Asn Asp Asp Trp Ala 740 745 750Tyr Gly Asn Asp Leu Asp Ala Arg Pro Trp Asp Phe Gln Ala Glu Glu 755 760 765Cys Ala Leu Arg Ala Asn Ile Glu Arg Phe Asn Ala Arg Arg Tyr Asp 770 775 780Arg Ala His Ser Asn Pro Asp Phe Leu Pro Val Asp Asn Cys Leu Gln785 790 795 800Ser Val Leu Gly Gln Arg Val Asp Leu Pro Glu Asp Phe Gln Met Asn 805 810 815Tyr Asp Leu Trp Leu Glu Arg Glu Val Phe Ser Lys Pro Ile Ser Trp 820 825 830Glu Glu Leu Leu Gln 835131264DNAHomo sapiens 13cttgaacgca cctcaggatg gcccgtactt tggaaccact agcaaagaag atctttaaag 60gagttttggt agccgaactt gtaggcgttt ttggagcata ttttttgttt agcaagatgc 120acacaagcca agatttcagg caaacaatga gcaagaaata tcccttcatc ttggaagttt 180attacaaatc cactgagaag tctggaatgt atggaatcag agagctagat caaaaaacat 240ggttgaacag caaaaattag atgtaaggaa gatctgcatt caaatgtgag tgggcaccat 300ccaatctgct ggggccctgg agagaacaaa acaaagaggc aaacatgttg atctgctgtg 360ctgaggagga aaatggcgga taaggggaca ggactaacgt gcagctccca catggatgga 420cagaacagcg tgtggcaacg tgtttagtct ccttaaaagg atttcactct gtcacccagg 480ctggagtgca gtggcgtaat cttggctcac ggcaacctct gactcctgga ttcaggcgat 540tctcgtgcct ctgcttctcg agtagctggg actacaggtg cgtgccacca tgcccagctc 600attttttggg gtttttagtg gagacagggt ttcaccgtgt tggccaggct ggtctcgaac 660tcctgacctc aaacaatctt cctgcctcgg cctgccgagg tgctgggatt acaggtgtga 720gccacagcgc ctggccccaa atatttctta atcttccact gtgatttgca tgatattctt 780agctaagtga ttttttaaaa ctaaggccac ttctcccact aatgttccat ggtctattaa 840cacatagtag tagattattt tacaaagagt caacaaaaca aattaccaat cagctcttca 900aattcttcat catccacgtc ttctatactt tcttcatctg catcccgttt ttgtttctct 960ttaacagcaa cttttttata atacctataa tattcatgtt atatatttga caattttatt 1020aaaggtctaa tcttactata tatcatcaaa gcacctatga ccagtggcaa accacaactg 1080taaaatctta agtatactca attggaaata aatgactgaa atttgtatct aatatacaaa 1140aaatagttta actcaataaa aagtagctgg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260aaaa 12641480PRTHomo sapiens 14Met Ala Arg Thr Leu Glu Pro Leu Ala Lys Lys Ile Phe Lys Gly Val 1 5 10 15Leu Val Ala Glu Leu Val Gly Val Phe Gly Ala Tyr Phe Leu Phe Ser 20 25 30Lys Met His Thr Ser Gln Asp Phe Arg Gln Thr Met Ser Lys Lys Tyr 35 40 45Pro Phe Ile Leu Glu Val Tyr Tyr Lys Ser Thr Glu Lys Ser Gly Met 50 55 60Tyr Gly Ile Arg Glu Leu Asp Gln Lys Thr Trp Leu Asn Ser Lys Asn 65 70 75 80152671DNAHomo sapiens 15ccgtacacgc gcgctgcggc atggcggccc accgccccgg cccgctcaag cagcagaata 60aagctcataa aggcggacgg catcggggtc ggggatctgc acagcgggac ggcaagggcc 120gtctggcact gaaaacccta agcaagaagg tgagaaaaga actcagcaga gtcgaccaga 180ggcatcgcgc cagccagctc cgaaagcaga agaaggaggc ggttctggca gagaagagac 240agctgggtgg caaggatggc cctcctcatc aggtactggt ggtgcccctg cacagcagaa 300tttccctgcc agaggccatg cagctgcttc aagataggga cactggaaca gtacacttga 360atgaattggg aaacacccag aactttatgc tgctgtgccc ccgcttgaaa catctgtggt 420ttttcacctc agcaaggcca

ggggatctgc acgttgtgtt agacatggct aaagtagctg 480ataccatcct gttcctcctt gatccactag aaggctggga cagcacccgt gattactgtc 540tttcctgcct ctttgctcag ggccttccga cctatacact agctgtccag gggatttctg 600gcctcccact gaagaaacaa atagatacca ggaagaagct aagtaaagca gtggagaagc 660gctttccgca tgacaaactc ctcttgttag acactcaaca ggaggcaggg atgctgctta 720ggcagttggc taaccagaag caacagcatc ttgcttttcg agatcggcgg gcctacctat 780ttgcccatgc tgttgatttt gttcctagtg aagagaataa cttggtgggc accttgaaaa 840tttcaggcta tgttcgaggg cagactctga atgtcaatag gttgctgcat atcgttggat 900atggtgattt gccagatgaa cagatagatg cccccggaga ccctttccct ttaaatccta 960gaggaattaa accccaaaag gacccagaca tggcaatgga gatttgtgct acggatgctg 1020tagatgatat ggaagaaggt cttaaagtcc taatgaaggc agaccctggt agacaggaat 1080ccttgcaagc agaggttatc ccagatccaa tggagggaga gcaaacctgg cccactgagg 1140aggagctgag cgaggcaaag gatttcttga aggaaagttc taaggtggta aagaaggtcc 1200ccaaaggaac atccagttac caagctgaat ggattttgga tggtggcagc caaagtggtg 1260gggaaggaga tgaatatgaa tatgatgata tggaacatga ggattttatg gaggaggaat 1320ctcaggatga gagtagtgaa gaagaggaag aatatgaaac tatgactatt ggggagtctg 1380tgcatgatga tctgtatgat aagaaagtag atgaagaagc tgaggcaaaa atgttggaga 1440aatataaaca agaaagactg gaagagatgt ttccagatga agtggacacg ccccgtgatg 1500tggctgctcg aattcgattt cagaaataca gaggccttaa gagcttccgg acatctccat 1560gggatcctaa ggaaaacctt cctcaagatt atgctcgaat atttcagttt cagaacttta 1620ctaacactag gaaaagcatc tttaaagagg ttgaagaaaa agaggttgaa ggagctgagg 1680ttggctggta tgtcacactt catgtctctg aagtccccgt ctcagtggtc gagtgcttca 1740ggcaaggaac acccttgatt gcattttctt tactacctca tgaacagaag atgtcagtat 1800tgaatatggt ggtgaggcgt gaccctggca acactgaacc tgtgaaagcc aaggaagagc 1860tcatatttca ctgtggattc aggcgcttcc gagcctcacc tttattctct cagcacactg 1920cagcggacaa acataaattg cagagattcc tgactgctga catggccctg gtggcgacag 1980tctatgcgcc aatcactttt cctcctgcat ctgtgctgct tttcaagcaa aaaagcaatg 2040gaatgcacag cctcattgct acaggccatc ttatgtcagt agatccagac agaatggtca 2100tcaagagagt tgttctgagt ggtcatcctt tcaaaatttt tactaagatg gcagtagtac 2160gttacatgtt cttcaacaga gaggatgtgc tgtggtttaa accagtggaa ctgagaacga 2220agtggggccg gagaggacat atcaaggaac ctttaggtac ccatggccac atgaaatgca 2280gctttgatgg gaagctaaaa tctcaagaca cagtactgat gaacctgtat aaacgagtct 2340tccccaaatg gacttatgat ccatatgtac cagaaccagt accctggctg aaaagtgaga 2400tttcttcaac agtgcctcaa gggggcatgg agtaatggat tcaaagagat tctgtcttac 2460cggtgccagt cagtactcca gggatgggag gcacaagttg tgattgggca aagtttattt 2520tctatgtcag cctgtcagtc cactgcccca ttttgcaaga ctttttttta gccttgacaa 2580aatgtctcag ttaagtataa aagtttttcc actacttagt ccaaaaaaaa ctattaaatc 2640ttaatgaaat aaaaaaaaaa aaaaaaaaaa a 267116804PRTHomo sapiens 16Met Ala Ala His Arg Pro Gly Pro Leu Lys Gln Gln Asn Lys Ala His 1 5 10 15Lys Gly Gly Arg His Arg Gly Arg Gly Ser Ala Gln Arg Asp Gly Lys 20 25 30Gly Arg Leu Ala Leu Lys Thr Leu Ser Lys Lys Val Arg Lys Glu Leu 35 40 45Ser Arg Val Asp Gln Arg His Arg Ala Ser Gln Leu Arg Lys Gln Lys 50 55 60Lys Glu Ala Val Leu Ala Glu Lys Arg Gln Leu Gly Gly Lys Asp Gly 65 70 75 80Pro Pro His Gln Val Leu Val Val Pro Leu His Ser Arg Ile Ser Leu 85 90 95Pro Glu Ala Met Gln Leu Leu Gln Asp Arg Asp Thr Gly Thr Val His 100 105 110Leu Asn Glu Leu Gly Asn Thr Gln Asn Phe Met Leu Leu Cys Pro Arg 115 120 125Leu Lys His Leu Trp Phe Phe Thr Ser Ala Arg Pro Gly Asp Leu His 130 135 140Val Val Leu Asp Met Ala Lys Val Ala Asp Thr Ile Leu Phe Leu Leu145 150 155 160Asp Pro Leu Glu Gly Trp Asp Ser Thr Arg Asp Tyr Cys Leu Ser Cys 165 170 175Leu Phe Ala Gln Gly Leu Pro Thr Tyr Thr Leu Ala Val Gln Gly Ile 180 185 190Ser Gly Leu Pro Leu Lys Lys Gln Ile Asp Thr Arg Lys Lys Leu Ser 195 200 205Lys Ala Val Glu Lys Arg Phe Pro His Asp Lys Leu Leu Leu Leu Asp 210 215 220Thr Gln Gln Glu Ala Gly Met Leu Leu Arg Gln Leu Ala Asn Gln Lys225 230 235 240Gln Gln His Leu Ala Phe Arg Asp Arg Arg Ala Tyr Leu Phe Ala His 245 250 255Ala Val Asp Phe Val Pro Ser Glu Glu Asn Asn Leu Val Gly Thr Leu 260 265 270Lys Ile Ser Gly Tyr Val Arg Gly Gln Thr Leu Asn Val Asn Arg Leu 275 280 285Leu His Ile Val Gly Tyr Gly Asp Leu Pro Asp Glu Gln Ile Asp Ala 290 295 300Pro Gly Asp Pro Phe Pro Leu Asn Pro Arg Gly Ile Lys Pro Gln Lys305 310 315 320Asp Pro Asp Met Ala Met Glu Ile Cys Ala Thr Asp Ala Val Asp Asp 325 330 335Met Glu Glu Gly Leu Lys Val Leu Met Lys Ala Asp Pro Gly Arg Gln 340 345 350Glu Ser Leu Gln Ala Glu Val Ile Pro Asp Pro Met Glu Gly Glu Gln 355 360 365Thr Trp Pro Thr Glu Glu Glu Leu Ser Glu Ala Lys Asp Phe Leu Lys 370 375 380Glu Ser Ser Lys Val Val Lys Lys Val Pro Lys Gly Thr Ser Ser Tyr385 390 395 400Gln Ala Glu Trp Ile Leu Asp Gly Gly Ser Gln Ser Gly Gly Glu Gly 405 410 415Asp Glu Tyr Glu Tyr Asp Asp Met Glu His Glu Asp Phe Met Glu Glu 420 425 430Glu Ser Gln Asp Glu Ser Ser Glu Glu Glu Glu Glu Tyr Glu Thr Met 435 440 445Thr Ile Gly Glu Ser Val His Asp Asp Leu Tyr Asp Lys Lys Val Asp 450 455 460Glu Glu Ala Glu Ala Lys Met Leu Glu Lys Tyr Lys Gln Glu Arg Leu465 470 475 480Glu Glu Met Phe Pro Asp Glu Val Asp Thr Pro Arg Asp Val Ala Ala 485 490 495Arg Ile Arg Phe Gln Lys Tyr Arg Gly Leu Lys Ser Phe Arg Thr Ser 500 505 510Pro Trp Asp Pro Lys Glu Asn Leu Pro Gln Asp Tyr Ala Arg Ile Phe 515 520 525Gln Phe Gln Asn Phe Thr Asn Thr Arg Lys Ser Ile Phe Lys Glu Val 530 535 540Glu Glu Lys Glu Val Glu Gly Ala Glu Val Gly Trp Tyr Val Thr Leu545 550 555 560His Val Ser Glu Val Pro Val Ser Val Val Glu Cys Phe Arg Gln Gly 565 570 575Thr Pro Leu Ile Ala Phe Ser Leu Leu Pro His Glu Gln Lys Met Ser 580 585 590Val Leu Asn Met Val Val Arg Arg Asp Pro Gly Asn Thr Glu Pro Val 595 600 605Lys Ala Lys Glu Glu Leu Ile Phe His Cys Gly Phe Arg Arg Phe Arg 610 615 620Ala Ser Pro Leu Phe Ser Gln His Thr Ala Ala Asp Lys His Lys Leu625 630 635 640Gln Arg Phe Leu Thr Ala Asp Met Ala Leu Val Ala Thr Val Tyr Ala 645 650 655Pro Ile Thr Phe Pro Pro Ala Ser Val Leu Leu Phe Lys Gln Lys Ser 660 665 670Asn Gly Met His Ser Leu Ile Ala Thr Gly His Leu Met Ser Val Asp 675 680 685Pro Asp Arg Met Val Ile Lys Arg Val Val Leu Ser Gly His Pro Phe 690 695 700Lys Ile Phe Thr Lys Met Ala Val Val Arg Tyr Met Phe Phe Asn Arg705 710 715 720Glu Asp Val Leu Trp Phe Lys Pro Val Glu Leu Arg Thr Lys Trp Gly 725 730 735Arg Arg Gly His Ile Lys Glu Pro Leu Gly Thr His Gly His Met Lys 740 745 750Cys Ser Phe Asp Gly Lys Leu Lys Ser Gln Asp Thr Val Leu Met Asn 755 760 765Leu Tyr Lys Arg Val Phe Pro Lys Trp Thr Tyr Asp Pro Tyr Val Pro 770 775 780Glu Pro Val Pro Trp Leu Lys Ser Glu Ile Ser Ser Thr Val Pro Gln785 790 795 800Gly Gly Met Glu172321DNAHomo sapiens 17ccgaccttgg aatcagaagc ctggggctcc tctagggagt ggctggcccc ccgggaggcc 60agaggaggcc catcgctgtc ttctgtgctg aacgagctgc ccagtgctgc cacccttcgg 120taccgagacc ctggggtgct gccttggggg gcgctggagg aggaggagga ggatggagga 180aggagcagaa aggccttcac agaagtcacc cagacagagc tgcaggaccc tcacccttcc 240cgggaactgc cctggcccat gcaggccaga cgggcataca ggcaaagaaa tgccagcagg 300gaccaggtgg tctatggctc tggaactaag acggaccgat gggcgcggct acttcggagg 360tccaaggaga aaacaaagga aggcttgcga agctgcagcc ctgggcgtgg acactgaaga 420ggatcggggg ccagtttggc gccggcacgg agtcctactt ctccctgctg cgcttcctgc 480tccttcttaa cgtgctggcc tctgtgctca tggcctgcat gacgctgctg cccacctggt 540tgggaggcgc tcccccaggc cctcccggcc ccgacatctc ctcgccctgc ggctcctata 600acccccactc ccagggcctg gtcacctttg ccacccagct cttcaacttg ctctcgggtg 660agggttacct ggaatggtcc cctctcttct atggcttcta cacgccccgc ccacgcctgg 720cggtcaccta cctgtgctgg gcctttgccg ttggcctcat ctgcctcctg ctcatcctgc 780atcgctcggt gtctgggctg aagcagacac tgctggcgga gtccgaggct ctgaccagct 840acagccaccg ggtgttctcg gcctgggact tcggtctctg cggggacgtc cacgtgcggc 900tgcgccagcg catcatcttg tacgaattaa aggtggagct ggaggagaca gtggtgcggc 960gccaggctgc ggtgcggacg ctgggccagc aagccagggt ttggttggtg cgggtgctgc 1020tcaacctgct ggtggtcgcg ctcctggggg cagccttcta tggcgtctac tgggctacgg 1080ggtgcaccgt ggagctgcag gagatgcccc ttgtccagga gttgccactg ctgaagcttg 1140gggtgaatta ccttccgtcc atcttcatcg ctggggtcaa ttttgtgctg ccgcccgtgt 1200tcaagctcat tgctccactg gagggctaca ctcggagtcg ccagatcgtt tttatcctgc 1260tcaggaccgt gtttcttcgc ctcgcctccc tggtggtcct gctcttctct ctctggaatc 1320agatcacttg tgggggcgac tccgaggctg aggactgcaa aacctgtggc tacaattaca 1380aacaacttcc gtgctgggag actgtcctgg gccaggaaat gtacaaactt ctgctctttg 1440atctgctgac tgtcttggca gtcgcgctgc tcatccagtt tcctagaaag ctcctctgtg 1500gcctctgtcc tggggcgctg ggtcttctgg cggggaccca ggagttccag gtgcccgacg 1560aggtgctggg gctcatctac gcgcagacgg tggtctgggt ggggagtttt ttctgccctt 1620tactgcccct gcttaacacg gtcaagttcc tgctgctttt ctacctgaag aagcttaccc 1680tcttctccac ctgctccccg gctgcccgca ccttccgggc ctccgcggcg aatttctttt 1740tccccttggt ccttctcctg ggtctggcca tctccagcgt tcccctgctt tacagcatct 1800tcctgatccc gccttctaag ctgtgtggtc cattccgggg gcagtcgtcc atctgggccc 1860agatccctga gtctatttcc agcctccctg agaccaccca gaatttcctc ttcttcctgg 1920ggacccaggc ttttgctgtg ccccttctgc tgatctccag catcctgatg gcgtacactg 1980tggctctggc taactcctac ggacgcctca tctctgagct caaacgtcag agagagacgg 2040aggcgcagaa taaagtcttc ctggcacggc gcgctgtggc gctgacctcc accaaaccgg 2100ctctttgacc cccgcagccc acgtcccgct ttcagacccc aggcccattg taagcctagg 2160tcacaacatc tgtaaactag gagaactgga gaagactcca cgcccttcca gctttggtat 2220ctggagattt ccagggcccc tcgccgccac gtccctgact ctcgggtgat cttccttgta 2280tcaataaata cagccgaggt tgcaaaaaaa aaaaaaaaaa a 232118589PRTHomo sapiens 18Met Gly Ala Ala Thr Ser Glu Val Gln Gly Glu Asn Lys Gly Arg Leu 1 5 10 15Ala Lys Leu Gln Pro Trp Ala Trp Thr Leu Lys Arg Ile Gly Gly Gln 20 25 30Phe Gly Ala Gly Thr Glu Ser Tyr Phe Ser Leu Leu Arg Phe Leu Leu 35 40 45Leu Leu Asn Val Leu Ala Ser Val Leu Met Ala Cys Met Thr Leu Leu 50 55 60Pro Thr Trp Leu Gly Gly Ala Pro Pro Gly Pro Pro Gly Pro Asp Ile 65 70 75 80Ser Ser Pro Cys Gly Ser Tyr Asn Pro His Ser Gln Gly Leu Val Thr 85 90 95Phe Ala Thr Gln Leu Phe Asn Leu Leu Ser Gly Glu Gly Tyr Leu Glu 100 105 110Trp Ser Pro Leu Phe Tyr Gly Phe Tyr Thr Pro Arg Pro Arg Leu Ala 115 120 125Val Thr Tyr Leu Cys Trp Ala Phe Ala Val Gly Leu Ile Cys Leu Leu 130 135 140Leu Ile Leu His Arg Ser Val Ser Gly Leu Lys Gln Thr Leu Leu Ala145 150 155 160Glu Ser Glu Ala Leu Thr Ser Tyr Ser His Arg Val Phe Ser Ala Trp 165 170 175Asp Phe Gly Leu Cys Gly Asp Val His Val Arg Leu Arg Gln Arg Ile 180 185 190Ile Leu Tyr Glu Leu Lys Val Glu Leu Glu Glu Thr Val Val Arg Arg 195 200 205Gln Ala Ala Val Arg Thr Leu Gly Gln Gln Ala Arg Val Trp Leu Val 210 215 220Arg Val Leu Leu Asn Leu Leu Val Val Ala Leu Leu Gly Ala Ala Phe225 230 235 240Tyr Gly Val Tyr Trp Ala Thr Gly Cys Thr Val Glu Leu Gln Glu Met 245 250 255Pro Leu Val Gln Glu Leu Pro Leu Leu Lys Leu Gly Val Asn Tyr Leu 260 265 270Pro Ser Ile Phe Ile Ala Gly Val Asn Phe Val Leu Pro Pro Val Phe 275 280 285Lys Leu Ile Ala Pro Leu Glu Gly Tyr Thr Arg Ser Arg Gln Ile Val 290 295 300Phe Ile Leu Leu Arg Thr Val Phe Leu Arg Leu Ala Ser Leu Val Val305 310 315 320Leu Leu Phe Ser Leu Trp Asn Gln Ile Thr Cys Gly Gly Asp Ser Glu 325 330 335Ala Glu Asp Cys Lys Thr Cys Gly Tyr Asn Tyr Lys Gln Leu Pro Cys 340 345 350Trp Glu Thr Val Leu Gly Gln Glu Met Tyr Lys Leu Leu Leu Phe Asp 355 360 365Leu Leu Thr Val Leu Ala Val Ala Leu Leu Ile Gln Phe Pro Arg Lys 370 375 380Leu Leu Cys Gly Leu Cys Pro Gly Ala Leu Gly Leu Leu Ala Gly Thr385 390 395 400Gln Glu Phe Gln Val Pro Asp Glu Val Leu Gly Leu Ile Tyr Ala Gln 405 410 415Thr Val Val Trp Val Gly Ser Phe Phe Cys Pro Leu Leu Pro Leu Leu 420 425 430Asn Thr Val Lys Phe Leu Leu Leu Phe Tyr Leu Lys Lys Leu Thr Leu 435 440 445Phe Ser Thr Cys Ser Pro Ala Ala Arg Thr Phe Arg Ala Ser Ala Ala 450 455 460Asn Phe Phe Phe Pro Leu Val Leu Leu Leu Gly Leu Ala Ile Ser Ser465 470 475 480Val Pro Leu Leu Tyr Ser Ile Phe Leu Ile Pro Pro Ser Lys Leu Cys 485 490 495Gly Pro Phe Arg Gly Gln Ser Ser Ile Trp Ala Gln Ile Pro Glu Ser 500 505 510Ile Ser Ser Leu Pro Glu Thr Thr Gln Asn Phe Leu Phe Phe Leu Gly 515 520 525Thr Gln Ala Phe Ala Val Pro Leu Leu Leu Ile Ser Ser Ile Leu Met 530 535 540Ala Tyr Thr Val Ala Leu Ala Asn Ser Tyr Gly Arg Leu Ile Ser Glu545 550 555 560Leu Lys Arg Gln Arg Glu Thr Glu Ala Gln Asn Lys Val Phe Leu Ala 565 570 575Arg Arg Ala Val Ala Leu Thr Ser Thr Lys Pro Ala Leu 580 585195263DNAHomo sapiensunsure(848)unsure(1060)unsure(1248)unsure(1377)unsure(2310)unsure(- 2319)unsure(2839) 19agtggaagga gcaggcgctt gagctcgagc gacggcgctg gcggagacgc cggctgctcc 60tcccctcccc gccggtatta atctctggag aagacacatc cacagttagc actttcttca 120gatgctgacg ctcggtgaac agttgccttt ggtcacaaga tttagaagac acagtgtcca 180tcctcccaga ttggatctct ttttcatatg gatcttctgt ttctatgtct ttttaaaaaa 240taactttttg ggaaaccttt tggattacaa ctgttcatcc tcacctatgc aaagaaaggg 300aagctattgc tgggattttg aggagctttt cctaaaagga ttgtacacct tagaagtgct 360taaggaagag tgatgaagat aggcatgaag ccttcgtctc acagctgcat gcgtagtcac 420tgttgaagca aatgcctacc taatttgaca ctcttggtgt gtttaaaaaa tttttttgag 480tttgcaaata agcatattaa gtctactgat ggagccttcg ggcagtgaac agttatttga 540ggaccctgat cctggaggca aatcccaaga tgcagaggcc agaaagcaga cagaatcaga 600acaaaaattg tctaaaatga cccacaatgc tttggagaac attaacgtga ttggccaagg 660cttgaagcat ctcttccagc accagcgcag gaggtcatca gtgtctccac atgatgtgca 720gcaaattcag gcagatccag aacctgaaat ggatctggaa agccagaacg catgtgctga 780gattgatggt gtccccaccc accccacagc tctgaatcgt gtcctgcagc agattcgagt 840gccacccnag atgaagagag ggacaagctt gcatagtagg cggggcaagc cagaggcccc 900aaagggaagt ccccaaatca acaggaagtc tggtcaggag atgacagctg ttatgcagtc 960aggccgaccc atgtcttcat ccacaactga tgcacctacc ggctctgcta tgatggaaat 1020agcttgtgct gctgctgctg ctgctgctgc atgtctaccn ggagaggagg gaactgcgga 1080gcggatcgaa cggttggaag taagcagcct tgcccaaaca tccagtgcag tggcctccag 1140taccgatggc agcatccaca cagactctgt ggatggaaca ccagaccctc agcgcacaaa 1200ggctgccatt gctcacctgc agcagaagat cctgaagctc acagaacnaa tcaagattgc 1260acaaacagcc cgggacgaca acgttgctga atacttgaag cttgccaaca gtgcagacaa 1320acagcaggct gcccgcatca agcaagtctt tgagaagaag aaccagaaat ctgcccnaac 1380tatcctccag ctgcaaaaga aacttgagca ctaccacagg aagctcagag aggtagagca 1440gaatgggatc ccccggcagc caaaggatgt cttcagggac atgcaccagg gtctgaagga 1500tgtaggagca aaggtgactg gcttcagtga aggtgtggtg gatagtgtca aaggtgggtt 1560ttccagcttc tcccaggcca cccattcagc agcaggcgct gtagtctcaa agcccagaga 1620gattgcctca ctcattcgga acaaatttgg cagtgcagac aacatcccca acctgaagga 1680ctctttagag gaagggcaag tggatgatgc ggggaaggct ttgggagtga tttcaaactt 1740tcagtctagc ccaaaatatg gtagtgaaga agattgttct agtgccactt caggctcagt 1800gggagccaac agcaccacag ggggcatcgc tgtaggagca tccagctcca

aaacaaacac 1860cctggacatg cagagctcag gatttgatgc actactacat gagatccagg agatccggga 1920aacccaggcc agactagagg aatcctttga gactctcaag gaacattatc agagggacta 1980ttccttaata atgcagacct tacaggagga gcgatataga tgtgaacgat tggaagaaca 2040gctaaatgac ctaacagagc tccaccagaa tgaaatcttg aacttgaagc aggaactggc 2100aagcatggaa gaaaaaatcg cgtatcagtc ctatgaacgg gcccgggaca tccaggaggc 2160cctggaggca tgccagacgc gcatctccaa gatggagctg cagcagcagc agcagcaggt 2220ggtgcagcta gaagggctgg agaatgccac tgcccggaac cttctgggca aactcatcaa 2280catcctcctg gctgtcatgg cagtcctttn ggtctttgnc tccactgtag ccaactgtgt 2340ggtccccctc atgaagactc gcaacaggac gttcagcact ttattccttg tggtttttat 2400tgcctttctc tggaagcact gggacgccct cttcagctat gtggaacggt tcttttcatc 2460ccctagatga tgctggcaca gaaggcattg ttccctaccc tctggcgagt gcatgcagca 2520gagagttaga cagcaactta cctactctga agttttctac aacaaaaaaa gagttgagtg 2580aatctgttta catttagaat aatgtttttt tcttcaagag acgcaattgc aatagtattt 2640tttagatttt atccaagaag ttttttgggc gaaaatcttg gatcattttt atgtagcatg 2700attttccttg ggatgcaaat cttaaaacag tcctttaata tgaaccaaca atctggagca 2760caccgaaggg caatctaaat tgtggcttga aggactgcac taaaacccac taaaaagatg 2820cgaaaacctg atgagggcna accagttaaa cctaacaccc tgccttgtct gggctcatca 2880cctctcccta tcccagacta actttactgt gaaatcctac acattccatg tctgaatttt 2940tggattcggg gtggattttc gttgtccgtg gaagaacaca tggatctctc tggctttctc 3000acccaagttg gccacttacg ctaatcctgg aagtatgatc acttttgaac ctgcccctta 3060accttgacga ggatacaaaa gtgaaagcat catcccccaa aggatcactg cacagtccta 3120ctacagtatt tttaagtagc cctctaaata cttaatttta agcaaaatcc cttggccgca 3180cttttaaggt ttttttatat gtgtatagtt accaacctaa aaataaaaaa tccgaacagc 3240atacttgaag aatgtaatac tcaaactctc agtgcttcct tatggtttct aataggattt 3300tttattattg ttattattat tattgggttt ttttggacag ggttgggagg gtcttttatt 3360tttcctttga aataaagaag tgatgttttt aaatgaagaa atgtgtggat atttaagtgt 3420gctgctccct cttgtcttga aacagtttga gtaagaaagt cttgctgtaa atgctgccct 3480ctgccgcctt tgttttgaga tgcagtttaa actccctctg gctgctgctg ctgctttttg 3540gtgtcccgac atacctacgc ccccgtttta tgggtttggc ttagttgaag aggaaagggt 3600tgtgcaagga gagcaggagg ctgtttccaa aaaccagtgt agtaggatag ggattttttt 3660tttttttttg ccccaagaaa acgttcaccc agtgatcttg ggctggggtt gtctttagga 3720aaagttgaga ctataagagt cataaataag tccttgtgtt tccttaattt attttgttaa 3780cacccctaat tacaaccaaa gtgatgatgt ggagtcttct gtcttcattt tggccccagc 3840attcttaatt tcaaagcttt attctgtctg cctaagagaa tcaaccaaag gtgattctcc 3900taaagagcag tgaaggaaat gtcaggttag caggacccaa gttttgggtg tgaaatgttg 3960ccagcttcct ataatgtaaa cggacttgtt aacctaacct aattatgctc agtggacttc 4020tatagatggt tttgaaaaat gaactgagct gccttcccgc atcgcataac cagttccatc 4080atcctggtgg aacttgaaca tttagagttt atctagagag cttggttaat ctttccatat 4140tatttgtagt attggtcaca aatgctgttc cctcttagcc tcattctgtg caaccaagtg 4200catataagat gccctgaaaa gagtaacaaa gtatgctttg cctgtttcca cttaccagga 4260aattccttca gaactagatt agcattgccc tgcctgtctg aaaggacagt ttacctaatg 4320gtgccagcct ccttttgctt tggcaagctg gatttctcag agccagcatg ttgtttccat 4380aactactttg atattttaac tcaggtactc cagtcttcac cccaacctca gctgattgta 4440gtacacctgc tagctctgtt gccccctcaa aactgcaccc agagcagggc cacaagggtg 4500ctttttttct ttaaaaaaaa aaaaattaga accaattcat gttcatgcca aaaacaaatt 4560gtccccaagc ctatatgtat taaaatgtta actttgccta aaaatattgc agtgactttt 4620taggcaggag tgccaaagga cactatgaac tttttgaact gacagtttct cctaactttc 4680tgctttagcg taattgctca gagtagagag cccccacaaa gttatttaaa agatgcccta 4740gcagcaatcc accagttttt ctaagctaga acctttgagt cccccaaact gcctgaagac 4800ttaagttttg tgggcactgg aagtcacttt gatagatgga ttgaaactgt tcctatttgc 4860cctgggacgg tttctatcta tcaaaggaag gttttcacct gtagaaagcc ccctgcctcc 4920agccaaatag tcccatgctg actttctatc ttcctttctc aaactgtctt aggaaggacc 4980ttcagtgcag atcaggtgca gtaatggctt tcttgtccct taattattca ccagacccag 5040aagttgtacg catttaatgc tgtttgtaac catgcatctg ttttcattct ttgctgtacc 5100ttttgctgcc catcctgtta cttttgagtt tctttcattg tggttgttct tgggttcttt 5160tgtcttgtca gagctcttct ataacctcgc tctaatggct taacagttgt tctgggtgga 5220aacgtcccct catttgaatg ctcctctaaa aaaaaaaaaa aaa 526320653PRTHomo sapiensUNSURE(114)UNSURE(247)UNSURE(290)UNSURE(601)UNSURE(604) 20Met Glu Pro Ser Gly Ser Glu Gln Leu Phe Glu Asp Pro Asp Pro Gly 1 5 10 15Gly Lys Ser Gln Asp Ala Glu Ala Arg Lys Gln Thr Glu Ser Glu Gln 20 25 30Lys Leu Ser Lys Met Thr His Asn Ala Leu Glu Asn Ile Asn Val Ile 35 40 45Gly Gln Gly Leu Lys His Leu Phe Gln His Gln Arg Arg Arg Ser Ser 50 55 60Val Ser Pro His Asp Val Gln Gln Ile Gln Ala Asp Pro Glu Pro Glu 65 70 75 80Met Asp Leu Glu Ser Gln Asn Ala Cys Ala Glu Ile Asp Gly Val Pro 85 90 95Thr His Pro Thr Ala Leu Asn Arg Val Leu Gln Gln Ile Arg Val Pro 100 105 110Pro Xaa Met Lys Arg Gly Thr Ser Leu His Ser Arg Arg Gly Lys Pro 115 120 125Glu Ala Pro Lys Gly Ser Pro Gln Ile Asn Arg Lys Ser Gly Gln Glu 130 135 140Met Thr Ala Val Met Gln Ser Gly Arg Pro Met Ser Ser Ser Thr Thr145 150 155 160Asp Ala Pro Thr Gly Ser Ala Met Met Glu Ile Ala Cys Ala Ala Ala 165 170 175Ala Ala Ala Ala Ala Cys Leu Pro Gly Glu Glu Gly Thr Ala Glu Arg 180 185 190Ile Glu Arg Leu Glu Val Ser Ser Leu Ala Gln Thr Ser Ser Ala Val 195 200 205Ala Ser Ser Thr Asp Gly Ser Ile His Thr Asp Ser Val Asp Gly Thr 210 215 220Pro Asp Pro Gln Arg Thr Lys Ala Ala Ile Ala His Leu Gln Gln Lys225 230 235 240Ile Leu Lys Leu Thr Glu Xaa Ile Lys Ile Ala Gln Thr Ala Arg Asp 245 250 255Asp Asn Val Ala Glu Tyr Leu Lys Leu Ala Asn Ser Ala Asp Lys Gln 260 265 270Gln Ala Ala Arg Ile Lys Gln Val Phe Glu Lys Lys Asn Gln Lys Ser 275 280 285Ala Xaa Thr Ile Leu Gln Leu Gln Lys Lys Leu Glu His Tyr His Arg 290 295 300Lys Leu Arg Glu Val Glu Gln Asn Gly Ile Pro Arg Gln Pro Lys Asp305 310 315 320Val Phe Arg Asp Met His Gln Gly Leu Lys Asp Val Gly Ala Lys Val 325 330 335Thr Gly Phe Ser Glu Gly Val Val Asp Ser Val Lys Gly Gly Phe Ser 340 345 350Ser Phe Ser Gln Ala Thr His Ser Ala Ala Gly Ala Val Val Ser Lys 355 360 365Pro Arg Glu Ile Ala Ser Leu Ile Arg Asn Lys Phe Gly Ser Ala Asp 370 375 380Asn Ile Pro Asn Leu Lys Asp Ser Leu Glu Glu Gly Gln Val Asp Asp385 390 395 400Ala Gly Lys Ala Leu Gly Val Ile Ser Asn Phe Gln Ser Ser Pro Lys 405 410 415Tyr Gly Ser Glu Glu Asp Cys Ser Ser Ala Thr Ser Gly Ser Val Gly 420 425 430Ala Asn Ser Thr Thr Gly Gly Ile Ala Val Gly Ala Ser Ser Ser Lys 435 440 445Thr Asn Thr Leu Asp Met Gln Ser Ser Gly Phe Asp Ala Leu Leu His 450 455 460Glu Ile Gln Glu Ile Arg Glu Thr Gln Ala Arg Leu Glu Glu Ser Phe465 470 475 480Glu Thr Leu Lys Glu His Tyr Gln Arg Asp Tyr Ser Leu Ile Met Gln 485 490 495Thr Leu Gln Glu Glu Arg Tyr Arg Cys Glu Arg Leu Glu Glu Gln Leu 500 505 510Asn Asp Leu Thr Glu Leu His Gln Asn Glu Ile Leu Asn Leu Lys Gln 515 520 525Glu Leu Ala Ser Met Glu Glu Lys Ile Ala Tyr Gln Ser Tyr Glu Arg 530 535 540Ala Arg Asp Ile Gln Glu Ala Leu Glu Ala Cys Gln Thr Arg Ile Ser545 550 555 560Lys Met Glu Leu Gln Gln Gln Gln Gln Gln Val Val Gln Leu Glu Gly 565 570 575Leu Glu Asn Ala Thr Ala Arg Asn Leu Leu Gly Lys Leu Ile Asn Ile 580 585 590Leu Leu Ala Val Met Ala Val Leu Xaa Val Phe Xaa Ser Thr Val Ala 595 600 605Asn Cys Val Val Pro Leu Met Lys Thr Arg Asn Arg Thr Phe Ser Thr 610 615 620Leu Phe Leu Val Val Phe Ile Ala Phe Leu Trp Lys His Trp Asp Ala625 630 635 640Leu Phe Ser Tyr Val Glu Arg Phe Phe Ser Ser Pro Arg 645 650213349DNAHomo sapiens 21ccccctccag gccccgctcc tgcgccctat ttggtcattc ggggggcaag cggcgggagg 60ggaaacgtgc gcggccgaag gggaagcgga gccggcgccg gctgcgcaga ggagccgctc 120tcgccgccgc cacctcggct gggagcccac gaggctgccg catcctgccc tcggaacaat 180gggactcggc gcgcgaggtg cttgggccgc gctgctcctg gggacgctgc aggtgctagc 240gctgctgggg gccgcccatg aaagcgcagc catggcggca tctgcaaaca tagagaattc 300tgggcttcca cacaactcca gtgctaactc aacagagact ctccaacatg tgccttctga 360ccatacaaat gaaacttcca acagtactgt gaaaccacca acttcagttg cctcagactc 420cagtaataca acggtcacca ccatgaaacc tacagcggca tctaatacaa caacaccagg 480gatggtctca acaaatatga cttctaccac cttaaagtct acacccaaaa caacaagtgt 540ttcacagaac acatctcaga tatcaacatc cacaatgacc gtaacccaca atagttcagt 600gacatctgct gcttcatcag taacaatcac aacaactatg cattctgaag caaagaaagg 660atcaaaattt gatactggga gctttgttgg tggtattgta ttaacgctgg gagttttatc 720tattctttac attggatgca aaatgtatta ctcaagaaga ggcattcggt atcgaaccat 780agatgaacat gatgccatca tttaaggaaa tccatggacc aaggatggaa tacagattga 840tgctgcccta tcaattaatt ttggtttatt aatagtttaa aacaatattc tctttttgaa 900aatagtataa acaggccatg catataatgt acagtgtatt agtaaatatg taaagattct 960tcaaggtaac aagggtttgg gttttgaaat aaacatctgg atcttataga ccgttcatac 1020aatggtttta gcaagttcat agtaagacaa acaagtccta tctttttttt tttggctggg 1080gtgggggcat tggtcacata tgaccagtaa ttgaaagacg tcatcactga aagacagaat 1140gccatctggg catacaaata agaagtttgt cacagcactc aggattttgg gtatcttttg 1200tagctcacat aaagaacttc agtgcttttc agagctggat atatcttaat tactaatgcc 1260acacagaaat tatacaatca aactagatct gaagcataat ttaagaaaaa catcaacatt 1320ttttgtgctt taaactgtag tagttggtct agaaacaaaa tactccaaga aaaagaaaat 1380tttcaaataa aacccaaaat aatagctttg cttagccctg ttagggatcc attggagcat 1440taaggagcac atatttttat taacttcttt tgagctttca atgttgatgt aatttttgtt 1500ctctgtgtaa tttaggtaaa ctgcagtgtt taacataata atgttttaaa gacttagttg 1560tcagtattaa ataatcctgg cattataggg aaaaaacctc ctagaagtta gattatttgc 1620tactgtgaga atattgtcac cactggaagt tactttagtt catttaattt taattttata 1680ttttgtgaat attttaagaa ctgtagagct gctttcaata tctagaaatt tttaattgag 1740tgtaaacaca cctaacttta agaaaaagaa ccccttgtat gattttcaaa agaacattta 1800gaattctata gagtcaaaac tatagcgtaa tgctgtgttt attaagccag ggattgtggg 1860acttccccca ggctactaaa cctgcaggat gaaaatgcta tattttcttt catgcactgt 1920cgatattact cagatttggg gaaatgacat ttttatacta aaacaaacac caaaatattt 1980tagaataaat tcttagaaag ttttgagagg aatttttaga gaggacattt cctccttcct 2040gatttggata ttccctcaaa tccctcctct tactccatgc tgaaggagaa gtactctcag 2100atgcattatg ttaatggaga gaaaaagcac agtattgtag agacaccaat attagctaat 2160gtattttgga gtgttttcca ttttacagtt tatattccag cactcaaaac tcagggtcaa 2220gttttaacaa aagaggtatg tagtcacagt aaatactaag atggcatttc tatctcagag 2280ggccaaagtg aatcacacca gtttctgaag gtcctaaaaa tagctcagat gtcctaatga 2340acatgcacct acatttaata ggagtacaat aaaactgttg tcagcttttg ttttacagag 2400aacgctagat attaagaatt ttgaaatgga tcatttctac ttgctgtgca ttttaaccaa 2460taatctgatg aatatagaaa aaaatgatcc aaaatatgga tatgattgga tgtatgtaac 2520acatacatgg agtatggagg aaattttctg aaaaatacat ttagattagt ttagtttgaa 2580ggagaggtgg gctgatggct gagttgtatg ttactaactt ggccctgact ggttgtgcaa 2640ccattgcttc atttctttgc aaaatgtagt taagatatac tttattctaa tgaaggcctt 2700ttaaatttgt ccactgcatt cttggtattt cactacttca agtcagtcag aacttcgtag 2760accgacctga agtttctttt tgaatacttg tttctttagc actttgaaga tagaaaaacc 2820actttttaag tactaagtca tcatttgcct tgaaagtttc ctctgcattg ggtttgaagt 2880agtttagtta tgtctttttc tctgtatgta agtagtataa tttgttactt tcaaataccc 2940gtactttgaa tgtaggtttt tttgttgttg ttatctataa aaattgaggg aaatggttat 3000gcaaaaaaat attttgcttt ggaccatatt tcttaagcat aaaaaaaatg ctcagttttg 3060cttgcattcc ttgagaatgt atttatctga agatcaaaac aaacaatcca gatgtataag 3120tactaggcag aagccaattt taaaatttcc ttgaataatc catgaaagga ataattcaaa 3180tacagataaa cagagttggc agtatattat agtgataatt ttgtattttc acaaaaaaaa 3240agttaaactc ttcttttctt tttattataa tgaccagctt ttggtatttc attgttacca 3300agttctattt ttagaataaa attgttctcc ttctaaaaaa aaaaaaaaa 334922208PRTHomo sapiens 22Met Gly Leu Gly Ala Arg Gly Ala Trp Ala Ala Leu Leu Leu Gly Thr 1 5 10 15Leu Gln Val Leu Ala Leu Leu Gly Ala Ala His Glu Ser Ala Ala Met 20 25 30Ala Ala Ser Ala Asn Ile Glu Asn Ser Gly Leu Pro His Asn Ser Ser 35 40 45Ala Asn Ser Thr Glu Thr Leu Gln His Val Pro Ser Asp His Thr Asn 50 55 60Glu Thr Ser Asn Ser Thr Val Lys Pro Pro Thr Ser Val Ala Ser Asp 65 70 75 80Ser Ser Asn Thr Thr Val Thr Thr Met Lys Pro Thr Ala Ala Ser Asn 85 90 95Thr Thr Thr Pro Gly Met Val Ser Thr Asn Met Thr Ser Thr Thr Leu 100 105 110Lys Ser Thr Pro Lys Thr Thr Ser Val Ser Gln Asn Thr Ser Gln Ile 115 120 125Ser Thr Ser Thr Met Thr Val Thr His Asn Ser Ser Val Thr Ser Ala 130 135 140Ala Ser Ser Val Thr Ile Thr Thr Thr Met His Ser Glu Ala Lys Lys145 150 155 160Gly Ser Lys Phe Asp Thr Gly Ser Phe Val Gly Gly Ile Val Leu Thr 165 170 175Leu Gly Val Leu Ser Ile Leu Tyr Ile Gly Cys Lys Met Tyr Tyr Ser 180 185 190Arg Arg Gly Ile Arg Tyr Arg Thr Ile Asp Glu His Asp Ala Ile Ile 195 200 205232361DNAHomo sapiens 23aagaggccta gacttaagaa gcttctgaaa gaccatgcct catccatgcc taacgcagag 60tcctggcctg tcgtaggtca gttttcaagc gttggctcct tgggagccga tgaatcaaag 120tggttatgtt ctgagtttaa agagagcatg ctgacactgg ggaaggaaag caagactcca 180ggaaaaagct ctgttcctct ttacttgatc tatccttctg tggaaaatgt gcggaccagt 240ttagaaggat atcctgctgg gggctctctt ccctatagca tccagacagc tgaaaaacag 300aattggctgc attcctattt tcacaaatgg tcagctgaga cttctggccg cagcaatgcc 360atgccacata ttaagacata tatgaggcct tctccagact tcagtaaaat tgcttggttc 420cttgtcacaa gcgcaaatct gtccaaggct gcctggggag cattggagaa gaatggcacc 480cagctgatga tccgctccta cgagctcggg gtccttttcc tcccttcagc atttggtcta 540gacagtttca aagtgaaaca gaagttcttc gctggcagcc aggagccaat ggccaccttt 600cctgtgccat atgatttgcc tccagaactg tatggaagta aagatcggcc atggatatgg 660aacattcctt atgtcaaagc accggatacg catgggaaca tgtgggtgcc ctcctgagaa 720tcttgaggca ctgtgaaatt taagtgtaag acattgagcc acaaacatgg aatctcttct 780ttgtactgga tgtccacttc ccttaaagtc ttatttgcac ccttacaaaa tctttccaaa 840ggtcactctt atgaatggat gttggttata cttttaatgg acattaacat tcctaataaa 900gtattagttt cttaattcac ttttatatgt tttggaaaga aaattagtga acttctctat 960gttaaaaata cgtactgctt gagtatcccc tgtctgaaat gcttgggacc agaagtgttt 1020cagcttttgg atttttttga attttggaat atttgcatag cataatgaga tatcttggga 1080atgggaccca aatctaaaca caaaattcat ttatgtttca tatacacctt atatacaata 1140acctaaaggt gattttatat gatattttga gtaattttat gcatgaaaca aagttttgac 1200aggcttttga ccgtgattca tcacatgagt tcaggcatgg aaattttcat ttggagcatc 1260atgtcagcac tcaaaaagtt ctggatcttg gagcagttca gattttcaga ttagggatgc 1320tcaaatctat atagatataa aattatcctc acagtaacat agaatctctt ggtgctgtca 1380gctgttggga attgaagatt gactttgtgc ttccaccctc catccagaaa ggcacccttc 1440attccaccag aattttaccc aggaagaaca cgatcatttc ctttttcacc gatgccctct 1500ctcagctttc tgagtacgtc tcttggggtc gctggaggtg atcctaggat ctgtctctga 1560gaccaatgtg ctgtttcagc cccctgcagc taagaattgt attgactgtc ctcacagcgg 1620cttttcatag ctttcagctt cagctttacg aggcttctcc tctctccctg gcacctgctg 1680gctgcctcac tgcttacaga caggtcccac caaacccaaa cacctgccta gggtaaatgg 1740gtctctcttc tatccccaga aactttcaga ggaagcagct catagaaaca tacaaaagca 1800cacaagtatt ttgggaaaaa atcctaaaag gtgacttaat ttgatgcctt aaattcacaa 1860gtgaggaagc taaggcctag aaggttaagg atgtccccag ggtcacacag tgagcggggc 1920tcagagcttg agtgtctttg tgctttgtgt acattgtgtt ctccctaggg tgctttagac 1980cctgtttgtt ttcttctgca tgaggctgat ttccagtttg tcatcaacct ctttatctta 2040taatttagga tagagttgaa cgttagtctt gaaagatttt ctaaagtagt ctttcaaact 2100gttcctcaga ggcctaggat tttccaaaag taccttagga accttgtagg ctgcagtggg 2160ggtgtggcga tagagcagga ggcagggaga cagggctgca gggcctccca ccttccaaca 2220gacaggctct gctgtatctg ttgtacatac tgggattctg taaaggacat tatctggggt 2280gtcgtaggta tttttgtgtg ttctgctttt tttaaataaa cttgaaaagc tactgaacta 2340aaaaaaaaaa aaaaaaaaaa a 236124223PRTHomo sapiens 24Met Pro Asn Ala Glu Ser Trp Pro Val Val Gly Gln Phe Ser Ser Val 1 5 10 15Gly Ser Leu Gly Ala Asp Glu Ser Lys Trp Leu Cys Ser Glu Phe Lys 20 25 30Glu Ser Met Leu Thr Leu Gly Lys Glu Ser Lys Thr Pro Gly Lys Ser 35 40 45Ser Val Pro Leu Tyr Leu Ile Tyr Pro Ser Val Glu Asn Val Arg Thr 50 55 60Ser Leu Glu Gly Tyr Pro Ala Gly Gly Ser Leu Pro Tyr Ser Ile Gln 65

70 75 80Thr Ala Glu Lys Gln Asn Trp Leu His Ser Tyr Phe His Lys Trp Ser 85 90 95Ala Glu Thr Ser Gly Arg Ser Asn Ala Met Pro His Ile Lys Thr Tyr 100 105 110Met Arg Pro Ser Pro Asp Phe Ser Lys Ile Ala Trp Phe Leu Val Thr 115 120 125Ser Ala Asn Leu Ser Lys Ala Ala Trp Gly Ala Leu Glu Lys Asn Gly 130 135 140Thr Gln Leu Met Ile Arg Ser Tyr Glu Leu Gly Val Leu Phe Leu Pro145 150 155 160Ser Ala Phe Gly Leu Asp Ser Phe Lys Val Lys Gln Lys Phe Phe Ala 165 170 175Gly Ser Gln Glu Pro Met Ala Thr Phe Pro Val Pro Tyr Asp Leu Pro 180 185 190Pro Glu Leu Tyr Gly Ser Lys Asp Arg Pro Trp Ile Trp Asn Ile Pro 195 200 205Tyr Val Lys Ala Pro Asp Thr His Gly Asn Met Trp Val Pro Ser 210 215 220253370DNAHomo sapiens 25cgcgctgtgg ctgctgctgc tgctgctgcc ccggacccgg gcggacgagc acgaacacac 60gtatcaagat aaagaggaag ttgtcttatg gatgaatact gttgggccct accataatcg 120tcaagaaaca tataagtact tttcacttcc attctgtgtg gggtcaaaaa aaagtatcag 180tcattaccat gaaactctgg gagaagcact tcaaggggtt gaattggaat ttagtggtct 240ggatattaaa tttaaagatg atgtgatgcc agccacttac tgtgaaattg atttagataa 300agaaaagaga gatgcatttg tatatgccat aaaaaatcat tactggtacc agatgtacat 360agatgattta ccaatatggg gtattgttgg tgaggctgat gaaaatggag aagattacta 420tctttggacc tataaaaaac ttgaaatagg ttttaatgga aatcgaattg ttgatgttaa 480tctaactagt gaaggaaagg tgaaactggt tccaaatact aaaatccaga tgtcatattc 540agtaaaatgg aaaaagtcag atgtgaaatt tgaagatcga tttgacaaat atcttgatcc 600gtcctttttt caacatcgga ttcattggtt ttcaattttc aactccttca tgatggtgat 660cttcttggtg ggcttagttt caatgatttt aatgagaaca ttaagaaaag attatgctcg 720gtacagtaaa gaggaagaaa tggatgatat ggatagagac ctaggagatg aatatggatg 780gaaacaggtg catggagatg tatttagacc atcaagtcac ccactgatat tttcctctct 840gattggttct ggatgtcaga tatttgctgt gtctctcatc gttattattg ttgcaatgat 900agaagattta tatactgaga ggggatcaat gctcagtaca gccatatttg tctatgctgc 960tacgtctcca gtgaatggtt attttggagg aagtctgtat gctagacaag gaggaaggag 1020atggataaag cagatgttta ttggggcatt ccttatccca gctatggtgt gtggcactgc 1080cttcttcatc aatttcatag ccatttatta ccatgcttca agagccattc cttttggaac 1140aatggtggcc gtttgttgca tctgtttttt tgttattctt cctctaaatc ttgttggtac 1200aatacttggc cgaaatctgt caggtcagcc caactttcct tgtcgtgtca atgctgtgcc 1260tcgtcctata ccggagaaaa aatggttcat ggagcctgcg gttattgttt gcctgggtgg 1320aattttacct tttggttcaa tctttattga aatgtatttc atcttcacgt ctttctgggc 1380atataagatc tattatgtct atggcttcat gatgctggtg ctggttatcc tgtgcattgt 1440gactgtctgt gtgactattg tgtgcacata ttttctacta aatgcagaag attacccgtg 1500gcaatggaca agttttctct ctgctgcatc aactgcaatc tatgtttaca tgtattcctt 1560ttactactat tttttcaaaa caaagatgta tggcttattt caaacatcat tttactttgg 1620atatatggcg gtatttagca cagccttggg gataatgtgt ggagcgattg gttacatggg 1680aacaagtgcc tttgtccgaa aaatctatac taatgtgaaa attgactaga gacccaagaa 1740aacctggaac tttggatcaa tttctttttc ataggggtgg aacttgcaca gcaaaaacaa 1800acaaacgcaa gaagagattt gggctttaac acactgggta ctttgtgggt ctgtctttcg 1860tcggtggctt aaagtaacat ctatttccat tgatcctagg ttcttcctga ctgctttctc 1920caactgttca cagcaaatgc ttggatttta tgcagtaggc attactacag tacatggcta 1980atcttcccaa aaactagctc attaaagatg aaatagacca gctctcttca gtgaagagga 2040caaatagttt atttaaagca tttgttccaa taaaataaat agagggaaac ttggatgcta 2100aaattacatg aataggaatc ttcctggcac ttagtgtttc tatgttattg aaaaatgatg 2160ttccagaaag attacttttt tcctcttatt tttactgcca ttgtcgacct attgtgggac 2220atttttatat attgaatctg ggttcttttt tgactttttt ttttcccaat ccaacagcat 2280cctttttttt aaaagagaga attagaaaat attaaatcct gcatgtaata tatctgctgt 2340catcttagtt ggaccaactt cccatttatt tatcttaaaa ctatacagtt acatcttaat 2400tccatccaaa gaagatacag tttgaagaca gaagtgtact ctctacaatg caatttactg 2460tacagttaga aagcaaagtg ttaaatggag aagatacttg tttttattaa acattttgag 2520atttagataa actacatttt aactgaatgt ctaaagtgat tatctttttt ccccccaagt 2580tagtcttaaa tcttttgggt ttgaatgaag gttttacata agaaattatt aaaaacaagg 2640ggggtgggta ataaatgtat ataacattaa ataatgtaac gtaggtgtag attcccaaat 2700gcatttggat gtacagatcg actacagagt acttttttct tatgatgatt ggtgtagaaa 2760tgtgtgattt gggtgggctt ttacatcttg cctaccattg catgaaacat tggggtttct 2820tcaaaatgtg tgtgtcatac ttcttttggg aggggggttg ttttcttctg tttattttct 2880gagactccta caggacccaa atttgtaatt tagagacact taattttgtt aatcctgcct 2940gggacactta agtaacatct aaagcattat tgctttagaa tgttcaaata aaatttcctg 3000accaaattgt tttgtggaaa tagatgtgtt tgcaatttga agatatcttt ctgtccagaa 3060ggcaaaatta ccgaatgcca tttttaaaag tatgctataa actatgctac tctcatacag 3120gggacccgta ttttaaaatc tccagacttg cttacatcta gattatccag cacaatcata 3180aagtgaatga caaacccttt gaatgaaatt gtggcacaaa atctgttcag gttggtgtac 3240cgtgtaaagt ggggatgggg taaaagtggt taacgtactg ttggatcaac aaataaaggt 3300tacagttttg tttgagaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3360aaaaaaaaaa 337026545PRTHomo sapiens 26Met Asn Thr Val Gly Pro Tyr His Asn Arg Gln Glu Thr Tyr Lys Tyr 1 5 10 15Phe Ser Leu Pro Phe Cys Val Gly Ser Lys Lys Ser Ile Ser His Tyr 20 25 30His Glu Thr Leu Gly Glu Ala Leu Gln Gly Val Glu Leu Glu Phe Ser 35 40 45Gly Leu Asp Ile Lys Phe Lys Asp Asp Val Met Pro Ala Thr Tyr Cys 50 55 60Glu Ile Asp Leu Asp Lys Glu Lys Arg Asp Ala Phe Val Tyr Ala Ile 65 70 75 80Lys Asn His Tyr Trp Tyr Gln Met Tyr Ile Asp Asp Leu Pro Ile Trp 85 90 95Gly Ile Val Gly Glu Ala Asp Glu Asn Gly Glu Asp Tyr Tyr Leu Trp 100 105 110Thr Tyr Lys Lys Leu Glu Ile Gly Phe Asn Gly Asn Arg Ile Val Asp 115 120 125Val Asn Leu Thr Ser Glu Gly Lys Val Lys Leu Val Pro Asn Thr Lys 130 135 140Ile Gln Met Ser Tyr Ser Val Lys Trp Lys Lys Ser Asp Val Lys Phe145 150 155 160Glu Asp Arg Phe Asp Lys Tyr Leu Asp Pro Ser Phe Phe Gln His Arg 165 170 175Ile His Trp Phe Ser Ile Phe Asn Ser Phe Met Met Val Ile Phe Leu 180 185 190Val Gly Leu Val Ser Met Ile Leu Met Arg Thr Leu Arg Lys Asp Tyr 195 200 205Ala Arg Tyr Ser Lys Glu Glu Glu Met Asp Asp Met Asp Arg Asp Leu 210 215 220Gly Asp Glu Tyr Gly Trp Lys Gln Val His Gly Asp Val Phe Arg Pro225 230 235 240Ser Ser His Pro Leu Ile Phe Ser Ser Leu Ile Gly Ser Gly Cys Gln 245 250 255Ile Phe Ala Val Ser Leu Ile Val Ile Ile Val Ala Met Ile Glu Asp 260 265 270Leu Tyr Thr Glu Arg Gly Ser Met Leu Ser Thr Ala Ile Phe Val Tyr 275 280 285Ala Ala Thr Ser Pro Val Asn Gly Tyr Phe Gly Gly Ser Leu Tyr Ala 290 295 300Arg Gln Gly Gly Arg Arg Trp Ile Lys Gln Met Phe Ile Gly Ala Phe305 310 315 320Leu Ile Pro Ala Met Val Cys Gly Thr Ala Phe Phe Ile Asn Phe Ile 325 330 335Ala Ile Tyr Tyr His Ala Ser Arg Ala Ile Pro Phe Gly Thr Met Val 340 345 350Ala Val Cys Cys Ile Cys Phe Phe Val Ile Leu Pro Leu Asn Leu Val 355 360 365Gly Thr Ile Leu Gly Arg Asn Leu Ser Gly Gln Pro Asn Phe Pro Cys 370 375 380Arg Val Asn Ala Val Pro Arg Pro Ile Pro Glu Lys Lys Trp Phe Met385 390 395 400Glu Pro Ala Val Ile Val Cys Leu Gly Gly Ile Leu Pro Phe Gly Ser 405 410 415Ile Phe Ile Glu Met Tyr Phe Ile Phe Thr Ser Phe Trp Ala Tyr Lys 420 425 430Ile Tyr Tyr Val Tyr Gly Phe Met Met Leu Val Leu Val Ile Leu Cys 435 440 445Ile Val Thr Val Cys Val Thr Ile Val Cys Thr Tyr Phe Leu Leu Asn 450 455 460Ala Glu Asp Tyr Pro Trp Gln Trp Thr Ser Phe Leu Ser Ala Ala Ser465 470 475 480Thr Ala Ile Tyr Val Tyr Met Tyr Ser Phe Tyr Tyr Tyr Phe Phe Lys 485 490 495Thr Lys Met Tyr Gly Leu Phe Gln Thr Ser Phe Tyr Phe Gly Tyr Met 500 505 510Ala Val Phe Ser Thr Ala Leu Gly Ile Met Cys Gly Ala Ile Gly Tyr 515 520 525Met Gly Thr Ser Ala Phe Val Arg Lys Ile Tyr Thr Asn Val Lys Ile 530 535 540Asp545273136DNAHomo sapiens 27gctgcgagta cctccatggt cccggtggct gtgacggcgg cagtggcgcc tgtcctgtcc 60ataaacagcg atttctcaga tttgcgggaa attaaaaagc aactgctgct tattgcgggc 120cttacccggg agcggggcct actacacagt agcaaatggt cggcggagtt ggctttctct 180ctccctgcat tgcctctggc cgagctgcaa ccgcctccgc ctattacaga ggaagatgcc 240caggatatgg atgcctatac cctggccaag gcctactttg acgttaaaga gtatgatcgg 300gcagcacatt tcctgcatgg ctgcaatagc aagaaagcct attttctgta tatgtattcc 360agatatctgt ctggagaaaa aaagaaggac gatgaaacag ttgatagctt aggccccctg 420gaaaaaggac aagtgaaaaa tgaggcgctt agagaattga gagtggagct cagcaaaaaa 480caccaagctc gagaacttga tggatttgga ctttatctgt atggtgtggt gcttcgaaaa 540ctggacttgg ttaaagaggc cattgatgtg tttgtggaag ctactcatgt tttgcccttg 600cattggggag cctggttaga actctgtaac ctgatcacag acaaagagat gctgaagttc 660ctgtctttgc cagacacctg gatgaaagag ttttttctgg ctcatatata cacagagttg 720cagttgatag aggaggccct gcaaaagtat cagaatctca ttgatgtggg cttctctaag 780agctcgtata ttgtttccca aattgcagtt gcctatcaca atatcagaga tattgacaaa 840gccctctcca tttttaatga gctaaggaaa caagaccctt acaggattga aaatatggac 900acattctcca accttcttta tgtcaggagc atgaaatcgg agttgagtta tctggctcat 960aacctctgtg agattgataa atatcgtgta gaaacgtgct gtgtaattgg caattattac 1020agtttacgtt ctcagcatga gaaagcagcc ttatatttcc agagagccct gaaattaaat 1080cctcggtatc ttggtgcctg gacactaatg ggacatgagt acatggagat gaagaacacg 1140tctgctgcta tccaggctta tagacatgcc attgaggtca acaaacggga ctacagagct 1200tggtatggcc tcgggcagac ctatgaaatc cttaagatgc cattttactg cctttattat 1260tatagacggg cccaccagct tcgacccaat gattctcgca tgctggttgc tttaggagaa 1320tgttacgaga aactcaatca actagtggaa gccaaaaagt gtttttggat agcttacgcc 1380gtgggagatg tggagaaaat ggctctggtg aaactggcaa agcttcatga acagttgact 1440gagtcagaac aggctgccca gtgttacatc aaatatatcc aagatatcta tacctgtggg 1500gaaatagtag aacacttgga ggaaagcact gcctttcgct atctggccca gtactatttt 1560aagtgcaaac tgtgggatga agcttcaact tgtgcacaaa agtgttgtgc atttaatgat 1620acccgggaag aaggtaaggc cttactccgg caaatcctac agcttcggaa ccaaggcgag 1680actcctacca ccgaggtgcc tgctcccttt ttcctacctg cttcactctc tgctaacaat 1740acccccacac gcagagtttc tccactcaac ttgtcttctg tcacgccata gttggctact 1800ctcaagccag cacattgtta gacccatctt aattaagcct tacctccatg taaagaacag 1860cacgtctgtt ccaaggacct cagctcttct tgtgtctaca gatggcaaca gctccatagg 1920ggacagcttg tataattacc ttcagaggcc aactgacaga atcctggcag gaacagacat 1980tatcttgcca gttagaagta cttctgtctc acttatgtcc aaagagtggc tatagatctt 2040ggccttcttc cctgaatgct tttttttttt tggcccccaa gaaagtccct tttatagcac 2100tttagcacag gcaatgctac aggaacaaag tttcaatgct gctgagagtg aaagaaagga 2160ggaaagtctg ccactctacc ctgagctggc agtagggcac tgagtaccct aggaagaagt 2220cagagcaatg gatacaaatg accttgctct tggatttgct gagcatgatc cctattctga 2280tgtcagagat taggtttaaa tggaatagag ctatccattt gttcttactc tctagggaga 2340caatcttcca aaacagtttt gggggggtct tctaaagctt tcaaattgga agtaacttta 2400ttcaactaga gttgaataaa agaagggcaa aaataatctc acagagcttg gaactgctga 2460tagcccttac tgagggcaaa agatggctat attgttagct atactcctac caaagcaagc 2520aaggagatag gattatagat aatttcacgg acatttggaa ataacattgg tgattataca 2580gacaagaata aactcacttc aagctggtct gttttaataa attttcaacg taattgtcta 2640tttttttccc tcccatctgc aacagaatac atttttttca gcctttatct agatgaggta 2700aagggaatca ttcttatggt gctcttggag agtttcaggc ctgtgcatgt gtgtacagca 2760ggaggtaata tgctataatg tctgctgtaa tatatttgca cagtagatgc tatggatcat 2820tctgagctca gggtccagac tttattctta ttcccagaat tttgtgttac gtttttacct 2880cctaacatat gacacttcat cttatattaa ggaaggttta gaatatctaa tacgacttga 2940attcatttgt tactaagcct tctcaggcaa gctgtatact agttactggt ctccactgcc 3000atgccttttc aaggttccca tggtccagaa tgatgtttga ttcttaattt ttctgtccct 3060tttataattt gttttaatga ttttgctaca tttggaattc aataaaaaat gtgaacaata 3120aaaaaaaaaa aaaaaa 313628591PRTHomo sapiens 28Met Val Pro Val Ala Val Thr Ala Ala Val Ala Pro Val Leu Ser Ile 1 5 10 15Asn Ser Asp Phe Ser Asp Leu Arg Glu Ile Lys Lys Gln Leu Leu Leu 20 25 30Ile Ala Gly Leu Thr Arg Glu Arg Gly Leu Leu His Ser Ser Lys Trp 35 40 45Ser Ala Glu Leu Ala Phe Ser Leu Pro Ala Leu Pro Leu Ala Glu Leu 50 55 60Gln Pro Pro Pro Pro Ile Thr Glu Glu Asp Ala Gln Asp Met Asp Ala 65 70 75 80Tyr Thr Leu Ala Lys Ala Tyr Phe Asp Val Lys Glu Tyr Asp Arg Ala 85 90 95Ala His Phe Leu His Gly Cys Asn Ser Lys Lys Ala Tyr Phe Leu Tyr 100 105 110Met Tyr Ser Arg Tyr Leu Ser Gly Glu Lys Lys Lys Asp Asp Glu Thr 115 120 125Val Asp Ser Leu Gly Pro Leu Glu Lys Gly Gln Val Lys Asn Glu Ala 130 135 140Leu Arg Glu Leu Arg Val Glu Leu Ser Lys Lys His Gln Ala Arg Glu145 150 155 160Leu Asp Gly Phe Gly Leu Tyr Leu Tyr Gly Val Val Leu Arg Lys Leu 165 170 175Asp Leu Val Lys Glu Ala Ile Asp Val Phe Val Glu Ala Thr His Val 180 185 190Leu Pro Leu His Trp Gly Ala Trp Leu Glu Leu Cys Asn Leu Ile Thr 195 200 205Asp Lys Glu Met Leu Lys Phe Leu Ser Leu Pro Asp Thr Trp Met Lys 210 215 220Glu Phe Phe Leu Ala His Ile Tyr Thr Glu Leu Gln Leu Ile Glu Glu225 230 235 240Ala Leu Gln Lys Tyr Gln Asn Leu Ile Asp Val Gly Phe Ser Lys Ser 245 250 255Ser Tyr Ile Val Ser Gln Ile Ala Val Ala Tyr His Asn Ile Arg Asp 260 265 270Ile Asp Lys Ala Leu Ser Ile Phe Asn Glu Leu Arg Lys Gln Asp Pro 275 280 285Tyr Arg Ile Glu Asn Met Asp Thr Phe Ser Asn Leu Leu Tyr Val Arg 290 295 300Ser Met Lys Ser Glu Leu Ser Tyr Leu Ala His Asn Leu Cys Glu Ile305 310 315 320Asp Lys Tyr Arg Val Glu Thr Cys Cys Val Ile Gly Asn Tyr Tyr Ser 325 330 335Leu Arg Ser Gln His Glu Lys Ala Ala Leu Tyr Phe Gln Arg Ala Leu 340 345 350Lys Leu Asn Pro Arg Tyr Leu Gly Ala Trp Thr Leu Met Gly His Glu 355 360 365Tyr Met Glu Met Lys Asn Thr Ser Ala Ala Ile Gln Ala Tyr Arg His 370 375 380Ala Ile Glu Val Asn Lys Arg Asp Tyr Arg Ala Trp Tyr Gly Leu Gly385 390 395 400Gln Thr Tyr Glu Ile Leu Lys Met Pro Phe Tyr Cys Leu Tyr Tyr Tyr 405 410 415Arg Arg Ala His Gln Leu Arg Pro Asn Asp Ser Arg Met Leu Val Ala 420 425 430Leu Gly Glu Cys Tyr Glu Lys Leu Asn Gln Leu Val Glu Ala Lys Lys 435 440 445Cys Phe Trp Ile Ala Tyr Ala Val Gly Asp Val Glu Lys Met Ala Leu 450 455 460Val Lys Leu Ala Lys Leu His Glu Gln Leu Thr Glu Ser Glu Gln Ala465 470 475 480Ala Gln Cys Tyr Ile Lys Tyr Ile Gln Asp Ile Tyr Thr Cys Gly Glu 485 490 495Ile Val Glu His Leu Glu Glu Ser Thr Ala Phe Arg Tyr Leu Ala Gln 500 505 510Tyr Tyr Phe Lys Cys Lys Leu Trp Asp Glu Ala Ser Thr Cys Ala Gln 515 520 525Lys Cys Cys Ala Phe Asn Asp Thr Arg Glu Glu Gly Lys Ala Leu Leu 530 535 540Arg Gln Ile Leu Gln Leu Arg Asn Gln Gly Glu Thr Pro Thr Thr Glu545 550 555 560Val Pro Ala Pro Phe Phe Leu Pro Ala Ser Leu Ser Ala Asn Asn Thr 565 570 575Pro Thr Arg Arg Val Ser Pro Leu Asn Leu Ser Ser Val Thr Pro 580 585 590292472DNAHomo sapiens 29tatgagcctt cggaacttgt ggagagacta caaagttttg gttgttatgg tccctttagt 60tgggctcata catttggggt ggtacagaat caaaagcagc cctgttttcc aaatacctaa 120aaacgacgac attcctgagc aagatagtct gggactttca aatcttcaga agagccaaat 180ccaggggaag tagcaggctt gcaatcttca ggtaaagaag cagctttgaa tctgagcttc 240atatcgaaag aagagatgaa aaataccagt tggattagaa agaactggct tcttgtagct 300gggatatctt tcataggtgt ccatcttgga acatactttt tgcagaggtc tgcaaagcag 360tctgtaaaat ttcagtctca aagcaaacaa aagagtattg aagagtgaag taaaataaat 420atttggaatt actaatttgt cattaaatca ttctatgctg attagcttca taaacattga 480actttttgat tttatagcca caatgctgca tattcatact ttaattccta aagaataatt 540tttaatgtta aaacgtgata

atgcaataaa tagaaaaatg tggtttacaa aataaaaacg 600gtcttcacta gttaccacct gaagtaagat gtctcgtttg gaagctaaga agccatcatt 660gtgtaagagt gaaccactga caactgagag agtcaggacc acactttctg tcttgaaaag 720aattgtaaca tcatgctatg gcccctcagg taggctgaag cagctgcaca atggctttgg 780aggttacgtg tgtacaacct cacagtcctc agctctgctc agtcaccttt tggtcacaca 840tcccatttta aagatcctga cagcctccat acagaatcat gtgtcaagct tcagtgattg 900tggcttattc acagctattc tttgctgcaa cctgattgaa aatgttcaga gattaggctt 960gacacccacc actgtcatta gattaaataa acatcttttg agtctttgca tcagttatct 1020caagtctgat acctgtggtt gtcgaatccc agtggacttt agtagtactc agatcctcct 1080ttgtttggtg cgtagtatat taacaagtaa acctgcctgt atgctcacca gaaaggaaac 1140agagcatgtc agtgctttga tcctgagagc ctttttgctt acaattccag aaaatgctga 1200aggccacatc attttaggaa agagtttaat tgtaccttta aaaggtcaaa gagttataga 1260ttccactgta ttacctggga tactcattga aatgtcagaa gttcaattaa tgaggctatt 1320acctatcaaa aaatcaactg ccctcaaggt ggcactcttt tgtacaactt tatccggaga 1380cacttctgac actggagaag gaactgtggt ggtcagttat ggggtttctc ttgaaaatgc 1440agtcttggac cagctgctta acctaggaag gcagctaatc agtgaccacg tagatcttgt 1500cctgtgccaa aaagttatac atccatcttt gaagcagttt ctcaatatgc atcgtattat 1560tgccatagac agaattggag tgactctgat ggaacccctg actaaaatga caggaacaca 1620gcctattgga tccctaggct caatatgtcc taatagttat ggaagtgtga aagatgtgtg 1680cactgcaaaa tttggctccc aacatttttt tcatcttatt cctaatgaag caacaatctg 1740cagcttgctt ctctgcaaca gaaatgacac tgcctgggat gagctgaagc tcacgtgtca 1800gacggcactg catgtcctgc agttaacact caaggaacca tgggctttgt tgggaggtgg 1860ctgtactgaa actcatttgg ctgcatatat cagacacaag actcacaacg acccagaaag 1920cattctcaaa gatgatgaat gtactcaaac agaacttcaa ttaattgctg aagcattttg 1980cagtgcccta gaatctgttg ttggctcttt agaacatgat ggaggtgaaa ttctcactga 2040catgaagtat ggacaccttt ggtcagttca ggcagattct ccctgtgttg ctaactggcc 2100agatttgctt tcacagtgtg gctgtggatt atacaatagc caggaagaac tcaactggtc 2160tttcttaaga agcacacgtc gtccatttgt gccacaaagc tgccttccac atgaagctgt 2220gggctcagcc agcaacctga ccttggactg tttgactgca aagcttagtg gcctacaggt 2280ggctgtagag acagccaatt tgatttggga tctttcatat gttattgaag ataaaaacta 2340agagaatagc atgttcgtat tacaagagaa acaaataaac tagtctgttg gcaattgaga 2400aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2460aaaaaaaaaa aa 247230570PRTHomo sapiens 30Met Ser Arg Leu Glu Ala Lys Lys Pro Ser Leu Cys Lys Ser Glu Pro 1 5 10 15Leu Thr Thr Glu Arg Val Arg Thr Thr Leu Ser Val Leu Lys Arg Ile 20 25 30Val Thr Ser Cys Tyr Gly Pro Ser Gly Arg Leu Lys Gln Leu His Asn 35 40 45Gly Phe Gly Gly Tyr Val Cys Thr Thr Ser Gln Ser Ser Ala Leu Leu 50 55 60Ser His Leu Leu Val Thr His Pro Ile Leu Lys Ile Leu Thr Ala Ser 65 70 75 80Ile Gln Asn His Val Ser Ser Phe Ser Asp Cys Gly Leu Phe Thr Ala 85 90 95Ile Leu Cys Cys Asn Leu Ile Glu Asn Val Gln Arg Leu Gly Leu Thr 100 105 110Pro Thr Thr Val Ile Arg Leu Asn Lys His Leu Leu Ser Leu Cys Ile 115 120 125Ser Tyr Leu Lys Ser Asp Thr Cys Gly Cys Arg Ile Pro Val Asp Phe 130 135 140Ser Ser Thr Gln Ile Leu Leu Cys Leu Val Arg Ser Ile Leu Thr Ser145 150 155 160Lys Pro Ala Cys Met Leu Thr Arg Lys Glu Thr Glu His Val Ser Ala 165 170 175Leu Ile Leu Arg Ala Phe Leu Leu Thr Ile Pro Glu Asn Ala Glu Gly 180 185 190His Ile Ile Leu Gly Lys Ser Leu Ile Val Pro Leu Lys Gly Gln Arg 195 200 205Val Ile Asp Ser Thr Val Leu Pro Gly Ile Leu Ile Glu Met Ser Glu 210 215 220Val Gln Leu Met Arg Leu Leu Pro Ile Lys Lys Ser Thr Ala Leu Lys225 230 235 240Val Ala Leu Phe Cys Thr Thr Leu Ser Gly Asp Thr Ser Asp Thr Gly 245 250 255Glu Gly Thr Val Val Val Ser Tyr Gly Val Ser Leu Glu Asn Ala Val 260 265 270Leu Asp Gln Leu Leu Asn Leu Gly Arg Gln Leu Ile Ser Asp His Val 275 280 285Asp Leu Val Leu Cys Gln Lys Val Ile His Pro Ser Leu Lys Gln Phe 290 295 300Leu Asn Met His Arg Ile Ile Ala Ile Asp Arg Ile Gly Val Thr Leu305 310 315 320Met Glu Pro Leu Thr Lys Met Thr Gly Thr Gln Pro Ile Gly Ser Leu 325 330 335Gly Ser Ile Cys Pro Asn Ser Tyr Gly Ser Val Lys Asp Val Cys Thr 340 345 350Ala Lys Phe Gly Ser Gln His Phe Phe His Leu Ile Pro Asn Glu Ala 355 360 365Thr Ile Cys Ser Leu Leu Leu Cys Asn Arg Asn Asp Thr Ala Trp Asp 370 375 380Glu Leu Lys Leu Thr Cys Gln Thr Ala Leu His Val Leu Gln Leu Thr385 390 395 400Leu Lys Glu Pro Trp Ala Leu Leu Gly Gly Gly Cys Thr Glu Thr His 405 410 415Leu Ala Ala Tyr Ile Arg His Lys Thr His Asn Asp Pro Glu Ser Ile 420 425 430Leu Lys Asp Asp Glu Cys Thr Gln Thr Glu Leu Gln Leu Ile Ala Glu 435 440 445Ala Phe Cys Ser Ala Leu Glu Ser Val Val Gly Ser Leu Glu His Asp 450 455 460Gly Gly Glu Ile Leu Thr Asp Met Lys Tyr Gly His Leu Trp Ser Val465 470 475 480Gln Ala Asp Ser Pro Cys Val Ala Asn Trp Pro Asp Leu Leu Ser Gln 485 490 495Cys Gly Cys Gly Leu Tyr Asn Ser Gln Glu Glu Leu Asn Trp Ser Phe 500 505 510Leu Arg Ser Thr Arg Arg Pro Phe Val Pro Gln Ser Cys Leu Pro His 515 520 525Glu Ala Val Gly Ser Ala Ser Asn Leu Thr Leu Asp Cys Leu Thr Ala 530 535 540Lys Leu Ser Gly Leu Gln Val Ala Val Glu Thr Ala Asn Leu Ile Trp545 550 555 560Asp Leu Ser Tyr Val Ile Glu Asp Lys Asn 565 570311527DNAHomo sapiens 31cactccgcgc gcggggctag cgcgggtttc agcgacggga gccctcaagg gacatggcaa 60ctacagcggc gccggcgggc ggcgccgaaa tggagctggc ccggaatggg gagggttcga 120agaaaacatc cagggcggag gctcagctgt gattgacatg gagaacatgg atgatacctc 180aggctctagc ttcgaggata tgggtgagct gcatcagcgc ctgcgcgagg aagaagtaga 240cgctgatgca gctgatgcag ctgctgctga agaggaggat ggagagttcc tgggcatgaa 300gggctttaag ggacagctga gccggcaggt ggcagatcag atgtggcagg ctgggaaaag 360acaagcctcc agggccttca gcttgtacgc caacatcgac atcctcagac cctactttga 420tgtggagcct gctcaggtgc gaagcaggct cctggagtcc atgatcccta tcaagatggt 480caacttcccc cagaaaattg caggtgaact ctatggacct ctcatgctgg tcttcactct 540ggttgctatc ctactccatg ggatgaagac gtctgacact attatccggg agggcaccct 600gatgggcaca gccattggca cctgcttcgg ctactggctg ggagtctcat ccttcattta 660cttccttgcc tacctgtgca acgcccagat caccatgctg cagatgttgg cactgctggg 720ctatggcctc tttgggcatt gcattgtcct gttcatcacc tataatatcc acctccacgc 780cctcttctac ctcttctggc ggttggtggg tggactgtcc acactgcgca tggtagcagt 840gttggtgtct cggaccgtgg gccccacaca gcggctgctc ctctgtggca ccctggctgc 900cctacacatg ctcttcctgc tctatctgca ttttgcctac cacaaagtgg tagaggggat 960cctggacaca ctggagggcc ccaacatccc gcccatccag agggtcccca gagacatccc 1020tgccatgctc cctgctgctc ggcttcccac caccgtcctc aacgccacag ccaaagctgt 1080tgcggtgacc ctgcagtcac actgacccca cctgaaattc ttggccagtc ctctttcccg 1140cagctgcaga gaggaggaag actattaaag gacagtcctg atgacatgtt tcgtagatgg 1200ggtttgcagc tgccactgag ctgtagctgc gtaagtacct ccttgatgcc tgtcggcact 1260tctgaaaggc acaaggccaa gaactcctgg ccaggactgc aaggctctgc agccaatgca 1320gaaaatgggt cagctccttt gagaacccct ccccacctac cccttccttc ctctttatct 1380ctcccacatt gtcttgctta aatatagaac ttggtcttaa aaaaaaaaaa aaaaaaaaaa 1440aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1500aaaaaaaaaa aaaaaaaaaa aaaaaaa 152732315PRTHomo sapiens 32Met Glu Asn Met Asp Asp Thr Ser Gly Ser Ser Phe Glu Asp Met Gly 1 5 10 15Glu Leu His Gln Arg Leu Arg Glu Glu Glu Val Asp Ala Asp Ala Ala 20 25 30Asp Ala Ala Ala Ala Glu Glu Glu Asp Gly Glu Phe Leu Gly Met Lys 35 40 45Gly Phe Lys Gly Gln Leu Ser Arg Gln Val Ala Asp Gln Met Trp Gln 50 55 60Ala Gly Lys Arg Gln Ala Ser Arg Ala Phe Ser Leu Tyr Ala Asn Ile 65 70 75 80Asp Ile Leu Arg Pro Tyr Phe Asp Val Glu Pro Ala Gln Val Arg Ser 85 90 95Arg Leu Leu Glu Ser Met Ile Pro Ile Lys Met Val Asn Phe Pro Gln 100 105 110Lys Ile Ala Gly Glu Leu Tyr Gly Pro Leu Met Leu Val Phe Thr Leu 115 120 125Val Ala Ile Leu Leu His Gly Met Lys Thr Ser Asp Thr Ile Ile Arg 130 135 140Glu Gly Thr Leu Met Gly Thr Ala Ile Gly Thr Cys Phe Gly Tyr Trp145 150 155 160Leu Gly Val Ser Ser Phe Ile Tyr Phe Leu Ala Tyr Leu Cys Asn Ala 165 170 175Gln Ile Thr Met Leu Gln Met Leu Ala Leu Leu Gly Tyr Gly Leu Phe 180 185 190Gly His Cys Ile Val Leu Phe Ile Thr Tyr Asn Ile His Leu His Ala 195 200 205Leu Phe Tyr Leu Phe Trp Arg Leu Val Gly Gly Leu Ser Thr Leu Arg 210 215 220Met Val Ala Val Leu Val Ser Arg Thr Val Gly Pro Thr Gln Arg Leu225 230 235 240Leu Leu Cys Gly Thr Leu Ala Ala Leu His Met Leu Phe Leu Leu Tyr 245 250 255Leu His Phe Ala Tyr His Lys Val Val Glu Gly Ile Leu Asp Thr Leu 260 265 270Glu Gly Pro Asn Ile Pro Pro Ile Gln Arg Val Pro Arg Asp Ile Pro 275 280 285Ala Met Leu Pro Ala Ala Arg Leu Pro Thr Thr Val Leu Asn Ala Thr 290 295 300Ala Lys Ala Val Ala Val Thr Leu Gln Ser His305 310 31533988DNAHomo sapiens 33caaggctata gtaactaaaa gagaatagta ctggtacaaa aataggatca gatcaatgta 60acagagtaga gaacccagca ataaagccat gtgcctgcaa ccaactgatc tttgataaag 120ttgagaaaaa taaacaatga agaaaagaca ctgtattcaa taaatgttgc taggaaaatt 180ggctagccat atacagaaaa atgaaactga acccgtatct ctcactttat acaaaaatta 240agttggatta aagacttaaa tgtaaaacct gatactataa aaattataga agaaaaccca 300ggaaaagctc ttctggacac tggcctaggc aaagaattta tgactaagtc atcaaaagca 360tatgtaacaa aaaaaaaaaa aaagcgcccg ggtgaggggc ggagctgggg gcatggcgtc 420cggagcggct cgctggctag tattggcacc cgtcaggtcc ggggctctcc ggagcgggcc 480tagcttgagg aaagatggcg atgtctccgc cgcatggagc ggctcaggcc ggagcctggt 540accgtcgagg tcagtcatcg ttacccgcag cggcgccatt ttgcccaaac cggtgaaaat 600gtccttcggc cttctccgtg tgttctccat tgtgatcccc tttctctatg tcgggacact 660cattagcaag aactttgctg ctctacttga ggaacatgac atttttgttc cagaggatga 720tgatgatgat gactaacagg aattacagaa aggagaaagc actaactgaa gaaatggtga 780tgctctcagt ttctctgcct tccctatcag cagaaaggct cggggaaggc cctcagcctc 840ccagtctggt gaagcttcct gtatggtcca tgaccgtatt ccaccccagg ctctgggagg 900ctccctgaga tgtgctgtcc actaagcact gcacaaacaa gcaatcaaat tatgaataaa 960cataataaat atcaaaaaaa aaaaaaaa 98834107PRTHomo sapiens 34Met Ala Ser Gly Ala Ala Arg Trp Leu Val Leu Ala Pro Val Arg Ser 1 5 10 15Gly Ala Leu Arg Ser Gly Pro Ser Leu Arg Lys Asp Gly Asp Val Ser 20 25 30Ala Ala Trp Ser Gly Ser Gly Arg Ser Leu Val Pro Ser Arg Ser Val 35 40 45Ile Val Thr Arg Ser Gly Ala Ile Leu Pro Lys Pro Val Lys Met Ser 50 55 60Phe Gly Leu Leu Arg Val Phe Ser Ile Val Ile Pro Phe Leu Tyr Val 65 70 75 80Gly Thr Leu Ile Ser Lys Asn Phe Ala Ala Leu Leu Glu Glu His Asp 85 90 95Ile Phe Val Pro Glu Asp Asp Asp Asp Asp Asp 100 105351759DNAHomo sapiens 35tttttttttt tgaggtgtaa tgcaacttca tcactttatt caaatcttca aaatagtctt 60tattctacat ttttagtata aaaattccac aagttaagtg caccacagtg tagagagaga 120catacaacgc tgaacttcca taacagtcaa tggtacagtc aaacatcaca tgtacagaac 180acacaattta gatgaactga aattataaga taaaataaaa taaaatccaa tttcagaaaa 240caaaaatcaa aacattaagg atccctgaaa tattcttaaa ccctaatgag atttcactgg 300actcaagtca ttttgtagtg agacattcac aatatgaccc tatcaaccca gtctaggaat 360tctggggagc cgaatgagtg gccgcatcag acactctgac aaaaaatggt aaccaatttt 420tgatctgaaa actcctctta atttagctct gaacacagag atttatccaa gtgccagatt 480actcagtgct ataattttct tttagttaaa caaagggggt cagacagaca ttgcatcatc 540cagacatgcc ttgttggaca tgtagaatcc gatggagcac tgcacaccag aatgattggc 600caatgagcag cttctctccc tgaaacaata actgcccatt tggcaaaggg aaagatgaca 660ataatcagaa gaagaaaatg aatgggatgc ataccataga cgaacgaggc ggagactatt 720gcgggaatct tactgttcag gagctgttcc tagaactaac tcccttactg tcattgatgt 780gcattccact ctgtgctttt ctgtacaacc attcaagttt taatttccca ggtgaaccat 840ctttatctgc cattaccaca agctttcaag tttccagtta ttttcatcat cataaccagt 900acggtgctat tatttaccta tgtacgtgta gttatgtata attttgtaat tagttacaat 960ggtaaaaaaa atcgaaatat ataaaaagtg atttgtacag aactttattt tagctctttt 1020ttaaaaatga tttgcatggt tagaaaacgg cgaggacagc caggggaggg aagggcctct 1080agggaacttt gcactttcta taacctttgt acttatgcca ctgccctatt tgattctaca 1140cccaataatg attattactt gaaacccatc tgtaagaaac tgcttcggaa attcatttgt 1200gtgtatgtaa ataacacaac atagaaacag gaagggaaaa aaagtctgca gtaatgcacg 1260tatttttttc tttcctgttt attttcggtt ttgctttaag tccttttatt tttaattccc 1320tttttgtttt tctttttggg ttttggttcc ttttgggttt atgggtgccc tgatactcca 1380gcagagatca gaaggctaca gatccattct atccatccgt tatgtggctt tgccatccca 1440gcttggagtg tctttacaaa gataataaca gttgtgttct ttgctctcgt tttggatgca 1500tagactgaaa aattaaaaca aataacttgt aaaatggctt gttaaaaaat acaattacct 1560ctaattagta gtacgcgtaa atgttttaca gaatgaaagg cgtgcttttt attttcttac 1620ttcgttacat tggtggcgaa agaagtctgt atgaaaatca gttctttgct gacacaagtt 1680ccatttgtta caaatgaatt ctaataaaaa tgtcagtgtt aaaaaaaaaa aaaaaaaaaa 1740aaaaaaaaaa aaaaaaaaa 17593687PRTHomo sapiens 36Met Asn Gly Met His Thr Ile Asp Glu Arg Gly Gly Asp Tyr Cys Gly 1 5 10 15Asn Leu Thr Val Gln Glu Leu Phe Leu Glu Leu Thr Pro Leu Leu Ser 20 25 30Leu Met Cys Ile Pro Leu Cys Ala Phe Leu Tyr Asn His Ser Ser Phe 35 40 45Asn Phe Pro Gly Glu Pro Ser Leu Ser Ala Ile Thr Thr Ser Phe Gln 50 55 60Val Ser Ser Tyr Phe His His His Asn Gln Tyr Gly Ala Ile Ile Tyr 65 70 75 80Leu Cys Thr Cys Ser Tyr Val 8537643DNAHomo sapiens 37tcagcctccg cctccgagcc tcagttgtct tctctgtgag gtgggaatgc cggtgaatcc 60tgccgctggc gtggatgaga agtgaatgcg tgctcggagc tgcgagtgac agcgggcagg 120aggcgcccag ggacacttgg tttctccagg gctggaaggc ttctagaagg ttcctcatca 180agggaagtgt ggctgggggc gccgtctacc tggtgtacga ccaggagctg ctggggccca 240gcgacaagag ccaggcagcc ctacagaagg ctggggaggt ggtccccccc gccatgtacc 300agttcagcca gtacgtgtgt cagcagacag gcctgcagat accccagctc ccagcccctc 360caaagattta ctttcccatc cgtgactcct ggaatgcagg catcatgacg gtgatgtcag 420ctctgtcggt ggccccctcc aaggcccgcg agtactccaa ggagggctgg gagtatgtga 480aggcgcgcac caagtagcga gtcagcaggg gccgcctgcc ccggccagaa cgggcagggc 540tgccactgac ctgaagactc cggactggga ccccactccg agggcagctc ccggccttgc 600cggcccaata aaggacttca gaagtgaaaa aaaaaaaaaa aaa 64338140PRTHomo sapiens 38Met Arg Ser Glu Cys Val Leu Gly Ala Ala Ser Asp Ser Gly Gln Glu 1 5 10 15Ala Pro Arg Asp Thr Trp Phe Leu Gln Gly Trp Lys Ala Ser Arg Arg 20 25 30Phe Leu Ile Lys Gly Ser Val Ala Gly Gly Ala Val Tyr Leu Val Tyr 35 40 45Asp Gln Glu Leu Leu Gly Pro Ser Asp Lys Ser Gln Ala Ala Leu Gln 50 55 60Lys Ala Gly Glu Val Val Pro Pro Ala Met Tyr Gln Phe Ser Gln Tyr 65 70 75 80Val Cys Gln Gln Thr Gly Leu Gln Ile Pro Gln Leu Pro Ala Pro Pro 85 90 95Lys Ile Tyr Phe Pro Ile Arg Asp Ser Trp Asn Ala Gly Ile Met Thr 100 105 110Val Met Ser Ala Leu Ser Val Ala Pro Ser Lys Ala Arg Glu Tyr Ser 115 120 125Lys Glu Gly Trp Glu Tyr Val Lys Ala Arg Thr Lys 130 135 140392015DNAHomo sapiens 39aggctgtctg ctagtcagaa ttgcctcaaa aagagtctag aagatgttgt cattgacatc 60cagtcatctc tttctaaggg aatcagaggc aatgagcccg tatatacttc aactcaagaa 120gactgcatta attcttgctg ttcaacaaaa aacatatcag gggacaaagc atgtaacttg 180atgatcttcg acactcgaaa aacagctaga caacccaact gctacctatt tttctgtccc 240aacgaggaag cctgtccatt gaaaccagca aaaggactta tgagttacag gataattaca 300gattttccat ctttgaccag aaatttgcca agccaagagt taccccagga agattctctc 360ttacatggcc aattttcaca agcagtcact cccctagccc atcatcacac agattattca 420aagcccaccg atatctcatg

gagagacaca ctttctcaga agtttggatc ctcagatcac 480ctggagaaac tatttaagat ggatgaagca agtgcccagc tccttgctta taaggaaaaa 540ggccattctc agagttcaca attttcctct gatcaagaaa tagctcatct gctgcctgaa 600aatgtgagtg cgctcccagc tacggtggca gttgcttctc cacataccac ctcggctact 660ccaaagcccg ccacccttct acccaccaat gcttcagtga caccttctgg gacttcccag 720ccacagctgg ccaccacagc tccacctgta accactgtca cttctcagcc tcccacgacc 780ctcatttcta cagtttttac acgggctgcg gctacactcc aagcaatggc tacaacagca 840gttctgacta ccacctttca ggcacctacg gactcgaaag gcagcttaga aaccataccg 900tttacagaaa tctccaactt aactttgaac acagggaatg tgtataaccc tactgcactt 960tctatgtcaa atgtggagtc ttccactatg aataaaactg cttcctggga aggtagggag 1020gccagtccag gcagttcctc cccagggcag tgttccagaa aatcagtacg gccttccatt 1080tgaaaaatgg cttcttatcg ggtccctgct ctttggtgtc ctgttcctgg tgataggcct 1140cgtcctcctg ggtagatcct ctcggaatca ctccgcagga aacgttactc aagactggat 1200tatttgatca atgggatcta tgtggacatc taaggatgga actcggtgtc tcttaattca 1260tttagtaacc agaagcccaa atgcaatgag tttctgctga cttgctagtc ttagcaggag 1320gttgtatttt gaagacagga aaatgccccc ttctgctttc cttttttttt ttggagacag 1380agtcttgctc tgttgcccag gctggagtgc agtagcacga tctcggctct caccgcaacc 1440tccgtctcct gggttcaagc gattctcctg cctcagcctc ctagtatctg ggattacagg 1500catgtgccac cacacctggg tgatttttgt atttttagta gagacgggtt tcaccatgtt 1560ggtcaggctg gtctcaaact cctgacctag tgatccaccc tcctcggcct cccaaagtgc 1620tgggataaca ggcatgagcc accacagctg gcccccttct gttttatgtt tggtttttga 1680gaaggaatga agtgggaacc aaattaggta attttgggta atctgtctct aaaatattag 1740ctgaaaacaa agctgtatgt aaagtaataa ggtataattg ccatataaat ttcaaaattc 1800aactggcttt tatgcaaaga aacaggttag gacatctagg ttccaattca ttcacattct 1860tggttccaga taaaatcaac tgtttatatc aatttctaat ggatttgcct ttctttttat 1920atggattcct ttaaaactta ttccagatgt agttccttcc aattaaatat ttgaataaat 1980cttttgttac tcaaaaaaaa aaaaaaaaaa aaaaa 201540300PRTHomo sapiens 40Met Ile Phe Asp Thr Arg Lys Thr Ala Arg Gln Pro Asn Cys Tyr Leu 1 5 10 15Phe Phe Cys Pro Asn Glu Glu Ala Cys Pro Leu Lys Pro Ala Lys Gly 20 25 30Leu Met Ser Tyr Arg Ile Ile Thr Asp Phe Pro Ser Leu Thr Arg Asn 35 40 45Leu Pro Ser Gln Glu Leu Pro Gln Glu Asp Ser Leu Leu His Gly Gln 50 55 60Phe Ser Gln Ala Val Thr Pro Leu Ala His His His Thr Asp Tyr Ser 65 70 75 80Lys Pro Thr Asp Ile Ser Trp Arg Asp Thr Leu Ser Gln Lys Phe Gly 85 90 95Ser Ser Asp His Leu Glu Lys Leu Phe Lys Met Asp Glu Ala Ser Ala 100 105 110Gln Leu Leu Ala Tyr Lys Glu Lys Gly His Ser Gln Ser Ser Gln Phe 115 120 125Ser Ser Asp Gln Glu Ile Ala His Leu Leu Pro Glu Asn Val Ser Ala 130 135 140Leu Pro Ala Thr Val Ala Val Ala Ser Pro His Thr Thr Ser Ala Thr145 150 155 160Pro Lys Pro Ala Thr Leu Leu Pro Thr Asn Ala Ser Val Thr Pro Ser 165 170 175Gly Thr Ser Gln Pro Gln Leu Ala Thr Thr Ala Pro Pro Val Thr Thr 180 185 190Val Thr Ser Gln Pro Pro Thr Thr Leu Ile Ser Thr Val Phe Thr Arg 195 200 205Ala Ala Ala Thr Leu Gln Ala Met Ala Thr Thr Ala Val Leu Thr Thr 210 215 220Thr Phe Gln Ala Pro Thr Asp Ser Lys Gly Ser Leu Glu Thr Ile Pro225 230 235 240Phe Thr Glu Ile Ser Asn Leu Thr Leu Asn Thr Gly Asn Val Tyr Asn 245 250 255Pro Thr Ala Leu Ser Met Ser Asn Val Glu Ser Ser Thr Met Asn Lys 260 265 270Thr Ala Ser Trp Glu Gly Arg Glu Ala Ser Pro Gly Ser Ser Ser Pro 275 280 285Gly Gln Cys Ser Arg Lys Ser Val Arg Pro Ser Ile 290 295 300411549DNAHomo sapiens 41tgatcctaat aatactgcac atgaagaaac taaaactgtc ttatcagata cagaagaaat 60aaaaccacag acaaaaaagg agacatacat ttcttgtcct ctaagaggag tattgaatgt 120aattattaca aatggagtta tactgtttgt gatatggtgt atgacctggt caatcttagg 180ctctgaagct ctccctggtg gaaatttatt tgggttgttc attatttttt atagtgccat 240tattggggga aaaattttac aactcattag aataccttta gtgcctccac ttccacctct 300tcttgggatg ttactggctg gttttacgat taggaatgtt ccattcatca atgaacatgt 360ccatgttcct aacacatggt cttcaatttt aagaagcatt gcccttacca ttattctaat 420aagagctggg cttggactcg atccacaggc tttgaggcat ttgaaggtcg tttgtttcag 480attggctgta ggtccatgcc ttatggaggc aagtgcagct gctgtttttt cacacttcat 540tatgaaattt ccctggcaat gggcatttct attaggtttt gttctaggtg ctgtctctcc 600tgctgttgtt gtcccttaca tgatggtgct gcaagaaaat ggatatggtg ttgaggaagg 660cattccaacc ttattaatgg ctgctagcag tatggatgac attctggcta tcactggatt 720caatacatgc ttgagcatag tcttttcctc aggtggtata cttaataacg ccatagcctc 780tataaggaac gtatgtatta gtctgctggc aggaattgtt ttgggatttt ttgttcgata 840ttttccaagt gaagaccaga aaaaacttac attgaagaga ggattccttg ttttgactat 900gtgtgtttct gccgtcttag gcagccaacg tattggttta catggatctg gaggattatg 960cacactagtg ttgagtttca ttgcagggac aaaatggtcc caagaaaaga tgaaagtcca 1020aaagattatt acgactgtat gggatatttt tcaaccactt ctttttggtt tagttggagc 1080agaagtatct gtttcatcgc ttgaatcaaa tattgttggc atatctgttg ccactctaag 1140tttggcatta tgtgttcgaa ttttaaccac atatctattg atgtgctttg ctggttttag 1200ttttaaggag aaaatattta ttgctttagc atggatgccc aaagctacag tacagattaa 1260tcaagctatc cttctgttgt ttcttcttcg ggaggaatgg acgaactgca aggtagccaa 1320gaagtgcgag tacaccaagg aaaggcaata accgaagcca ttctgaaact aaacatgtag 1380atgtgtcaga atctgcagtg ctcttggaaa agaattcaaa atagcatgtc gtttcatcct 1440tgagcttatt ctttgttact ttttacatta attccttttt aatggatcca taaaactgtg 1500aataaataac acaataaagc cagctctacc aaaaaaaaaa aaaaaaaaa 154942396PRTHomo sapiens 42Met Thr Trp Ser Ile Leu Gly Ser Glu Ala Leu Pro Gly Gly Asn Leu 1 5 10 15Phe Gly Leu Phe Ile Ile Phe Tyr Ser Ala Ile Ile Gly Gly Lys Ile 20 25 30Leu Gln Leu Ile Arg Ile Pro Leu Val Pro Pro Leu Pro Pro Leu Leu 35 40 45Gly Met Leu Leu Ala Gly Phe Thr Ile Arg Asn Val Pro Phe Ile Asn 50 55 60Glu His Val His Val Pro Asn Thr Trp Ser Ser Ile Leu Arg Ser Ile 65 70 75 80Ala Leu Thr Ile Ile Leu Ile Arg Ala Gly Leu Gly Leu Asp Pro Gln 85 90 95Ala Leu Arg His Leu Lys Val Val Cys Phe Arg Leu Ala Val Gly Pro 100 105 110Cys Leu Met Glu Ala Ser Ala Ala Ala Val Phe Ser His Phe Ile Met 115 120 125Lys Phe Pro Trp Gln Trp Ala Phe Leu Leu Gly Phe Val Leu Gly Ala 130 135 140Val Ser Pro Ala Val Val Val Pro Tyr Met Met Val Leu Gln Glu Asn145 150 155 160Gly Tyr Gly Val Glu Glu Gly Ile Pro Thr Leu Leu Met Ala Ala Ser 165 170 175Ser Met Asp Asp Ile Leu Ala Ile Thr Gly Phe Asn Thr Cys Leu Ser 180 185 190Ile Val Phe Ser Ser Gly Gly Ile Leu Asn Asn Ala Ile Ala Ser Ile 195 200 205Arg Asn Val Cys Ile Ser Leu Leu Ala Gly Ile Val Leu Gly Phe Phe 210 215 220Val Arg Tyr Phe Pro Ser Glu Asp Gln Lys Lys Leu Thr Leu Lys Arg225 230 235 240Gly Phe Leu Val Leu Thr Met Cys Val Ser Ala Val Leu Gly Ser Gln 245 250 255Arg Ile Gly Leu His Gly Ser Gly Gly Leu Cys Thr Leu Val Leu Ser 260 265 270Phe Ile Ala Gly Thr Lys Trp Ser Gln Glu Lys Met Lys Val Gln Lys 275 280 285Ile Ile Thr Thr Val Trp Asp Ile Phe Gln Pro Leu Leu Phe Gly Leu 290 295 300Val Gly Ala Glu Val Ser Val Ser Ser Leu Glu Ser Asn Ile Val Gly305 310 315 320Ile Ser Val Ala Thr Leu Ser Leu Ala Leu Cys Val Arg Ile Leu Thr 325 330 335Thr Tyr Leu Leu Met Cys Phe Ala Gly Phe Ser Phe Lys Glu Lys Ile 340 345 350Phe Ile Ala Leu Ala Trp Met Pro Lys Ala Thr Val Gln Ile Asn Gln 355 360 365Ala Ile Leu Leu Leu Phe Leu Leu Arg Glu Glu Trp Thr Asn Cys Lys 370 375 380Val Ala Lys Lys Cys Glu Tyr Thr Lys Glu Arg Gln385 390 395434433DNAHomo sapiens 43ggctcaagta gcggacacgg aacagggaac tatcagcccg tcggcctccg ggccctgcat 60tctctagcca tggaccggga ccttttgcgg cagtcgctaa attgccacgg gtcgtctttg 120ctctctctac ttcggagcga acagcaggac aatccacact tccgtagcct cctggggtcg 180gccgccgagc cagcccgggg cccgccgccc cagcacccgt tgcagggcag aaaagagaag 240agagttgaca acatcgagat acagaaattc atctccaaaa aagcggatct gctttttgca 300ctttcctgga aatcagatgc acctgcaact tctgaaatta atgaagacag tgaagatcat 360tatgcaatca tgccaccttt agagcaattc atggagatac ctagtatgga tcggagagag 420ctgtttttcc gagatattga gcgtggtgat atagtgattg gaagaattag ttctattcgg 480gaattcggtt ttttcatggt gttgatctgt ttaggaagtg gtatcatgag agatatagcc 540cacttagaaa tcacagctct ttgtccctta agagatgtgc cttctcacag taaccatggg 600gatcctttat catattacca aactggtgac atcattcgag ctggaatcaa ggatattgac 660agataccatg aaaagctagc agtatctctg tatagctctt ctcttccacc acacctatct 720ggtattaaat taggtgtaat tagctctgaa gagcttcctt tatactacag gagaagtgtt 780gagctaaata gcaattcttt ggagtcctat gaaaatgtca tgcagagttc cttgggattt 840gttaatccag gagtagttga attccttcta gaaaaactag gaatagatga atctaatcca 900ccatctttaa tgagaggcct acaaagcaaa aatttctctg aagatgattt tgcttctgca 960ttgagaaaaa aacaatccgc atcttgggct ttaaaatgtg tgaagatcgg agttgactat 1020tttaaagttg gacgccatgt ggatgctatg aatgaataca ataaagcttt ggaaatagac 1080aaacaaaacg tggaagcttt ggtagctcgt ggagcattat atgcgacaaa aggaagtttg 1140aacaaagcaa tagaagattt tgagcttgca ttagaaaact gtccaactca cagaaatgca 1200agaaaatacc tctgccagac acttgtagag agaggaggac agttagaaga agaagaaaag 1260tttttaaatg ctgaaagtta ctataagaaa gccttggctt tggatgagac ttttaaagat 1320gcagaggatg ctttgcagaa acttcataaa tatatgcagg tgattcctta tttcctctta 1380gaaatttagt gatatttgaa ataatgccca aacttaattt tctcctgagg aaaaactatt 1440ctacattact taagtaaggc attatgaaaa gtttcttttt aggtatagtt tttcctaatt 1500gggtttgaca ttgcttcata gtgcctctgt ttttgtccat aatcgaaagt aaagatagct 1560gtgagaaaac tattacctaa atttggtatg ttgttttgag aaatgtcctt atagggagct 1620cacctggtgg tttttaaatt attgttgcta ctataattga gctaattata aaaacctttt 1680tgagacatat tttaaattgt cttttcctgt aatactgatg atgatgtttt ctcatgcatt 1740ttcttctgaa ttggaccatt gctgctgtgt ctgtgacatc tggtgctgct catccccatc 1800cacaaactgg aaaatgattt cctatgtaat catgcattca actgggctgt gctatttttt 1860taaatggttt gtatttgaac atggtgattc ctccttcact tcaccttaac ggaatgtctt 1920tatttgaatt ttatttgtaa aatgtgtcct gtttaaattt ttcaatcttt aaaaataatt 1980tttatgtact tttttttttt tttaaccttt cttgcactct gggtcatggg taccactgca 2040atggcttccc ctttttttat gggataccaa ctgcaatatg gtcctcaatg ctgttctggc 2100catttcaatg actaatgcca aacatctgta tgactaattt ttttatgtta aaaaaatact 2160gtttaatgct ggctctatgg tgatttggtt ttactaaatt gggtttctcg ttgggggtgg 2220tcttttgaat actgggtttt atatattctg ctatttttaa cgtgtggttt ttttcgatat 2280ctgggttcta aaagaaatct ttggaattaa gagaaaaaca agctgaaaag gaagaaaagc 2340agaaaacaaa gaaaatagaa acaagtgcag aaaagttgcg taagctctta aaagaagaga 2400agaggtaaac tataatattc agtattttta aacttaaggc actactgaat tgaacccaaa 2460gtgccatact ggaagtaaag taaataaaaa tatgaaagta tttcaagtgc caatcagtga 2520ctgttaagaa tctttagcaa atatgtgttc catgtatttc ctattaaaga gatgaagtgg 2580aatttaaggc tgaattctac aaaaaagagt acttagaaat taaaatatag aaaaagttac 2640ttcaattatg ttttaggaag aaatattttt aaaactagag cagtggtctc actaggaggt 2700gagttcatca gaccggaccc ttgacagatt atttggctga aaataccaat aatcaggtga 2760agaaaccatg aactagaggt agccaaataa aaaagttgag ttctccttta tgtgttcagt 2820agtcttaagt ttttaaggta gtgttgaaaa aagtctgtct ttcagagatg atggatttgc 2880ttacaatgat acctgtctgc aagcattttt tcccccaaaa gtgcttaata gtaaaattag 2940atcttgtagt agccgagatt attgtatcat ttatctgaac cacagctttt ataaaatctt 3000taaaggaaac aaatagggcc cacatcttta tgaataattt agaaacattt ttgtatatat 3060atgacaaatg aactgttttt tttaggctaa agaagaaaag aagaaaatca acttcttctt 3120caagtgtttc ttctgctgat gaatcagtgt cttcatcatc atcctcttcc tcttctggtc 3180acaaaaggca taagaaacat aagaggaacc gttcagagtc ttctcgcagt tccagaaggc 3240attcatctag ggcatcctca aatcagatag atcagaatag gaaagatgag tgctacccag 3300ttccagctaa tacttcagca tcttttctta accataaaca agaagtggag aaactactgg 3360ggaagcagga taggttacag tatgaaaaga cacagataaa agagaaagat agacgccctc 3420tctcttcatc ttcacttgaa ataccggatg attttggagt gtactcctat ttatttaaaa 3480agttaactat aaaacagcct caggcaggtc cttcaggaga tattccagaa gagggcattg 3540ttatcataga tgacagctcc attcatgtta ctgaccctga agaccttcaa gtgggacaag 3600atatggaggt ggaagacagt ggtattgatg atcctgacca cgggtaggct taggtttatg 3660tgtgtgtatg tgtcttagtt tttaacaaaa aaattaaaaa gtaaaaaaac taaaaataga 3720aaaatgctta gagaataagg atataaagaa tatttttgtg cagttgaaca atgagtgctt 3780aagctaaatg tcatcacaaa agagtaaaaa aattttacaa aattaaaaat gtttaaagtt 3840aaaaagctct aggaagctaa ggtcaattta ttattggaga aataaaatta tttttatgaa 3900tttactgtag cctaggtgta cattatttat catgtctaca gtagtgttca gcaattaggc 3960cttcacattc tctcaccact cactcactca gtcactcacc cagagcagct tccagtcccg 4020caagctccat ttatggtaag tgccctgtac aggtgtacca tttttttaat ccattatacc 4080atatttttat tgtacctttt ctatgtttag atttgtttag atacacaagt accactgtgt 4140tacagttgcc tatagtactc agtacagtaa cacactttac aagcttatag cctaggaaca 4200ataggctata ccatctaggt ttgtgtaagt acactcttat gatgttcaca cagtgacaaa 4260atcgcccaag gatgcattca tcagaacaca ttcccattgt tatccaatgc atgactgtat 4320aatggtttta tggattaaat tttttatgta attcaactgg aaagtatttt tatgttattt 4380tggaaaaaat aaaacaatga caattggaaa aaaaaaaaaa aaaaaaaaaa aaa 443344439PRTHomo sapiens 44Met Asp Arg Asp Leu Leu Arg Gln Ser Leu Asn Cys His Gly Ser Ser 1 5 10 15Leu Leu Ser Leu Leu Arg Ser Glu Gln Gln Asp Asn Pro His Phe Arg 20 25 30Ser Leu Leu Gly Ser Ala Ala Glu Pro Ala Arg Gly Pro Pro Pro Gln 35 40 45His Pro Leu Gln Gly Arg Lys Glu Lys Arg Val Asp Asn Ile Glu Ile 50 55 60Gln Lys Phe Ile Ser Lys Lys Ala Asp Leu Leu Phe Ala Leu Ser Trp 65 70 75 80Lys Ser Asp Ala Pro Ala Thr Ser Glu Ile Asn Glu Asp Ser Glu Asp 85 90 95His Tyr Ala Ile Met Pro Pro Leu Glu Gln Phe Met Glu Ile Pro Ser 100 105 110Met Asp Arg Arg Glu Leu Phe Phe Arg Asp Ile Glu Arg Gly Asp Ile 115 120 125Val Ile Gly Arg Ile Ser Ser Ile Arg Glu Phe Gly Phe Phe Met Val 130 135 140Leu Ile Cys Leu Gly Ser Gly Ile Met Arg Asp Ile Ala His Leu Glu145 150 155 160Ile Thr Ala Leu Cys Pro Leu Arg Asp Val Pro Ser His Ser Asn His 165 170 175Gly Asp Pro Leu Ser Tyr Tyr Gln Thr Gly Asp Ile Ile Arg Ala Gly 180 185 190Ile Lys Asp Ile Asp Arg Tyr His Glu Lys Leu Ala Val Ser Leu Tyr 195 200 205Ser Ser Ser Leu Pro Pro His Leu Ser Gly Ile Lys Leu Gly Val Ile 210 215 220Ser Ser Glu Glu Leu Pro Leu Tyr Tyr Arg Arg Ser Val Glu Leu Asn225 230 235 240Ser Asn Ser Leu Glu Ser Tyr Glu Asn Val Met Gln Ser Ser Leu Gly 245 250 255Phe Val Asn Pro Gly Val Val Glu Phe Leu Leu Glu Lys Leu Gly Ile 260 265 270Asp Glu Ser Asn Pro Pro Ser Leu Met Arg Gly Leu Gln Ser Lys Asn 275 280 285Phe Ser Glu Asp Asp Phe Ala Ser Ala Leu Arg Lys Lys Gln Ser Ala 290 295 300Ser Trp Ala Leu Lys Cys Val Lys Ile Gly Val Asp Tyr Phe Lys Val305 310 315 320Gly Arg His Val Asp Ala Met Asn Glu Tyr Asn Lys Ala Leu Glu Ile 325 330 335Asp Lys Gln Asn Val Glu Ala Leu Val Ala Arg Gly Ala Leu Tyr Ala 340 345 350Thr Lys Gly Ser Leu Asn Lys Ala Ile Glu Asp Phe Glu Leu Ala Leu 355 360 365Glu Asn Cys Pro Thr His Arg Asn Ala Arg Lys Tyr Leu Cys Gln Thr 370 375 380Leu Val Glu Arg Gly Gly Gln Leu Glu Glu Glu Glu Lys Phe Leu Asn385 390 395 400Ala Glu Ser Tyr Tyr Lys Lys Ala Leu Ala Leu Asp Glu Thr Phe Lys 405 410 415Asp Ala Glu Asp Ala Leu Gln Lys Leu His Lys Tyr Met Gln Val Ile 420 425 430Pro Tyr Phe Leu Leu Glu Ile 435454017DNAHomo sapiens 45acactggcaa agtacatacc ctactcactg tggaagtatt cggtgttatc cggtcactca 60tggcctttag gctgacaggt ggcaccaaag actacattgt agttggcagt gactctggtc 120gaattgttat tttggaatac cagccatcta agaatatgtt tgagaagatt caccaagaaa 180cctttggcaa gagtggatgc agtcgcatcg ttcctggcca gttcttagct gtggatccca 240aagggcgagc cgttatgatt agtgccattg agaaacagaa attggtgtat attttgaaca 300gagatgctgc agcccgactt accatttcat ctcccctgga agcccacaaa gcaaacactt 360tagtgtatca tgtagttgga gtagatgtcg gatttgaaaa tccaatgttt gcttgtctgg 420aaatggatta tgaggaagca gacaatgatc caacagggga

agcagcagct aatacccagc 480agacacttac tttctatgag ctagaccttg gtttaaatca tgtggtccga aaatacagtg 540aacctttgga ggaacacggc aacttcctta ttacagttcc aggagggtca gatggtccaa 600gtggagtact gatctgctct gaaaactata ttacttacaa gaactttggt gaccagccag 660atatccgctg tccaattccc aggaggcgga atgacctgga tgaccctgaa agaggaatga 720tttttgtctg ctctgcaacc cataaaacca aatcgatgtt cttctttttg gctcaaactg 780agcagggaga tatctttaag atcactttgg agacagatga agatatggtt actgagatcc 840ggctcaaata ttttgatact gtacccgttg ctgctgccat gtgtgtgctt aaaacagggt 900tcctttttgt agcatcagaa tttggaaacc attacttata tcaaattgca catcttggag 960atgatgatga agaacctgag ttttcatcag ccatgcctct ggaagaagga gacacattct 1020tttttcagcc aagaccactt aaaaaccttg tgctggttga tgagttggac agcctctctc 1080ccattctgtt ttgccagata gctgatctgg ccaatgaaga tactccacag ttgtatgtgg 1140cctgtggtag gggaccccga tcatctctga gagtcctaag acatggactt gaggtgtcag 1200aaatggctgt ttctgagcta cctggtaacc ccaacgctgt ctggacagtg cgtcgacaca 1260ttgaagatga gtttgatgcc tacatcattg tgtctttcgt gaatgccacc ctagtgttgt 1320ccattggaga aactgtagaa gaagtgactg actctgggtt cctggggacc accccgacct 1380tgtcctgctc cttattagga gatgatgcct tggtgcaggt ctatccagat ggcattcggc 1440acatacgagc agacaagaga gtcaatgagt ggaagacccc tggaaagaaa acaattgtga 1500agtgtgcagt gaaccagcga caagtggtga ttgccctgac aggaggagag ctggtctatt 1560tcgagatgga tccttcagga cagctgaatg agtacacaga acggaaggag atgtcagcag 1620atgtggtgtg catgagtctg gccaatgtac cccctggaga gcagcggtct cgcttcctgg 1680ctgtggggct tgtggacaac actgtcagaa tcatctccct ggatccctca gactgtttgc 1740aacctctaag catgcaggct ctcccagccc agcctgagtc cttgtgtatc gtggaaatgg 1800gtgggactga gaagcaggat gagctgggtg agaggggctc gattggcttc ctatacctga 1860atattgggct acagaacggt gtgctgctga ggactgtctt ggaccctgtc actggggatt 1920tgtctgatac tcgcactcgg tacctggggt cccgtcctgt gaagctcttc cgagtccgaa 1980tgcaaggcca ggaggcagta ttggccatgt caagccgctc atggttgagc tattcttacc 2040aatctcgctt ccatctcacc ccactgtctt acgagacact ggaatttgca tcgggttttg 2100cctcggaaca gtgtcccgag ggcattgtgg ccatctccac caacacccta cggattttgg 2160cattagagaa gctcggtgct gtcttcaatc aagtagcctt cccactgcag tacacaccca 2220ggaaatttgt catccaccct gagagtaaca accttattat cattgaaacg gaccacaatg 2280cctacactga ggccacgaaa gctcagagaa agcagcagat ggcagaggaa atggtggaag 2340cagcagggga ggatgagcgg gagctggccg cagagatggc agcagcattc ctcaatgaaa 2400acctccctga atccatcttt ggagctccca aggctggcaa tgggcagtgg gcctctgtga 2460tccgagtgat gaatcccatt caagggaaca cactggacct tgtccagctg gaacagaatg 2520aggcagcttt tagtgtggct gtgtgcaggt tttccaacac tggtgaagac tggtatgtgc 2580tggtgggtgt ggccaaggac ctgatactaa acccccgatc tgtggcaggg ggcttcgtct 2640atacttacaa gcttgtgaac aatggggaaa aactggagtt tttgcacaag actcctgtgg 2700aagaggtccc tgctgctatt gccccattcc aggggagggt gttgattggt gtggggaagc 2760tgttgcgtgt ctatgacctg ggaaagaaga agttactccg aaaatgtgag aataagcata 2820ttgccaatta tatctctggg atccagacta tcggacatag ggtaattgta tctgatgtcc 2880aagaaagttt catctgggtt cgctacaagc gtaatgaaaa ccagcttatc atctttgctg 2940atgataccta cccccgatgg gtcactacag ccagcctcct ggactatgac actgtggctg 3000gggcagacaa gtttggcaac atatgtgtgg tgaggctccc acctaacacc aatgatgaag 3060tagatgagga tcctacagga aacaaagccc tgtgggaccg tggcttgctc aatggggcct 3120cccagaaggc agaggtgatc atgaactacc atgtcgggga gacggtgctg tccttgcaga 3180agaccacgct gatccctgga ggctcagaat cacttgtcta taccaccttg tctggaggaa 3240ttggcatcct tgtgccattc acgtcccatg aggaccatga cttcttccag catgtggaaa 3300tgcacctgcg gtctgaacat ccccctctct gtgggcggga ccacctcagc tttcgctcct 3360actacttccc tgtgaagaat gtgattgatg gagacctctg tgagcagttc aattccatgg 3420aacccaacaa acaaaagaac gtctctgaag aactggaccg aaccccaccc gaagtgtcca 3480agaaactcga ggatatccgg acccgctacg ccttctgagc cctcctttcc cggtggggct 3540tgccagagac tgtgtgtttt gtttccccca ccaccatcac tgccacctgg cttctgccat 3600gtggcaggag ggtgactgga taattaagac tgcattatga aagtcaacag ctctttcccc 3660tcagctcttc tcctggaatg actggcttcc cctcaaattg gcactgagat ttgctacact 3720tctccccacc tggtacatga tacatgaccc caggttccag tgtagaacct gagtccccca 3780ttccccaaag ccatccctgc attgatatgt cttgactctc ctgtctactt ttgcacacac 3840ccttaatttt taattggttt tcttgtaaat acagttttgt acaatgttat ctctgtggga 3900ggaaggaggc aggctgtggt gggactgggt agggtatagt atcactcctg agttccactg 3960ctctagaatc taaccagaaa tagaaaccta gtttttaagg tgaaaaaaaa aaaaaaa 4017461152PRTHomo sapiens 46Met Ala Phe Arg Leu Thr Gly Gly Thr Lys Asp Tyr Ile Val Val Gly 1 5 10 15Ser Asp Ser Gly Arg Ile Val Ile Leu Glu Tyr Gln Pro Ser Lys Asn 20 25 30Met Phe Glu Lys Ile His Gln Glu Thr Phe Gly Lys Ser Gly Cys Ser 35 40 45Arg Ile Val Pro Gly Gln Phe Leu Ala Val Asp Pro Lys Gly Arg Ala 50 55 60Val Met Ile Ser Ala Ile Glu Lys Gln Lys Leu Val Tyr Ile Leu Asn 65 70 75 80Arg Asp Ala Ala Ala Arg Leu Thr Ile Ser Ser Pro Leu Glu Ala His 85 90 95Lys Ala Asn Thr Leu Val Tyr His Val Val Gly Val Asp Val Gly Phe 100 105 110Glu Asn Pro Met Phe Ala Cys Leu Glu Met Asp Tyr Glu Glu Ala Asp 115 120 125Asn Asp Pro Thr Gly Glu Ala Ala Ala Asn Thr Gln Gln Thr Leu Thr 130 135 140Phe Tyr Glu Leu Asp Leu Gly Leu Asn His Val Val Arg Lys Tyr Ser145 150 155 160Glu Pro Leu Glu Glu His Gly Asn Phe Leu Ile Thr Val Pro Gly Gly 165 170 175Ser Asp Gly Pro Ser Gly Val Leu Ile Cys Ser Glu Asn Tyr Ile Thr 180 185 190Tyr Lys Asn Phe Gly Asp Gln Pro Asp Ile Arg Cys Pro Ile Pro Arg 195 200 205Arg Arg Asn Asp Leu Asp Asp Pro Glu Arg Gly Met Ile Phe Val Cys 210 215 220Ser Ala Thr His Lys Thr Lys Ser Met Phe Phe Phe Leu Ala Gln Thr225 230 235 240Glu Gln Gly Asp Ile Phe Lys Ile Thr Leu Glu Thr Asp Glu Asp Met 245 250 255Val Thr Glu Ile Arg Leu Lys Tyr Phe Asp Thr Val Pro Val Ala Ala 260 265 270Ala Met Cys Val Leu Lys Thr Gly Phe Leu Phe Val Ala Ser Glu Phe 275 280 285Gly Asn His Tyr Leu Tyr Gln Ile Ala His Leu Gly Asp Asp Asp Glu 290 295 300Glu Pro Glu Phe Ser Ser Ala Met Pro Leu Glu Glu Gly Asp Thr Phe305 310 315 320Phe Phe Gln Pro Arg Pro Leu Lys Asn Leu Val Leu Val Asp Glu Leu 325 330 335Asp Ser Leu Ser Pro Ile Leu Phe Cys Gln Ile Ala Asp Leu Ala Asn 340 345 350Glu Asp Thr Pro Gln Leu Tyr Val Ala Cys Gly Arg Gly Pro Arg Ser 355 360 365Ser Leu Arg Val Leu Arg His Gly Leu Glu Val Ser Glu Met Ala Val 370 375 380Ser Glu Leu Pro Gly Asn Pro Asn Ala Val Trp Thr Val Arg Arg His385 390 395 400Ile Glu Asp Glu Phe Asp Ala Tyr Ile Ile Val Ser Phe Val Asn Ala 405 410 415Thr Leu Val Leu Ser Ile Gly Glu Thr Val Glu Glu Val Thr Asp Ser 420 425 430Gly Phe Leu Gly Thr Thr Pro Thr Leu Ser Cys Ser Leu Leu Gly Asp 435 440 445Asp Ala Leu Val Gln Val Tyr Pro Asp Gly Ile Arg His Ile Arg Ala 450 455 460Asp Lys Arg Val Asn Glu Trp Lys Thr Pro Gly Lys Lys Thr Ile Val465 470 475 480Lys Cys Ala Val Asn Gln Arg Gln Val Val Ile Ala Leu Thr Gly Gly 485 490 495Glu Leu Val Tyr Phe Glu Met Asp Pro Ser Gly Gln Leu Asn Glu Tyr 500 505 510Thr Glu Arg Lys Glu Met Ser Ala Asp Val Val Cys Met Ser Leu Ala 515 520 525Asn Val Pro Pro Gly Glu Gln Arg Ser Arg Phe Leu Ala Val Gly Leu 530 535 540Val Asp Asn Thr Val Arg Ile Ile Ser Leu Asp Pro Ser Asp Cys Leu545 550 555 560Gln Pro Leu Ser Met Gln Ala Leu Pro Ala Gln Pro Glu Ser Leu Cys 565 570 575Ile Val Glu Met Gly Gly Thr Glu Lys Gln Asp Glu Leu Gly Glu Arg 580 585 590Gly Ser Ile Gly Phe Leu Tyr Leu Asn Ile Gly Leu Gln Asn Gly Val 595 600 605Leu Leu Arg Thr Val Leu Asp Pro Val Thr Gly Asp Leu Ser Asp Thr 610 615 620Arg Thr Arg Tyr Leu Gly Ser Arg Pro Val Lys Leu Phe Arg Val Arg625 630 635 640Met Gln Gly Gln Glu Ala Val Leu Ala Met Ser Ser Arg Ser Trp Leu 645 650 655Ser Tyr Ser Tyr Gln Ser Arg Phe His Leu Thr Pro Leu Ser Tyr Glu 660 665 670Thr Leu Glu Phe Ala Ser Gly Phe Ala Ser Glu Gln Cys Pro Glu Gly 675 680 685Ile Val Ala Ile Ser Thr Asn Thr Leu Arg Ile Leu Ala Leu Glu Lys 690 695 700Leu Gly Ala Val Phe Asn Gln Val Ala Phe Pro Leu Gln Tyr Thr Pro705 710 715 720Arg Lys Phe Val Ile His Pro Glu Ser Asn Asn Leu Ile Ile Ile Glu 725 730 735Thr Asp His Asn Ala Tyr Thr Glu Ala Thr Lys Ala Gln Arg Lys Gln 740 745 750Gln Met Ala Glu Glu Met Val Glu Ala Ala Gly Glu Asp Glu Arg Glu 755 760 765Leu Ala Ala Glu Met Ala Ala Ala Phe Leu Asn Glu Asn Leu Pro Glu 770 775 780Ser Ile Phe Gly Ala Pro Lys Ala Gly Asn Gly Gln Trp Ala Ser Val785 790 795 800Ile Arg Val Met Asn Pro Ile Gln Gly Asn Thr Leu Asp Leu Val Gln 805 810 815Leu Glu Gln Asn Glu Ala Ala Phe Ser Val Ala Val Cys Arg Phe Ser 820 825 830Asn Thr Gly Glu Asp Trp Tyr Val Leu Val Gly Val Ala Lys Asp Leu 835 840 845Ile Leu Asn Pro Arg Ser Val Ala Gly Gly Phe Val Tyr Thr Tyr Lys 850 855 860Leu Val Asn Asn Gly Glu Lys Leu Glu Phe Leu His Lys Thr Pro Val865 870 875 880Glu Glu Val Pro Ala Ala Ile Ala Pro Phe Gln Gly Arg Val Leu Ile 885 890 895Gly Val Gly Lys Leu Leu Arg Val Tyr Asp Leu Gly Lys Lys Lys Leu 900 905 910Leu Arg Lys Cys Glu Asn Lys His Ile Ala Asn Tyr Ile Ser Gly Ile 915 920 925Gln Thr Ile Gly His Arg Val Ile Val Ser Asp Val Gln Glu Ser Phe 930 935 940Ile Trp Val Arg Tyr Lys Arg Asn Glu Asn Gln Leu Ile Ile Phe Ala945 950 955 960Asp Asp Thr Tyr Pro Arg Trp Val Thr Thr Ala Ser Leu Leu Asp Tyr 965 970 975Asp Thr Val Ala Gly Ala Asp Lys Phe Gly Asn Ile Cys Val Val Arg 980 985 990Leu Pro Pro Asn Thr Asn Asp Glu Val Asp Glu Asp Pro Thr Gly Asn 995 1000 1005Lys Ala Leu Trp Asp Arg Gly Leu Leu Asn Gly Ala Ser Gln Lys Ala 1010 1015 1020Glu Val Ile Met Asn Tyr His Val Gly Glu Thr Val Leu Ser Leu Gln1025 1030 1035 1040Lys Thr Thr Leu Ile Pro Gly Gly Ser Glu Ser Leu Val Tyr Thr Thr 1045 1050 1055Leu Ser Gly Gly Ile Gly Ile Leu Val Pro Phe Thr Ser His Glu Asp 1060 1065 1070His Asp Phe Phe Gln His Val Glu Met His Leu Arg Ser Glu His Pro 1075 1080 1085Pro Leu Cys Gly Arg Asp His Leu Ser Phe Arg Ser Tyr Tyr Phe Pro 1090 1095 1100Val Lys Asn Val Ile Asp Gly Asp Leu Cys Glu Gln Phe Asn Ser Met1105 1110 1115 1120Glu Pro Asn Lys Gln Lys Asn Val Ser Glu Glu Leu Asp Arg Thr Pro 1125 1130 1135Pro Glu Val Ser Lys Lys Leu Glu Asp Ile Arg Thr Arg Tyr Ala Phe 1140 1145 1150472635DNAHomo sapiens 47aaggggttac acttccagct tttaaaattc tcctttacat gtgctcagtg ttttgttttg 60tgttttggtt tctgtttttt attttaattc ccacattggg cacaagaatc agaatatgga 120tagctagttt aagaaacttt tgtgggtgca ctgtagcata gatgacagaa tatttatgag 180ttgctgtgtt tgttgattag ttccatctct ttcccatttt aactgagaat tgattatata 240tagctctaag tatataggta tttaaacaac cccacaagcg gctgtatcag taacatttat 300taattccact atagtgaggg aggatttcca ttctaaatac cttattttga gggatttata 360aaacttagtt gtaaaagaga aagcccacat agtgggaata aattgcttca gccattttta 420gtatttgaga gcactaggga agatgtttag tagctgtgtg gatgcctttt ttcacaccct 480gtctattgaa tgctgcatcc attcacgaag ttaaatgtta catgcagtta gtccttaatg 540tggactggat ctgtactttt gttttggatt aaaacattta aagatttttg aagtgcagct 600actccccacg tgcatttgat acacataaaa gtcatactgt gtgtgcacaa agagtacatg 660gattttccag catattgctt taaaaaatta tataaactgt taaaatatta acacctcagg 720ctacctgctg tattctgtcc cattgacccc tggaattgga tttactgcaa gtgattgata 780attcaattat gtggcttttc ccctttaatc ttgccattta aattacagta gaaagacaaa 840atcaagtaaa ataaagtgtt agataataga aagagtgtta agaccagccc acttttctca 900tgtttatgtt ctttcatttg gaccaagaat ctccgcatgg aggttgattt gccactgggg 960actttggcta agactattag gtttgctttc aactagatgt tcctgagaca agcagaggga 1020cactgcaatt ccccttccat gcctgctgtt ctcccccatg taagtcttct ttgaaattaa 1080cggatgtgtc tcctttggaa cagccccata acaaaagaga actactgatc tgagcatagg 1140aaagtagagg ctctaccact tttcagttga aaaagcaaga ctttctctgt gtttctgaaa 1200caaggcataa tgttgtcaca gaatcagaga tccagtctca cttttccaca aatctccaaa 1260tctccagtct tatcttgtgt gctctaatgg tttggttcaa tccctttcca actcttgttt 1320tcaaagcatg gggcctgagt gttctccact cctcctaaga aaggagcttg ggtggaaggg 1380accatgctga cctcctccat cagagggctc ttccagtagt attctcggat gcaacctcca 1440tttctcagtt accattattt cctgtatcag ctttgtcctt cctggaggga tgcacagtga 1500tccggcccac cactgttgtt gtcttgtgct tctgctcttt cctatggttt caggttattt 1560tctgggtttc ccctattctt cttttatttc tttttttttt atatttgctt tcctttctac 1620tgcttttaga tttgcaggag atgcaagttt cagctcaatg tttggcttct ctcaatatgg 1680aaatttcaga aggacagagg agaggaggga ggaagaagaa agtatactcc tccagaattt 1740cagtgatctg ttgtggcagt ccagtggaag gaaggtcttt tgaggtcact tagaagcatc 1800tttttgggac atccttttgg gatctctgta ggctaggcat ctcatatctt gagactcacc 1860cccagcctcc aagcctctct ccatttctct aacctatgca ttttagagcg agaggaccgc 1920ctcactagtg tcaccatcct gccttttcta aaacatgcag gctcacacat tctactcctg 1980cttaatgtct gtgttaaatg ttttctaacc atttttgttt tatttttctg aaaaagttaa 2040cccctcccaa ctcctcacac attggctctt cctcttgagc cacaaagttt tgattcttgc 2100gatgtatgtg ccttatttta tgttaatctt gtcaatgaga gggaccagtt ggtgttgccc 2160aatcagcact ccaaggctgt gtgtgcacca gccagagagc gcacggtggt agcagagtcg 2220aggctgtctt gtatcctggt atcatatgtt gttttgaact gataggagga tgttctcttc 2280tgacaagtta cccttgtgta tcctgcagac atgtaaaata aaatacaagt tcattttttt 2340cacctttttt agattttttt aaaaaataaa atgtgtaatc ctttttttaa aagaaacaca 2400tgtaaataca tttaagtatt gtaggcatag cgttcagatg tgactggccc aggcgttcct 2460cggacaagcc tgcattcccc gtgatcacgc ccacctcaag cccaggggct gcagcccagc 2520cacagatgaa ctctaccttt gctttcagaa ccacttagtc cttttgtaac aaagaaaaaa 2580aaatgtttct tacaatgtca ataaaaaatt ctttgtatgg aaaaaaaaaa aaaaa 26354897PRTHomo sapiens 48Met His Ser Asp Pro Ala His His Cys Cys Cys Leu Val Leu Leu Leu 1 5 10 15Phe Pro Met Val Ser Gly Tyr Phe Leu Gly Phe Pro Tyr Ser Ser Phe 20 25 30Ile Ser Phe Phe Phe Ile Phe Ala Phe Leu Ser Thr Ala Phe Arg Phe 35 40 45Ala Gly Asp Ala Ser Phe Ser Ser Met Phe Gly Phe Ser Gln Tyr Gly 50 55 60Asn Phe Arg Arg Thr Glu Glu Arg Arg Glu Glu Glu Glu Ser Ile Leu 65 70 75 80Leu Gln Asn Phe Ser Asp Leu Leu Trp Gln Ser Ser Gly Arg Lys Val 85 90 95Phe491594DNAHomo sapiens 49gccagtgaga aaggagctta ccaaaggcag tgtacgaaga aggttcctgg gagactgtca 60gaaatgagtt tttcactgaa cttcaccctg ccggcgaaca caacgtcctc tcctgtcaca 120ggtgggaaag aaacggactg tgggccctct cttggattag cggcgggcat accattgctg 180gtggccacag ccctgctggt ggctttacta tttactttga ttcacccaag aagaagcagc 240attgaggcca tggaggaaag tgacagacca tgtgaaattt cagaaattga tgacaatccc 300aagatatctg agaatcctag gagatcaccc acacatgaga agaatacgat gggagcacaa 360gaggcccaca tatatgtgaa gactgtagca ggaagcgagg aacctgtgca tgaccgttac 420cgtcctacta tagaaatgga aagaaggagg ggattgtggt ggcttgtgcc cagactgagc 480ctggaatgat gcagctcagt caaggagcag cagacctggc ctggaacagg ttgaaaaccc 540agggttttgt acttggagag gaaagatgcc aagctgcttc ttaatcaatc caaatttcat 600ttacagctct ggaacacttt ggggctgatt tgtctcttta ggggacatcc ccaacatggt 660taattccaac tctcagatct tgtgctttag ttagtacatg tgactcacca gatggggtcc 720ttagatccta ttcctgctcc cagtgggaat ttgcttttct ttgtcatttt gggaaagggg 780cttggtttct gagtgtcttg ccttctcatc tttttttttc atatcctttt tctcaaaaaa 840gccatcagat ctgactttca tggaagtgtt gctgaggtca gcctggtgca agttgggata 900caaatgaaac ttatgcagga tgtgtgagag gaagcagtta attgtttctg aatatctcag 960ggtaggaacc atgtggagcc acacattccc tgaccacagg gaagcacctg gctcaatcat 1020gtcacacagc agtggaaaga atacggactc ttaagtcaca cctaccactg agcagctgta 1080cgactttgga gaagttgttt aacattttca agcctcagtt tttgcttttt taaaggaggg 1140gaaatatttg cctcatgtca taattgaaaa

gattaaataa gaaataaagg gaagtgtctg 1200ctacttagtt gccagtcaaa atgttagttc tctctctcta ccaccttctt cctacctctt 1260cccatattgc ttgcctgata aaacagctaa tcaccagcat ttgttcccca tagtcacagg 1320gccacacaag ggaacattta ggacaaactt tctccatggc ctatgatcca aattgttatc 1380taaagatgat tctaggtgtt gctggtagta tgtgaatctt ccaatctagg tgtgatcgtg 1440tcctcatatg aatcaggaaa aggcagtttc ttacaagttc cgaattccaa atacagagac 1500tggtggtgtt acatttaacc ttaaagatgt taatgttgat ggaaattcat gtttcatatt 1560aaaacaacac tttgtcttta aaaaaaaaaa aaaa 159450141PRTHomo sapiens 50Met Ser Phe Ser Leu Asn Phe Thr Leu Pro Ala Asn Thr Thr Ser Ser 1 5 10 15Pro Val Thr Gly Gly Lys Glu Thr Asp Cys Gly Pro Ser Leu Gly Leu 20 25 30Ala Ala Gly Ile Pro Leu Leu Val Ala Thr Ala Leu Leu Val Ala Leu 35 40 45Leu Phe Thr Leu Ile His Pro Arg Arg Ser Ser Ile Glu Ala Met Glu 50 55 60Glu Ser Asp Arg Pro Cys Glu Ile Ser Glu Ile Asp Asp Asn Pro Lys 65 70 75 80Ile Ser Glu Asn Pro Arg Arg Ser Pro Thr His Glu Lys Asn Thr Met 85 90 95Gly Ala Gln Glu Ala His Ile Tyr Val Lys Thr Val Ala Gly Ser Glu 100 105 110Glu Pro Val His Asp Arg Tyr Arg Pro Thr Ile Glu Met Glu Arg Arg 115 120 125Arg Gly Leu Trp Trp Leu Val Pro Arg Leu Ser Leu Glu 130 135 140515160DNAHomo sapiens 51gatatcttaa gcccgggtac gtcgacccac gcgtccggaa tcgctcagga aagacacact 60gcagactcca ccggcaccct gcaatagatg gattccgact acacaaggga gaaaacgcgg 120aggtgacact ctcctgcctg gaaagaggac gaacgaccaa acaaacgcaa ggactggact 180ccatgccgaa ggtatctgga agtcgtgaca cggtgtgtat aaaacaaaag tttgcgagct 240gttaattgct gtgctgtgtt attaagagac gctttcaagt ttcaagtacc aaatgtagct 300ttacgttgcc aaaggaagtt gaggcaattg ctttgctgtt ttaacttgct ctgtgaggga 360aatctcataa actgaccaat gcaccaaatg aatgctaaaa tgcactttag gtttgttttt 420gcacttctga tagtatcttt caaccacgat gtactgggca agaatttgaa atacaggatt 480tatgaggaac agagggttgg atcagtaatt gcaagactat cagaggatgt ggctgatgtt 540ttattgaagc ttcctaatcc ttctactgtt cgatttcgag ccatgcagag gggaaattct 600cctctacttg tagtaaacga ggataatggg gaaatcagca taggggctac aattgaccgt 660gaacaactgt gccagaaaaa cttgaactgt tccatagagt ttgatgtgat cactctaccc 720acagagcatc tgcagctttt ccatattgaa gttgaagtgc tggatattaa tgacaattct 780ccccagtttt caagatctct catacctatt gagatatctg agagtgcagc agttgggact 840cgcattcccc tggacagtgc atttgatcca gatgttgggg aaaattccct ccacacatac 900tcgctctctg ccaatgattt ttttaatatc gaggttcgga ccaggactga tggagccaag 960tatgcagaac tcatagtggt cagagagtta gatcgggagc tgaagtcaag ctacgagctt 1020cagctcactg cctcagacat gggagtacct cagaggtctg gctcatccat actaaaaata 1080agcatttcag actccaatga caacagccct gcttttgagc agcaatctta tataatacaa 1140ctcttagaaa actccccggt tggcactttg ctcttagatc tgaatgccac ggatccagat 1200gagggcgcta atgggaaaat tgtatattcc ttcagcagtc atgtgtctcc caaaattatg 1260gagactttta aaattgattc tgaaagagga catttgactc ttttcaagca agtggattat 1320gaaatcacca aatcctatga gattgatgtt caggctcaag atttgggtcc aaattcaatc 1380ccagcccatt gcaaaattat aattaaggtt gtggatgtta atgacaataa acctgaaatt 1440aacatcaacc tcatgtcccc tggaaaagaa gaaatatctt atatttttga aggggatcct 1500attgatacat ttgttgcttt ggtcagagtt caggacaagg attctgggct gaatggagaa 1560atagtttgta agcttcatgg acatggtcac tttaaacttc agaagacata tgaaaacaat 1620tatttaatct taactaatgc cacactggat agagaaaaga gatctgagta tagtttgact 1680gtaatcgctg aggacagggg gacacccagt ctctctacag tgaaacattt tacagttcaa 1740atcaatgata tcaatgacaa tccaccccac ttccagagaa gccgatatga atttgtaatt 1800tcagaaaata actcaccagg ggcatatatc accactgtta cagccacaga tcctgatctt 1860ggagaaaatg ggcaagtgac atacaccatc ttggagagtt ttattctagg aagttccata 1920actacatatg taaccattga cccatctaat ggagccatct atgccctcag aatctttgat 1980catgaagaag tgagtcagat cacttttgtg gtagaagcaa gagatggagg aagcccgaag 2040caactggtaa gcaataccac agttgtgctc accatcattg acgaaaatga caacgttcct 2100gtggttatag ggcctgcatt gcgtaataat acggcagaaa tcaccattcc caaaggggct 2160gaaagtggct ttcatgtcac aagaataagg gcaattgaca gagactctgg tgtgaatgct 2220gaactcagct gcgccatagt agcaggtaat gaggagaata tcttcataat tgatccacga 2280tcatgtgaca tccataccaa cgttagcatg gattctgttc cctacacaga atgggagctg 2340tcagttatca ttcaggacaa aggcaatcct cagctacata ccaaagtcct tctgaagtgc 2400atgatctttg aatatgcaga gtcggtgaca agtacagcaa tgacttcagt aagccaggca 2460tccttggatg tctccatgat aataattatt tccttaggag caatttgtgc agtgttgctg 2520gttattatgg tgctatttgc aactaggtgt aaccgcgaga agaaagacac tagatcctat 2580aactgcaggg tggccgaatc aacttaccag caccacccaa aaaggccatc ccggcagatt 2640cacaaagggg acatcacatt ggtgcctacc ataaatggca ctctgcccat cagatctcat 2700cacagatcgt ctccatcttc atctcctacc ttagaaagag ggcagatggg cagccggcag 2760agtcacaaca gtcaccagtc actcaacagt ttggtgacaa tctcatcaaa ccacgtgcca 2820gagaatttct cattagaact cacccacgcc actcctgctg ttgagcaggt ctctcagctt 2880ctttcaatgc ttcaccaggg gcaatatcag ccaagaccaa gttttcgagg aaacaaatat 2940tccaggagct acagatatgc ccttcaagac atggacaaat ttagcttgaa agacagtggc 3000cgtggtgaca gtgaggcagg agacagtgat tatgatttgg ggcgagattc tccaatagat 3060aggctgttgg gtgaaggatt cagcgacctg tttctcacag atggaagaat tccagcagct 3120atgagactct gcacggagga gtgcagggtc ctgggacact ctgaccagtg ctggatgcca 3180ccactgccct caccgtcttc tgattatagg agtaacatgt tcattccagg ggaagaattc 3240ccaacgcaac cccagcagca gcatccacat cagagtcttg aggatgacgc tcagcctgca 3300gattccggtg aaaagaagaa gagtttttcc acctttggaa aggactcccc aaacgatgag 3360gacactgggg ataccagcac atcatctctg ctctcggaaa tgagcagtgt gttccagcgt 3420ctcttaccgc cttccctgga cacctattct gaatgcagtg aggtggatcg gtccaactcc 3480ctggagcgca ggaagggacc cttgccagcc aaaactgtgg gttacccaca gggggtagcg 3540gcatgggcag ccagtacgca ttttcaaaat cccaccacca actgtgggcc gccacttgga 3600actcactcca gtgtgcagcc ttcttcaaaa tggctgccag ccatggagga gatccctgaa 3660aattatgagg aagatgattt tgacaatgtg ctcaaccacc tcaatgatgg gaaacacgaa 3720ctcatggatg ccagtgaact ggtggcagag attaacaaac tgcttcaaga tgtccgccag 3780agctaggaga ttttagcgaa gcatttttgt ttccatgtat atggaaatag ggaacaacaa 3840caacaacaaa aaaccctgaa agaactggca ttgccaaata gttgcattta tcataaatgt 3900gtctgtgtat attgaatatt aaatactgta ttttcgtatg tacacaatgc aagtgtgatt 3960attttaatct gtattttaaa aatacatttg taccttatat ttatgtgtaa tttaacaaac 4020aaattttatt tttttactcc catgacagac atgtttttcc tagtcgtgta gaaactagcc 4080actgttcaaa tctgatacac tattcaacca caaagtgtaa aggcactgct tagattagtt 4140ttgttgggga agaattatta tgttgtatga acaaccccac tgaagcatta tacaattctt 4200aattccatta agtgatccca ctttttttca ataacttttt agaaattaag aatcattaaa 4260attgttaagc tattttattg ttattttctc tactttctac tagccccaat agttgaactc 4320ttataggaaa atcgaaagat aaagtgaaag tttatttcag gactgagaaa tatcttgaag 4380gttatttatt agatgactat ctcaaatgaa ctttttatag acaatgatga aaacagaatt 4440aaagtcaatg tttcctgact cccaggcccc tactattcca ggccatcaca ctggcctgtt 4500ccggagaata tttctctcac aatattatta tctacttata attatggtaa acaataaatt 4560ttattccatc cttgtagtat gaaacatgct ccaaggaaat ggaatctgtc ctttaaatgg 4620ataacagtat gtgttctaat ggcataaaat attactggat aaaaacagtt gtgtcagtgt 4680ctctcctaag gtagtaaata taattgactt attctgaacc cattctattt tgaatctccc 4740ctttcctctc acaatacttg aacattttaa tcttttggaa tattgtcttt ctttgttata 4800actattcatt tttagctttt gtctccagtg catgatctca tatttttgct tttattttta 4860gtataagaac atttataaaa tcatattttt gttactgcaa ttgttttatt tgttgtgtgg 4920caaatgagaa atcctttatt tattgtgctg tgatctctct gtgtggaatg ccttggtgag 4980agagatgctt attatgacta ttatcatttc tgaccaagct tctattaatg ttatttctaa 5040taatacacta tcttgattgt actctccaga aaatttttct gtcagtgaaa ataaaagaaa 5100aattaaagta aagctaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 5160521135PRTHomo sapiens 52Met His Gln Met Asn Ala Lys Met His Phe Arg Phe Val Phe Ala Leu 1 5 10 15Leu Ile Val Ser Phe Asn His Asp Val Leu Gly Lys Asn Leu Lys Tyr 20 25 30Arg Ile Tyr Glu Glu Gln Arg Val Gly Ser Val Ile Ala Arg Leu Ser 35 40 45Glu Asp Val Ala Asp Val Leu Leu Lys Leu Pro Asn Pro Ser Thr Val 50 55 60Arg Phe Arg Ala Met Gln Arg Gly Asn Ser Pro Leu Leu Val Val Asn 65 70 75 80Glu Asp Asn Gly Glu Ile Ser Ile Gly Ala Thr Ile Asp Arg Glu Gln 85 90 95Leu Cys Gln Lys Asn Leu Asn Cys Ser Ile Glu Phe Asp Val Ile Thr 100 105 110Leu Pro Thr Glu His Leu Gln Leu Phe His Ile Glu Val Glu Val Leu 115 120 125Asp Ile Asn Asp Asn Ser Pro Gln Phe Ser Arg Ser Leu Ile Pro Ile 130 135 140Glu Ile Ser Glu Ser Ala Ala Val Gly Thr Arg Ile Pro Leu Asp Ser145 150 155 160Ala Phe Asp Pro Asp Val Gly Glu Asn Ser Leu His Thr Tyr Ser Leu 165 170 175Ser Ala Asn Asp Phe Phe Asn Ile Glu Val Arg Thr Arg Thr Asp Gly 180 185 190Ala Lys Tyr Ala Glu Leu Ile Val Val Arg Glu Leu Asp Arg Glu Leu 195 200 205Lys Ser Ser Tyr Glu Leu Gln Leu Thr Ala Ser Asp Met Gly Val Pro 210 215 220Gln Arg Ser Gly Ser Ser Ile Leu Lys Ile Ser Ile Ser Asp Ser Asn225 230 235 240Asp Asn Ser Pro Ala Phe Glu Gln Gln Ser Tyr Ile Ile Gln Leu Leu 245 250 255Glu Asn Ser Pro Val Gly Thr Leu Leu Leu Asp Leu Asn Ala Thr Asp 260 265 270Pro Asp Glu Gly Ala Asn Gly Lys Ile Val Tyr Ser Phe Ser Ser His 275 280 285Val Ser Pro Lys Ile Met Glu Thr Phe Lys Ile Asp Ser Glu Arg Gly 290 295 300His Leu Thr Leu Phe Lys Gln Val Asp Tyr Glu Ile Thr Lys Ser Tyr305 310 315 320Glu Ile Asp Val Gln Ala Gln Asp Leu Gly Pro Asn Ser Ile Pro Ala 325 330 335His Cys Lys Ile Ile Ile Lys Val Val Asp Val Asn Asp Asn Lys Pro 340 345 350Glu Ile Asn Ile Asn Leu Met Ser Pro Gly Lys Glu Glu Ile Ser Tyr 355 360 365Ile Phe Glu Gly Asp Pro Ile Asp Thr Phe Val Ala Leu Val Arg Val 370 375 380Gln Asp Lys Asp Ser Gly Leu Asn Gly Glu Ile Val Cys Lys Leu His385 390 395 400Gly His Gly His Phe Lys Leu Gln Lys Thr Tyr Glu Asn Asn Tyr Leu 405 410 415Ile Leu Thr Asn Ala Thr Leu Asp Arg Glu Lys Arg Ser Glu Tyr Ser 420 425 430Leu Thr Val Ile Ala Glu Asp Arg Gly Thr Pro Ser Leu Ser Thr Val 435 440 445Lys His Phe Thr Val Gln Ile Asn Asp Ile Asn Asp Asn Pro Pro His 450 455 460Phe Gln Arg Ser Arg Tyr Glu Phe Val Ile Ser Glu Asn Asn Ser Pro465 470 475 480Gly Ala Tyr Ile Thr Thr Val Thr Ala Thr Asp Pro Asp Leu Gly Glu 485 490 495Asn Gly Gln Val Thr Tyr Thr Ile Leu Glu Ser Phe Ile Leu Gly Ser 500 505 510Ser Ile Thr Thr Tyr Val Thr Ile Asp Pro Ser Asn Gly Ala Ile Tyr 515 520 525Ala Leu Arg Ile Phe Asp His Glu Glu Val Ser Gln Ile Thr Phe Val 530 535 540Val Glu Ala Arg Asp Gly Gly Ser Pro Lys Gln Leu Val Ser Asn Thr545 550 555 560Thr Val Val Leu Thr Ile Ile Asp Glu Asn Asp Asn Val Pro Val Val 565 570 575Ile Gly Pro Ala Leu Arg Asn Asn Thr Ala Glu Ile Thr Ile Pro Lys 580 585 590Gly Ala Glu Ser Gly Phe His Val Thr Arg Ile Arg Ala Ile Asp Arg 595 600 605Asp Ser Gly Val Asn Ala Glu Leu Ser Cys Ala Ile Val Ala Gly Asn 610 615 620Glu Glu Asn Ile Phe Ile Ile Asp Pro Arg Ser Cys Asp Ile His Thr625 630 635 640Asn Val Ser Met Asp Ser Val Pro Tyr Thr Glu Trp Glu Leu Ser Val 645 650 655Ile Ile Gln Asp Lys Gly Asn Pro Gln Leu His Thr Lys Val Leu Leu 660 665 670Lys Cys Met Ile Phe Glu Tyr Ala Glu Ser Val Thr Ser Thr Ala Met 675 680 685Thr Ser Val Ser Gln Ala Ser Leu Asp Val Ser Met Ile Ile Ile Ile 690 695 700Ser Leu Gly Ala Ile Cys Ala Val Leu Leu Val Ile Met Val Leu Phe705 710 715 720Ala Thr Arg Cys Asn Arg Glu Lys Lys Asp Thr Arg Ser Tyr Asn Cys 725 730 735Arg Val Ala Glu Ser Thr Tyr Gln His His Pro Lys Arg Pro Ser Arg 740 745 750Gln Ile His Lys Gly Asp Ile Thr Leu Val Pro Thr Ile Asn Gly Thr 755 760 765Leu Pro Ile Arg Ser His His Arg Ser Ser Pro Ser Ser Ser Pro Thr 770 775 780Leu Glu Arg Gly Gln Met Gly Ser Arg Gln Ser His Asn Ser His Gln785 790 795 800Ser Leu Asn Ser Leu Val Thr Ile Ser Ser Asn His Val Pro Glu Asn 805 810 815Phe Ser Leu Glu Leu Thr His Ala Thr Pro Ala Val Glu Gln Val Ser 820 825 830Gln Leu Leu Ser Met Leu His Gln Gly Gln Tyr Gln Pro Arg Pro Ser 835 840 845Phe Arg Gly Asn Lys Tyr Ser Arg Ser Tyr Arg Tyr Ala Leu Gln Asp 850 855 860Met Asp Lys Phe Ser Leu Lys Asp Ser Gly Arg Gly Asp Ser Glu Ala865 870 875 880Gly Asp Ser Asp Tyr Asp Leu Gly Arg Asp Ser Pro Ile Asp Arg Leu 885 890 895Leu Gly Glu Gly Phe Ser Asp Leu Phe Leu Thr Asp Gly Arg Ile Pro 900 905 910Ala Ala Met Arg Leu Cys Thr Glu Glu Cys Arg Val Leu Gly His Ser 915 920 925Asp Gln Cys Trp Met Pro Pro Leu Pro Ser Pro Ser Ser Asp Tyr Arg 930 935 940Ser Asn Met Phe Ile Pro Gly Glu Glu Phe Pro Thr Gln Pro Gln Gln945 950 955 960Gln His Pro His Gln Ser Leu Glu Asp Asp Ala Gln Pro Ala Asp Ser 965 970 975Gly Glu Lys Lys Lys Ser Phe Ser Thr Phe Gly Lys Asp Ser Pro Asn 980 985 990Asp Glu Asp Thr Gly Asp Thr Ser Thr Ser Ser Leu Leu Ser Glu Met 995 1000 1005Ser Ser Val Phe Gln Arg Leu Leu Pro Pro Ser Leu Asp Thr Tyr Ser 1010 1015 1020Glu Cys Ser Glu Val Asp Arg Ser Asn Ser Leu Glu Arg Arg Lys Gly1025 1030 1035 1040Pro Leu Pro Ala Lys Thr Val Gly Tyr Pro Gln Gly Val Ala Ala Trp 1045 1050 1055Ala Ala Ser Thr His Phe Gln Asn Pro Thr Thr Asn Cys Gly Pro Pro 1060 1065 1070Leu Gly Thr His Ser Ser Val Gln Pro Ser Ser Lys Trp Leu Pro Ala 1075 1080 1085Met Glu Glu Ile Pro Glu Asn Tyr Glu Glu Asp Asp Phe Asp Asn Val 1090 1095 1100Leu Asn His Leu Asn Asp Gly Lys His Glu Leu Met Asp Ala Ser Glu1105 1110 1115 1120Leu Val Ala Glu Ile Asn Lys Leu Leu Gln Asp Val Arg Gln Ser 1125 1130 1135531207DNAHomo sapiens 53atggcgtccc gcggccggcg tccggagcat ggcggacccc cagagctgtt ttatgacgag 60acagaagccc ggaaatacgt tcgcaactca cggatgattg atatccagac caggatggct 120gggcgagcat tggagcttct ttatctgcca gagaataagc cctgttacct gctggatatt 180ggctgtggca ctgggctgag tggaagttat ctgtcagatg aagggcacta ttgggtgggc 240ctggatatca gccctgccat gctggatgag gctgtggacc gagagataga gggagacctg 300ctgctggggg atatgggcca gggcatccca ttcaagccag gcacatttga tggttgcatc 360agcatttctg ctgtgcattg gctctgtaat gctaacaaga agtctgaaaa ccctgccaag 420cgcctgtact gcttttttgc ttctcttttt tctgttctcg tccggggatc ccgagctgtc 480ctgcagctgt accctgagaa ctcagagcag ttggagctga tcacaaccca ggccacaaag 540gcaggcttct ccggtggcat ggtggtagac taccctaaca gtgccaaagc aaagaaattc 600tacctctgct tgttttctgg gccttcgacc tttataccag aggggctgag tgaaaatcag 660gatgaagttg aacccaggga gtctgtgttc accaatgaga ggttcccatt aaggatgtcg 720aggcggggaa tggtgaggaa gagtcgggca tgggtgctgg agaagaagga gcggcacagg 780cgccagggca gggaagtcag acctgacacc cagtacaccg gccgcaagcg caagccccgc 840ttctaagtca ccacgcggtt ctggaaaggc acttgcctct gcacttttct atattgttca 900gctgacaaag tagtatttta gaaaagttct aaagttataa aaatgttttc tgcagtaaaa 960aaaaagttct ctgggccggg cgtggtggct cacacctgta atcccagcac cttgggaggc 1020tgaggtggga ggatcatttg aggccaggag tttgagacct gcctgggcaa cataatgaaa 1080cttcctttcc agggagaaaa aaaaaaaaaa aaaaaaaagc tctgagagca tcttattttg 1140tttaaaggca agaaataaaa tttccttttg tggaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200aaaaaaa 120754281PRTHomo sapiens 54Met Ala Ser Arg Gly Arg Arg Pro Glu His Gly Gly Pro Pro Glu Leu 1 5 10 15Phe Tyr Asp Glu Thr Glu Ala Arg Lys Tyr Val Arg Asn Ser Arg Met 20 25 30Ile Asp Ile Gln Thr Arg Met Ala Gly Arg Ala Leu Glu Leu Leu Tyr 35 40 45Leu Pro Glu Asn Lys Pro Cys Tyr Leu

Leu Asp Ile Gly Cys Gly Thr 50 55 60Gly Leu Ser Gly Ser Tyr Leu Ser Asp Glu Gly His Tyr Trp Val Gly 65 70 75 80Leu Asp Ile Ser Pro Ala Met Leu Asp Glu Ala Val Asp Arg Glu Ile 85 90 95Glu Gly Asp Leu Leu Leu Gly Asp Met Gly Gln Gly Ile Pro Phe Lys 100 105 110Pro Gly Thr Phe Asp Gly Cys Ile Ser Ile Ser Ala Val His Trp Leu 115 120 125Cys Asn Ala Asn Lys Lys Ser Glu Asn Pro Ala Lys Arg Leu Tyr Cys 130 135 140Phe Phe Ala Ser Leu Phe Ser Val Leu Val Arg Gly Ser Arg Ala Val145 150 155 160Leu Gln Leu Tyr Pro Glu Asn Ser Glu Gln Leu Glu Leu Ile Thr Thr 165 170 175Gln Ala Thr Lys Ala Gly Phe Ser Gly Gly Met Val Val Asp Tyr Pro 180 185 190Asn Ser Ala Lys Ala Lys Lys Phe Tyr Leu Cys Leu Phe Ser Gly Pro 195 200 205Ser Thr Phe Ile Pro Glu Gly Leu Ser Glu Asn Gln Asp Glu Val Glu 210 215 220Pro Arg Glu Ser Val Phe Thr Asn Glu Arg Phe Pro Leu Arg Met Ser225 230 235 240Arg Arg Gly Met Val Arg Lys Ser Arg Ala Trp Val Leu Glu Lys Lys 245 250 255Glu Arg His Arg Arg Gln Gly Arg Glu Val Arg Pro Asp Thr Gln Tyr 260 265 270Thr Gly Arg Lys Arg Lys Pro Arg Phe 275 280551490DNAHomo sapiens 55agcccacctg gtggggagga ggccctgctg tggaatccct accccaggag ccctggccct 60cctcctggtg gggctcccta gaggagggtc ctctcagccc gagaacgcag ctcagtgtgt 120caggctccaa ctgtttttct gtgacttgct cgccgtgtag gctgctaaac atctggctga 180accaagcgtt catcctgacc tgaagccaga acctcagaaa ccaaagtaag gcctgatcat 240gccctcgccc cactgcccca gagacctcct cttgtctctt tgatgttttg ttttctattt 300tatttttcgt ttttgtgtgt ctgcatggtg tttttcgggc agtggcttct gccatcatca 360ccacatgttt ctctgctgcc cactgtcctg aggtgggccg tcgtggaagc cctgcttcct 420gccgtttgcg ggacgagtcc cgccctcttt tttcctgtcc ccatcggtag tctgcgtgca 480cgtgttttcc acagtaaaac cgtgttgtgt aactctttcc agcaaagtaa caatccgcca 540ttacaaaggt cgtcctcctt gatccagtta acgagtcaga actcttctcc caatcagcag 600agaaccccgc aggtcatcgg ggtcatgcag agtcaaaaca gcagcggggg caaccgggga 660cccggccact ggagcaggtc acctgttaca agtgtggcga gaaaggacac tacgccaaca 720gatgcaccaa agggcacttg gcctttctca gtggacagtg acagcagctg gagccagctc 780cgagcagccc gggggccccg ctgttgggag tgtgcattta actgtttcat gcgcttgttg 840gcgcgactgt ggctcgagct ggcccgcaga cacgtgggtt tcatcactct gaggggccac 900gtctgttagt ttcctatcat tttgccttag tattttttga aaaaggacat gtgtcctgtg 960ggtccctgca gtcgacatca tgtttggctg ggcatcgatg cctcctttct gggactcccg 1020gcacaactcc ctgccctgct gaatcctaaa gctgtgccta tatctgtgat ttgaatgagg 1080gagccctttg gggcaaattc aggtgccccc attgcctcag gctggccctg gtcccaggtg 1140gcagcggttg aggaggggta cagggctctc aagcctgagg ttttcttctc tgggcttaat 1200tttctcttgg ggtacgtgcc tgacagtgtt taaggtgtcc gttgaactgg agttgcagac 1260ttttaaatag atgacccctt cagatcatct gtgcctacct cctgcccatc aggcgtctac 1320actgtcactc agacacctgt ggcatgtgga ggagactgcc ctgtcctgag cctggaaaat 1380gtgaaactgt ctcctgcaac ctgctgggca tgtgggcctg gctgtgttca attgcaagaa 1440caatttttat gaaatggatt aaagcttgtt ttttaaaaaa aaaaaaaaaa 149056208PRTHomo sapiens 56Met Phe Cys Phe Leu Phe Tyr Phe Ser Phe Leu Cys Val Cys Met Val 1 5 10 15Phe Phe Gly Gln Trp Leu Leu Pro Ser Ser Pro His Val Ser Leu Leu 20 25 30Pro Thr Val Leu Arg Trp Ala Val Val Glu Ala Leu Leu Pro Ala Val 35 40 45Cys Gly Thr Ser Pro Ala Leu Phe Phe Pro Val Pro Ile Gly Ser Leu 50 55 60Arg Ala Arg Val Phe His Ser Lys Thr Val Leu Cys Asn Ser Phe Gln 65 70 75 80Gln Ser Asn Asn Pro Pro Leu Gln Arg Ser Ser Ser Leu Ile Gln Leu 85 90 95Thr Ser Gln Asn Ser Ser Pro Asn Gln Gln Arg Thr Pro Gln Val Ile 100 105 110Gly Val Met Gln Ser Gln Asn Ser Ser Gly Gly Asn Arg Gly Pro Gly 115 120 125His Trp Ser Arg Ser Pro Val Thr Ser Val Ala Arg Lys Asp Thr Thr 130 135 140Pro Thr Asp Ala Pro Lys Gly Thr Trp Pro Phe Ser Val Asp Ser Asp145 150 155 160Ser Ser Trp Ser Gln Leu Arg Ala Ala Arg Gly Pro Arg Cys Trp Glu 165 170 175Cys Ala Phe Asn Cys Phe Met Arg Leu Leu Ala Arg Leu Trp Leu Glu 180 185 190Leu Ala Arg Arg His Val Gly Phe Ile Thr Leu Arg Gly His Val Cys 195 200 205574184DNAHomo sapiens 57agcagggaaa gaaaaacttg acgtgtggaa tacagaggga ggagatttta acattatggc 60agggaggcat cagaatcgta gttttcctct tccaggagtt cagtcaagtg gtcaagtaca 120tgcatttgga aattgttcag acagtgatat tttggaggag gatgctgaag tgtatgagct 180tcgatccaga ggaaaagaga aagtccgaag aagtacatca agagatagac ttgacgacat 240tatagtatta acaaaagata tacaagaagg agatacatta aatgcaatag cccttcagta 300ctgttgtacg gtagcagata tcaagagagt taacaatctc atcagtgatc aagacttttt 360tgcccttagg tctatcaaaa ttccagtaaa aaagttcagt tccttgaccg aaacactttg 420tcctccaaaa ggaagacaga cttcacgtca ttcatctgtt caatactctt ccgaacaaca 480ggaaattttg ccagctaatg attctcttgc ttacagtgac tcagctggta gctttttaaa 540agaagtagac cgagacatag aacaaatagt aaagtgtaca gacaataaga gagagaacct 600ccatgaggta gtatcggcct tcacagcaca acaaatgcgt tttgaacctg ataacaaaaa 660cactcaacgt aaagacccct attatggagc agactgggga atagggtggt ggacagctgt 720agtgataatg ttgatagtag gtataataac accagtgttt tatttgttgt attatgaaat 780tttagctaag gtggatgtta gtcatcattc aacagtggac tcttcacatt tacattcaaa 840aatcacaccc ccatcacagc agagagaaat ggaaaatgga attgtgccaa ctaaaggaat 900acatttcagc caacaagatg atcataaact gtatagtcaa gattctcagt cacctgctgc 960tcaacaggaa acatagcaat tagctcataa tcaaatgtta gtggtcaggt cacatgtgca 1020tctggaatgt ggtgaatcag ttatatccaa taatagcttc aaaggcagaa tttagagaga 1080ttgaggatgc ttttgttttt aacaaaaggg tttcacactt tgaaaatttt ttgagcaact 1140agttgttgat gttgagagca gttgatccat aaatctggtg tgtgaatgtt tcaagcagaa 1200attaatttaa atgtgtgttt aggaagtact taacttggaa gatgtatcat ttttcttaaa 1260atgcatgttt aaattttatt tttttaagta atttttaaaa agtttattaa tgttaaattt 1320atgatgcaga atgatagcat cagatgtctg cagctgaaaa aaatttacta ctatgaaccc 1380ccaaaatatt cagttgcaag aaaatttgat tctaaaatta ttcatggtag gatacgtaac 1440acaccccttc caaactttta aaaaatacat ttagcacatg tgctatgaaa gcatacgtac 1500aaagagaaag gggaaagtga tttataattc ctacaacaga ggccaagaaa tagattaaaa 1560tattttcaag accccaaaat aatgtattat ggttgggaag tcagtagaac actggaatag 1620gtgaagacct gacagtaatt tttgtcttaa gaatgctttc tttaggacag accctttaac 1680ctcacctctg tgcatctgtt tttaaaatga ttatatttgc ctctgatatt tgaaagcact 1740tttgtagttt tgatgatgaa aaatatatta aacgtgcata ttaccattat ttaggaaata 1800attccttata tactgtgata aatcattgct gttacataca gtaacatgcc ttaattacat 1860ttaatgcctt actgctttat gtaagtaaat ccaagtttca gaattaaaaa taagcattat 1920ttcatatggt ccaatcagat tcgttacata ggctatataa atttgtctcc attttcacca 1980tcaagcacaa ataattgggt caaaactgcc tttgaggtct gttgaagaaa atggttcatt 2040aagcaaaaaa agagtagagg tattttatat tagcagtaac agacaaatta tttagtaatc 2100ccttaacctc tgtttttcaa agagaaaata tccaatttag acttttttcc tgatctctat 2160atatagcatc aaattgggaa acaaaggcca aaggtgtata gattgcttga aagggggtgg 2220taggcctctt tttaagatct gtgagtcggc tacagtctgg ctaagtaaga agcatttgca 2280tactgattcc atcatttaat ctttaaaagt atgtgtttta aaaatgtaac cagaatgatt 2340cttcaataga aatgagattt ggtggagtct ggattgcctg ttttgtatat aatatatact 2400taagatatat aataccacct cattttctgg gcattatttc ctaattgttg atgtttcagg 2460cttttgataa gtcattttat atatttcaaa tttaactcag aataagtaaa tatttatggc 2520aaatgcagtt ttatgtactt tcaggagaag accatcagga aaagacagga caaagaagtc 2580aaacattaaa gcccttgcaa atattagagg accttagaca attaccaaaa agtgtttaat 2640agggaagttg caaatgattc tcttagtaaa ttaaacattt aaaaagtagt tttaatgtgc 2700cttgggcatc ttgaaaagaa gagtgtgata taatttatgc ttagtgttaa ctggtcattt 2760tacattgtat ttattaagtc tgctgaaaaa tgaggtttta aggaagaaaa tgcagattat 2820tttagggtaa acaggccagg tgtcctttga agaactttgt ttacatcaaa ttgatgaaat 2880tacagtcagt gattccttac tttttttgct agttgtactt tgaaattgtt atgggttcgt 2940tttccaaaat atgtaactta ttttttaaag gaataaggtg tgctgtgtat ttgttgatta 3000aaaatcattt gtcttgcaga gtatcctttt ttgaaggaaa tatacatcct tataacacat 3060caggtagttt tcttttttct gtatttaaat tatatatttg aattaattga atataatttg 3120agttacatat aattctatat aaaggttaca tattgaatta tggttctaat ctgtttagga 3180aagaaatgaa ttttctaagc atttaataca tttggaataa ttttagtttc taaaaagtac 3240taatgtaagt taagtttata tcaaatgcaa attaccttgt ataactaaca agcacagtta 3300ttgtttaaca ttatggattt taattgtgtt gacacccttc tttgaatttg ttgctttaca 3360tgtgtgtctg tgtgtgtgtc tgcatgtgtg cacgcatgta cttgtatgca atgtaaaagt 3420aacagcagaa tcattgcatt tggtttactt aaaattttgg agttagcaag taaacaaaaa 3480gctgatagtt ttatgaagtc tcggttaaaa taaaatttct ttgctatctc actcctagga 3540agttatggag ttcatatttt caaaagatat gttaaaaatg gttacacact ctgctggcca 3600cattaaaaat tagaagactc atgttaaatt atctcctcca aaggactttt tatttacagc 3660ttttcttttc ctggactcta cctgcttggt tcagtgtcct gaagagttat ttaaatgaac 3720cactacttag taattagttc ttttttaaag tatctacttc taaaattacc tagttgaaaa 3780tatgaaggat atgcttagtt ttagaaatat catgaagcaa ggatctagtc agtgttacag 3840ggtaaaggtg gagtttttta aagtctgtat ttaaatggtg cactgatgga ttcattttta 3900atttgcatta caaaaatgtt gctcaggtaa tcagtatttt cttccacgta tgtgcatatt 3960gcactgttag atcatagaaa tatctgaatg ctttaatttt tatgtatgca aaatctataa 4020atcttttgta taatgtattt tatacaaatg taactgtaga acattgttag catgtgtatc 4080tgtaaaacca gtttttaaaa ttttttgccc cttatttttc atattttgaa agatctccaa 4140catgtaataa agtttctctt attcaatcta aaaaaaaaaa aaaa 418458306PRTHomo sapiens 58Met Ala Gly Arg His Gln Asn Arg Ser Phe Pro Leu Pro Gly Val Gln 1 5 10 15Ser Ser Gly Gln Val His Ala Phe Gly Asn Cys Ser Asp Ser Asp Ile 20 25 30Leu Glu Glu Asp Ala Glu Val Tyr Glu Leu Arg Ser Arg Gly Lys Glu 35 40 45Lys Val Arg Arg Ser Thr Ser Arg Asp Arg Leu Asp Asp Ile Ile Val 50 55 60Leu Thr Lys Asp Ile Gln Glu Gly Asp Thr Leu Asn Ala Ile Ala Leu 65 70 75 80Gln Tyr Cys Cys Thr Val Ala Asp Ile Lys Arg Val Asn Asn Leu Ile 85 90 95Ser Asp Gln Asp Phe Phe Ala Leu Arg Ser Ile Lys Ile Pro Val Lys 100 105 110Lys Phe Ser Ser Leu Thr Glu Thr Leu Cys Pro Pro Lys Gly Arg Gln 115 120 125Thr Ser Arg His Ser Ser Val Gln Tyr Ser Ser Glu Gln Gln Glu Ile 130 135 140Leu Pro Ala Asn Asp Ser Leu Ala Tyr Ser Asp Ser Ala Gly Ser Phe145 150 155 160Leu Lys Glu Val Asp Arg Asp Ile Glu Gln Ile Val Lys Cys Thr Asp 165 170 175Asn Lys Arg Glu Asn Leu His Glu Val Val Ser Ala Phe Thr Ala Gln 180 185 190Gln Met Arg Phe Glu Pro Asp Asn Lys Asn Thr Gln Arg Lys Asp Pro 195 200 205Tyr Tyr Gly Ala Asp Trp Gly Ile Gly Trp Trp Thr Ala Val Val Ile 210 215 220Met Leu Ile Val Gly Ile Ile Thr Pro Val Phe Tyr Leu Leu Tyr Tyr225 230 235 240Glu Ile Leu Ala Lys Val Asp Val Ser His His Ser Thr Val Asp Ser 245 250 255Ser His Leu His Ser Lys Ile Thr Pro Pro Ser Gln Gln Arg Glu Met 260 265 270Glu Asn Gly Ile Val Pro Thr Lys Gly Ile His Phe Ser Gln Gln Asp 275 280 285Asp His Lys Leu Tyr Ser Gln Asp Ser Gln Ser Pro Ala Ala Gln Gln 290 295 300Glu Thr305593191DNAHomo sapiens 59cagaggcttt tatccatggg gccaatataa ccgaggaggc tatggaaact atcgctcaaa 60ttggcagaat taccggcaag catacagtcc tcgtcgaggc cgttcaagat cccggtcccc 120aaagagaagg tccccttcac caaggtccag gagccattct agaaactctg ataagtcgtc 180ttctgaccgg tcaaggcgct cctcatcctc ccgttcttcc tccaaccata gccgagttga 240atcttctaag cgcaagtctg caaaggagaa aaagtcctct tctaaggata gccggccatc 300tcaggctgcc ggggataacc agggagatga ggtcaaggag cagacattct ctggaggcac 360ctctcaagat acaaaagcat ctgagagctc gaagccatgg ccagatgcca cctacggcac 420tggttctgca tcacgggcct cagcagtttc tgagctgagt cctcgggagc gaagcccagc 480tctcaaaagc cccctccagt ctgtggtggt gaggcggcgg tcaccccgtc ctagcccgtg 540ccaaaaacct agtcctccac tttccagcac atcccagatg ggctcaactc tgccgagtgg 600tgccgggtat cagtctggga cacaccaagg tcagttcgac catggttctg ggtccctgag 660tccatccaaa aagagccctg tgggtaagag tccaccatcc actggctcca catatggctc 720atctcagaag gaggagagtg ctgcttcagg aggagcagcc tatacaaaga ggtttctaga 780agagcagaag acagagaatg gaaaagataa ggaacagaaa caaacaaata ccgattaaga 840aaaaataaaa gagaaaggga gcttctctga cacaggcttg ggtgatggaa aaatgaaatc 900tgattctttt gctcccaaaa ctgattctga gaagcctttt cggggcagtc agtctcccaa 960aaggtataag ctccgagatg actttgagaa gaagatggct gacttccaca aggaggagat 1020ggatgatcaa gataaggaca aagctaaggg aagaaaggaa tctgagtttg atgatgaacc 1080caaatttatg tctaaagtca taggtgcaaa caaaaaccag gaggaggaga agtcaggcaa 1140atgggagggc ctggtatatg cacctccagg gaaggaaaag cagagaaaaa cagaggagct 1200ggaggaggag tctttcccag agagatccaa aaaggaagat cggggcaaga gaagcgaagg 1260tgggcacagg ggctttgtgc ctgagaagaa tttccgagtg actgcttata aagcagtcca 1320ggagaaaagc tcatcacctc ccccaagaaa gacctctgag agccgagaca agctgggagc 1380gaaaggagat tttcccacag gaaagtcttc cttttccatt actcgagagg cacaggtcaa 1440tgtccggatg gactcttttg atgaggacct cgcacgaccc agtggcttat tggctcagga 1500acgcaagctt tgccgagatc tagtccatag caacaaaaag gaacaggagt ttcgttccat 1560tttccagcac atacaatcag ctcagtctca gcgtagcccc tcagaactgt ttgcccaaca 1620tatagtgacc attgttcacc atgttaaaga gcatcacttt gggtcctcag gaatgacatt 1680acatgaacgc tttactaaat acctaaagag aggaactgag caggaggcag ccaaaaacaa 1740gaaaagccca gagatacaca ggagaataga catttccccc agtacattca gaaaacatgg 1800tttggctcat gatgaaatga aaagtccccg ggaacctggc tacaaggctg agggaaaata 1860caaagatgat cctgttgatc tccgccttga tattgaacgt cgtaaaaaac ataaggagag 1920agatcttaaa cgaggtaaat cgagagaatc agtggattcc cgagactcca gtcactcaag 1980ggaaaggtca gctgaaaaaa cagagaaaac tcataaagga tcaaagaaac agaagaagca 2040tccgagagca agagacaggt ccagatcctc ctcctcttcc tcccagtcat ctcactccta 2100caaagcagaa gagtacactg aagagacaga ggaaagagag gagagcacca cgggctttga 2160caaatcaaga ctggggacca aagactttgt gggtccaagt gaaagaggag gtggcagagc 2220tcgaggaacc tttcagtttc gagccagagg aagaggctgg ggcagaggca actactctgg 2280gaacaataac aacaacagca acaacgattt tcaaaaaaga aaccgggaag aggagtggga 2340cccagagtac acacccaaaa gcaagaagta taacttgcat gatgaccgtg aaggcgaagg 2400cagtgacaag tgggtgagcc ggggccgggg ccgaggagcc tttcctcggg gtcggggccg 2460gttcatgttc cggaaatcaa gtaccagccc caagtgggcc catgacaagt tcagtgggga 2520ggaaggggag attgaagacg acgagagtgg gacagagaac cgagaagaga aggacaatat 2580acagcccaca accgagtagg ggccaccctt gacgggattc ctgcccaggg gagagaggcg 2640ctgggaagat ggctggtgag gagcttaaca gaggaacctc aagaagattc tgaaaatcct 2700acccccaccc cccaccagcc gcacagattg tactaccgcg agaggcatcc ctggcgctgt 2760ctcccactgg acagaggagg ctggccatgg ggcccagggg tcaggcccag cttttgagca 2820gaatacaacg cattgggctt tagctgtttt tctcatttgt tggtgtgtgg ggtgggggca 2880ggggtagggc gggagagcga tgcttggatt tttgtttcct attagaaacc aacagttttg 2940ttctaatttc atttcattgg gagctaagat gactaattgg atgattttcg atctcttttc 3000ccctgtcctg attttaaaag ccccctcctt tttttttttt tttttctttt tttaggcata 3060tgtagtaata ttagaaacat ttaatttggg aaactttgat tcttgaaaga gaaaacaaaa 3120gcatgtgaat aaactttgaa gtgttcacct caaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3180aaaaaaaaaa a 319160568PRTHomo sapiens 60Met Lys Ser Asp Ser Phe Ala Pro Lys Thr Asp Ser Glu Lys Pro Phe 1 5 10 15Arg Gly Ser Gln Ser Pro Lys Arg Tyr Lys Leu Arg Asp Asp Phe Glu 20 25 30Lys Lys Met Ala Asp Phe His Lys Glu Glu Met Asp Asp Gln Asp Lys 35 40 45Asp Lys Ala Lys Gly Arg Lys Glu Ser Glu Phe Asp Asp Glu Pro Lys 50 55 60Phe Met Ser Lys Val Ile Gly Ala Asn Lys Asn Gln Glu Glu Glu Lys 65 70 75 80Ser Gly Lys Trp Glu Gly Leu Val Tyr Ala Pro Pro Gly Lys Glu Lys 85 90 95Gln Arg Lys Thr Glu Glu Leu Glu Glu Glu Ser Phe Pro Glu Arg Ser 100 105 110Lys Lys Glu Asp Arg Gly Lys Arg Ser Glu Gly Gly His Arg Gly Phe 115 120 125Val Pro Glu Lys Asn Phe Arg Val Thr Ala Tyr Lys Ala Val Gln Glu 130 135 140Lys Ser Ser Ser Pro Pro Pro Arg Lys Thr Ser Glu Ser Arg Asp Lys145 150 155 160Leu Gly Ala Lys Gly Asp Phe Pro Thr Gly Lys Ser Ser Phe Ser Ile 165 170 175Thr Arg Glu Ala Gln Val Asn Val Arg Met Asp Ser Phe Asp Glu Asp 180 185 190Leu Ala Arg Pro Ser Gly Leu Leu Ala Gln Glu Arg Lys Leu Cys Arg 195 200 205Asp Leu Val His Ser Asn Lys Lys Glu Gln Glu Phe Arg Ser Ile Phe 210 215 220Gln His Ile Gln Ser Ala Gln Ser Gln Arg Ser Pro Ser Glu Leu Phe225 230 235 240Ala Gln His Ile Val Thr Ile Val His His Val Lys Glu His His

Phe 245 250 255Gly Ser Ser Gly Met Thr Leu His Glu Arg Phe Thr Lys Tyr Leu Lys 260 265 270Arg Gly Thr Glu Gln Glu Ala Ala Lys Asn Lys Lys Ser Pro Glu Ile 275 280 285His Arg Arg Ile Asp Ile Ser Pro Ser Thr Phe Arg Lys His Gly Leu 290 295 300Ala His Asp Glu Met Lys Ser Pro Arg Glu Pro Gly Tyr Lys Ala Glu305 310 315 320Gly Lys Tyr Lys Asp Asp Pro Val Asp Leu Arg Leu Asp Ile Glu Arg 325 330 335Arg Lys Lys His Lys Glu Arg Asp Leu Lys Arg Gly Lys Ser Arg Glu 340 345 350Ser Val Asp Ser Arg Asp Ser Ser His Ser Arg Glu Arg Ser Ala Glu 355 360 365Lys Thr Glu Lys Thr His Lys Gly Ser Lys Lys Gln Lys Lys His Pro 370 375 380Arg Ala Arg Asp Arg Ser Arg Ser Ser Ser Ser Ser Ser Gln Ser Ser385 390 395 400His Ser Tyr Lys Ala Glu Glu Tyr Thr Glu Glu Thr Glu Glu Arg Glu 405 410 415Glu Ser Thr Thr Gly Phe Asp Lys Ser Arg Leu Gly Thr Lys Asp Phe 420 425 430Val Gly Pro Ser Glu Arg Gly Gly Gly Arg Ala Arg Gly Thr Phe Gln 435 440 445Phe Arg Ala Arg Gly Arg Gly Trp Gly Arg Gly Asn Tyr Ser Gly Asn 450 455 460Asn Asn Asn Asn Ser Asn Asn Asp Phe Gln Lys Arg Asn Arg Glu Glu465 470 475 480Glu Trp Asp Pro Glu Tyr Thr Pro Lys Ser Lys Lys Tyr Asn Leu His 485 490 495Asp Asp Arg Glu Gly Glu Gly Ser Asp Lys Trp Val Ser Arg Gly Arg 500 505 510Gly Arg Gly Ala Phe Pro Arg Gly Arg Gly Arg Phe Met Phe Arg Lys 515 520 525Ser Ser Thr Ser Pro Lys Trp Ala His Asp Lys Phe Ser Gly Glu Glu 530 535 540Gly Glu Ile Glu Asp Asp Glu Ser Gly Thr Glu Asn Arg Glu Glu Lys545 550 555 560Asp Asn Ile Gln Pro Thr Thr Glu 565613145DNAHomo sapiens 61gtccccgtcc ggcagactac tctcccccat ggcggacttc gctgggccgt cttctgccgg 60ccgcaaggcc ggggctcccc gctgctctcg aaaagccgca ggtactaaac agacgagtac 120tttgaaacaa gaagatgctt ctaaaagggg aggttcatta cgacctgctc actacagtga 180tgtcgtggat gaacgttcta ttgtcaaact ctgtggttat cctttatgtc agaagaagct 240gggaattgta ccaaaacaga aatataaaat ttctaccaaa accaataaag tctatgatat 300tactgaaaga aagtcttttt gcagcaattt ttgttatcaa gcatctaagt tttttgaagc 360acaaattccc aaaactccag tatgggttcg agaagaagag aggcatcctg attttcaact 420gctaaaggaa gaacaaagtg gccattctgg agaagaagta cagttatgca gtaaagccat 480taaaacatca gatatcgaca atcctagcca ctttgaaaag caatatgaat ctagttcttc 540tagcactcac agtgatagta gcagtgacaa tgagcaagac tttgtttcct ccattctacc 600aggaaacaga ccaaattcaa caaatattag accacagctg caccaaaaaa gcataatgaa 660aaagaaagct ggtcacaaag ctaactccaa acacaagcac aaagaacaga cagtagtaga 720tgtcactgag cagttaggcg attgcaaatt agatagtcag gagaaagatg ctacatgtga 780acttccttta cagaaagtaa atactcagag ttcttcaaat agcactttgc ctgaaagatt 840aaaagcgtca gaaaattctg aaagtgaata cagtaggtca gaaataactc tggtaggcat 900aagtaagaaa agtgcagagc attttaagag aaaatttgcc aaatcaaacc aagtgtctag 960gtcagtgtct aattcagtgc aggtgtgtcc tgaagttgga aagagaaact tacttaaagt 1020tttgaaggag actttgattg agtggaagac agaagaaaca ttgaggtttt tgtatggcca 1080gaattatgct tctgtgtgtc tgaaacccga agcctctctg gttaaagaag aacttgatga 1140agatgacata atctcagatc cagatagtcc tttccctgcc tggagggaat ctcagaacag 1200cttggatgag tctttacctt ttaggggctc aggtacagcc attaaaccac tgccaagtta 1260cgagaatttg aaaaaagaaa ctgaaaagtt aaatctgagg atcagggagt tttacagagg 1320acggtatgtt ttgggtgaag aaaccaccaa atcacaagac tcagaagagc atgattccac 1380ctttccactg atagactcaa gttcccagaa ccagattaga aaacgcatcg tacttgaaaa 1440gttgagtaaa gtgttgcctg ggcttctggt tcctcttcag attacattgg gagatattta 1500cacacaactt aaaaatcttg ttcgaacttt caggttaaca aatagaaata ttatacacaa 1560acctgcggaa tggactttaa ttgctatggt gttgctgtca ttactgaccc caattcttgg 1620cattcagaaa cattctcagg aaggtatggt gtttacacgg tttctagaca ccctccttga 1680agaattacat ctaaaaaatg aagaccttga aagtctaacc atcatattta gaaccagctg 1740tttaccagag tgatatattc catgaagaca aaatagaaga tgaacttcta ttcaccgttt 1800ctggaattct agccgccatg atggtctggt ggtgactgat aactagtttt attccaagac 1860atacctttac ctctttaagt ttcaatctcc catctcccag tccttcagtc cccaactgca 1920gaggatgacc tccccagata gaggagaatc attactccaa caagaataac caagtctttg 1980tatccctagt acaagacata gtatttttat tcgaaaatga atgtttaagt attaaattga 2040aacttgaatg aatattcaag aaaatataat gatctctact ttttctggat gatttccagc 2100catcatatca gtttgccaaa aaaattgaga aagttatgat tttgacctcc caacctaaac 2160tctaaattct aaagatcagt aaacaattag gtcaataaat acatacaatt taagatgaag 2220ccctttggaa gtctagtcca aaacaggaaa atctcagaac tttctggact caaggaaatg 2280ctttaaatgg aatctgtagt ttgtttgcag gagagacaat ttctagaatt tagattgctt 2340ttcaaaatgt ttatcaggta ggcaagttag cagttgaggc ggaacacaga caacttgggg 2400agctttactg gaaggccaag aaaatactct tggacactgg aggaaatgac agctactaaa 2460gcccaatcat ggaaaaggac cagaaagcag cccactggaa tggggagctt agtgggcaag 2520gaggtaggga tataatttct cttcttggct ccaccagtaa ttagctctgt ggcccagtca 2580cctaaacttt ctggacttca gttcaggttg tatggcagta ggccatagaa ttggctactg 2640ccatacaatc tctatgggaa aggactgcaa aaactaaatt ttatctctgt atgggcaaag 2700gctactgtca tcctgttgtt ggtctggggc cactctgaca atttttttta acctcatttg 2760attgtgtaag ggtctaacca caacaaaaaa tcatagtgta atagaattaa tcaagttcag 2820caaggtcaca ggctagatca atatacagaa aatcaattgt atttttctgt tcagaaaact 2880ccaaaaatga aataaagaaa attgtgttca caatatcacc aaagagatta aatacttagg 2940aataaattta acaaaataag tgtaagactt gtataacgaa aactataaaa cattcaagag 3000ggctgggcat ggtggctcat gcctttagtt ctagcgcttt ggaggcagag gcaggaggac 3060tgcttgagcc caggagttca agaccagcct gggcaacaaa gtgagaccct gtctccacaa 3120aaaaaaaaaa aaaaaaaaaa aaaaa 314562574PRTHomo sapiens 62Met Ala Asp Phe Ala Gly Pro Ser Ser Ala Gly Arg Lys Ala Gly Ala 1 5 10 15Pro Arg Cys Ser Arg Lys Ala Ala Gly Thr Lys Gln Thr Ser Thr Leu 20 25 30Lys Gln Glu Asp Ala Ser Lys Arg Gly Gly Ser Leu Arg Pro Ala His 35 40 45Tyr Ser Asp Val Val Asp Glu Arg Ser Ile Val Lys Leu Cys Gly Tyr 50 55 60Pro Leu Cys Gln Lys Lys Leu Gly Ile Val Pro Lys Gln Lys Tyr Lys 65 70 75 80Ile Ser Thr Lys Thr Asn Lys Val Tyr Asp Ile Thr Glu Arg Lys Ser 85 90 95Phe Cys Ser Asn Phe Cys Tyr Gln Ala Ser Lys Phe Phe Glu Ala Gln 100 105 110Ile Pro Lys Thr Pro Val Trp Val Arg Glu Glu Glu Arg His Pro Asp 115 120 125Phe Gln Leu Leu Lys Glu Glu Gln Ser Gly His Ser Gly Glu Glu Val 130 135 140Gln Leu Cys Ser Lys Ala Ile Lys Thr Ser Asp Ile Asp Asn Pro Ser145 150 155 160His Phe Glu Lys Gln Tyr Glu Ser Ser Ser Ser Ser Thr His Ser Asp 165 170 175Ser Ser Ser Asp Asn Glu Gln Asp Phe Val Ser Ser Ile Leu Pro Gly 180 185 190Asn Arg Pro Asn Ser Thr Asn Ile Arg Pro Gln Leu His Gln Lys Ser 195 200 205Ile Met Lys Lys Lys Ala Gly His Lys Ala Asn Ser Lys His Lys His 210 215 220Lys Glu Gln Thr Val Val Asp Val Thr Glu Gln Leu Gly Asp Cys Lys225 230 235 240Leu Asp Ser Gln Glu Lys Asp Ala Thr Cys Glu Leu Pro Leu Gln Lys 245 250 255Val Asn Thr Gln Ser Ser Ser Asn Ser Thr Leu Pro Glu Arg Leu Lys 260 265 270Ala Ser Glu Asn Ser Glu Ser Glu Tyr Ser Arg Ser Glu Ile Thr Leu 275 280 285Val Gly Ile Ser Lys Lys Ser Ala Glu His Phe Lys Arg Lys Phe Ala 290 295 300Lys Ser Asn Gln Val Ser Arg Ser Val Ser Asn Ser Val Gln Val Cys305 310 315 320Pro Glu Val Gly Lys Arg Asn Leu Leu Lys Val Leu Lys Glu Thr Leu 325 330 335Ile Glu Trp Lys Thr Glu Glu Thr Leu Arg Phe Leu Tyr Gly Gln Asn 340 345 350Tyr Ala Ser Val Cys Leu Lys Pro Glu Ala Ser Leu Val Lys Glu Glu 355 360 365Leu Asp Glu Asp Asp Ile Ile Ser Asp Pro Asp Ser Pro Phe Pro Ala 370 375 380Trp Arg Glu Ser Gln Asn Ser Leu Asp Glu Ser Leu Pro Phe Arg Gly385 390 395 400Ser Gly Thr Ala Ile Lys Pro Leu Pro Ser Tyr Glu Asn Leu Lys Lys 405 410 415Glu Thr Glu Lys Leu Asn Leu Arg Ile Arg Glu Phe Tyr Arg Gly Arg 420 425 430Tyr Val Leu Gly Glu Glu Thr Thr Lys Ser Gln Asp Ser Glu Glu His 435 440 445Asp Ser Thr Phe Pro Leu Ile Asp Ser Ser Ser Gln Asn Gln Ile Arg 450 455 460Lys Arg Ile Val Leu Glu Lys Leu Ser Lys Val Leu Pro Gly Leu Leu465 470 475 480Val Pro Leu Gln Ile Thr Leu Gly Asp Ile Tyr Thr Gln Leu Lys Asn 485 490 495Leu Val Arg Thr Phe Arg Leu Thr Asn Arg Asn Ile Ile His Lys Pro 500 505 510Ala Glu Trp Thr Leu Ile Ala Met Val Leu Leu Ser Leu Leu Thr Pro 515 520 525Ile Leu Gly Ile Gln Lys His Ser Gln Glu Gly Met Val Phe Thr Arg 530 535 540Phe Leu Asp Thr Leu Leu Glu Glu Leu His Leu Lys Asn Glu Asp Leu545 550 555 560Glu Ser Leu Thr Ile Ile Phe Arg Thr Ser Cys Leu Pro Glu 565 570631812DNAHomo sapiens 63atttacttta aaaagaaatt aatatggctt caccaagaag caaagttcaa cttatttcat 60aattgcctac atttatcatg gtcctgaatg tagcgtgtaa gcttgtgttt cttgggcagt 120ctttcttgaa attgaagagg tgaaatgggg gtggggagtg ggaggaaagg tgacttcctc 180tggtgtttat tataaagctt aaattttata tcattttaaa atgtcttggt cttctactgc 240cttgaaaaat gacaattgtg aacatgatag ttaaactacc acttttttta accattatta 300tgcaaaattt agaagaaaag ttattggcat ggttgttgca tatagttaaa ctgagagtaa 360ttcatctgtg aatctgcttt aattacctgg tgagtaactt agaaaagtgg tgtaaacttg 420tacatggaat tttttgaata tgccttaatt tagaaactga aaaatatctg gttatatcat 480tctgggtgtg ttcttactga caccaggggt ccgctgcccc atgtgtcctg gtgagaaata 540tatgcctggc acagcttttg tatagaaaat tcttgagaag taactgtccg ctagaagtct 600gtccaaattt aaaatgtgtg ccatattctg gttcttgaaa ataagattcc agagctcttt 660gatcgctttt ataactgcag ttcattttaa tgaagggcca gcatatatac ttgcaagata 720attttcagct gcaaggattc agcaccagtt atgtttgaat gaacctcttt tctctgagat 780tctggtcctg gaaatccctt ctgctagtgg tgagcatgta agtgtaagtt ttaatctggg 840agcagggcat aggaagaaaa tgtcagtagt gctaatgcat tttgcactag aacgcttcgg 900gaaaatattc atgcttgcca tctgttcatt tctaaattta tattcataaa gttacagttt 960gatacaggaa ttattaggag taattctttt cttgtttctg tttataatga agaacactgt 1020agctacattt tcagaagtta acatcaagcc atcaaacctg ggtatagtgc agaaaacgtg 1080gcacacactg accacacatt aggctgtgtc accattgtgt ggtgtacctg ctggaagaat 1140tctagcatgc tacttgggga cataatttca gtgggaaata tgccactgac cgattttttt 1200tttttcctct ttgcagtggg gctaggacag ttgattcaac aaagtatttt tttctttttt 1260ctcagtccta atttgaacag gtcaaagatg tgttcaggca ttccaggtaa caggtgtgta 1320tgtaaagtta aaaataggct ttttaggaac tcactcttta gatatttaca tccagcttct 1380catgttaaat atttgtcctt aaagggtttg agatgtacat ctttcatttc gtatttctca 1440taggctatgc catgtgcgga attcaagtta ccaatgtaac actggccagc gggcccagca 1500atctccatgt gtacttatta cagtcttatt taaccagggg tcctaaccac taacattgtg 1560actttgcttt gagacctttc ctctcctggg tactgaggtg ctatgaagcc aactgacaaa 1620gatgcatcac gtgtcttagg ctgatgccac tacccgattt gtttatttgc aatttgagcc 1680atttaaagac caataaactt ccttttttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1800aaaaaaaaaa aa 18126498PRTHomo sapiens 64Met Leu Leu Gly Asp Ile Ile Ser Val Gly Asn Met Pro Leu Thr Asp 1 5 10 15Phe Phe Phe Phe Leu Phe Ala Val Gly Leu Gly Gln Leu Ile Gln Gln 20 25 30Ser Ile Phe Phe Phe Phe Leu Ser Pro Asn Leu Asn Arg Ser Lys Met 35 40 45Cys Ser Gly Ile Pro Gly Asn Arg Cys Val Cys Lys Val Lys Asn Arg 50 55 60Leu Phe Arg Asn Ser Leu Phe Arg Tyr Leu His Pro Ala Ser His Val 65 70 75 80Lys Tyr Leu Ser Leu Lys Gly Leu Arg Cys Thr Ser Phe Ile Ser Tyr 85 90 95Phe Ser651558DNAHomo sapiens 65gtcgacaggg ccgcagctag agtcggcgcc accagggggc cgagcatggt gcggcggcgg 60cggggcgctc cggggaggcc aggacagctg atggttgtgg cagaaacatc tcaaggtagc 120tggtccgccc cccacttccc catctacctc ttgtcctccc ccccaacacc accaccaccc 180tggctcccct ccctcatgac cgcctggatc ctcctgcctg tcagcctgtc agcgttctcc 240atcactggca tatggactgt gtatgccatg gctgtgatga accaccatgt atgccctgtg 300gagaactggt cctacaacga gtcctgccct cctgaccctg ctgagcaagg gggtcccaag 360acctgctgca ccctggacga tgtccccctc atcagcaagt gtggctccta tcccccagaa 420agctgcctct tcagcctcat tggcaacatg ggtgctttca tggtggccct gatctgcctc 480ctgcgctacg ggcagctcct ggagcagagt cggcactctt gggttaacac cacggcactc 540atcacaggct gcaccaacgc tgcgggcctc ttggtggttg gcaactttca ggtggatcat 600gccaggtctc tgcactacgt tggagctggc gtggccttcc ctgcggggct gctctttgtt 660tgcctgcact gtctctctcc taccaagggg ccaccgcccc gctggacctg gctgtggcct 720atctgcgaag tgtgctggct gtcatcgcct ttatcaccct ggtcctcagt ggagtcttct 780ttgtccatga gagttctcag ctgcaacatg gggcagccct gtgtgagtgg gtgtgtgtca 840tccatatcgt cattttctat ggcaccttca gctacgagtt tggggcagtc tcctcagaca 900cactggtggc tgcactgcag cctacccctg gccgggcctg caagtcctcc gggagcagca 960gcactccacc cacctcaact gtgcccccga gagcatcgct atgatctaag gtctggggag 1020ggtggctggc ccggctccac agcaccccac cccatatctt ctttccattt atttcgtacc 1080aaaaacaatt ttgagaaagt attctgttgg gatctgggct tcctcacttc tggagaagtg 1140gccatcccat gcccacctgt gccatggagg agtgggccct gccagctgcc acagctgcat 1200gacctgcttc ccaccccacg gtgtcgtttt gtttttaaag gtcacctgtc ctcactcacc 1260cagccagccc ttcaggtgcc ttctactccc agtgccaaag ccagaccact ggggtttcct 1320gctgcaggaa ttgggggctg ggaacagcag aggggataga agtctggtgg aggtggagtg 1380ggcacgcctt agcctacgga aaggcccatt tctgggccca ctgagctgca ctgggattct 1440tcagtctgcc cctcacttcc tttagggcaa ataacacagc agaaccacgt gggtatttta 1500gtactttttt ttatattaaa agaattctaa tttgaaatcc cgattgaatt ctagacct 155866437PRTHomo sapiens 66Met Val Arg Arg Arg Arg Gly Ala Pro Gly Arg Pro Gly Gln Leu Met 1 5 10 15Val Val Ala Glu Thr Ser Gln Gly Ser Trp Ser Ala Pro His Phe Pro 20 25 30Ile Tyr Leu Leu Ser Ser Pro Pro Thr Pro Pro Pro Pro Trp Leu Pro 35 40 45Ser Leu Met Thr Ala Trp Ile Leu Leu Pro Val Ser Leu Ser Ala Phe 50 55 60Ser Ile Thr Gly Ile Trp Thr Val Tyr Ala Met Ala Val Met Asn His 65 70 75 80His Val Cys Pro Val Glu Asn Trp Ser Tyr Asn Glu Ser Cys Pro Pro 85 90 95Asp Pro Ala Glu Gln Gly Gly Pro Lys Thr Cys Cys Thr Leu Asp Asp 100 105 110Val Pro Leu Ile Ser Lys Cys Gly Ser Tyr Pro Pro Glu Ser Cys Leu 115 120 125Phe Ser Leu Ile Gly Asn Met Gly Ala Phe Met Val Ala Leu Ile Cys 130 135 140Leu Leu Arg Tyr Gly Gln Leu Leu Glu Gln Ser Arg His Ser Trp Val145 150 155 160Asn Thr Thr Ala Leu Ile Thr Gly Cys Thr Asn Ala Ala Gly Leu Leu 165 170 175Val Val Gly Asn Phe Gln Val Asp His Ala Arg Ser Leu His Tyr Val 180 185 190Gly Ala Gly Val Ala Phe Pro Ala Gly Leu Leu Phe Val Cys Leu His 195 200 205Cys Leu Ser Pro Thr Lys Gly Pro Pro Pro Arg Trp Thr Trp Leu Trp 210 215 220Pro Ile Cys Glu Val Cys Trp Leu Ser Ser Pro Leu Ser Pro Trp Ser225 230 235 240Ser Val Glu Ser Ser Leu Ser Met Arg Val Leu Ser Cys Asn Met Gly 245 250 255Gln Pro Cys Val Ser Gly Cys Val Ser Ser Ile Ser Ser Phe Ser Met 260 265 270Ala Pro Ser Ala Thr Ser Leu Gly Gln Ser Pro Gln Thr His Trp Trp 275 280 285Leu His Cys Ser Leu Pro Leu Ala Gly Pro Ala Ser Pro Pro Gly Ala 290 295 300Ala Ala Leu His Pro Pro Gln Leu Cys Pro Arg Glu His Arg Tyr Asp305 310 315 320Leu Arg Ser Gly Glu Gly Gly Trp Pro Gly Ser Thr Ala Pro His Pro 325 330 335Ile Ser Ser Phe His Leu Phe Arg Thr Lys Asn Asn Phe Glu Lys Val 340 345 350Phe Cys Trp Asp Leu Gly Phe Leu Thr Ser Gly Glu Val Ala Ile Pro 355 360 365Cys Pro Pro Val Pro Trp Arg Ser Gly Pro Cys Gln Leu Pro Gln Leu 370

375 380His Asp Leu Leu Pro Thr Pro Arg Cys Arg Phe Val Phe Lys Gly His385 390 395 400Leu Ser Ser Leu Thr Gln Pro Ala Leu Gln Val Pro Ser Thr Pro Ser 405 410 415Ala Lys Ala Arg Pro Leu Gly Phe Pro Ala Ala Gly Ile Gly Gly Trp 420 425 430Glu Gln Gln Arg Gly 435672336DNAHomo sapiensunsure(418) 67atttattgag tgtctactgt gtgccaggca ctatatctat gtgcatagaa aaacctggaa 60gggcctacca caatacatat agagtgatcg tctctgcttg ctgagctaac aggggtgtca 120agcttccatt ttggtatcta cttctaaata cactcagaac aggagaaatt tggactaatt 180ttcaaactac agacactttc taatcatgat gcatttcaaa agtggactcg aattaactga 240gttgcaaaac atgacagtgc ccgaggatga taacatcagc aatgactcca atgatttcac 300cgaagtagaa aatggtcaga taaatagcaa gtttatttct gatcgtgaaa gtagaagaag 360tctcacaaac agccatttgg aaaaaaagaa gtgtgatgag tatattccag gtacaacntc 420cttaggcatg tttgttttta acctaagcaa ctccatgatg ggcagtggga tttgggactc 480gctttgccct ggcaacactg gaatcctact ttttctggta cttttgactt cagtgacatt 540gctgtctata tattcaataa acctcctatt gatctgttca aaagaaacag gctgcatggt 600gtatgaaaag ctgggggaac aagtctttgg caccacaggg aagttcgtaa tctttggagc 660cacctctcta cagaacactg gagcaatgct gagctacctc ttcatcgtaa aaaatgaact 720accctctgcc ataaagtttc taatgggaaa ggaagagaca ttttcagcct ggtacgtgga 780tggccgcgtt ctggtggtga tagttacctt tggcataatt ctccctctgt gtctcttgaa 840gaacttaggg tatcttggct atactagtgg attttccttg agctgtatgg tttttttcct 900aattgtggtt atttacaaga aatttcaaat tccctgcatt gttccagagc taaattcaac 960aataagtgct aattcaacaa atgctgacac gtgtacgcca aaatatgtta ccttcaattc 1020aaagaccgtg tatgctttac ccaccattgc atgtgcattt gtttgccacc cgtcagtcct 1080gccaatttac agtgagctta aagaccgatc acagaaaaaa atgcagatgg tttcaaacat 1140ctcctttttc gccatgtttg ttatgtactt cttgactgcc atttttggct acttgacatt 1200ctatgacaac gtgcagtccg acctccttca caaatatcag agtaaagatg acattctcat 1260cctgacagtg cggctggctg tcattgttgc tgtgatcctc acagtgccgg tgttattttt 1320cacggttcgt tcatctttat ttgaactggc taagaaaaca aagtttaatt tatgtcgtca 1380taccgtggtt acctgcatac tcttggttgt tatcaacttg ttggtgatct tcataccctc 1440catgaaggat atttttggag tcgtaggagt tacatctgct aacatgctta ttttcattct 1500tccttcatct ctttatttaa aaatcacaga ccaggatgga gataaaggaa ctcaaagaat 1560ttgggtatgt ctcttgccag ccactctaac ttttctgatt agttttccat ttaaatttac 1620aaaataaata gtccacctct ctatcaagac tactttcagt tgccttgaaa ggaggcagaa 1680gccctgtagc tttgctactt gggagatatt taaaatatca tatcagaatc ttctcccatc 1740cctccaaata tcttttctgg ttttactctt tttttttgag atggagtctc actctgtcgc 1800ccaggctgga gtgcagtggc cagatctcag ctcactgtaa gctccacctc ccgggttcat 1860gccattcttc tgcctcagag agtagctggg actacaggcg cccgccacca tgcctggcta 1920attttttttc ttttttcttt tttctttttt gtatttttag tagagacggg gtttcaccat 1980gttagccagg atggtctgta tctcctgacc tcatgatccg tctgcctcgg cctcccacag 2040tgctgggatt acaggcatga gccatcgcgc ccggccctct ggttttactg ttattgtgcc 2100tcagcttttg ttctgatcca gggcatggcc agtcagaaga atggacattc atcctcctgt 2160gtctgtatag gacagtgtct agtcttcagc aagagaggaa gtgacgaggg actcacagat 2220gttatgcagt ccactgtttc catatgattt ctagtcatgt aactcctccc tacagcccag 2280ggaacatgca atgccttaat taaaatgtct gagttagctt aaaaaaaaaa aaaaaa 233668473PRTHomo sapiens 68Met Met His Phe Lys Ser Gly Leu Glu Leu Thr Glu Leu Gln Asn Met 1 5 10 15Thr Val Pro Glu Asp Asp Asn Ile Ser Asn Asp Ser Asn Asp Phe Thr 20 25 30Glu Val Glu Asn Gly Gln Ile Asn Ser Lys Phe Ile Ser Asp Arg Glu 35 40 45Ser Arg Arg Ser Leu Thr Asn Ser His Leu Glu Lys Lys Lys Cys Asp 50 55 60Glu Tyr Ile Pro Gly Thr Thr Ser Leu Gly Met Phe Val Phe Asn Leu 65 70 75 80Ser Asn Ser Met Met Gly Ser Gly Ile Trp Asp Ser Leu Cys Pro Gly 85 90 95Asn Thr Gly Ile Leu Leu Phe Leu Val Leu Leu Thr Ser Val Thr Leu 100 105 110Leu Ser Ile Tyr Ser Ile Asn Leu Leu Leu Ile Cys Ser Lys Glu Thr 115 120 125Gly Cys Met Val Tyr Glu Lys Leu Gly Glu Gln Val Phe Gly Thr Thr 130 135 140Gly Lys Phe Val Ile Phe Gly Ala Thr Ser Leu Gln Asn Thr Gly Ala145 150 155 160Met Leu Ser Tyr Leu Phe Ile Val Lys Asn Glu Leu Pro Ser Ala Ile 165 170 175Lys Phe Leu Met Gly Lys Glu Glu Thr Phe Ser Ala Trp Tyr Val Asp 180 185 190Gly Arg Val Leu Val Val Ile Val Thr Phe Gly Ile Ile Leu Pro Leu 195 200 205Cys Leu Leu Lys Asn Leu Gly Tyr Leu Gly Tyr Thr Ser Gly Phe Ser 210 215 220Leu Ser Cys Met Val Phe Phe Leu Ile Val Val Ile Tyr Lys Lys Phe225 230 235 240Gln Ile Pro Cys Ile Val Pro Glu Leu Asn Ser Thr Ile Ser Ala Asn 245 250 255Ser Thr Asn Ala Asp Thr Cys Thr Pro Lys Tyr Val Thr Phe Asn Ser 260 265 270Lys Thr Val Tyr Ala Leu Pro Thr Ile Ala Cys Ala Phe Val Cys His 275 280 285Pro Ser Val Leu Pro Ile Tyr Ser Glu Leu Lys Asp Arg Ser Gln Lys 290 295 300Lys Met Gln Met Val Ser Asn Ile Ser Phe Phe Ala Met Phe Val Met305 310 315 320Tyr Phe Leu Thr Ala Ile Phe Gly Tyr Leu Thr Phe Tyr Asp Asn Val 325 330 335Gln Ser Asp Leu Leu His Lys Tyr Gln Ser Lys Asp Asp Ile Leu Ile 340 345 350Leu Thr Val Arg Leu Ala Val Ile Val Ala Val Ile Leu Thr Val Pro 355 360 365Val Leu Phe Phe Thr Val Arg Ser Ser Leu Phe Glu Leu Ala Lys Lys 370 375 380Thr Lys Phe Asn Leu Cys Arg His Thr Val Val Thr Cys Ile Leu Leu385 390 395 400Val Val Ile Asn Leu Leu Val Ile Phe Ile Pro Ser Met Lys Asp Ile 405 410 415Phe Gly Val Val Gly Val Thr Ser Ala Asn Met Leu Ile Phe Ile Leu 420 425 430Pro Ser Ser Leu Tyr Leu Lys Ile Thr Asp Gln Asp Gly Asp Lys Gly 435 440 445Thr Gln Arg Ile Trp Val Cys Leu Leu Pro Ala Thr Leu Thr Phe Leu 450 455 460Ile Ser Phe Pro Phe Lys Phe Thr Lys465 470691999DNAHomo sapiens 69tttttttttt tttttttttt ttttttaaag acagggtctc actctgtcac tcaggctgga 60atgtagtggc atgattatgg ctcactgcag cctctacttc ctgggcccag gcaatcctct 120cacctcagct cctgagtagc tgggactaca ggcgcacacc acctcacttg gctaattaaa 180aaaaattttt ttttgtagaa atgggggtct tccaatgttg cccatgctgg tcttgaactc 240ctggcctcaa gtgatcctcc caccttggcc tcctaaattg ctgagattac agatgtgagc 300caccacgccc aacctaactt caagaactct tgaccatctc tgtttctttc ctgattttag 360gcccacaatg ttcactgtct tagttttagg atgagactct aaatcttttt ttttttgaga 420tggagtctcg ctctgttgcc caggctggag tgcagtggca cgatctcggc tcaccacaac 480ctctgcctcc aggattcaag cgattgtcct gcctcagcta ctcctcggga ggctgaggca 540ggagaatggc gtgaactccg gaggtggagc ctgtagtgag ccgagatggc accactgcgc 600tccagcctgg gcgacagagc aagactccat atcaaaaaaa aaaaaaaaaa aaaagataat 660ccaaagaatt taaattgtaa tcatgtttca tgtatttgtt ttattactta cttttatagc 720acttagtccc agtggtatta gactgctatt tggtttcata caaaaaggat taaatttaaa 780ttcattcatg tttagacttg agttattaca tttttaaaac tatcatcttg cctttaatgt 840ttgtggtcct acacaaacta ttagtacatt tcagtatcct cttacccctt tgtttttaag 900tttttgattg ctaaagcaag acttttttct tctagaattt aagtcaacca agtgttatct 960atgttgtaaa aatggataat agtagatttt aggtgataaa acaacttgtt agtaagacat 1020ttcctagctt aaaaaaaaaa atcaaaaatt ccatgataga aatgcagacc tgtgagggaa 1080actcctgaaa agcataagaa gcatcccaga gagccatggg ttttctagac cagagaattt 1140agagggagat tgtggaactg aggcttaggt ggtcagatcg tttcccttat cactgtaata 1200tttctggggg aaaaatgctt tctgagttgt ttaaacaagc atccttacat tttttttttt 1260aattaaacag cctgtctagg cttgggattc cctaatacta cagtagcagt atatgaatat 1320gattttgtga ttgtgttttt taaaagataa gtaatttgat gaactgttct tttgcagtca 1380gaaaaacact cacaaaaaga caaaaaaagt tccacagtat tatatttcat gtcagttcag 1440gcctaaaatc ctttgcaaat aagatgttta taggctggtc acaattaaca atgtattatt 1500ggcagcactt cttggatgga taccttttgg gacctttcat tagaaagagg gaaagaatgg 1560ggtggttttg tatgggctcc tgtttggggg taaaaatagc agagtcagtt gctgaggaca 1620atgaccttcc ttataacatt agtttcatac ccatattagg tcttgtcttg aggacccttt 1680atatgtgctt gtttactagt ggccttccag ccatagcatt cttacctttt tttcctattc 1740taagaattaa aaaaaaaaat tatagagcca gcaagggagg aggcaggaaa cagaaatcga 1800atttcatcat tccagtatag ttgtcccttt ttttgtattt ctgacttggt tttataatta 1860tatttactta ctaattattg ttttttaaca ttctttattg tggcttactc ttcatactta 1920gaattgaaat tgttggacat cacatgtata ttcacattat aaatacatca ttcttccact 1980gttaaaaaaa aaaaaaaaa 199970153PRTHomo sapiens 70Met Asn Cys Ser Phe Ala Val Arg Lys Thr Leu Thr Lys Arg Gln Lys 1 5 10 15Lys Phe His Ser Ile Ile Phe His Val Ser Ser Gly Leu Lys Ser Phe 20 25 30Ala Asn Lys Met Phe Ile Gly Trp Ser Gln Leu Thr Met Tyr Tyr Trp 35 40 45Gln His Phe Leu Asp Gly Tyr Leu Leu Gly Pro Phe Ile Arg Lys Arg 50 55 60Glu Arg Met Gly Trp Phe Cys Met Gly Ser Cys Leu Gly Val Lys Ile 65 70 75 80Ala Glu Ser Val Ala Glu Asp Asn Asp Leu Pro Tyr Asn Ile Ser Phe 85 90 95Ile Pro Ile Leu Gly Leu Val Leu Arg Thr Leu Tyr Met Cys Leu Phe 100 105 110Thr Ser Gly Leu Pro Ala Ile Ala Phe Leu Pro Phe Phe Pro Ile Leu 115 120 125Arg Ile Lys Lys Lys Asn Tyr Arg Ala Ser Lys Gly Gly Gly Arg Lys 130 135 140Gln Lys Ser Asn Phe Ile Ile Pro Val145 150712020DNAHomo sapiens 71ggaggggtgt gtgtgtgtgt atttggtttg ctgtcctttt ttaaaggatt ccaagccatg 60tgaaacttcc cttctggatg tgattctggg tcgcaagtcc ttatttatat gtgaggctgg 120ggaatgggct gggggtattg gcagtccttt tgcagggcag tgtgtgtggt ggggtgacac 180cgctgtggct tagcccaaga cactcccaga ggaaaacact gcagaaggaa ctggtttgca 240gactgtggaa ggatctgcag ttttgttttt gaccaaaaaa ataataataa gttagctctg 300aagggcagag ggaataccca agcccctgat gcctatgaga agtccctgga cttcaaccct 360cctgttgttt ggccttagcc cagagggagc tgctcacctg agcacccttg ggggtgggca 420gagaggcagg gtgggatttt agagttagtg tctgtgcggg ggcagccctg agcctggagt 480tgagactttg gggtctctta gtttggaggt gttgagtgca tttgtgcccc tgcctggttg 540agagcttctt ggtacctctt gccacccctt ctcactgccc tgacccaacc ccactggacc 600ttgatgctgc gaggagtggt gtcctgacgg actcagcact cccgcctgat gtattggatc 660ataggagagc acttgctctc ctgcctctgc caggagaggg cttgttcctc caactctagg 720aggccaggca agcatggaca ggagccaagg gagcagggtc attaactttt tcttctttgc 780aaagtgggca cttggcatca gggtcccaat caccagaaag caccaaagcc cctggcaccc 840cacccactcc atcctaccca gggaccccaa gtaggcaact gttatggcag tgggtccagc 900ccaggccagc actggcagcc tcctctccct gcagtatgca ccagctctac ctcccccggc 960aggcaatgtc ctggcttctc agcccagcac catctgttcc cctatacttc tcaggggcca 1020gcccagtctg ggccaccctt tgtttccctc atcctcggct cccacacagg tgacagaccc 1080agcagatagc ttctctctgg gaaaggttgg atgctgcctt acatcccctt ctagccctcc 1140tcccatccac acacacaggc acccacccac accaggtcgg cttgtttctc acatgtaggg 1200agagagggga gaccaacccc tttgtgtctt ttgaaatacg aagaaaaatg tgtgttcagg 1260agcatgactc cagtgctgcg ctcttgggcc cagttcagtc tgtcttgtct caaatctagg 1320catttttgct tcaattttat tttttttaag aatacaaaaa cagaaatctg cactaattta 1380cctggtttcg taggaaaact tttttttatt ttttacattt tttggtgtcc gtttgtattg 1440aataatttgc tacatttgta aaatgtaaga ggtatataat atatgtatat ttctaacgta 1500aaaaacataa tttttttctt ttcaagattt ttttcttaaa aagatgagag aaacatattt 1560tttcaggaaa aacaaacttt aaaaaaaaaa gaggagaaat aaaacctttt ctcccctttc 1620cccatcctct atctatccct ctttcccagg aacaaatcaa aaggtggatt atcttctgaa 1680gaatggaaac tgttagtcca gaatgatgtg tttttctcaa tgcagtgagt gatagattct 1740ctagttttct ccctagggat gggaaggggg cattgaggca agcctggaga ggagcctggg 1800gagcagggtc atgaactttt ttctttagtg aaggaggaat acaatcaagg gttttgtatt 1860cagaatgttg tgcaatattt tggaatggga cattggtgtg tttagagatt ttagtttaaa 1920aacaaaacaa aaagattgat caaatctgta cagtttctat tgttccagat ttttttaagt 1980ttgtattaaa agcacgatac ataataaaaa aaaaaaaaaa 202072104PRTHomo sapiens 72Met Ala Val Gly Pro Ala Gln Ala Ser Thr Gly Ser Leu Leu Ser Leu 1 5 10 15Gln Tyr Ala Pro Ala Leu Pro Pro Pro Ala Gly Asn Val Leu Ala Ser 20 25 30Gln Pro Ser Thr Ile Cys Ser Pro Ile Leu Leu Arg Gly Gln Pro Ser 35 40 45Leu Gly His Pro Leu Phe Pro Ser Ser Ser Ala Pro Thr Gln Val Thr 50 55 60Asp Pro Ala Asp Ser Phe Ser Leu Gly Lys Val Gly Cys Cys Leu Thr 65 70 75 80Ser Pro Ser Ser Pro Pro Pro Ile His Thr His Arg His Pro Pro Thr 85 90 95Pro Gly Arg Leu Val Ser His Met 10073760DNAHomo sapiens 73cttaagtctt ggcgcgctcg cctcgcagcc tgcaacccgc gctcagctgc ccgcctcctc 60agccagccat gctggagcat ctgagctcgc tgcccacgca gatggattac aagggccaga 120agctagctga acagatgttt cagggaatta ttcttttttc tgcaatagtt ggatttatct 180acgggtacgt ggctgaacag ttcgggtgga ctgtctatat agttatggcc ggatttgctt 240tttcatgttt gctgacactt cctccatggc ccatctatcg ccggcatcct ctcaagtggt 300tacctgttca agaatcaagc acagacgaca agaaaccagg ggaaagaaaa attaagaggc 360atgctaaaaa taattgaggt tttcatgatt cagcacctgc ttttgtttct gtgagatgag 420ctaaattgct ttcatacccc agataagagc taaaaccacc taatgctctt atggcacagc 480tgtgtataga tttagttctc tttatacttc atttctagcc cagttgggtt ttgatttata 540taagtagttt agaccttctc ttcataatct tgctctgaga tggggaacag aacacacaag 600tatgaagttt ctttcaggtg taaataatga aaaataaatg cctcataaat gatagtacaa 660tgtaactatc aaagttttat aattcattat gagttaacca ttttaatgtt tccaattaac 720cctcatagtg caaaaaaaaa aaaaaaaaaa aaaaaaaaaa 76074102PRTHomo sapiens 74Met Leu Glu His Leu Ser Ser Leu Pro Thr Gln Met Asp Tyr Lys Gly 1 5 10 15Gln Lys Leu Ala Glu Gln Met Phe Gln Gly Ile Ile Leu Phe Ser Ala 20 25 30Ile Val Gly Phe Ile Tyr Gly Tyr Val Ala Glu Gln Phe Gly Trp Thr 35 40 45Val Tyr Ile Val Met Ala Gly Phe Ala Phe Ser Cys Leu Leu Thr Leu 50 55 60Pro Pro Trp Pro Ile Tyr Arg Arg His Pro Leu Lys Trp Leu Pro Val 65 70 75 80Gln Glu Ser Ser Thr Asp Asp Lys Lys Pro Gly Glu Arg Lys Ile Lys 85 90 95Arg His Ala Lys Asn Asn 10075875DNAHomo sapiens 75ctagctcatg ctgctcttgt cagcctctgg ttctcctcga gtccttgggg acgtggcaga 60tgccagcgac catcagacaa cgtggaggcc ctcatgggca atggctgagg gggccgggct 120gaggctgtgc acatgcagtc tgcacgccac tcttgggctc tgctggcgga gatccccttc 180cttctgggtg cagactgcac ctccggatgc agttttgatg tccatcttcc aggagagaga 240cggtctcggg tccagggagt ggagggggct gcccctgccg tgcaggtcct ggccgatggc 300gccttaccct gctgccctgg gcttttggcc tgaagcaaat tcctgagtgg ggggtactgg 360ggcctgccgc atcctgtcct gtccactgcc cacccccgtg tgctggctcc ctcacttctg 420gctgcagtgg gagccgccag tctgaccctt gtcaccgcac gctctgcccc caccccgttg 480caagaggtca caccatgtca gcagccttgc actgaccgca gccggccccc aggcctcaga 540gttctggatg cttccgtgcg gctccaacag gcatcgtctt cccttccgca ggtggagggg 600ccgcttcccg caggcatctg agctctgtgc cggggccgtg gccatgggaa gatgttccac 660gctgcctcct cctcgagttt tcctcggaaa cactcttgaa tgtctgagtg agggtcctgc 720ttagctcttt ggcctgtgag atgctttgaa aatttttatt tttttaagat gaagcaagat 780gtctgtagcg gtaattgcct cacattaaac tgtcgccgac tgcaggcgca gtgactgctg 840aatgtaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 87576112PRTHomo sapiens 76Met Leu Leu Leu Ser Ala Ser Gly Ser Pro Arg Val Leu Gly Asp Val 1 5 10 15Ala Asp Ala Ser Asp His Gln Thr Thr Trp Arg Pro Ser Trp Ala Met 20 25 30Ala Glu Gly Ala Gly Leu Arg Leu Cys Thr Cys Ser Leu His Ala Thr 35 40 45Leu Gly Leu Cys Trp Arg Arg Ser Pro Ser Phe Trp Val Gln Thr Ala 50 55 60Pro Pro Asp Ala Val Leu Met Ser Ile Phe Gln Glu Arg Asp Gly Leu 65 70 75 80Gly Ser Arg Glu Trp Arg Gly Leu Pro Leu Pro Cys Arg Ser Trp Pro 85 90 95Met Ala Pro Tyr Pro Ala Ala Leu Gly Phe Trp Pro Glu Ala Asn Ser 100 105 110772848DNAHomo sapiensunsure(2526) 77ctttgttctg tccttggtgt gtggtgcatt cgtgaaattc tgcagcacat cggcgaaaga 60aaacgttgtg tgacgtgatc ctcatggtcc aggaaagaaa gatacctgct catcgtgttg 120ttcttgctgc agccagtcat ttttttaact taatgttcac aactaacatg cttgaatcaa 180agtcctttga agtagaactc aaagatgctg aacctgatat tattgaacaa ctggtggaat 240ttgcttatac tgctagaatt tccgtgaata gcaacaatgt tcagtctttg ctggatgcag 300caaaccaata tcagattgaa cctgtgaaga aaatgtgtgt tgattttttg aaagaacaag 360ttgatgcttc aaattgtctt ggtataagtg tgctagcgga gtgtctagat tgtcctgaat 420tgaaagcaac tgcagatgac tttattcatc agcactttac tgaagtttac aaaactgatg 480aatttcttca acttgatgtc aagcgagtaa cacatcttct caaccaggac actctgactg 540tgagagcaga ggatcaggtt tatgatgctg cagtcaggtg gttgaaatac gatgaaccta 600atcgccagcc atttatggtt gatatccttg ctaaagtcag gtttcctctt atatcaaaga 660atttcttaag taaaacggta caagctgaac

cacttattca agacaatcct gaatgcctta 720agatggtgat aagtggaatg aggtaccatc tactgtctcc agaggaccga gaagaacttg 780tagatggccc aagacctaga agaaagaaac atgactaccg catagcccta tttggaggct 840ctcaaccaca gtcttgtaga tattttaacc ccaaggatta tagctggaca gacatccgct 900gcccctttga aaaaccaaga gatgcagcat gcgtgttttg ggacaatgta gtatacattt 960tgggaggctc tcagcttttc ccaataaagc gaatggactg ctataatgta gtgaaggata 1020gctggtattc gaaactgggt cctccgacac ctcgagacag ccttgctgca tgtgctgcag 1080aaggcaaaat ttatacatct ggaggttcag aagtaggaaa ctcagctctg tatttatttg 1140agtgctatga tacgagaact gaaagctggc acacaaagcc cagcatgctg acccagcgct 1200gcagccatgg gatggtggaa gccaatggcc taatctatgt ttgtggtgga agtttaggaa 1260acaatgtttc tgggagagtg cttaattcct gtgaagttta tgatcctgcc acagaaacat 1320ggactgagct gtgtccaatg attgaagcca ggaagaatca tgggctggta tttgtaaaag 1380acaagatatt tgctgtgggt ggtcagaatg gtttaggtgg tctggacaat gtggaatatt 1440acgatattaa gttgaacgaa tggaagatgg tctcaccaat gccatggaag ggtgtaacag 1500tgaaatgtgc agcagttggc tctatagttt atgtcttggc tggttttcaa ggtgttggtc 1560gattaggaca cattctccaa tataataccg aaacagacaa atgggttgcc aactcccaag 1620ttcgtgcttt tccagtcaca aagttgttta atttgtgttg tcgatacttg tggagcaaat 1680gaagagaccc ttgaaacatg aaaaatgagt ggacttcaga ctcatcagag actctaaaat 1740atagccacca gtgctttgtt ccaggagttt ggtgacaaag ttttggtttg gtgttttggt 1800aaagaaagtt tcaagtgaaa tgaggttcct ataaaataga tgtttctttt atatggattt 1860ccttaattca aagatcatat tttagctggc cacaaaacca agaacatatc tagcaagaaa 1920acttgaaaaa gtataagcat ttgttaaaaa tgtgaatttc ttgaatgaat ttcacatttg 1980taactatgat tttggcagaa tagaagattg gctcatcagt gaagcgcagt atcttagctc 2040tagattctat tttcatgcat cacagaagtg ctatacggtt aggtctgttt gtgctcagtc 2100aagaactaag aaatagtatg aattgtaagt caagatgggc aactcagatg gagcagctta 2160gtctcacagt ttgcttgtct atttatttta tttagtgcca aatgtattcc attttaaaag 2220taagccagag tgagtcaagg catatacaca ctttctcaca aaacttccta aacagatttg 2280ggggtttaat atgtccaact cctcatgaaa tatattcaat ccacttaaat atattccatc 2340tttttaacat aaaatgtaaa gcttagcacc catcattaat ttatgtctct gttttatcca 2400gtggttaaaa aaggattctg cctctttagt cctccctgtt aaataaaacc caatcatagt 2460aggtgattac ctagcaaaaa gtaaagctat ttatagcaaa tttttagatc attagaaaag 2520cggggnggtt gaacaataac agtgttgact ttgaacttct ttaacgagat catgaattct 2580tttcccttag ccaaaacatg aaatatttaa cctagttgtc tctaaaagtt ttgtaatcat 2640gagttagata tatgtcatct cctattcatt gcttttatgt gatcaataaa tcttttacaa 2700acccaactac tcatttcctt cctagtaata ctttgccttt ttcactgtgt atggaatgaa 2760acatgtaaag ctgtcacaat caatgttttt atctgataat attaaatatt ttttaacttc 2820aaaaaaaaaa aaaaaaaaaa aaaaaaaa 284878532PRTHomo sapiens 78Met Val Gln Glu Arg Lys Ile Pro Ala His Arg Val Val Leu Ala Ala 1 5 10 15Ala Ser His Phe Phe Asn Leu Met Phe Thr Thr Asn Met Leu Glu Ser 20 25 30Lys Ser Phe Glu Val Glu Leu Lys Asp Ala Glu Pro Asp Ile Ile Glu 35 40 45Gln Leu Val Glu Phe Ala Tyr Thr Ala Arg Ile Ser Val Asn Ser Asn 50 55 60Asn Val Gln Ser Leu Leu Asp Ala Ala Asn Gln Tyr Gln Ile Glu Pro 65 70 75 80Val Lys Lys Met Cys Val Asp Phe Leu Lys Glu Gln Val Asp Ala Ser 85 90 95Asn Cys Leu Gly Ile Ser Val Leu Ala Glu Cys Leu Asp Cys Pro Glu 100 105 110Leu Lys Ala Thr Ala Asp Asp Phe Ile His Gln His Phe Thr Glu Val 115 120 125Tyr Lys Thr Asp Glu Phe Leu Gln Leu Asp Val Lys Arg Val Thr His 130 135 140Leu Leu Asn Gln Asp Thr Leu Thr Val Arg Ala Glu Asp Gln Val Tyr145 150 155 160Asp Ala Ala Val Arg Trp Leu Lys Tyr Asp Glu Pro Asn Arg Gln Pro 165 170 175Phe Met Val Asp Ile Leu Ala Lys Val Arg Phe Pro Leu Ile Ser Lys 180 185 190Asn Phe Leu Ser Lys Thr Val Gln Ala Glu Pro Leu Ile Gln Asp Asn 195 200 205Pro Glu Cys Leu Lys Met Val Ile Ser Gly Met Arg Tyr His Leu Leu 210 215 220Ser Pro Glu Asp Arg Glu Glu Leu Val Asp Gly Pro Arg Pro Arg Arg225 230 235 240Lys Lys His Asp Tyr Arg Ile Ala Leu Phe Gly Gly Ser Gln Pro Gln 245 250 255Ser Cys Arg Tyr Phe Asn Pro Lys Asp Tyr Ser Trp Thr Asp Ile Arg 260 265 270Cys Pro Phe Glu Lys Pro Arg Asp Ala Ala Cys Val Phe Trp Asp Asn 275 280 285Val Val Tyr Ile Leu Gly Gly Ser Gln Leu Phe Pro Ile Lys Arg Met 290 295 300Asp Cys Tyr Asn Val Val Lys Asp Ser Trp Tyr Ser Lys Leu Gly Pro305 310 315 320Pro Thr Pro Arg Asp Ser Leu Ala Ala Cys Ala Ala Glu Gly Lys Ile 325 330 335Tyr Thr Ser Gly Gly Ser Glu Val Gly Asn Ser Ala Leu Tyr Leu Phe 340 345 350Glu Cys Tyr Asp Thr Arg Thr Glu Ser Trp His Thr Lys Pro Ser Met 355 360 365Leu Thr Gln Arg Cys Ser His Gly Met Val Glu Ala Asn Gly Leu Ile 370 375 380Tyr Val Cys Gly Gly Ser Leu Gly Asn Asn Val Ser Gly Arg Val Leu385 390 395 400Asn Ser Cys Glu Val Tyr Asp Pro Ala Thr Glu Thr Trp Thr Glu Leu 405 410 415Cys Pro Met Ile Glu Ala Arg Lys Asn His Gly Leu Val Phe Val Lys 420 425 430Asp Lys Ile Phe Ala Val Gly Gly Gln Asn Gly Leu Gly Gly Leu Asp 435 440 445Asn Val Glu Tyr Tyr Asp Ile Lys Leu Asn Glu Trp Lys Met Val Ser 450 455 460Pro Met Pro Trp Lys Gly Val Thr Val Lys Cys Ala Ala Val Gly Ser465 470 475 480Ile Val Tyr Val Leu Ala Gly Phe Gln Gly Val Gly Arg Leu Gly His 485 490 495Ile Leu Gln Tyr Asn Thr Glu Thr Asp Lys Trp Val Ala Asn Ser Gln 500 505 510Val Arg Ala Phe Pro Val Thr Lys Leu Phe Asn Leu Cys Cys Arg Tyr 515 520 525Leu Trp Ser Lys 530792232DNAHomo sapiensunsure(2168) 79gttcttcatg cccttctaga gaacgttcta cagctcttct tcacctgcat cctccttgga 60agtctccagc catgtcgaga tattatttag agttgtttca gtgtccaact tgtatgaaag 120gagcatggtc tttagtagaa gtccttatca ggtcttgcct tttcaatgaa agcttttgtc 180atcaaatttc agaaaatatt ggctccaagg tgctccacct gacgctactc aaatttttct 240ttaatttaat tgaaagtgaa gtacaacatc tgagtcaaaa gttgtatgac tggtcagatt 300ctcagaatct gaaaataaca ggaaaggcaa tgcttcttga aattttttgg tcaggaagtg 360aaacctctgg gcttttgacc aaaccagtaa atatgctttt ggaatggact atatattctc 420acaaggaaaa attcaagtct aatgatactt ttcttccaca ggaattagag attttcattt 480gctccttttc ctcctcctgg cttcaaatgt ttgttgcaga ggcagtcttt aaaaagttgt 540gtctacagag ctctggcagt gtttcttctg agccactctc tcttcagaaa atggtatatt 600cctatttacc agccttgggg aaaactggtg tgcttgggtc tggaaagatt caggtgtcaa 660agaaaatagg acagcggcct tgttttgact ctcagagaac cttactaatg ctgaatggta 720ctaaacaaaa acaagtcgaa gggctgccag agttactaga cctgaacctt gctaaatgtt 780cctcatcatt aaaaaaattg aaaaagaagt cagaaggaga attgtcatgt tccaaggaga 840attgcccctc tgtagttaaa aagatgaatt ttcacaagac taatctaaaa ggagaaacag 900ccctgcatag agcttgcata aataaccaag tggagaaatt gattcttctt ctctctttgc 960caggaataga catcaatgtt aaagacaatg ctggctggac gcctttgcat gaagcctgta 1020actatggcaa cacagtgggt gtccaggaaa ttttgcaacg ttgtccagag gtagatctgc 1080tcactcaagt ggacggggtg actcctttgc atgatgcact gtcaaacgga catgtagaaa 1140ttggcaagct gctactacag catgggggcc cagtgctttt acaacagagg aatgctaagg 1200gagaattgcc cttggattat gtggtttcac ctcaaatcaa agaagaactg tttgctatta 1260caaaaataga agatacagtg gagaactttc atgcacaagc agagaaacat tttcattacc 1320agcaacttga atttggctcc tttttactta gtaggatgtt gctaaatttt tgttcaattt 1380ttgatttatc ttcagagttc attttagctt ccaaagggtt aactcatcta aatgaactgc 1440ttatggcttg taaaagtcat aaagaaacca ccagtgttca tactgactgg ttactggatc 1500tttatgctgg aaatataaag acattgcaga aactcccaca cattcttaag gaactgcctg 1560agaatttgaa agtgtgtcct ggggtacaca ctgaggcctt gatgataaca ttggaaatga 1620tgtgtcggtc agtcatggag ttttcatgat gatgctagaa agtatggatt gactttctaa 1680atctgttcag tttgcattgg tacttactgt ggacttcata gcttactgac agatagtaat 1740ttgatttatt tattgacaga ctttgcagcc ttgctaaatt ttaaaagcat ttttaaaaaa 1800acttctacaa aactctagta tgggcttctg actttttcca gggtgtagaa tttgactcaa 1860aagtaaaaat aattttgttt tagtatattc tactttcatt aatgtttttt tgttctgaaa 1920gtgatattat attgtacatg taaaattaat ttaaatattt tttcaaataa aaatgtaatg 1980tcctgtattc tagatgttct aggtcttaga atcatggcaa gcatattcat acaaatgcgt 2040acctataaac ttgtagctcc tgactcttag ggatggattt tgaggaaaaa acaagactaa 2100acaaaaacat gtagctccct atttcttctc tctaggttgt tggactgaaa tatgcatttt 2160agctttgntg tttctaaaat aaacatttct aaaatttaca ggaaaaaaaa aaaaaaaaaa 2220aaaaaaaaaa aa 223280525PRTHomo sapiens 80Met Ser Arg Tyr Tyr Leu Glu Leu Phe Gln Cys Pro Thr Cys Met Lys 1 5 10 15Gly Ala Trp Ser Leu Val Glu Val Leu Ile Arg Ser Cys Leu Phe Asn 20 25 30Glu Ser Phe Cys His Gln Ile Ser Glu Asn Ile Gly Ser Lys Val Leu 35 40 45His Leu Thr Leu Leu Lys Phe Phe Phe Asn Leu Ile Glu Ser Glu Val 50 55 60Gln His Leu Ser Gln Lys Leu Tyr Asp Trp Ser Asp Ser Gln Asn Leu 65 70 75 80Lys Ile Thr Gly Lys Ala Met Leu Leu Glu Ile Phe Trp Ser Gly Ser 85 90 95Glu Thr Ser Gly Leu Leu Thr Lys Pro Val Asn Met Leu Leu Glu Trp 100 105 110Thr Ile Tyr Ser His Lys Glu Lys Phe Lys Ser Asn Asp Thr Phe Leu 115 120 125Pro Gln Glu Leu Glu Ile Phe Ile Cys Ser Phe Ser Ser Ser Trp Leu 130 135 140Gln Met Phe Val Ala Glu Ala Val Phe Lys Lys Leu Cys Leu Gln Ser145 150 155 160Ser Gly Ser Val Ser Ser Glu Pro Leu Ser Leu Gln Lys Met Val Tyr 165 170 175Ser Tyr Leu Pro Ala Leu Gly Lys Thr Gly Val Leu Gly Ser Gly Lys 180 185 190Ile Gln Val Ser Lys Lys Ile Gly Gln Arg Pro Cys Phe Asp Ser Gln 195 200 205Arg Thr Leu Leu Met Leu Asn Gly Thr Lys Gln Lys Gln Val Glu Gly 210 215 220Leu Pro Glu Leu Leu Asp Leu Asn Leu Ala Lys Cys Ser Ser Ser Leu225 230 235 240Lys Lys Leu Lys Lys Lys Ser Glu Gly Glu Leu Ser Cys Ser Lys Glu 245 250 255Asn Cys Pro Ser Val Val Lys Lys Met Asn Phe His Lys Thr Asn Leu 260 265 270Lys Gly Glu Thr Ala Leu His Arg Ala Cys Ile Asn Asn Gln Val Glu 275 280 285Lys Leu Ile Leu Leu Leu Ser Leu Pro Gly Ile Asp Ile Asn Val Lys 290 295 300Asp Asn Ala Gly Trp Thr Pro Leu His Glu Ala Cys Asn Tyr Gly Asn305 310 315 320Thr Val Gly Val Gln Glu Ile Leu Gln Arg Cys Pro Glu Val Asp Leu 325 330 335Leu Thr Gln Val Asp Gly Val Thr Pro Leu His Asp Ala Leu Ser Asn 340 345 350Gly His Val Glu Ile Gly Lys Leu Leu Leu Gln His Gly Gly Pro Val 355 360 365Leu Leu Gln Gln Arg Asn Ala Lys Gly Glu Leu Pro Leu Asp Tyr Val 370 375 380Val Ser Pro Gln Ile Lys Glu Glu Leu Phe Ala Ile Thr Lys Ile Glu385 390 395 400Asp Thr Val Glu Asn Phe His Ala Gln Ala Glu Lys His Phe His Tyr 405 410 415Gln Gln Leu Glu Phe Gly Ser Phe Leu Leu Ser Arg Met Leu Leu Asn 420 425 430Phe Cys Ser Ile Phe Asp Leu Ser Ser Glu Phe Ile Leu Ala Ser Lys 435 440 445Gly Leu Thr His Leu Asn Glu Leu Leu Met Ala Cys Lys Ser His Lys 450 455 460Glu Thr Thr Ser Val His Thr Asp Trp Leu Leu Asp Leu Tyr Ala Gly465 470 475 480Asn Ile Lys Thr Leu Gln Lys Leu Pro His Ile Leu Lys Glu Leu Pro 485 490 495Glu Asn Leu Lys Val Cys Pro Gly Val His Thr Glu Ala Leu Met Ile 500 505 510Thr Leu Glu Met Met Cys Arg Ser Val Met Glu Phe Ser 515 520 525812625DNAHomo sapiensunsure(2559)unsure(2561) 81gtctcctagc accgcatctg tccaggaagc cactgcctgc ttgttgctca tctgtagttt 60gcaggtgggg gttgcttttc ctttgttctg ccaggcggct tcagggctcc ctgtctgtag 120gtcagtatat ttcaccagtt ctgaaaaccc caacctactc cttgacagcc attgtttcct 180ctgcctctgg gacatccatc aaatgtacgt tagccctcat tccatcttcc gcgtccctta 240ttctgtcctc tgccttccca cgttattctc tgtaataatt tatctgaaat ttttttatct 300tcctattcac tgggtaagtt cttaatcttc ctatttactg tttctctctt ctactgtatc 360tagactggca ccaaatatgt ccactgagta cattagtgtt tcatttctaa aagagctgtt 420tggttttctt tcaaatttgc tgtatctgtt tttagaattt tcagttcccg tcatattcag 480agtttgttgt tcatttctgc aaacgctgag cgtagctgcc tcacggtgcg tctgcggtgc 540catctgagtg ttcttggcag cactgccagg tctccctggg agctgcgctc tttgaccctg 600tgacgtcctg aggcctgggc cagatgctgc ttcctccagg gaagatttgt tctccctccc 660agtagctccc cagggacctc ccacaccact gccctgggcc ctgtgtgtat aggcccagat 720ttttctctgt gtcctttatt accagctctg tttacagatc cctggagtca ggggaagggg 780tgagctcaga tctgaggcca agaggccatt tcccagctgg ctgcagctga gcctggtggc 840tgtgtctgag cgtcgtggag ccagggtcca cggcacccag gtggcggggg gcaggcgccc 900tgaccagcca cggcctcaaa gtgactctcc tgctctgctc cagccacacc tgcatgctgt 960ggcgggcgct ggcggtggag cctcgcctag ctgcccaggt cctggggctg ctgctggaga 1020agatgagtag ggacgtccct ttcaaggaga gccgggcctt cctgctgggc cgcaccccag 1080accgcgtggc cacgctgctg cctctctcgg ctacctgtgc actgtttgag gtcatgtcca 1140cgcctgcagc ggggcccgcg gtgctcgagc tctaccccca gctgtttgtg gtgcttctgc 1200tgcgcgtcag ctgcaccgtg ggtgtccagc tgccccggaa cctgcaggcc caggaaagga 1260ggggtgccag tccagcccta gccaccagga acctggaacc ctgcagctct gcagtggaca 1320ccctgcggtc catgctactc cgcagcggca gcgaggatgt ggtacagcgc atggacctgg 1380agggaggctg ggaactgctc aggacctcgg cggggcatga ggagggggcc accaggttgg 1440ccagggccat ggctgagcac gcagggcccc gactccccct ggtgctgaag acgctggcat 1500gcacacacag cagtgcgtat gagaaccaga gggtgaccac caccgccttc ctggccgagc 1560tgctgaacag caacgtggcc aacgacctca tgctcttgga ctcgctgctg gagagcctgg 1620cggctcgcca gaaggacaca tgcgccagcg tgcggaggct ggtgctccgc ggcctggcca 1680acctggcctc cggctgccct gacaaggtgc gaacccacgg cccccagctc ctcacagcca 1740tgattggcgg gctggacgac ggggacaacc ctcacagccc agtggccctg gaggccatgc 1800tgggccttgc gaggctggtg cacctggtgg agtcctggga cctgcgctca gggctgctgc 1860acgtggccat ccgcatccgg cctttcttcg acagtgagaa gatggagttc cggacggcat 1920ctatccgcct ctttgggcac cttaacaagg tctgccacgg agactgtgag gacgtcttcc 1980tggaccaggt ggtgggcggg ctggcgcccc tgctgctgca cctgcaggac cctcaggcca 2040ccgtggccag cgcctgcagg tttgccctgc gcatgtgtgg ccccaatctg gcatgtgagg 2100agctctcagc tgctttccag aaacacctgc aggagggccg agccctgcac ttcggggagt 2160tcctcaacac cacctgcaag cacctgatgc accatttccc agacctgctg ggccgtctcc 2220tgaccacctg cctgttctac ttcaagagca gctgggagaa cgtccgagct gctgcacccc 2280tgttcaccgg taagcaccac cccctgcccc acccccacgc cgcccggcag ccccgcctga 2340tgcccccact tcacagggtt cctggtgctg cactcggagc ccaggcagca gccgcaggtg 2400gacctggacc agctcattgc gggtgagcac ccctccacgg ggcccctccg ctgggccctg 2460ctgaccctgt aggcacccgc agggactaag tgattttcct ggatttcagg actttttccc 2520tgtcactggt gacctcatcg tctctagtaa ttcacggana nttcttaact gttccaaaag 2580agcttaaaaa acaccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 262582490PRTHomo sapiens 82Met Leu Trp Arg Ala Leu Ala Val Glu Pro Arg Leu Ala Ala Gln Val 1 5 10 15Leu Gly Leu Leu Leu Glu Lys Met Ser Arg Asp Val Pro Phe Lys Glu 20 25 30Ser Arg Ala Phe Leu Leu Gly Arg Thr Pro Asp Arg Val Ala Thr Leu 35 40 45Leu Pro Leu Ser Ala Thr Cys Ala Leu Phe Glu Val Met Ser Thr Pro 50 55 60Ala Ala Gly Pro Ala Val Leu Glu Leu Tyr Pro Gln Leu Phe Val Val 65 70 75 80Leu Leu Leu Arg Val Ser Cys Thr Val Gly Val Gln Leu Pro Arg Asn 85 90 95Leu Gln Ala Gln Glu Arg Arg Gly Ala Ser Pro Ala Leu Ala Thr Arg 100 105 110Asn Leu Glu Pro Cys Ser Ser Ala Val Asp Thr Leu Arg Ser Met Leu 115 120 125Leu Arg Ser Gly Ser Glu Asp Val Val Gln Arg Met Asp Leu Glu Gly 130 135 140Gly Trp Glu Leu Leu Arg Thr Ser Ala Gly His Glu Glu Gly Ala Thr145 150 155 160Arg Leu Ala Arg Ala Met Ala Glu His Ala Gly Pro Arg Leu Pro Leu 165 170 175Val Leu Lys Thr Leu Ala Cys Thr His Ser Ser Ala Tyr Glu Asn Gln 180 185 190Arg Val Thr Thr Thr Ala Phe Leu Ala Glu Leu Leu Asn Ser Asn Val 195 200 205Ala Asn Asp Leu Met Leu Leu Asp Ser Leu Leu Glu Ser Leu Ala Ala 210 215 220Arg Gln Lys Asp Thr Cys Ala Ser Val Arg Arg Leu

Val Leu Arg Gly225 230 235 240Leu Ala Asn Leu Ala Ser Gly Cys Pro Asp Lys Val Arg Thr His Gly 245 250 255Pro Gln Leu Leu Thr Ala Met Ile Gly Gly Leu Asp Asp Gly Asp Asn 260 265 270Pro His Ser Pro Val Ala Leu Glu Ala Met Leu Gly Leu Ala Arg Leu 275 280 285Val His Leu Val Glu Ser Trp Asp Leu Arg Ser Gly Leu Leu His Val 290 295 300Ala Ile Arg Ile Arg Pro Phe Phe Asp Ser Glu Lys Met Glu Phe Arg305 310 315 320Thr Ala Ser Ile Arg Leu Phe Gly His Leu Asn Lys Val Cys His Gly 325 330 335Asp Cys Glu Asp Val Phe Leu Asp Gln Val Val Gly Gly Leu Ala Pro 340 345 350Leu Leu Leu His Leu Gln Asp Pro Gln Ala Thr Val Ala Ser Ala Cys 355 360 365Arg Phe Ala Leu Arg Met Cys Gly Pro Asn Leu Ala Cys Glu Glu Leu 370 375 380Ser Ala Ala Phe Gln Lys His Leu Gln Glu Gly Arg Ala Leu His Phe385 390 395 400Gly Glu Phe Leu Asn Thr Thr Cys Lys His Leu Met His His Phe Pro 405 410 415Asp Leu Leu Gly Arg Leu Leu Thr Thr Cys Leu Phe Tyr Phe Lys Ser 420 425 430Ser Trp Glu Asn Val Arg Ala Ala Ala Pro Leu Phe Thr Gly Lys His 435 440 445His Pro Leu Pro His Pro His Ala Ala Arg Gln Pro Arg Leu Met Pro 450 455 460Pro Leu His Arg Val Pro Gly Ala Ala Leu Gly Ala Gln Ala Ala Ala465 470 475 480Ala Gly Gly Pro Gly Pro Ala His Cys Gly 485 490831476DNAHomo sapiens 83cctctctcca aattggcctc tcaactcaca ggaagacaca gctgcccaga gcagcccagg 60ccgtggtgag gaggcggagg catcggcggc ggaggctcag ggtggggagc aggcctacct 120ggcaggcctg gcagggcagt accacttgga gcggtacccg gacagttacg agtccatgtc 180cgagccgccc attgctcatc ttttgcgccc cgtgcttccc cgggccttcg ccttccccgt 240ggacccccag gtccagtctg ccgctgatga gactgctgtg cagctgagcg agttgctgac 300gctgcccgtg ctcatgaagc gctccatcac ggcaccgctg gccgcccaca tctccttggt 360gaacaaggcc gctgtcgact acttcttcgt ggagctgcac ctggaggcgc actatgaggc 420actgcggcac ttcctgctga tggaggacgg cgagttcgcc cagtccctca gcgacctgct 480ctttgagaag cttggagctg ggcaaacgcc ccggagagct gctcaacccg ctggtgctga 540actctgtgct gacaaggccc tgcagtgcag cctgcatggg gacaccccgc acgcctccaa 600cctctccctc gctctcaagt acctgcccga ggtgtttgcc cccaacgccc cggatgtgct 660gagctgcctg gagctcaggt acaaggtgga ctggcctctc aacattgtca tcaccgaggg 720ctgcctgagc aagtacagcg gcgtcttctc cttcctgctg cagctgaagc tcatgatgtg 780ggcgctcaag gacgtctgct tccacctcaa gcgcacagcc ctgctgagcc acatggccgg 840ctctgtgcag ttccgtcagc tgcagctgtt caagcacgag atgcagcatt tcgtgaaggt 900catccagggc tacatcgcca accagatcct gcacgtcacc tggtgcgagt tcagggccag 960gttggccacc gtgggcgacc tggaggagat ccagcgtgcg cacgcagagt acctgcacaa 1020ggccgtcttc aggggcctgc tcacggagaa ggcggcgccc gtcatgaacg tcatccacag 1080catcttcagc ctcgtgctca agttccgcag ccagctcatc tcccaggcct gggggccccc 1140tgggggcccg cggggtgcag agcaccccaa ctttgcactc atgcagcagt cctacaacac 1200cttcaagtac tactcccact ttctcttcaa agtggtgacc aagctggtga accgcggcta 1260ccagccccac ctggaggact ttctgctgcg catcaacttc aacaactact accaggacgc 1320ctgaggctgc tctgcggggg acgtgcacaa taaaggtgtt ctcgggaaaa aaaaaaaaaa 1380aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1440aaaaataaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 147684382PRTHomo sapiens 84Met Ser Glu Pro Pro Ile Ala His Leu Leu Arg Pro Val Leu Pro Arg 1 5 10 15Ala Phe Ala Phe Pro Val Asp Pro Gln Val Gln Ser Ala Ala Asp Glu 20 25 30Thr Ala Val Gln Leu Ser Glu Leu Leu Thr Leu Pro Val Leu Met Lys 35 40 45Arg Ser Ile Thr Ala Pro Leu Ala Ala His Ile Ser Leu Val Asn Lys 50 55 60Ala Ala Val Asp Tyr Phe Phe Val Glu Leu His Leu Glu Ala His Tyr 65 70 75 80Glu Ala Leu Arg His Phe Leu Leu Met Glu Asp Gly Glu Phe Ala Gln 85 90 95Ser Leu Ser Asp Leu Leu Phe Glu Lys Leu Gly Ala Gly Gln Thr Pro 100 105 110Arg Arg Ala Ala Gln Pro Ala Gly Ala Glu Leu Cys Ala Asp Lys Ala 115 120 125Leu Gln Cys Ser Leu His Gly Asp Thr Pro His Ala Ser Asn Leu Ser 130 135 140Leu Ala Leu Lys Tyr Leu Pro Glu Val Phe Ala Pro Asn Ala Pro Asp145 150 155 160Val Leu Ser Cys Leu Glu Leu Arg Tyr Lys Val Asp Trp Pro Leu Asn 165 170 175Ile Val Ile Thr Glu Gly Cys Leu Ser Lys Tyr Ser Gly Val Phe Ser 180 185 190Phe Leu Leu Gln Leu Lys Leu Met Met Trp Ala Leu Lys Asp Val Cys 195 200 205Phe His Leu Lys Arg Thr Ala Leu Leu Ser His Met Ala Gly Ser Val 210 215 220Gln Phe Arg Gln Leu Gln Leu Phe Lys His Glu Met Gln His Phe Val225 230 235 240Lys Val Ile Gln Gly Tyr Ile Ala Asn Gln Ile Leu His Val Thr Trp 245 250 255Cys Glu Phe Arg Ala Arg Leu Ala Thr Val Gly Asp Leu Glu Glu Ile 260 265 270Gln Arg Ala His Ala Glu Tyr Leu His Lys Ala Val Phe Arg Gly Leu 275 280 285Leu Thr Glu Lys Ala Ala Pro Val Met Asn Val Ile His Ser Ile Phe 290 295 300Ser Leu Val Leu Lys Phe Arg Ser Gln Leu Ile Ser Gln Ala Trp Gly305 310 315 320Pro Pro Gly Gly Pro Arg Gly Ala Glu His Pro Asn Phe Ala Leu Met 325 330 335Gln Gln Ser Tyr Asn Thr Phe Lys Tyr Tyr Ser His Phe Leu Phe Lys 340 345 350Val Val Thr Lys Leu Val Asn Arg Gly Tyr Gln Pro His Leu Glu Asp 355 360 365Phe Leu Leu Arg Ile Asn Phe Asn Asn Tyr Tyr Gln Asp Ala 370 375 380851212DNAHomo sapiensunsure(1146)..(1147) 85taggctcttt ggccgcccag ctctccctgt gctaactgcc tgcaccttgg acagagcggg 60tgcgcaaatc agaaggatta gttgggacct gccttggcga ccccatggca tcccccagaa 120ccgtaactat tgtggccctc tcagtggccc tgggactctt ctttgttttc atggggacta 180tcaagctgac ccccaggctc agcaaggatg cctacagtga gatgaaacgt gcttacaaga 240gctatgttcg agccctccct ctgctgaaga aaatggggat caattccatt ctcctccgaa 300aaagcattgg tgcccttgaa gtggcctgtg gcatcgtcat gacccttgtg cctgggcgtc 360ccaaagatgt ggccaacttc ttcctactgt tgctggtgtt ggctgtgctc ttcttccacc 420agctggtcgg tgatcctctc aaacgctacg cccatgctct ggtgtttgga atcctgctca 480cttgccgcct gctgattgct cgcaagcccg aagaccggtc ttctgagaag aagcctttgc 540cagggaatgc tgaggagcaa ccctccttat atgagaaggc ccctcagggc aaagtgaagg 600tgtcatagaa aagtggaagt gcaaagagtg gaccttccag gcagttgcgt ccatgacacc 660aggaagatgt cagtgtgtgt ttttcatttg atttatttat cttggggaaa gtgaaaaatg 720taatctgcaa gttaatgatc tattggcttg tgtacatcta tatgctaaaa tgacttcccc 780acattgacat ttgtgcgcca cctttaatca ctctggggca actctcacat cttgctgcat 840gtacatgtat acggctacta ttgaagtgta attgtgagat ggactccaac aagcatgtga 900ctgtgagatt gtgtgtggga aaatgtattt aactactctg tgtgtgtgtg tgtgtgtgtg 960tgcgcgcgcg cgcacgcgca cacactcacg cacacacaag cagagaaggc gctgatcttg 1020aactaatcct gcacaggcat ccttcccttt atagattgat tccagcaaag gcggaataaa 1080acaaatttcc tatgaagaga atcctgatat gaaacaagtc atgtagtctc atggccggga 1140atctcnncac agatactaac aacttaaact tactacttta ggaaaaaaaa aaaaaaaaaa 1200aaaaaaaaaa aa 121286167PRTHomo sapiens 86Met Ala Ser Pro Arg Thr Val Thr Ile Val Ala Leu Ser Val Ala Leu 1 5 10 15Gly Leu Phe Phe Val Phe Met Gly Thr Ile Lys Leu Thr Pro Arg Leu 20 25 30Ser Lys Asp Ala Tyr Ser Glu Met Lys Arg Ala Tyr Lys Ser Tyr Val 35 40 45Arg Ala Leu Pro Leu Leu Lys Lys Met Gly Ile Asn Ser Ile Leu Leu 50 55 60Arg Lys Ser Ile Gly Ala Leu Glu Val Ala Cys Gly Ile Val Met Thr 65 70 75 80Leu Val Pro Gly Arg Pro Lys Asp Val Ala Asn Phe Phe Leu Leu Leu 85 90 95Leu Val Leu Ala Val Leu Phe Phe His Gln Leu Val Gly Asp Pro Leu 100 105 110Lys Arg Tyr Ala His Ala Leu Val Phe Gly Ile Leu Leu Thr Cys Arg 115 120 125Leu Leu Ile Ala Arg Lys Pro Glu Asp Arg Ser Ser Glu Lys Lys Pro 130 135 140Leu Pro Gly Asn Ala Glu Glu Gln Pro Ser Leu Tyr Glu Lys Ala Pro145 150 155 160Gln Gly Lys Val Lys Val Ser 165871059DNAHomo sapiens 87tcaggattta aacttgtcaa ctttggatgt gattatcatc aataccgaga taaattttcc 60aaacacctga ctctgtgtgt ttttaccaac catacaggaa gtttgtgtgt atgttacagc 120ccgaagtgtg cctcttggga acaaatcaca tattcagtgt tttacattca taaaggacac 180agcaagacct tcaccacttc tcttgagaat gttggctcac acatgacaaa gggcattact 240tttctcaacc ttgactatta tgtggctgtt tacttacctg gtcatttctt ccacctactt 300aatgttcaac atccagacct gatctgccac aatctctttc tgacaggaaa taatgaaatg 360attgatatgc tacctcattg ccctttacag tcattgtcag ggtccctggt attggattgt 420tgttctggaa agctctatag agcactgctc agccagtcgt ctttattaca gcttctgcag 480aacacttgct tagactgtga gaagatggct gcgttgcact gtgcgctcta ctgcggtcaa 540ggtgcgcagt tcctggaagc ccagattatt cagtggattt ctgagaatgt ctctgcctgc 600cattcatttg acctcattca ggaatttata attgcttctt catactggag tgtatattca 660gagacaagta acatggacaa actattgcca cattcctcag tgctcacttg gaatacagaa 720attcctggaa taactcttgt gacagaagac attgcattgc ctcttatgaa ggttttgaaa 780aatgtcctgg gcagtaaata aatttagcag gaaagtacgc ctactccatt tatccaaatg 840ttaatgaact ttctcttagt gaacatggca ctgttgacac cacctaagtc ataaaaacgg 900gtctcaaggg aggaaatgac tcagtgtgtt taatacaggt ttccctgcta agcctcaatc 960tggggaagtc ctgttggttt tgggaagtga gcagcagttc tctatgtggt ttaaaaaaac 1020aacgacaaca aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 105988192PRTHomo sapiens 88Met Thr Lys Gly Ile Thr Phe Leu Asn Leu Asp Tyr Tyr Val Ala Val 1 5 10 15Tyr Leu Pro Gly His Phe Phe His Leu Leu Asn Val Gln His Pro Asp 20 25 30Leu Ile Cys His Asn Leu Phe Leu Thr Gly Asn Asn Glu Met Ile Asp 35 40 45Met Leu Pro His Cys Pro Leu Gln Ser Leu Ser Gly Ser Leu Val Leu 50 55 60Asp Cys Cys Ser Gly Lys Leu Tyr Arg Ala Leu Leu Ser Gln Ser Ser 65 70 75 80Leu Leu Gln Leu Leu Gln Asn Thr Cys Leu Asp Cys Glu Lys Met Ala 85 90 95Ala Leu His Cys Ala Leu Tyr Cys Gly Gln Gly Ala Gln Phe Leu Glu 100 105 110Ala Gln Ile Ile Gln Trp Ile Ser Glu Asn Val Ser Ala Cys His Ser 115 120 125Phe Asp Leu Ile Gln Glu Phe Ile Ile Ala Ser Ser Tyr Trp Ser Val 130 135 140Tyr Ser Glu Thr Ser Asn Met Asp Lys Leu Leu Pro His Ser Ser Val145 150 155 160Leu Thr Trp Asn Thr Glu Ile Pro Gly Ile Thr Leu Val Thr Glu Asp 165 170 175Ile Ala Leu Pro Leu Met Lys Val Leu Lys Asn Val Leu Gly Ser Lys 180 185 190892529DNAHomo sapiens 89attttgcctt atgaaaacta agctgaatcg actgctgcca aacatctatt aggcaaaatt 60ggcctcttgc ccatgatttg actttccagc acagccagtt ctttttctcc tctgcagctg 120attggctctg gagtgtggcc agaagcctct ctcctgcaat taaaggagtc gggtctctaa 180ctgttgatct gtttttttcc cttctgagca atggagctta ccatctttat cctgagactg 240gccatttaca tcctgacatt tcccttgtac ctgctgaact ttctgggctt gtggagctgg 300atatgcaaaa aatggttccc ctacttcttg gtgaggttca ctgtgatata caacgaacag 360atggcaagca agaagcggga gctcttcagt aacctgcagg agtttgcggg cccctccggg 420aaactctccc tgctggaagt gggctgtggc acgggggcca acttcaagtt ctacccacct 480gggtgcaggg tgacctgtat tgaccccaac cccaactttg agaagttttt gatcaagagc 540attgcagaga accgacacct gcagtttgag cgctttgtgg tagctgccgg ggagaacatg 600caccaggtgg ctgatggctc tgtggatgtg gtggtctgca ccctggtgct gtgctctgtg 660aagaaccagg agcggattct ccgcgaggtg tgcagagtgc tgagaccggg aggggctttc 720tatttcatgg agcatgtggc agctgagtgt tcgacttgga attacttctg gcaacaagtc 780ctggatcctg cctggcacct tctgtttgat gggtgcaacc tgaccagaga gagctggaag 840gccctggagc gggccagctt ctctaagctg aagctgcagc acatccaggc cccactgtcc 900tgggagttgg tgcgccctca tatctatgga tatgctgtga aatagtgtga gctggcagtt 960aagagctgaa tggctcaaag aatttaaagc ttcagtttta catttaaaat gctaagtggg 1020agaagagaaa cctttttttt ggggggcggt ttttttggtt tgttgttggt tttttttttt 1080tttttggcgg gaagaaagag ttttgctctt gttgcccagg ctggagtgca atggcgtgat 1140ctccgctcac tgcaacctcc acctcgcggg tttaagcgat tcttctgcct cagcctccct 1200agtagctggg attacaggtg cccaccacca tgcccagcta atttgtattt ttagttgaga 1260cagggtttca ctacgttggc caggctggtc ttgaactcct gatctcaggc aatccaccca 1320cctcagcctc ccaaagtgct gggatgacag gcgtgagcaa ccgcacccag cttaaggttt 1380ttttgttttg ttttgagacg gagttttcgc tcttgttgcc caggctggag tgcaatgctg 1440tgatctcagc ttaccacaac ctccacctcc cgggttcaag tgattcacct gcctcagcct 1500cctgagtagc tggtattaca ggcatgcgtc accacgccgg ctaattttgt acttttagta 1560gagatggtgt ttccccacgt tggtcagtct ggtctcaaat tcctgacctc aggtgatctg 1620cctgcctcgg cctcccaaag tgctgtgatt acagacgtca gccaccatgc ctggcctgaa 1680acctttttta ggtaaagttg aattccatcc ttaaaagttt ctgttatcct atttagccat 1740tttctattgt ctcccaaaga attcacatca aaaaaacagc tttgaactcc cccttcaaag 1800gaaacagtcg actttcataa ttagcatcta ccattatccc caaatcttat tttattcatt 1860gacttgaaat tttttccaat tgcttttttt tttttttttt ttaaggttaa gagcagaggt 1920ttactaggcc aaagaaagag aatagctctc tgttgcagag aggggtcctg gagaaatggg 1980ttaccccagt tgtcttattt aaatggttac ccatcagatt ttaattttat cttctctttg 2040agagcttggt aataagaagc acttaaatca ctccaaagaa gactttaaaa agggagcagt 2100gaaaaggtct taataattta ttgattgaat taagaaatac tagctaatta agaatctgag 2160tctaaacagc acagattttt tctttctgct tttaaattgt gttttaaaaa aagagacagg 2220gggctgggcg tggtgctcac gcctgtaatc ctagcacttt gggaggccga ggcgggtgga 2280tcacgaggta ggagttaaag accagcctgg ccaacatggc aaaaccctac taaagataca 2340aaaaaaaaaa aaaattagcc aggcgtggtg gtgggtgcct gtaatcccag gtacttggag 2400ggctgaggca ggagaatctc ttgaacccag aaggcgaagg ttgcagtgaa ccgagatcat 2460gccattgtac tctagcctgg gtgacaagag caagactccg tctcgaaaaa aaaaaaaaaa 2520aaaaaaaaa 252990244PRTHomo sapiens 90Met Glu Leu Thr Ile Phe Ile Leu Arg Leu Ala Ile Tyr Ile Leu Thr 1 5 10 15Phe Pro Leu Tyr Leu Leu Asn Phe Leu Gly Leu Trp Ser Trp Ile Cys 20 25 30Lys Lys Trp Phe Pro Tyr Phe Leu Val Arg Phe Thr Val Ile Tyr Asn 35 40 45Glu Gln Met Ala Ser Lys Lys Arg Glu Leu Phe Ser Asn Leu Gln Glu 50 55 60Phe Ala Gly Pro Ser Gly Lys Leu Ser Leu Leu Glu Val Gly Cys Gly 65 70 75 80Thr Gly Ala Asn Phe Lys Phe Tyr Pro Pro Gly Cys Arg Val Thr Cys 85 90 95Ile Asp Pro Asn Pro Asn Phe Glu Lys Phe Leu Ile Lys Ser Ile Ala 100 105 110Glu Asn Arg His Leu Gln Phe Glu Arg Phe Val Val Ala Ala Gly Glu 115 120 125Asn Met His Gln Val Ala Asp Gly Ser Val Asp Val Val Val Cys Thr 130 135 140Leu Val Leu Cys Ser Val Lys Asn Gln Glu Arg Ile Leu Arg Glu Val145 150 155 160Cys Arg Val Leu Arg Pro Gly Gly Ala Phe Tyr Phe Met Glu His Val 165 170 175Ala Ala Glu Cys Ser Thr Trp Asn Tyr Phe Trp Gln Gln Val Leu Asp 180 185 190Pro Ala Trp His Leu Leu Phe Asp Gly Cys Asn Leu Thr Arg Glu Ser 195 200 205Trp Lys Ala Leu Glu Arg Ala Ser Phe Ser Lys Leu Lys Leu Gln His 210 215 220Ile Gln Ala Pro Leu Ser Trp Glu Leu Val Arg Pro His Ile Tyr Gly225 230 235 240Tyr Ala Val Lys912390DNAHomo sapiens 91tgccttcaaa gaaaaacctc ggtatccacc aagtcaggct caagcagctc ttcaagacag 60tccccctgaa gagtactcct ataagaaatc aataagaaac ctgtttaaaa acattccttt 120tgtccttctg ttgatcactt atggtatcat gactggtgcc ttttattcag tctcaacgtt 180attaaatcaa atgatattga catattatga gggagaagaa gtcaatgctg gaaggattgg 240gctaacgcta gtagtagctg gaatggtggg ctctattctt tgtggcttat ggctggatta 300tactaaaaca tacaaacaga ctactctgat agtttatatt ttgtctttta ttggaatggt 360tatctttact ttcacattgg accttagata tattatcatc gtgtttgtta ctggaggggt 420gcttggcttc ttcatgactg gttacctccc tttgggtttt gaatttgctg ttgaaatcac 480ttaccctgaa tctgaaggta cttcatctgg tcttcttaat gcttctgcac agatatttgg 540aattttgttc acattggctc aaggaaagct cacatcagac tatggtccta aggcagggaa 600catttttctc tgtgtctgga tgtttatagg catcatatta acagcattaa tcaagtctga 660tctgcgaaga cacaacataa atataggaat tacaaatgtt gatgttaaag ctataccagc 720tgacagtccc acagaccaag aaccaaaaac ggttatgttg tccaagcagt cagaatcagc 780aatttgaaga gaaaggcaaa gttactgtcc tgtagtaatt ggggacaatg tgatcatcct 840tggagagaga tgtgagcacc aaggctgggt ttgtatgtgg

tgggggaata aacacactta 900cttgaaaatt accatatgaa ctctaaatgc ataattattg ttttgcttaa ttgttaaatt 960aagggaaatt ttcttaaaat tcttctgttt acatcatgtt aacactactg tttatctaat 1020tagtatccgg tttttagtct catattgtat ctgaaagtaa gcttcttgac gtttactttt 1080taaaagtcga tgtttttctt ttttgtagaa aatggaagct tagaatactt tttaaagtga 1140taatatgggg tgttcagtcc ccataagata taatagttca tgcagtttat atattaaagt 1200atccagtgga actaaatgta caatatattc ctaattggct gcctttttca ctgtgctgac 1260cagctgttca agccacttca gtttgagtac aacataccaa catgacacta ctcacccaca 1320aaggacagca ttgggatcag gctttcagat gacctctaag atttttccca tttattgtac 1380tcttgttaca aagtactttt taacacatgc agtcaatggc tataaaaact attctgtgta 1440cagattctac ccagactttg gtcttagaat tatgttctaa ttaaggagcc tggttacagg 1500ttcattctgt cttgagttct tttctgtgct gcctttctat catggataaa tgctaacgct 1560gtattttttc actccaactt gagatagagt agttttgtac ccattgcctt ttttttcttt 1620taaactctct tttttttttt ttcctgatgt gtaactttct agtaagataa tttcatcatg 1680tatgttactg gctatttcat gatttcatgt atcacatcgt atattttgcc ttgaagattc 1740ctgaaataag gaaatctata ataacttcag atagcctaca tgtccccatt tagtggagac 1800ctcttgaatg ctatttgaat tctgcagtat catttttatg accattctcc tttgaggaat 1860actatgccca ggtacatgct ctatcagtgt gccgggagag tggattcttt tcttcactgc 1920agagtcatca cactgttaga atagtctgct cttttacatg ctcaggtagg gaaaatagga 1980ccaaatatat ttccacagtg cctaccactg tgtcatgttt acagtgagag tttaaatatt 2040gttgatgtcc tgactctgtg agctcatagg gagtatcttc atagtaatga catttgatca 2100gccataaaat ttacattatg ttcatatgca cccaaaaaag ctagtcaggt aatgaatacc 2160cttgaagtga atagcaattt tgatttaggc agtgtgttag gccatccttg cattgctata 2220aagaaatatt taggctgggc gtggtggctc acgcctgtaa tcccagcact ttgggaggct 2280gaagcgtgtg gatcacctga ggtcaggagt tcaagaccag cctggccaac atggtaaaac 2340cccatctcta ctaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 239092212PRTHomo sapiens 92Met Thr Gly Ala Phe Tyr Ser Val Ser Thr Leu Leu Asn Gln Met Ile 1 5 10 15Leu Thr Tyr Tyr Glu Gly Glu Glu Val Asn Ala Gly Arg Ile Gly Leu 20 25 30Thr Leu Val Val Ala Gly Met Val Gly Ser Ile Leu Cys Gly Leu Trp 35 40 45Leu Asp Tyr Thr Lys Thr Tyr Lys Gln Thr Thr Leu Ile Val Tyr Ile 50 55 60Leu Ser Phe Ile Gly Met Val Ile Phe Thr Phe Thr Leu Asp Leu Arg 65 70 75 80Tyr Ile Ile Ile Val Phe Val Thr Gly Gly Val Leu Gly Phe Phe Met 85 90 95Thr Gly Tyr Leu Pro Leu Gly Phe Glu Phe Ala Val Glu Ile Thr Tyr 100 105 110Pro Glu Ser Glu Gly Thr Ser Ser Gly Leu Leu Asn Ala Ser Ala Gln 115 120 125Ile Phe Gly Ile Leu Phe Thr Leu Ala Gln Gly Lys Leu Thr Ser Asp 130 135 140Tyr Gly Pro Lys Ala Gly Asn Ile Phe Leu Cys Val Trp Met Phe Ile145 150 155 160Gly Ile Ile Leu Thr Ala Leu Ile Lys Ser Asp Leu Arg Arg His Asn 165 170 175Ile Asn Ile Gly Ile Thr Asn Val Asp Val Lys Ala Ile Pro Ala Asp 180 185 190Ser Pro Thr Asp Gln Glu Pro Lys Thr Val Met Leu Ser Lys Gln Ser 195 200 205Glu Ser Ala Ile 210932922DNAHomo sapiens 93gaggcgggtt aaggtctgag ggtcttgtgg ggccacggcg ctgatcacca ggtgtttggc 60ttggtcggtt cttatttctc gcctggcaat ggcgacgtac acctgcataa cttgccgggt 120ggcgttccgc gacgcggaca tgcagcgggc ccactataag acggactggc accgctacaa 180cctgcggcgg aaggtggcca gcatggcccc agtgaccgcc gagggcttcc aggagcgagt 240gcgggcgcag cgggccgtcg cggaggagga gagcaagggc tcggccacct actgcaccgt 300ttgcagtaag aagtttgcct ctttcaacgc ctacgagaac cacctcaagt cccggcgtca 360cgttgagctg gagaagaagg ccgtgcaggc agtgaatcgg aaagtggaga tgatgaatga 420aaagaacttg gagaaaggac tgggcgtgga cagtgtggac aaggatgcca tgaacgcggc 480catccagcag gccatcaagg cccagccgtc catgtctccc aagaaggcgc ccccagcgcc 540tgcaaaggag gccaggaatg tcgtggccgt gggtactggt ggccgtggga cccacgaccg 600agacccgagt gagaaaccac cccggctcca gtggtttgaa cagcaggcga agaagttggc 660aaagcagcag gaggaggaca gcgaggagga ggaagaggac ctggatggag acgattggga 720agatattgat tctgatgaag aattggaatg tgaggatact gaagcaatgg acgatgtggt 780ggagcaggat gcagaggagg aagaggctga ggaaggccca ccccttggtg ccatccctat 840cacggactgc ttattttgtt cccatcattc cagctcgctg atgaagaatg tggctcacat 900gaccaaagac cacagtttct ttattcctga tatagaatat ctttcagata ttaagggact 960gattaaatac ttgggagaga aagttggtgt tggcaagatt tgcttgtggt gcaacgagaa 1020agggaagtcc ttctactcca cagaagctgt acaggcacat atgaatgaca aaagccactg 1080taagctcttc acagatggcg atgctgcttt ggaatttgca gacttctatg attttaggag 1140tagctatcca gatcacaagg aaggggagga ccccaataag gctgaggagt tgccctcaga 1200aaagaacttg gaatatgatg atgaaaccat ggaattgatt ctgccttctg gtgccagagt 1260gggtcatcgc tccttgatga gatactacaa acagcgattt ggcttgtcaa gagctgtggc 1320agttgccaaa aatcggaagg ccgtgggccg agtacttcag cagtacagag ccctgggatg 1380gactggcagc acaggtacat tgatctttac aactacagac cagtctgaga acttgtattt 1440ctagaagggg tctggggaaa gttgtttcca tttatgttgt ccatgtggat tctctctagg 1500ggaaacgtaa cgtcttggct ccagggactt ccattaccac ttgatatgtt taaggcaata 1560agcccaaagt gctatgactt agaaatttca tattcctggc acagtgattt tatataccat 1620taactttttc agaagataat agttacaaaa agaattattt agtaatcacc aaaggttgaa 1680attatcctgg aggttatgca gaggaattag atagtatcct agtggttaat agcttgagct 1740gtggagtcag acgtgactta tgtgatgtac ttagaggttc ttatatgatg aacatgagta 1800atttaattaa tataagcttc tgtttcctca tttataaaac agagatgata gtaataagac 1860ctacctctta gagttgagtg ggttgaatgt catgcatgtg tgatatagtg catgcccata 1920gtcgaggtta gctatcagtc cccttttttg taattttccc atagaaaatt tagcaaaagt 1980tagaagagta aagcatgcca ctgcaattgt tgagttttga aacctcatca gtatggtact 2040ctttacatct attctgatgt gtcttctgga tgaagctggt tatatcctta gatcttcagg 2100gaaagcatct atccaactga ggactgtgga gaaaataaga ggcgggctgc cttctgatgg 2160cctgggaagc tctaggcaac taaaatccat ttgaaaaggc actgtgttta tatgtggttt 2220ccttcactgt ggctgcttgt gagctgtgtg gccacttgaa tctggcagag acttgacttc 2280atcttactct tatcaggaag tattgtctga ctcgatatat agcttctgcc tttctgatta 2340atggggcttt accttttggg cttataaact cttccagatg atgaaaacta aagctactaa 2400tcccagataa gtgtatatat acaaaagttc tggtatgcaa ttctggagtc cacagagacc 2460cctgaggcgc atggcttaga gaccccaagt tagcaactct gttttaaata caagaaccta 2520gttaccccaa actaaccttt tgaattctct gccaaggttg gattttctct gatcacaaat 2580aacagaactt tgcctaattt cttaactgcc ttccaatcat aggagcggct cttatgcgag 2640agcgagacat gcagtatgtc caaaggatga aatcaaaatg gatgctgaag acaggaatga 2700agaacaatgc caccaagcag atgcactttc gggtccaagt gagattctga gagtctgctg 2760ggattgagca atcatctcct gcccaagttt cctccttgcc ctgaggacca gtgaaagaca 2820gatcatagga gagacccttt tgctgctact tcattcgttc tgacctaata ataaaagtta 2880gaaccataaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 292294451PRTHomo sapiens 94Met Ala Thr Tyr Thr Cys Ile Thr Cys Arg Val Ala Phe Arg Asp Ala 1 5 10 15Asp Met Gln Arg Ala His Tyr Lys Thr Asp Trp His Arg Tyr Asn Leu 20 25 30Arg Arg Lys Val Ala Ser Met Ala Pro Val Thr Ala Glu Gly Phe Gln 35 40 45Glu Arg Val Arg Ala Gln Arg Ala Val Ala Glu Glu Glu Ser Lys Gly 50 55 60Ser Ala Thr Tyr Cys Thr Val Cys Ser Lys Lys Phe Ala Ser Phe Asn 65 70 75 80Ala Tyr Glu Asn His Leu Lys Ser Arg Arg His Val Glu Leu Glu Lys 85 90 95Lys Ala Val Gln Ala Val Asn Arg Lys Val Glu Met Met Asn Glu Lys 100 105 110Asn Leu Glu Lys Gly Leu Gly Val Asp Ser Val Asp Lys Asp Ala Met 115 120 125Asn Ala Ala Ile Gln Gln Ala Ile Lys Ala Gln Pro Ser Met Ser Pro 130 135 140Lys Lys Ala Pro Pro Ala Pro Ala Lys Glu Ala Arg Asn Val Val Ala145 150 155 160Val Gly Thr Gly Gly Arg Gly Thr His Asp Arg Asp Pro Ser Glu Lys 165 170 175Pro Pro Arg Leu Gln Trp Phe Glu Gln Gln Ala Lys Lys Leu Ala Lys 180 185 190Gln Gln Glu Glu Asp Ser Glu Glu Glu Glu Glu Asp Leu Asp Gly Asp 195 200 205Asp Trp Glu Asp Ile Asp Ser Asp Glu Glu Leu Glu Cys Glu Asp Thr 210 215 220Glu Ala Met Asp Asp Val Val Glu Gln Asp Ala Glu Glu Glu Glu Ala225 230 235 240Glu Glu Gly Pro Pro Leu Gly Ala Ile Pro Ile Thr Asp Cys Leu Phe 245 250 255Cys Ser His His Ser Ser Ser Leu Met Lys Asn Val Ala His Met Thr 260 265 270Lys Asp His Ser Phe Phe Ile Pro Asp Ile Glu Tyr Leu Ser Asp Ile 275 280 285Lys Gly Leu Ile Lys Tyr Leu Gly Glu Lys Val Gly Val Gly Lys Ile 290 295 300Cys Leu Trp Cys Asn Glu Lys Gly Lys Ser Phe Tyr Ser Thr Glu Ala305 310 315 320Val Gln Ala His Met Asn Asp Lys Ser His Cys Lys Leu Phe Thr Asp 325 330 335Gly Asp Ala Ala Leu Glu Phe Ala Asp Phe Tyr Asp Phe Arg Ser Ser 340 345 350Tyr Pro Asp His Lys Glu Gly Glu Asp Pro Asn Lys Ala Glu Glu Leu 355 360 365Pro Ser Glu Lys Asn Leu Glu Tyr Asp Asp Glu Thr Met Glu Leu Ile 370 375 380Leu Pro Ser Gly Ala Arg Val Gly His Arg Ser Leu Met Arg Tyr Tyr385 390 395 400Lys Gln Arg Phe Gly Leu Ser Arg Ala Val Ala Val Ala Lys Asn Arg 405 410 415Lys Ala Val Gly Arg Val Leu Gln Gln Tyr Arg Ala Leu Gly Trp Thr 420 425 430Gly Ser Thr Gly Thr Leu Ile Phe Thr Thr Thr Asp Gln Ser Glu Asn 435 440 445Leu Tyr Phe 450951395DNAHomo sapiens 95ctgcagtctg tctgagggcg gccgaagtgg ctggctcatt taagatgagg cttctgctgc 60ttctcctagt ggcggcgtct gcgatggtcc ggagcgaggc ctcggccaat ctgggcggcg 120tgcccagcaa gagattaaag atgcagtacg ccacggggcc gctgctcaag ttccagattt 180gtgtttcctg aggttatagg cgggtgtttg aggagtacat gcgggttatt agccagcggt 240acccagacat ccgcattgaa ggagagaatt acctccctca accaatatat agacacatag 300catctttcct gtcagtcttc aaactagtat taataggctt aataattgtt ggcaaggatc 360cttttgcttt ctttggcatg caagctccta gcatctggca gtggggccaa gaaaataagg 420tttatgcatg tatgatggtt ttcttcttga gcaacatgat tgagaaccag tgtatgtcaa 480caggtgcatt tgagataact ttaaatgatg tacctgtgtg gtctaagctg gaatctggtc 540accttccatc catgcaacaa cttgttcaaa ttcttgacaa tgaaatgaag ctcaatgtgc 600atatggattc aatcccacac catcgatcat agcaccacct atcagcactg aaaactcttt 660tgcattaagg gatcattgca agagcagcgt gactgacatt atgaaggcct gtactgaaga 720cagcaagctg ttagtacaga ccagatgctt tcttggcagg ctcgttgtac ctcttggaaa 780acctcaatgc aagatagtgt ttcagtgctg gcatattttg gaattctgca cattcatgga 840gtgcaataat actgtatagc tttccccacc tcccacaaag tcacccagtt aatgtgtgtg 900tgtgtttttt ttttaaggta aacattacta cttgtaactt tttttcttag tcatatttga 960aaaagtagaa aattgagtta caatttgatt ttttttccaa agatgtctgt taaatctgtt 1020gtgcttttat atgaatattt gttttttata gtttaaaatt gatcctttgg gaatccagtt 1080gaagttccca aatactttat aagagtttat cagacatctc taatttggcc atgtccagtt 1140tatacagttt acaaaatata gcagatgcaa gattatgggg gaaatcctat attcagagta 1200ctctataaat ttttgtgtat gtgtgtatgt gcgtgtgatt accagagaac tactaaaaaa 1260accaactgct ttttaaatcc tattgtgtag ttaaagtgtc atgccttgac caatctaatg 1320aattgattaa ttaactgggc ctttatactt aactaaataa aaaactaagc agatatgaaa 1380aaaaaaaaaa aaaaa 139596137PRTHomo sapiens 96Met Arg Val Ile Ser Gln Arg Tyr Pro Asp Ile Arg Ile Glu Gly Glu 1 5 10 15Asn Tyr Leu Pro Gln Pro Ile Tyr Arg His Ile Ala Ser Phe Leu Ser 20 25 30Val Phe Lys Leu Val Leu Ile Gly Leu Ile Ile Val Gly Lys Asp Pro 35 40 45Phe Ala Phe Phe Gly Met Gln Ala Pro Ser Ile Trp Gln Trp Gly Gln 50 55 60Glu Asn Lys Val Tyr Ala Cys Met Met Val Phe Phe Leu Ser Asn Met 65 70 75 80Ile Glu Asn Gln Cys Met Ser Thr Gly Ala Phe Glu Ile Thr Leu Asn 85 90 95Asp Val Pro Val Trp Ser Lys Leu Glu Ser Gly His Leu Pro Ser Met 100 105 110Gln Gln Leu Val Gln Ile Leu Asp Asn Glu Met Lys Leu Asn Val His 115 120 125Met Asp Ser Ile Pro His His Arg Ser 130 135971299DNAHomo sapiens 97aggatatcga attcaatcgg gaccaaaggt cagaaagaaa agttatctga gtagactgat 60gctctcaaac aggcttccgt tctctgcagc gaagagcctc ataaattccc cttcacaagg 120ggctttttca tccttaagag acctgagtcc tcaagaaaat ccttttctgg aagtatctgc 180tccttcagaa cattttatag aaaacaataa tacaaaagac acaactgcaa gaaatgcctt 240tgaagaaaat gtttttatgg aaaacactaa catgccagaa ggaaccatct ctgaaaacac 300aaactacaat catcctcctg aggcagattc cgctgggact gcattcaact tagggccaac 360tgttaaacaa actgagacaa aatgggaata caacaacgtg ggcactgacc tgtcccccga 420gcccaaaagc ttcaattacc cattgctctc gtcccaggtg atcagtttga aattcagcta 480acccagcagc tgcagtccgt tatccccaac aacaatgtga gaaggctcat tgctcatgtt 540atccggacct tgaagatgga ctgctctggg gcccatgtgc aagtgacctg tgccaagctc 600gtctccagga caggccacct gatgaagctt ctcagtgggc agcaggaagt aaaggcatcc 660aagatagaat gggatacgga ccaatggaag actgagaact acattaatga gagcacagaa 720gcccagagtg aacagaaaga gaagtcgctt gagttcacaa aagaacttcc aggatatggc 780tataccaaaa aactcatctt ggcgttaatt gtgactggaa tactaacgat tttgattata 840cttctctgcc tcattgagat ctgttgtcac cgaaggtcat tacaagaaga tgaagaagga 900ttctcaaggg acagcgaagc cccaacggag gaggagagtg aagccctgcc ataggaggag 960aacccagccc acctcaggcc tcctgcaaaa atacatagcg taaacaacgg ccatcaaaaa 1020agcaggactg aagccagcgg cccacacatc cacagaggca gcgggcagag caagcacagg 1080gccatcgttc ctgcccttgt ttcccagtct aattagtcac ccagacctga aaacatatgc 1140tcagggggtg gagattttac aattaaataa cattgttttt ggtgccctcc aaaaaaaaaa 1200aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 129998132PRTHomo sapiens 98Met Asp Cys Ser Gly Ala His Val Gln Val Thr Cys Ala Lys Leu Val 1 5 10 15Ser Arg Thr Gly His Leu Met Lys Leu Leu Ser Gly Gln Gln Glu Val 20 25 30Lys Ala Ser Lys Ile Glu Trp Asp Thr Asp Gln Trp Lys Thr Glu Asn 35 40 45Tyr Ile Asn Glu Ser Thr Glu Ala Gln Ser Glu Gln Lys Glu Lys Ser 50 55 60Leu Glu Phe Thr Lys Glu Leu Pro Gly Tyr Gly Tyr Thr Lys Lys Leu 65 70 75 80Ile Leu Ala Leu Ile Val Thr Gly Ile Leu Thr Ile Leu Ile Ile Leu 85 90 95Leu Cys Leu Ile Glu Ile Cys Cys His Arg Arg Ser Leu Gln Glu Asp 100 105 110Glu Glu Gly Phe Ser Arg Asp Ser Glu Ala Pro Thr Glu Glu Glu Ser 115 120 125Glu Ala Leu Pro 13099915DNAHomo sapiens 99cgagcatccc gctgccccgg accctcccgc gggcgcgcac caggctcaac tcaggctcag 60gactgcaggt agacatctcc actgcccagg aatcactgag cgtgcagaca gcacagcctc 120ctctgaaggc cggccatacc agagtcctgc ctcggcatgg gcctcaccat tgaggcagct 180ccactgtctg tgctggtctg agggtgctgc ctgtcatggg ggcagccatc tcccaggggg 240ccctcatcgc catcgtctgc aacggtctcg tgggcttctt gctgctgctg ctctgggtca 300tcctctgctg ggcctgccat tctcgctctg ccgacgttga ctctctctct gaatccagtc 360ccaactccag ccctggcccc tgtcctgaga aggccccacc accccagaag cccagccatg 420aaggcagcta cctgctgcag ccctgaaggc ccctggccta gcctggagcc caggacctaa 480gtccacctca cctagagcct ggaattagga tcccagagtt cagccagcct ggggtccaga 540actcaagagt ccgcctgctt ggagctggac ccagcggccc agagtctagc cagcttggct 600ccaataggag ctcagtggcc ctaaggagat gggcctgggg tgggggctta tgagttggtg 660ctagagccag ggccatctgg actatgctcc atcccaaggg ccaagggtca ggggccgggt 720ccactctttc cctaggctga gcacctctag gccctctagg ttggggaagc aaactggaac 780ccatggcaat aataggaggg tgtccaggct gggcccctcc cctggtcctc ccagtgtttg 840ctggataata aatggaacta tggctctaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 900aaaaaaaaaa aaaaa 91510076PRTHomo sapiens 100Met Gly Ala Ala Ile Ser Gln Gly Ala Leu Ile Ala Ile Val Cys Asn 1 5 10 15Gly Leu Val Gly Phe Leu Leu Leu Leu Leu Trp Val Ile Leu Cys Trp 20 25 30Ala Cys His Ser Arg Ser Ala Asp Val Asp Ser Leu Ser Glu Ser Ser 35 40 45Pro Asn Ser Ser Pro Gly Pro Cys Pro Glu Lys Ala Pro Pro Pro Gln 50 55 60Lys Pro Ser His Glu Gly Ser Tyr Leu Leu Gln Pro 65 70 751012915DNAHomo sapiens 101caaacttgga gggaaacttc attcatttgg tttattttta tttttatttt tatttatctt 60tttgagacag aatctcactc tggtttgaga cagaatctca ctgtgtcccc caggttggag 120tgcggtggtg cgatctcggc tcactgaaac ctctgcctcc tgggttcaag cgattctcct 180gcttcaccct ccgagtagct gggattacag gtgtgcacca ccacacccgg ctaatttttg 240tatttttggt agagacggtt tcgccacatt ggctaggttg gtgtcaaact cctggcctca 300aagtgatccg cccaccttgg cctcccaaag tggagccccc gtgccccttg tttgtgacct 360gtcaatataa atatgctcag tagcgggggg aggggtgggg ggtgaaaaag gaaatatgtt 420taatattaag actttggcct tttagtgtaa actgatattc aaaaatttct tcatagaaca 480tttgcttctt tgcttgatca tttttctaat tctgtacatc taaaatgccc agaatttgag 540ttgctgttat agtctactaa catagaactt tggagtaata

agatgggaat ttgtctctct 600tttgccaaga caagtattcg taatctaaca cagtattgtt gccacgagta cgagtatgtg 660atagactgtt gagaataaag aaagcaggca cagttggtca gtcctaagat aaaggagatg 720ttttttctta tatgtttgtg cattaaagaa aaaaaaatct tgaatctgac caatgatgtt 780ttttttcctt gtaagaaaat ttaacaaatg tttggcaagc ttctggaatc taaatttgaa 840attatacatt tgtcattttc tttaaatatt tcttcacctt agctttgatt atgagaaatc 900actgtcctct gctgttcttt tttttttttt ttcttttgag gcggagtctc actctgtgcc 960aggctggagt gcagtggtgc aatctcggct cactgcaacc tccacttcct gggttcaaat 1020gattctcctg ccgcagcctc ccgagtagct gggactacag gtgcatgcca ccacacccag 1080ctaatttttg tatttttggt agagacaggg tttcaccacg ttgtccatgg ccaggatggt 1140cttgatcttg accttgtgat ccgcccgcct cggcctccca aagtgctggg attgcaggca 1200tgagccaccg tgcccggcct gtcctctgtg gttttctggg cttatgttaa aattataact 1260caatcaccag tctttatata tttgcttttt tatatttaaa ccaaacctaa tgctaattgt 1320gatatgttat ttattctcac ctgatttgaa tcattggatt caattaaatg agtttaatta 1380tcattaaata attctaagag aaataatgtc tattcggatg gtgggaattt tctttctaca 1440tgcagcccca ttctgaatga atgaaatcaa atcatgtgaa gatcagggtc ctagagtaac 1500ctaatatttt gtacattggt tatttgactc ctcattttta tattaaatgt tatatcaagg 1560gagggggtat aaaagaaata caaaaattgc agaggtatct ggaatgtacc tatttgttaa 1620ttctatttgt catttctttt gtttcatctt ttgagtaata agctgcttgg aaaagtttct 1680gttctttagc tgatttttta gctataaaaa tgtatttgaa aagctcataa atttcaggat 1740tgaaaagata attggaagtt taaaaaaaac ctaattcatt gaagtaataa ccaaataatt 1800ttcaatcttg attcaactgt gattcaaatc ttacaccatt tgcccacttc tatgaatttt 1860atgtataaaa ttttttaaga gtcagagttt ttttttcttg attaattgga tgtatttcac 1920agaatttcca actgctcacg ttagttttct tccttttaga gttgatctct ctaatgtatt 1980agatcttcat gcctttgata gtctctctgg aataagttgt ttttagtttg cagaaaaaac 2040ttcagcatgt gccaggaaca caacctcacc ttgatcagag tattgttaca atcacatttg 2100aagtaccagg aaatgcaaag gaagaacatc ttaatatgtt tattcagaat ctcctgtggg 2160aaaagaatgt gagaaacaag gacaatcact gcatggaggt cataaggctg aagggattgg 2220tgtcaatcaa agacaaatca caacaagtga ttgtccaggg tgtccatgag ctctatgatc 2280tggaggagac tccagtgagc tggaaggatg acactgagag aacaaatcga ttggtcctca 2340ttggcagaaa tttagataag gatatcctta aacagctgtt tatagctact gtgacagaaa 2400cagaaaagca gtggacaaca catttcaaag aagatcaagt ttgtacataa cactagtggc 2460atttcttatc aaaaggattg gataataaaa ataagtttct actgggtata tttcaagcat 2520ttatttatta ctttagttac gaattccaat atactttaaa atggtatttg ttttacagca 2580tacataaaat gtagcaaatc agtactgtaa aacatttaac attcatacaa ttatatataa 2640tatccttttt tttaaagaat ggtatttcac aaaaatatct tttgaaattg gctttggagt 2700ttacatatac tgaacatgaa agtttataat aatgatgata caactttcaa cattgtcatt 2760ttttcttaga acttcagctg attgcagaga tataatgatt acattgttat taaatttttt 2820taacacaagt aagtgtcacc attttatgac atgaaataaa aggttatgac tgttaaaaaa 2880aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 2915102104PRTHomo sapiens 102Met Phe Ile Gln Asn Leu Leu Trp Glu Lys Asn Val Arg Asn Lys Asp 1 5 10 15Asn His Cys Met Glu Val Ile Arg Leu Lys Gly Leu Val Ser Ile Lys 20 25 30Asp Lys Ser Gln Gln Val Ile Val Gln Gly Val His Glu Leu Tyr Asp 35 40 45Leu Glu Glu Thr Pro Val Ser Trp Lys Asp Asp Thr Glu Arg Thr Asn 50 55 60Arg Leu Val Leu Ile Gly Arg Asn Leu Asp Lys Asp Ile Leu Lys Gln 65 70 75 80Leu Phe Ile Ala Thr Val Thr Glu Thr Glu Lys Gln Trp Thr Thr His 85 90 95Phe Lys Glu Asp Gln Val Cys Thr 1001031530DNAHomo sapiens 103atcgggagat atacctaatg ctagatgatg agttagtggg tgcagcgcac cagcacggca 60catgtataca tatgtaacta acctgcacaa tgtgcacatg taccctaaaa cttaaagtat 120atatatataa aaaaagacat cgctagtgag cacgctgtat acgacatcgc taatgaggac 180accatacaag gcatcgctaa cgatgacgct gtacacaaca tcactaatga tgacaccgta 240taagacatcg ctaattatga cgctgtatac gacatcgcta atgacaccgt acaaggcacg 300ctaacgagga tgctgtacac gacatcacta atgaggacag tgtacaagcc atcactaatg 360aggacactgt atatggcatc gctaacgagg acactgtaca aggcattgct aacgaggacg 420ctgtacacaa catcgctaat gaggacacca tataagacat caccaatgag gatgctgtat 480atgacatcgc taatggcacc cacaaggcat gctaacgagg acgctgtaga cgacattgct 540tataaggaca ccgtacaaga catcgctaac gaggacgctg tatacgacat cgctaatgag 600gacgttgtat atgacatcgc taatgaggat gctttacaag acatagctaa tgaggttgct 660gtatatgaca tcgctaatga ggacattgta tatgacatcg ctaatgagga cgctctatac 720gacatcacta atgaggacgc tgtatacaac atcgctaatg aggacgctgt atatggcatc 780gctaatgagg atgctgtata cgaattcgct aataaggacg ctgtatatga cattgctaat 840gaggacactg tacaagacat ctgtaaaaaa gaagatgctg ccaatgagcc attgacactg 900gagaatgata cgtaccctga aataactcac ttcctgagga aaaagcgcca tctctagggg 960atctcccggg gtgagtgagg aggcgggatc ggaccctggc agtctgacgg cagcacctgt 1020gttcctctgc actgggccgt ggatgacatt acacaccttg ccactcccac ggtcctgtgt 1080gttccggata ttttaaaata atggctataa ggttgagcac ttcaggatac gctgttttgc 1140tgtgtgcaga tggaggcagt ggctggagtg aatgaacggc aacacttgct ggcaaccggc 1200agaagctgag agacagggaa caggctctcc tccagagcct ccaggagcca ggcctttgga 1260caccttgaat gtgggcttct gggagaccat gcgtttctgt tataagcagc ccagtctctg 1320gcagttttta cggctgcccc ggaacactca tctatacctg tctgacaagg tcaagctcca 1380aggaagggac tctctacata tctacattgt ttgcagattt tacaataatc atttattctt 1440gcatggctga tcattgttaa ccaatacaaa taaaataata aagaaatgac ccacatttta 1500aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1530104215PRTHomo sapiens 104Met Leu Tyr Thr Thr Ser Leu Met Arg Thr Val Tyr Lys Pro Ser Leu 1 5 10 15Met Arg Thr Leu Tyr Met Ala Ser Leu Thr Arg Thr Leu Tyr Lys Ala 20 25 30Leu Leu Thr Arg Thr Leu Tyr Thr Thr Ser Leu Met Arg Thr Pro Tyr 35 40 45Lys Thr Ser Pro Met Arg Met Leu Tyr Met Thr Ser Leu Met Ala Pro 50 55 60Thr Arg His Ala Asn Glu Asp Ala Val Asp Asp Ile Ala Tyr Lys Asp 65 70 75 80Thr Val Gln Asp Ile Ala Asn Glu Asp Ala Val Tyr Asp Ile Ala Asn 85 90 95Glu Asp Val Val Tyr Asp Ile Ala Asn Glu Asp Ala Leu Gln Asp Ile 100 105 110Ala Asn Glu Val Ala Val Tyr Asp Ile Ala Asn Glu Asp Ile Val Tyr 115 120 125Asp Ile Ala Asn Glu Asp Ala Leu Tyr Asp Ile Thr Asn Glu Asp Ala 130 135 140Val Tyr Asn Ile Ala Asn Glu Asp Ala Val Tyr Gly Ile Ala Asn Glu145 150 155 160Asp Ala Val Tyr Glu Phe Ala Asn Lys Asp Ala Val Tyr Asp Ile Ala 165 170 175Asn Glu Asp Thr Val Gln Asp Ile Cys Lys Lys Glu Asp Ala Ala Asn 180 185 190Glu Pro Leu Thr Leu Glu Asn Asp Thr Tyr Pro Glu Ile Thr His Phe 195 200 205Leu Arg Lys Lys Arg His Leu 210 2151052423DNAHomo sapiens 105gactgcaccg tgactaacat gcagtgacag cttaattaat gttaaccctt atcattatca 60tataagaatg tgagttacat aagagaggag tcctgtcagt tcgttctctg ctgtgtcccc 120aagaccatga atcatggctg gcatgtagta ggcatttaat aatatatgtt caacaagtat 180ttggcagtct tggagggcag aaaaggaggt ggggaagatt tttaaataac attttttaaa 240aagtcacatt gtcctacaat actgattttt cttgcatatt taggaaattg agggtttttt 300tctaaaacat gcggacatat gggaaatagg atgcaacatt tgcactaatg tttcagacac 360agttagaggt ttccaagaga ttttgcgctg gggaggctgc ttgctacaag ctcccaaagc 420tctgggagga catagtattc attcctccct cagcagaagc ggtgaggcaa gaagctctgg 480ggagcaccca gcgttggact tttagcatag tgtgtcaggt cttcatagtt tgggcccagg 540gcacagagaa gtcacagctc tccggcatcc tgtgaccttt accctctttg ccaagggaaa 600atgtggccca ccaaagcaag aaacttgagg gcatgggtca ccccagccct ggcatctgcc 660cagagcccga gaaggaagga acaatgatcc tccagctacc tcacggggct ggcacaggtg 720accactgccc tggcatcacc cagctgtgtc cggcagcctg aaccccatct gtggggatgc 780gaggaggaaa atacaaaagt ccttaggtga acactgagaa ggcagatgca gcagaaacct 840ccaggccaga actacccagt cttggaccta tggtggagat agagcatagc tggcgatcat 900gtgtacttac actctaaggt cacctggttg cactatggcc tcatctgtgg ctctgaaaat 960gaagatttgg aaggagatca tcacagctaa tgtttaacaa gcccctcctg tgtgccaaat 1020cattcacccc tcaccacaac cgaatgagct aaggattctc attatatata gtttatggag 1080agggaagtgc agacataaag aggtgaatta tcttacccag atcacacagc tgataagtgg 1140tggaggcaga atagaatcta aacagtgtgg ctccggagcc cacatgcatt gattcgacaa 1200gtgtttattg agcacctgcc gcggacaagg ccttgtgtga ttaaataggg ttataattag 1260taatataaaa atgagaaatc actaatgctt tttagactta acattttgtt tttttgtagg 1320tttcaggcac agaactgtat atccaataat agtgaaatgg atcccactaa ttatgacaga 1380aatgatgata catttaaatg acttggatgt tttataggta tgatctcgtg aaatcttgag 1440agaaactgaa tgacgaatga aactattgtt cctgtttcac acagaagaaa actgaggtta 1500aaaggggtaa agtaattttg catggcatga agtagaaatt caaagtacag gaatttgaac 1560ttggttctgt ccttttctga agcccttgac cactatagac tcaaacatca ccttgttttt 1620ccactcattc aacacttttt tttttaaatt atctaatagg ttggcactca tcatgagccc 1680ctgttctcat tctgcaaatg gtgaagctct ctattgtcct gaccccacag ttcctgtccc 1740atgaccaggg ccagctcacc aaggagctgc agcagcatgt aaagtcagtg acatgcccat 1800gcgagtacct gaggaaggtg agtgagtgca gacagatggg gcctggtgcc cttgagcagt 1860tcccgggtct cagctgccac acatctcata gccggtgatg ctgggggaag cttacgcagt 1920cacagtactg gcttcttcct ctttttcttt ccatacaagt ggcttaggga tggggtagag 1980tagttgactt atttggatga aaaccactat cttctgtcag aaactcaaaa ggaatcattg 2040ctggcatggt aacctaaaga aaaacaacca gacaagtgcc caacgacact taaaaaggtg 2100atttattatc ttgccaagtt tgggctgggc atggtgactc atgcctctaa tcccagcatt 2160ttgggaggct gaggctggtg gatcaccgga ggccaggact ttgagaccag cctgaccaat 2220atggcgaaac ctcgtccctg ctgggaatgc aaaggttagc cgggcatggt ggtgtgagcc 2280tgtagtccca gctactcagg aggctgagac aggagaattg cttggattcg ggaggtgggg 2340gttttggtgg gccgagatca cgccattgca ctccagactg tgcgacagag cgagactctg 2400tcaaaaaaaa aaaaaaaaaa aaa 242310666PRTHomo sapiens 106Met Val Lys Leu Ser Ile Val Leu Thr Pro Gln Phe Leu Ser His Asp 1 5 10 15Gln Gly Gln Leu Thr Lys Glu Leu Gln Gln His Val Lys Ser Val Thr 20 25 30Cys Pro Cys Glu Tyr Leu Arg Lys Val Ser Glu Cys Arg Gln Met Gly 35 40 45Pro Gly Ala Leu Glu Gln Phe Pro Gly Leu Ser Cys His Thr Ser His 50 55 60Ser Arg 651071418DNAHomo sapiens 107cttttgggca gtttgatcac tgatcgagta aggaatgacc tttagattgt gcgacttttg 60tttttgtttt tttaaatttt tttaaaccaa gaatgatttc tcctgcttcc ttctcctcac 120catcttccca gacggagttc aaaggccact tctcaagcag cttttggcac cttcagcctc 180agagtggaat cttttaaaga caggacccct atgtccagga aaggggaaaa ggaactttgc 240caatgatagt gaccacagca aaagcaaata ataataatat taataataat aaagagaaat 300aaaataataa aataaaaaac aatagcacag cccttgttga ggtcagcagg gaggaggggc 360tgcccggagt tgggtccttg cctggatttt gacacagcaa cttcctgtag tgagcacttt 420gtatgaatcg tggacttcct gttctcaagg cgcaggtatt tattctgtat ctgtctagag 480cacacaccaa aatccaacct tctaataaac atgatggcgc agtcccactc cctgcctcgc 540ctgttcccct atccccccca ggcctgggat cttcaggcgt cggtgtgggg aggggcccct 600gccctccttg ccttgatttt gctcccctgg gtccagctgg ttccaggcct gtgaatgtca 660gttcgtcggg cactgactcc gtctgctctt ggccttgggt tcatttgaca aatatttgcc 720cagggcctcc caggcccagc cccatgccac ctgggccccg gcatctcttt gaggttctgc 780caatgtgctc ttagctgagg acgaaggagg aacacctttc tatgagtctt gcaaagttta 840cctccttcag gccacaaata tttgagtgca cactacgtgc caggcactgt gcagggctgc 900aggcatagag acagaatgta atctagctgg gccttggacc ccatagggag aggggaccac 960tcaggtccat acttcctttg gacttggggc tttggccttg ggaggggtgg aggtggggtg 1020gcaagatgaa aaagacatcc tgcccccatc cacttcggca gagcttctca aagtctcaag 1080catgtcttgg gagcttgtta aaagggctga ttccttgctg tggctcacgc ctgtaatcct 1140gacattttgg gaggccaagg caaattgcct gagctcaggg gtttgagacc agcctgggca 1200acatgtcgga accctgtttc tacaaaaaat acaagaatta gttgggcgtg gtggggcaca 1260ccacacctgt ggtcccagct actctgggac tgaggtggga gaactgcttg agcctgggag 1320gcagaggttg cagtaggtct agatcaggtc actgcactcc agcctgtgca acaaaacaac 1380agagcaggac cctgtctcaa aaaaaaaaaa aaaaaaaa 1418108123PRTHomo sapiens 108Met Asn Arg Gly Leu Pro Val Leu Lys Ala Gln Val Phe Ile Leu Tyr 1 5 10 15Leu Ser Arg Ala His Thr Lys Ile Gln Pro Ser Asn Lys His Asp Gly 20 25 30Ala Val Pro Leu Pro Ala Ser Pro Val Pro Leu Ser Pro Pro Gly Leu 35 40 45Gly Ser Ser Gly Val Gly Val Gly Arg Gly Pro Cys Pro Pro Cys Leu 50 55 60Asp Phe Ala Pro Leu Gly Pro Ala Gly Ser Arg Pro Val Asn Val Ser 65 70 75 80Ser Ser Gly Thr Asp Ser Val Cys Ser Trp Pro Trp Val His Leu Thr 85 90 95Asn Ile Cys Pro Gly Pro Pro Arg Pro Ser Pro Met Pro Pro Gly Pro 100 105 110Arg His Leu Phe Glu Val Leu Pro Met Cys Ser 115 1201091199DNAHomo sapiens 109gtcggttggc gaggtcactg caggtcagag gtcacgagat caaggatctg gaaccctgag 60cctcgaagcg gaggatccct gtgtcccagc cgggcatggc cgacccccac cagcttttcg 120atgacacaag ttcagcccag agccggggct atggggccca gcgggcacct ggtggcctga 180gttatcctgc agcctctccc acgccccatg cagccttcct ggctgacccg gtgtccaaca 240tggccatggc ctatgggagc agcctggccg cgcagggcaa ggagctggtg gataagaaca 300tcgaccgctt catccccatc accaagctca agtattactt tgctgtggac accatgtatg 360tgggcagaaa gctgggcctg ctgttcttcc cctacctaca ccaggactgg gaagtgcagt 420accaacagga caccccggtg gccccccgct ttgacgtcaa tgccccggac ctctacattc 480cagcaatggc tttcatcacc tacgttttgg tggctggtct tgcgctgggg acccaggata 540ggttctcccc agacctcctg gggctgcaag cgagctcagc cctggcctgg ctgaccctgg 600aggtgctggc catcctgctc agcctctatc tggtcactgt caacaccgac ctcaccacca 660tcgacctggt ggccttcttg ggctacaaat atgtcgggat gattggcggg gtcctcatgg 720gcctgctctt cgggaagatt ggctactacc tggtgctggg ctggtgctgc gtagccatct 780ttgtgttcat gatccggacg ctgcggctga agatcttggc agacgcagca gctgaggggg 840tcccggtgcg tggggcccgg aaccagctgc gcatgtacct gaccatggcg gtggcggcgg 900cgcagcctat gctcatgtac tggctcacct tccacctggt gcggtgagcg cgcccgctga 960acctcccgct gctgctgctg ctgctggggg ccactgtggc cgccgaactc atctcctgcc 1020tgcaggcccc aaggtccacc ctgtctggcc acaggcaccg cctccatccc atgtcccgcc 1080cagccccgcc cccaacccaa ggtgctgaga gatctccagc tgcacaggcc accgccccag 1140ggcgtggccg ctgttacaga aacaataaac cctgatgggc atggaaaaaa aaaaaaaaa 1199110283PRTHomo sapiens 110Met Ala Asp Pro His Gln Leu Phe Asp Asp Thr Ser Ser Ala Gln Ser 1 5 10 15Arg Gly Tyr Gly Ala Gln Arg Ala Pro Gly Gly Leu Ser Tyr Pro Ala 20 25 30Ala Ser Pro Thr Pro His Ala Ala Phe Leu Ala Asp Pro Val Ser Asn 35 40 45Met Ala Met Ala Tyr Gly Ser Ser Leu Ala Ala Gln Gly Lys Glu Leu 50 55 60Val Asp Lys Asn Ile Asp Arg Phe Ile Pro Ile Thr Lys Leu Lys Tyr 65 70 75 80Tyr Phe Ala Val Asp Thr Met Tyr Val Gly Arg Lys Leu Gly Leu Leu 85 90 95Phe Phe Pro Tyr Leu His Gln Asp Trp Glu Val Gln Tyr Gln Gln Asp 100 105 110Thr Pro Val Ala Pro Arg Phe Asp Val Asn Ala Pro Asp Leu Tyr Ile 115 120 125Pro Ala Met Ala Phe Ile Thr Tyr Val Leu Val Ala Gly Leu Ala Leu 130 135 140Gly Thr Gln Asp Arg Phe Ser Pro Asp Leu Leu Gly Leu Gln Ala Ser145 150 155 160Ser Ala Leu Ala Trp Leu Thr Leu Glu Val Leu Ala Ile Leu Leu Ser 165 170 175Leu Tyr Leu Val Thr Val Asn Thr Asp Leu Thr Thr Ile Asp Leu Val 180 185 190Ala Phe Leu Gly Tyr Lys Tyr Val Gly Met Ile Gly Gly Val Leu Met 195 200 205Gly Leu Leu Phe Gly Lys Ile Gly Tyr Tyr Leu Val Leu Gly Trp Cys 210 215 220Cys Val Ala Ile Phe Val Phe Met Ile Arg Thr Leu Arg Leu Lys Ile225 230 235 240Leu Ala Asp Ala Ala Ala Glu Gly Val Pro Val Arg Gly Ala Arg Asn 245 250 255Gln Leu Arg Met Tyr Leu Thr Met Ala Val Ala Ala Ala Gln Pro Met 260 265 270Leu Met Tyr Trp Leu Thr Phe His Leu Val Arg 275 2801112024DNAHomo sapiens 111gatatcttaa gcccgggtac gtcgacaaaa tttgctaagt taatccttct gtatttttgt 60ctcctagagc tgcttatcat ccagactttc caacagttct gacagcttta gaaatagata 120atgcggttgt ggcaaatagc ctaattgaca tgagaggcat agagacagtg ctactaatca 180aaaataattc tgtagctcgt gcagtaatgc agtcccaaaa gccacccaaa aattgtagag 240aagcttttac tgctgatggt gatcaagttt ttgcaggacg ttattattca tctgaaaata 300caagacctaa gttcctaagc agagatgtgg attctgaaat aagtgacttg gagaatgagg 360ttgaaaataa gacggcccag atattaaatc ttcagcaaca tttatctgcc cttgaaaaag 420atattaaaca caatgaggaa cttcttaaaa ggtgccaact acattataaa gaactaaaga 480tgaaaataag aaaaaatatt tctgaaattc gggaacttga gaacatagaa gaacaccagt 540ctgtagatat tgcaactttg gaagatgaag ctcaggaaaa taaaagcaaa atgaaaatgg 600ttgaggaaca tatggagcaa caaaaagaaa atatggagca tcttaaaagt ctgaaaatag 660aagcagaaaa taagtatgat gcaattaaat tcaaaattaa tcaactatcg gagctagcag 720acccacttaa ggatgaatta aaccttgctg attctgaagt ggataaccaa aaacgaggga 780aacgacatta tgaagaaaaa caaaaagaac acttggatac cttaaataaa aagaaacgag 840aactggatat gaaagagaaa gaactagagg agaaaatgtc acaagcaaga caaatctgcc 900cagagcgtat agaagtagaa aaatctgcat caattytgga caaagaaatt aatcgattaa 960ggcagaagat acaggcagaa catgctagtc atggagatcg agaggaaata atgaggcagt 1020accaagaagc aagagagacc

tatcttgatc tggatagtaa agtgaggact ttaaaaaagt 1080ttattaaatt actgggagaa atcatggagc acagattcaa gacatatcaa caatttagaa 1140ggtgtttgac tttacgatgc aaattatact ttgacaactt actatctcag cgggcctatt 1200gtggaaaaat gaattttgac cacaagaatg aaactctaag tatatcagtt cagcctggag 1260aaggaaataa agctgctttc aatgacatga gagccttgtc tggaggtgaa cgttctttct 1320ccacagtgtg ttttattctt tccctgtggt ccatcgcaga atctcctttc agatgcctgg 1380atgaatttga tgtctacatg gatatggtta ataggagaat tgccatggac ttgatactga 1440agatggcaga ttcccagcgt tttagacagt ttatcttgct cacacctcaa agcatgagtt 1500cacttccatc cagtaaactg ataagaattc tccgaatgtc tgatcctgaa agaggacaaa 1560ctacattgcc tttcagacct gtgactcaag aagaagatga tgaccaaagg tgatttgtaa 1620cttaacatgc cttgtcctga tgttgaagga tttgtgaagg gaaaaaaaat tctggactct 1680ttgatataat aaaatgagac tggaggcatt ctgaaatgaa agaaactcct ttatatatcc 1740aaccacaatc aaacatataa ataagcctgg aaaaccaact acaaccagca atttaagatt 1800actattactt taagaaaatc aatttcatag tattggtttt aaatcttttt aagttttttt 1860aatacgatct atttttatag gttctttttc agaagtaaaa ttttgtacat atatacatgt 1920acatatctgt ttagtttggg ttcatttcta taacattttg taagaaaata aaagtttgag 1980cacctgatta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2024112487PRTHomo sapiens 112Met Arg Gly Ile Glu Thr Val Leu Leu Ile Lys Asn Asn Ser Val Ala 1 5 10 15Arg Ala Val Met Gln Ser Gln Lys Pro Pro Lys Asn Cys Arg Glu Ala 20 25 30Phe Thr Ala Asp Gly Asp Gln Val Phe Ala Gly Arg Tyr Tyr Ser Ser 35 40 45Glu Asn Thr Arg Pro Lys Phe Leu Ser Arg Asp Val Asp Ser Glu Ile 50 55 60Ser Asp Leu Glu Asn Glu Val Glu Asn Lys Thr Ala Gln Ile Leu Asn 65 70 75 80Leu Gln Gln His Leu Ser Ala Leu Glu Lys Asp Ile Lys His Asn Glu 85 90 95Glu Leu Leu Lys Arg Cys Gln Leu His Tyr Lys Glu Leu Lys Met Lys 100 105 110Ile Arg Lys Asn Ile Ser Glu Ile Arg Glu Leu Glu Asn Ile Glu Glu 115 120 125His Gln Ser Val Asp Ile Ala Thr Leu Glu Asp Glu Ala Gln Glu Asn 130 135 140Lys Ser Lys Met Lys Met Val Glu Glu His Met Glu Gln Gln Lys Glu145 150 155 160Asn Met Glu His Leu Lys Ser Leu Lys Ile Glu Ala Glu Asn Lys Tyr 165 170 175Asp Ala Ile Lys Phe Lys Ile Asn Gln Leu Ser Glu Leu Ala Asp Pro 180 185 190Leu Lys Asp Glu Leu Asn Leu Ala Asp Ser Glu Val Asp Asn Gln Lys 195 200 205Arg Gly Lys Arg His Tyr Glu Glu Lys Gln Lys Glu His Leu Asp Thr 210 215 220Leu Asn Lys Lys Lys Arg Glu Leu Asp Met Lys Glu Lys Glu Leu Glu225 230 235 240Glu Lys Met Ser Gln Ala Arg Gln Ile Cys Pro Glu Arg Ile Glu Val 245 250 255Glu Lys Ser Ala Ser Ile Leu Asp Lys Glu Ile Asn Arg Leu Arg Gln 260 265 270Lys Ile Gln Ala Glu His Ala Ser His Gly Asp Arg Glu Glu Ile Met 275 280 285Arg Gln Tyr Gln Glu Ala Arg Glu Thr Tyr Leu Asp Leu Asp Ser Lys 290 295 300Val Arg Thr Leu Lys Lys Phe Ile Lys Leu Leu Gly Glu Ile Met Glu305 310 315 320His Arg Phe Lys Thr Tyr Gln Gln Phe Arg Arg Cys Leu Thr Leu Arg 325 330 335Cys Lys Leu Tyr Phe Asp Asn Leu Leu Ser Gln Arg Ala Tyr Cys Gly 340 345 350Lys Met Asn Phe Asp His Lys Asn Glu Thr Leu Ser Ile Ser Val Gln 355 360 365Pro Gly Glu Gly Asn Lys Ala Ala Phe Asn Asp Met Arg Ala Leu Ser 370 375 380Gly Gly Glu Arg Ser Phe Ser Thr Val Cys Phe Ile Leu Ser Leu Trp385 390 395 400Ser Ile Ala Glu Ser Pro Phe Arg Cys Leu Asp Glu Phe Asp Val Tyr 405 410 415Met Asp Met Val Asn Arg Arg Ile Ala Met Asp Leu Ile Leu Lys Met 420 425 430Ala Asp Ser Gln Arg Phe Arg Gln Phe Ile Leu Leu Thr Pro Gln Ser 435 440 445Met Ser Ser Leu Pro Ser Ser Lys Leu Ile Arg Ile Leu Arg Met Ser 450 455 460Asp Pro Glu Arg Gly Gln Thr Thr Leu Pro Phe Arg Pro Val Thr Gln465 470 475 480Glu Glu Asp Asp Asp Gln Arg 4851131424DNAHomo sapiens 113ggagcaagaa gggcgccgcg gcgtgcggcc cgcgcagccc ccggagccat gggcaagtgc 60agcgggcgct gcacgctggt cgccttctgc tgcctgcagc tggtggctgc gctggagcgg 120cagatctttg acttcctggg ctaccagtgg gctcccatcc tagccaactt cctgcacatc 180atggcagtca tcctgggcat ctttggcacc gtgcagtacc gctcccggta cctcatcctg 240tatgcagcct ggctggtgct ctgggttggc tggaatgcat ttatcatctg cttctacttg 300gaggttggac agctgtccca ggaccgggac ttcatcatga ccttcaacac atccctgcac 360cgctcctggt ggatggagaa tgggccaggc tgcctggtga cacctgttct gaactcccgc 420ctggctctgg aggaccacca tgtcatctct gtcactggct gcctgcttga ctacccctac 480attgaagccc tcagcagcgc cctgcagatc ttcctggcac tgttcggctt cgtgttcgcc 540tgctacgtga gcaaagtgtt cctggaggag gaggacagct ttgacttcat cggcggcttt 600gactcctacg gataccaggc gccccagaag acgtcgcatt tacagctgca gcctctgtac 660acgtcggggt agcctctgcc ccgcgcccac cccggcgcct cgccctgggc tgaccgcagc 720tgccgcgagc tcgggccaag gcgcaggcgt gtccccctgg tggcccgcgc gctcactgca 780gcctgtgccc aaccccgcgt ctgcatctgg agatgcggac ttggacgtgg acttggactt 840ggacttggat ttgagcttgg ctcttcgcag cccggacttc ggaggagtgg ggcggggcgg 900gggaggggca ccacggcttt tttgtttttt gtttgtttgt ttttaatctc agccttggcg 960tgagctgggg ccttcctctc ttctccagcc tctccctttc actcttcacc cagcatcctg 1020cccccctgtc caaaaacagc aggacatcag acccatccca tcccaccaca ctcactcacc 1080agctctgggg aaagctactg tgaactagga gcaggattcc tgggttctaa tcgcaggtcc 1140atcactgact gtgacgtcta gcaaagccct tgccctctct gagcctcggt ttccgcacct 1200caagtaatta atcccttagc aaatggactc tttcagactt ctcatttaac tcaattccct 1260gagctagact gggattaaaa ttctcatttt gcagtacatt aaaactgagg cccagagatg 1320tgatttgctt gaggccacac agctagattt ttggtggaag tgggccttga acacagtgta 1380ctttctgcag tttctgactg taaaaaaaaa aaaaaaaaaa aaaa 1424114207PRTHomo sapiens 114Met Gly Lys Cys Ser Gly Arg Cys Thr Leu Val Ala Phe Cys Cys Leu 1 5 10 15Gln Leu Val Ala Ala Leu Glu Arg Gln Ile Phe Asp Phe Leu Gly Tyr 20 25 30Gln Trp Ala Pro Ile Leu Ala Asn Phe Leu His Ile Met Ala Val Ile 35 40 45Leu Gly Ile Phe Gly Thr Val Gln Tyr Arg Ser Arg Tyr Leu Ile Leu 50 55 60Tyr Ala Ala Trp Leu Val Leu Trp Val Gly Trp Asn Ala Phe Ile Ile 65 70 75 80Cys Phe Tyr Leu Glu Val Gly Gln Leu Ser Gln Asp Arg Asp Phe Ile 85 90 95Met Thr Phe Asn Thr Ser Leu His Arg Ser Trp Trp Met Glu Asn Gly 100 105 110Pro Gly Cys Leu Val Thr Pro Val Leu Asn Ser Arg Leu Ala Leu Glu 115 120 125Asp His His Val Ile Ser Val Thr Gly Cys Leu Leu Asp Tyr Pro Tyr 130 135 140Ile Glu Ala Leu Ser Ser Ala Leu Gln Ile Phe Leu Ala Leu Phe Gly145 150 155 160Phe Val Phe Ala Cys Tyr Val Ser Lys Val Phe Leu Glu Glu Glu Asp 165 170 175Ser Phe Asp Phe Ile Gly Gly Phe Asp Ser Tyr Gly Tyr Gln Ala Pro 180 185 190Gln Lys Thr Ser His Leu Gln Leu Gln Pro Leu Tyr Thr Ser Gly 195 200 205115843DNAHomo sapiens 115ccagaatctg gcacgctgac ggggacctag ggacagacga ccgcacaaca cgccacgttg 60caggcgctgc caggccgggt gcctcaccta gctccttcat gtattcatca aagcctttgc 120tgtccaccag gcgccatctt ccttccagct gctgaactgt ggccatgggt acgcgacggc 180ctctcgggcg cctcctgcaa gcagggactc gcccggcgcg ccccacgcct catggacgcc 240ggcgcctgca cgtttcggcg cctctgcagg cccaggaagc cagaggggtc acctggaggc 300ctggccccgc ctctcctgca cccctccgtt tgacaacata tccaccgccg tttttccttt 360caaaataccc ggaccaatcg attagccctc gccggactcg gactgcagga agtgattgat 420cggctgtttg gtttattgat tcattaacta cggtgcctcc ctgaccttct gctcctcgcc 480agcgcacaag ctcacaatcc acaccctcct aagagaacct gctctcgcca tccgcaggtc 540tccctggccc aatagtgggg atatacctga gttgagctag aggattttat ccctgttggg 600atgggggacg tctcgggaag tgtggtttct aaactaaaag actgcaggaa gtgtcaactt 660tagtgactgt cattgccatt caagaatgtt tgattagttt atattccctt cgtagtgcac 720ccttcaccgt ttcttctcag acaccagcgg gtttcttctc agacaccagc gggttccctc 780tttctcttga actataataa taccctacac atgtgcgtaa aaaaaaaaaa aaaaaaaaaa 840aaa 84311684PRTHomo sapiens 116Met Gly Thr Arg Arg Pro Leu Gly Arg Leu Leu Gln Ala Gly Thr Arg 1 5 10 15Pro Ala Arg Pro Thr Pro His Gly Arg Arg Arg Leu His Val Ser Ala 20 25 30Pro Leu Gln Ala Gln Glu Ala Arg Gly Val Thr Trp Arg Pro Gly Pro 35 40 45Ala Ser Pro Ala Pro Leu Arg Leu Thr Thr Tyr Pro Pro Pro Phe Phe 50 55 60Leu Ser Lys Tyr Pro Asp Gln Ser Ile Ser Pro Arg Arg Thr Arg Thr 65 70 75 80Ala Gly Ser Asp1172232DNAHomo sapiensunsure(225) 117ataagctggg aggttcctgg cctgtctcct gctctctgct gagttgcttg gggcagggat 60ggtgaaaaga gcccccagga agtctctgga agtgaggagg gtccttgggc actaactgtg 120tgaccttggg caagtgactc cccatctctg ggcctcagga ggttgggcag gtccgggcca 180aggctgaaat actgagtgga ggaatggtgg gggaggagga ggaancgcct aataccccca 240accctcatct ttcccaacca cactcattcc aaattcttgc tctgggggtt ctgatccatg 300ggcaggtcac ggtgtgggag gcggaggctc cactccaggg aggatttgga gctccacaga 360gtacacctgg ggcaaaagga gcctgggcgt gggaggccag gactgggaag gttctgggac 420tctctccctc accccggact cctccccaga gcctggggct cagcaactct catgaccggg 480cactggtgaa gcgcaagttg aaggagatgg cagcagctgc cgagaaggag cgcaaggccc 540aggagaaggc tgcgcggcag cgggagaagc tccggcgccg agagcaggag gccaagaaga 600gctaggggag ggtgcacagg cgctggcacc cggcaggggc agccactggc tccgcgggca 660caggcctcac cagggaggct ggacctgggc gctgcacttg ggctagcctg gtcccacgct 720ctcagggggg acatgctctc tcttaccctg tcacttggtc tagacccaga gaccccagaa 780agggagaccc cagggagagg gcctagtaat aaatcctatt ttgaggactt gtttggcaca 840gagttcctgg gggaggagca gatgaagggg agagggcaga gaggccaggg ctgaggcaag 900tctgggagcc tgggtcaggc tgtcccattg ccctcaggcc atcgtggggc tggggtggag 960gggagctagg aggcctgcct gcctgcttgc ctgccagagg ccctgaggcc gggccccagg 1020gctcagagct gggctgggca tttcagcagg agcccatgtg ggagcggctc ctctccactc 1080ttccaggggg ctgtgtggtg ggagagctct gtcctgctcc cccaagaggc cagtgggcgc 1140tgcagcaagt cgcactcagg gtagactccc agccaaactc ctcaacagga gcgcagagaa 1200agcagcctgg ggcgagtgca gtctttgcca ggactcaaga ggggaggatg aacatcccct 1260tctccctctc ccctcctctg tcctgtgggt cccagggggc gagatgacac cacacaggtc 1320tgcctctcag ggcccattca agacctggtc tttgacccat tctccaagcc aggactccct 1380tcacttcctg ctgcttcctc agagggcacc taagtcctct ttgggagctg agcaaacagg 1440aactgatagg gacagaggac accacttcca ccagccaagg cctaggagct gctgacctgg 1500tcagccctca ccccagccag gcagagaggc aaaacctggg ggtccccggc agctacgaga 1560ttggaaaggt tcatcagccc tcccccatct gccccaggca ttgtcaggga atcagtgggc 1620tcagaactgg caggcggtgc aagctctgct tccctgggcc acactgaggg ctggggccag 1680ctccctggat gggggtggag tttaccagca gcctggggac agcatgtgtc ctttttagga 1740aatgtccttg gaggaagtgt tcatgtgtgg cgctggtcag cagctagtcc cgcttccagg 1800acactggtca gagttaccga tgaggcctgg gggctcccgc ttggaaaccc ctccagctcc 1860tcccatctgc ccagacagag cggcagatgg caccaatgca tgctggctcc ctcattcctg 1920cccaggggct gtggcttacg gccagcaccc tgtacctggg actcagccct tatcccccct 1980ctgctatctg tgctgggaga ggggcttcgg agggaaacag atatgaggac actggcacca 2040tctgggcctg gtggcagggc catgggaggt tggaaggcac ccacatcctt aaagccatca 2100gtagctctag tgggtgccca cctgcatgtg aaggggaggc agttctcaat ttatttcaat 2160aaatccttat gatgtgccag tgaccagaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2220aaaaaaaaaa aa 2232118133PRTHomo sapiensUNSURE(8) 118Met Val Gly Glu Glu Glu Glu Xaa Pro Asn Thr Pro Asn Pro His Leu 1 5 10 15Ser Gln Pro His Ser Phe Gln Ile Leu Ala Leu Gly Val Leu Ile His 20 25 30Gly Gln Val Thr Val Trp Glu Ala Glu Ala Pro Leu Gln Gly Gly Phe 35 40 45Gly Ala Pro Gln Ser Thr Pro Gly Ala Lys Gly Ala Trp Ala Trp Glu 50 55 60Ala Arg Thr Gly Lys Val Leu Gly Leu Ser Pro Ser Pro Arg Thr Pro 65 70 75 80Pro Gln Ser Leu Gly Leu Ser Asn Ser His Asp Arg Ala Leu Val Lys 85 90 95Arg Lys Leu Lys Glu Met Ala Ala Ala Ala Glu Lys Glu Arg Lys Ala 100 105 110Gln Glu Lys Ala Ala Arg Gln Arg Glu Lys Leu Arg Arg Arg Glu Gln 115 120 125Glu Ala Lys Lys Ser 1301194086DNAHomo sapiens 119aaaatagcgg gtactgtggt accggaggct ggcggtacca gtgtggattc caagtgatca 60tcacaggtac atatagtgat cttccttgtc cgtctcgtcc cactgggtac caggcgaatc 120ctactgggta ggtcgggtac gcggcatatg tggggtatgt ttggtatcca ggtatttgag 180gtacgaattc agtgtacgtt gccaggtgtg cttggtcttc taaatttgga atacataggc 240gaggatactg attctggata gtaaaattgt ttggagctcg gcaatcataa gaaacttgca 300gtttccaccc cctcttcacc tggagaactt gggctccatt aggtgcaatc gttggagtaa 360ttagcccatc ttttacattt cttgccacaa aatctcgaag agctgccatt tcaggttcgg 420acagtgaata cacatgtcca ctgggaatac tgtgtgctcc aggtatcatt tctatgtgag 480ggtcaaccag gcggtgatct gggtagacgt gctcatctac tggagtgtac acattctgga 540catagtaata cctcactggt tggtaaactc tgtatccatc tactggataa tagagtggcg 600gttgtggtgc tggtggtggg agcgatggtg gtattggaga atacatccgg cagtggtagc 660ggcagtattc agaatcaaag acgatagatc gagtgctcca tgtgatattg ggatcatgtg 720tgctcagcca gcgaacccct aggacgacag ggaagaatgg agactgagtc acatcaaatg 780acagcacctc tcggtgatct cccaggtcaa ctatcaggtc gtgagtttcg tggacaactg 840ggcccgatgc tatggggcgc ccatcaattg cttccacaag tattggccag tccttgattc 900ttagaggaat tccattttga gcaacatatt cgtgatcaat gaagttgcca gaagcaccag 960aatcgatcat ggctcggacg aacagggtgt gtctgcccgg aagatgaatc tggagcatca 1020cttgcaagtg tggagatgag gcatcatctt gtggggacct tattatttct ggcccggtcg 1080ctgaaggtcc ctctacagcg gggccgggga gtttcccgcc ggcgaagact ttgaggcctt 1140ggcaggacaa ttgtcagcgt agtgacctcc tgttccacag tagaggcaca ggttcagctt 1200tctgcgtctt tctttttctt cctgcgtcag gcgcatgcgg gcacctccca ccggctcggt 1260tggatctacc tggtggtggc ttgcaatgtg aggcaacacc agcgcccggg gtggcgagcg 1320tggcttgcga gctgcagcag ccctggccag ccttctctca atgtgaatgc actgcccaat 1380cagagcagac agcgacttgg cgacctcgag caacattaac tgaggaaaaa attgaaaaag 1440gggcgccctt gcttgggggc ttcctattgt ggaactgtta tggaaaggag ccccatccat 1500tgcttcctcc ttgaatggca aatgccttta tgatccctat aacttgtccc attatgttta 1560gacccttggt ggtcagaagg gttctattta gggcagtgtc ccctgcccct ccttgtcctc 1620caaaaatttt gggaggcact gacgtggatg tcatggggtc agcacaggca tcaacatccc 1680cagagggatg gaaccaagca gcctattgcc caggcattca ctaacaggca gcccatcctc 1740agcctcatag ctggccgggg agaagaaagg ctattttggg tcccagatct tttttttttt 1800ttttgagaca gagtctcgct ctgtcaccca ggctgaagtg caatggtgcg gtctcagctc 1860actacaacct ccgcctcccg agttcaagag attctcctgc ctcagcctcc tgagtagctg 1920ggactacagg tgcgtaccac caagcctggc taatttttgt gcttttagta gggacgtggt 1980ttcaccatgt tgcccaggtt ggtctcaaac tcctgggctc atgcagtccg cctacctcag 2040cctcccaaag tgctgggatt acaggcatga gccactgcac ccggtctctg tttacaaatt 2100tatcaccagc ttcatcccct aaggttataa gctccatgag ggtgggaagt ctgtattgtt 2160cacctctgta tcctaagcat ctagaacata gcccggcaca cagtaggtgc tgaagaattg 2220aatctgttaa tgtagaaagg atgtttcatc tagctgaagt gtcttgtaca gaataaactc 2280tcaataaatg aactgtggac acatggaagg gtgagctaga gctctgctca ggggttgagt 2340gctcctcttg tgcccttgtg gttgtctggt tacctgaact aattggagtg cgatgcagac 2400atagtcatgg agtgagacag cagaactttg ctgtcttgtt tgtgagccca catcaggggt 2460tctagactgg ctggttgaca tggtggcccc agcctgtctc ttcagcagct cggcttataa 2520aaaataacca cctcctattt tggcctcttt ggccgaattc ggccaaagag gcctagcctc 2580cgattactaa accccttgcc ccacaaacgt ccacattgac gagcctcttt ttagtaactg 2640cttccccgta attccttcag aggttgctgt acccttcgct gatgtgctgc cctcctgtaa 2700aacctccaga tgccttccca cgtaatgccc ctttcagatg ctttaagctg agagcttaaa 2760ccacaggtac catggctgac gcctgccagg tttctgctgc agataatcta tgatgggagg 2820ggcatatttt ttacttcatt acttatgtaa actcttgttc cagaaagctt taatgtgtgt 2880gggagtgttc tgggtctatt aggtctgtgc gcatgggtgt gggcatttgc ctgtgtccac 2940cgggtgggtc tcattatgaa atgtatgttt atgtagggct ttaatggctg aaaatggcaa 3000agagatgaat agaccacttg gccccatgtg taattgccag gccccttctg tgctcaaatg 3060aggtgtccga gtgaaggtca gcccttccct tctgtatttg gggcctattt atgccaccag 3120taattttata agaaatctga atagttctcc cctttgagtg catttaactc tttagtatct 3180tctctcttac ctatttgagc ccctctagct acagtctggc ttaaatgaaa ggggaattat 3240atgcttaaga aaaagtagga cacggttgag gcagtttgct gactgaatac gcgaagaagg 3300acctgatggg ctcatatgca ccactgccat cacagtcccc atcgtgatgc aagcttatat 3360gattcttgag gtaactctac cagatacttc cagatttaga aatgtgtcaa aggaaaaatt 3420ggtgatactc ttctttccct gccagaaaca gcccagatct cctcttaagc ggaaaagaga 3480ttgaccttct agcagaggca aaggtaaact cctgtaagtt acttctgtta ccaaagggag 3540gggggcggct tttgtgaatg tatgaggagc ttttgccaga gagatattcg gaggaggggt 3600gtgcccatat gcacacatat attttcccgc ataaccgtat ccaatgctag catttagagg 3660aaggcattta gccaccaaaa gtccatccat ctatgctgct tccacagaga

aaacattttc 3720tctttcctcc tcttgaactt acataatatc ctcctcccat tccaacctta gaatggagtc 3780ttctgggggc agctgcaaag cgttctccct aggacagatg gagcctccct ttcctcatct 3840actctgtggg tggtttcagg gcccacgagt caacatgagg agttgtgctg gtggtatgtg 3900tgttggaggc tgggctggct gattcacagt gacgaggatg tcaataataa caagaatgag 3960aatgatggta cctaataaag actttttttc ccaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4020aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4080aaaaaa 4086120102PRTHomo sapiens 120Met Ser Thr Gly Asn Thr Val Cys Ser Arg Tyr His Phe Tyr Val Arg 1 5 10 15Val Asn Gln Ala Val Ile Trp Val Asp Val Leu Ile Tyr Trp Ser Val 20 25 30His Ile Leu Asp Ile Val Ile Pro His Trp Leu Val Asn Ser Val Ser 35 40 45Ile Tyr Trp Ile Ile Glu Trp Arg Leu Trp Cys Trp Trp Trp Glu Arg 50 55 60Trp Trp Tyr Trp Arg Ile His Pro Ala Val Val Ala Ala Val Phe Arg 65 70 75 80Ile Lys Asp Asp Arg Ser Ser Ala Pro Cys Asp Ile Gly Ile Met Cys 85 90 95Ala Gln Pro Ala Asn Pro 1001211293DNAHomo sapiens 121ggtccagaag aaatgtggct tcagctctgc tgctactgtg cctcccttct cctgccccac 60tcagcccaca aaataggctg gacactcaaa aaacgttgcg tttatctacc ttttagagag 120ggtgaatagc agagaactgg aggtgggaat ggtaaggaac tcccagcagg gtagtggagg 180gaatgggctg acgcatctaa ggctgatgcc aggtctgctc cctatctggg tggcctcagc 240aaatgacgtc cagcacatcc aggggcaggc tcaagggaga acagccccca aagctaagat 300cctgccaagc taaatacagt agttctaatg aaatgtgaga ggctataatc ccatttggga 360aattcctaaa aagtcatgag gcaggggatt ggtttatgtt attatcatga cctgagagtc 420atggctcaga gccaaatgtt caggattgaa ttcaacagca tttaaatgtc tttagagcag 480gatggaaata tgttagcaat gcctgcagag tgccaagtaa acgcaaaagc caatgagatc 540ataaaggaag ttgttagcta acctagtgga gtcgccaact tccttctact ctaataatta 600aaataaaaat aatacttggg aggtaactgg aataaaggtt ctaaaatcaa aaccctctga 660agggtgaaaa ctgggagcct cctgttccca tagtaaccac agcactcagg gcactgtctc 720ccagcgctgg agtactgtct tatgaccaga gatcctaagc aacctctgct catctgagtt 780gtccaccata ttgtgggcat gagtccttga caatagtaaa tagcacctct gttcccttat 840tgggtaaatg attttccaac tctgggaatg tgtagaattc attatggaaa taatgcaata 900attcaaatcc ataatattga tactttcatg ttaagtttag gactaatctt gtgtatgctc 960cttaagtgat ttgaatcttt aaaaagctta tgattccaat ttgaaatgtg aaattgattt 1020tacgtttgtg atttgaagtt gaaaggtata agaatattta acttagctca tgaaaagtat 1080tagactagat ttactataag tttaatgtat tagatttaca agagatgctt aaatatatga 1140gaatgttttg tcttaattgg ttataatctt gtcatatcaa tgatttgaag tgctaaaata 1200gaaaattaaa tatgataaat tacacaagaa gtttagaatg tttaaaagat tttaataaac 1260aaagcctata actaagaaaa aaaaaaaaaa aaa 129312254PRTHomo sapiens 122Met Val Arg Asn Ser Gln Gln Gly Ser Gly Gly Asn Gly Leu Thr His 1 5 10 15Leu Arg Leu Met Pro Gly Leu Leu Pro Ile Trp Val Ala Ser Ala Asn 20 25 30Asp Val Gln His Ile Gln Gly Gln Ala Gln Gly Arg Thr Ala Pro Lys 35 40 45Ala Lys Ile Leu Pro Ser 501232509DNAHomo sapiens 123gagctgcatc gcgggaggcg catggcgggg atggcgctgg cgcgggcctg gaagcagatg 60tcctggttct actaccagta cctgctggtc acggcgctct acatgctgga gccctgggag 120cggacggtgt tcagctggtt tccattgtgg ggatggcact atacacagga tacgtcttca 180tgccccagca catcatggcg atattgcact actttgaaat cgtacaatga ccaagatgcg 240accaggatca gaggttcctt ggggaagacc caccctacga agttggaatg agaccatcag 300atgtgataag aaactcttct agatgtcaac ataaccaacc ttataaagac taaaattcat 360gagtagaaca ggaaaatcat cctgactcat gtgttgtgtt ctttattttt aattttcaaa 420gaggctcttg tatagcagtt tttgtctatt ttaacattgt agtcatttgt actttgatat 480cagtattttc ttaacctttg tgactgtttc aatattaccc ccgtgaaagc ttttcttaat 540gtaactttga gtacatttta attgccttct atttttaaaa ctcaaaatca ttagttgggc 600tttactgttc ttgctattgt atggcatata catctgcctg gatatatttc tactcttgac 660caaagttttg taaagaacaa tataagattt cgggtagggg tatggggagg gaagatattt 720tattgagaac tacttaacaa aagatttatc tgtaagcttg aactcaggag tacagtttta 780gctatctaga ctctaacagc ttttgcttta aaattattaa agtgtttctt aatgaaaaag 840aaaagatctt gctaaagtta aaataaggaa catttcacct tttaaatatt taattcttat 900gtggacttat ttccagaaaa ctttggtgat aattcttgag acaaaaggtg gttaagtagc 960attattatgt aatgcttata taccatagag tttttaatag aagagaaatc catttcctcc 1020gagggtcact attaacaatg tacttcctta aatttagttt aatgattgta atgggtgctg 1080catttgcaca ttgcattaag ttatgatgag acgaattgtt gttaaaaatt atagcaaaaa 1140gaaatgtaaa cttggttaaa atcctttcac tctttgtatt gtttttttta aggtttttat 1200tccttaaatg taaaatgact acctaatttt ttgatgtaaa tacattaaat tcaaagagaa 1260aaaaaatcag ctgatgtagc agtatatctt ttccttgatg gttaaatatt gatctagtat 1320ttatattgct gaattatttt ctgtggagga ccagataagc agtaagtatg tcttatccta 1380tatgttttgc aacataaaaa tattgctaat tgaaaagaat taggcaatta tgtgtgttgc 1440tgggttgttt ttttgttttt tttttttgag acggagtctt gccctgtcgc ccaggatgga 1500gtgcaacagc atgatctcgg ttcactgcaa cctccatctc ctgggatcaa gtgattctcc 1560tgcctcagcc tcctgaatag ctgggattac aggcacctgc caccatgcct ggctaatttt 1620ttgtatctgt agtagagacg gggtttcact gtgttggcca ggatggtctc aaactcctga 1680cctcctgatc cacctgcctc ggcctcccaa agtgctgggt ttacaggcgt gagccaccgc 1740gcccggccaa aattgaggta ttttttgccc tacgttttaa ggactagact tttgaagtat 1800tttatagtct agaggtctca agtaatatat atgtgtttaa tatttttaga gccaattgat 1860accacaatta gataggagta gtgagaataa tatggaatta cttggtttga agtagttaaa 1920aattggatat ggttatatct gagctgtagt catattatct caagaaaaat aatacgagga 1980tttaacataa gatttgttct attaatgccc aaatttggct ttcctctact atcccccata 2040gagaaccact aacaagtgga tgtctaatat tcctctggtg agttgaaggc aggagaagtt 2100gagaatcatt agtttcaatg agtatccagg tgacctatcc tggccctcta ctcagaaacc 2160ggcaatttgt cttcactctg agattcatta aattgctgtt gtataactga tggttattat 2220gaacactgac ctgtgagaca tatggaagat aaagtttggt cttacaggaa atcttgagga 2280gagtcaaaag agaaatggga gatgtctctt gagaggtgat cagagaagtt tatgctcact 2340gtctgatgca aatgtctggt ctatttgtta gtaaataaca gggaaatcat tttcactttt 2400tgttaaaaat aaggtattta caagcatacc ttgtagttat tgtgggttca gtttcagacc 2460actgcaataa agtgaatatc tcaataaaaa aaaaaaaaaa aaaaaaaaa 250912489PRTHomo sapiens 124Met Ala Gly Met Ala Leu Ala Arg Ala Trp Lys Gln Met Ser Trp Phe 1 5 10 15Tyr Tyr Gln Tyr Leu Leu Val Thr Ala Leu Tyr Met Leu Glu Pro Trp 20 25 30Glu Arg Thr Val Phe Ser Trp Phe Pro Leu Trp Gly Trp His Tyr Thr 35 40 45Gln Asp Thr Ser Ser Cys Pro Ser Thr Ser Trp Arg Tyr Cys Thr Thr 50 55 60Leu Lys Ser Tyr Asn Asp Gln Asp Ala Thr Arg Ile Arg Gly Ser Leu 65 70 75 80Gly Lys Thr His Pro Thr Lys Leu Glu 851252672DNAHomo sapiens 125ggaggagaga agaggaggtg gagaaggctt gggctcgcgc cgctgaagtc ggcttacccg 60ctggccgcct cctgacaagc gggagggatc cgcggtggac ccagggaagc ggaggagcct 120ggcggccacc ccctcttcct cacttccctg tactctcatc gctctcggcc tccgacacga 180aaaggaagca aatgagctga tggaagatct gtttgaaact ttccaagatg agatgggatt 240ctccaacatg gaagatgatg gcccagaaga ggaggagcgt gtggctgagc ctcaagctaa 300ctttaacacc cctcaagctc tacggtttga ggaactactg gccaacctac taaatgaaca 360acatcagata gcgaaggaac tatttgaaca gctgaagatg aagaaacctt cagccaaaca 420gcagaaggag gtagagaagg ttaaacccca gtgtaaggaa gttcatcaga ccctgattct 480ggacccagca caaaggaaga gactccagca gcagatgcag cagcatgttc agctcttgac 540acaaatccac cttcttgcca cctgcaaccc caatctcaat ccggaggcca gtagcaccag 600gatatgtctt aaagagctgg gaacctttgc tcaaagctcc atcgcccttc accatcagta 660caaccccaag tttcagaccc tgttccaacc ctgtaacttg atgggagcta tgcagctgat 720tgaagacttc agcacacatg tcagcattga ctgcagccct cataaaactg tcaagaagac 780tgccaatgaa tttccctgtt tgccaaagca agtggcttgg atcctggcca caagcaaggt 840tttcatgtat ccagagttac ttccagtgtg ttccctgaag gcaaagaatc cccaggataa 900gatcctcttc accaaggctg aggacaattt gttagcttta ggactgaagc attttgaagg 960gactgagttt cttaaccctc taatcagcaa gtaccttcta acctgcaaga ctgcccgcca 1020actgacagtg agaatcaaga acctcaacat gaacagagct cctgacaaca tcattaaatt 1080ttataagaag accaaacagc tgccagtcct aggaaaatgc tgtgaagaga tccagccaca 1140tcagtggaag ccacctatag agagagaaga acaccggctc ccattctggt taaaggccag 1200tctgccatcc atccaggaag aactgcggca catggctgat ggtgctagag aggtaggaaa 1260tatgactgga accactgaga tcaactcaga tcaaggccta gaaaaagaca actcagagtt 1320ggggagtgaa actcggtacc cactgctatt gcctaagggt gtagtcctga aactgaagcc 1380agttgccgac cgtttcccca agaaggcttg gagacagaag cgttcatcag tcctgaaacc 1440cctccttatc caacccagcc cctctctcca gcccagcttc aaccctggga aaacaccagc 1500ccaatcaact cattcagaag cccctccgag caaaatggtg ctccggattc ctcacccaat 1560acagccagcc actgttttac agacagttcc aggtgtccct ccactggggg tcagtggagg 1620tgagagtttt gagtctcctg cagcactgcc tgctatgccc cctgaggcca ggacaagctt 1680ccctctgtct gagtcccaga ctttgctctc ttctgcccct gtgcccaagg taatgatgcc 1740ctcccctgcc tcttccatgt ttcgaaagcc atatgtgaga cggagaccct caaaaagaag 1800gggagccagg gcctttcgct gtatcaaacc tgcccctgtt atccaccctg catctgttat 1860cttcactgtt cctgctacca ctgtgaagat tgtgagcctt ggcggtggct gtaacatgat 1920ccagcctgtc aatgcggctg tggcccagag tccccagact attcccatcg ccaccctctt 1980ggttaaccct acttccttcc cctgtccatt gaaccagccc cttgtggcct cctctgtctc 2040acccttaatt gtttctggca attctgtgaa tcttcctata ccatccaccc ctgaagataa 2100ggcccacatg aatgtggaca ttgcttgtgc tgtggctgat ggggaaaatg cctttcaggg 2160cctagaaccc aaattagagc cccaggaact atctcctctc tctgctactg ttttccccaa 2220agtggaacat agcccagggc ctccaccagt cgataaacag tgccaagaag gattgtcaga 2280gaacagtgcc tatcgctgga ccgttgtgaa aacagaggag ggaaggcaag ctctggagcc 2340gctccctcag ggcatccagg agtctctaaa caactcttcc cctggggatt tagaggaagt 2400tgtcaagatg gaacctgaag atgctacaga ggaaatcagt ggatttcttt gagctaggag 2460aataagagtc tggagactgg gagccttcac ttcggcctcc gattggtggc gcatagggtg 2520taaccaatag gaaaccccta aagggtactt aaaccccaga ttttgcaact ggggctcttg 2580agcagcttgc tttagcctgc tcccactctg tggaatatac ttttgcttca ataaatctgt 2640gcttttattg cttcaaaaaa aaaaaaaaaa aa 2672126750PRTHomo sapiens 126Met Glu Asp Leu Phe Glu Thr Phe Gln Asp Glu Met Gly Phe Ser Asn 1 5 10 15Met Glu Asp Asp Gly Pro Glu Glu Glu Glu Arg Val Ala Glu Pro Gln 20 25 30Ala Asn Phe Asn Thr Pro Gln Ala Leu Arg Phe Glu Glu Leu Leu Ala 35 40 45Asn Leu Leu Asn Glu Gln His Gln Ile Ala Lys Glu Leu Phe Glu Gln 50 55 60Leu Lys Met Lys Lys Pro Ser Ala Lys Gln Gln Lys Glu Val Glu Lys 65 70 75 80Val Lys Pro Gln Cys Lys Glu Val His Gln Thr Leu Ile Leu Asp Pro 85 90 95Ala Gln Arg Lys Arg Leu Gln Gln Gln Met Gln Gln His Val Gln Leu 100 105 110Leu Thr Gln Ile His Leu Leu Ala Thr Cys Asn Pro Asn Leu Asn Pro 115 120 125Glu Ala Ser Ser Thr Arg Ile Cys Leu Lys Glu Leu Gly Thr Phe Ala 130 135 140Gln Ser Ser Ile Ala Leu His His Gln Tyr Asn Pro Lys Phe Gln Thr145 150 155 160Leu Phe Gln Pro Cys Asn Leu Met Gly Ala Met Gln Leu Ile Glu Asp 165 170 175Phe Ser Thr His Val Ser Ile Asp Cys Ser Pro His Lys Thr Val Lys 180 185 190Lys Thr Ala Asn Glu Phe Pro Cys Leu Pro Lys Gln Val Ala Trp Ile 195 200 205Leu Ala Thr Ser Lys Val Phe Met Tyr Pro Glu Leu Leu Pro Val Cys 210 215 220Ser Leu Lys Ala Lys Asn Pro Gln Asp Lys Ile Leu Phe Thr Lys Ala225 230 235 240Glu Asp Asn Leu Leu Ala Leu Gly Leu Lys His Phe Glu Gly Thr Glu 245 250 255Phe Leu Asn Pro Leu Ile Ser Lys Tyr Leu Leu Thr Cys Lys Thr Ala 260 265 270Arg Gln Leu Thr Val Arg Ile Lys Asn Leu Asn Met Asn Arg Ala Pro 275 280 285Asp Asn Ile Ile Lys Phe Tyr Lys Lys Thr Lys Gln Leu Pro Val Leu 290 295 300Gly Lys Cys Cys Glu Glu Ile Gln Pro His Gln Trp Lys Pro Pro Ile305 310 315 320Glu Arg Glu Glu His Arg Leu Pro Phe Trp Leu Lys Ala Ser Leu Pro 325 330 335Ser Ile Gln Glu Glu Leu Arg His Met Ala Asp Gly Ala Arg Glu Val 340 345 350Gly Asn Met Thr Gly Thr Thr Glu Ile Asn Ser Asp Gln Gly Leu Glu 355 360 365Lys Asp Asn Ser Glu Leu Gly Ser Glu Thr Arg Tyr Pro Leu Leu Leu 370 375 380Pro Lys Gly Val Val Leu Lys Leu Lys Pro Val Ala Asp Arg Phe Pro385 390 395 400Lys Lys Ala Trp Arg Gln Lys Arg Ser Ser Val Leu Lys Pro Leu Leu 405 410 415Ile Gln Pro Ser Pro Ser Leu Gln Pro Ser Phe Asn Pro Gly Lys Thr 420 425 430Pro Ala Gln Ser Thr His Ser Glu Ala Pro Pro Ser Lys Met Val Leu 435 440 445Arg Ile Pro His Pro Ile Gln Pro Ala Thr Val Leu Gln Thr Val Pro 450 455 460Gly Val Pro Pro Leu Gly Val Ser Gly Gly Glu Ser Phe Glu Ser Pro465 470 475 480Ala Ala Leu Pro Ala Met Pro Pro Glu Ala Arg Thr Ser Phe Pro Leu 485 490 495Ser Glu Ser Gln Thr Leu Leu Ser Ser Ala Pro Val Pro Lys Val Met 500 505 510Met Pro Ser Pro Ala Ser Ser Met Phe Arg Lys Pro Tyr Val Arg Arg 515 520 525Arg Pro Ser Lys Arg Arg Gly Ala Arg Ala Phe Arg Cys Ile Lys Pro 530 535 540Ala Pro Val Ile His Pro Ala Ser Val Ile Phe Thr Val Pro Ala Thr545 550 555 560Thr Val Lys Ile Val Ser Leu Gly Gly Gly Cys Asn Met Ile Gln Pro 565 570 575Val Asn Ala Ala Val Ala Gln Ser Pro Gln Thr Ile Pro Ile Ala Thr 580 585 590Leu Leu Val Asn Pro Thr Ser Phe Pro Cys Pro Leu Asn Gln Pro Leu 595 600 605Val Ala Ser Ser Val Ser Pro Leu Ile Val Ser Gly Asn Ser Val Asn 610 615 620Leu Pro Ile Pro Ser Thr Pro Glu Asp Lys Ala His Met Asn Val Asp625 630 635 640Ile Ala Cys Ala Val Ala Asp Gly Glu Asn Ala Phe Gln Gly Leu Glu 645 650 655Pro Lys Leu Glu Pro Gln Glu Leu Ser Pro Leu Ser Ala Thr Val Phe 660 665 670Pro Lys Val Glu His Ser Pro Gly Pro Pro Pro Val Asp Lys Gln Cys 675 680 685Gln Glu Gly Leu Ser Glu Asn Ser Ala Tyr Arg Trp Thr Val Val Lys 690 695 700Thr Glu Glu Gly Arg Gln Ala Leu Glu Pro Leu Pro Gln Gly Ile Gln705 710 715 720Glu Ser Leu Asn Asn Ser Ser Pro Gly Asp Leu Glu Glu Val Val Lys 725 730 735Met Glu Pro Glu Asp Ala Thr Glu Glu Ile Ser Gly Phe Leu 740 745 7501272673DNAHomo sapiens 127aggtctagaa ttcaatcggg acgcctcgcg ctgattctca cgggcccggc tgccggcccc 60cgctctgccc tgcataataa aatggctaat caggtgaatg gtaatgcggt acagttaaaa 120gaagaggaag aaccaatgga tacttccagt gtaactcaca cagaacacta caagacactg 180atagaggcag gcctcccaca gaaggtggca gaaagacttg atgaaatatt tcagacagga 240ttggtagctt atgtcgatct tgatgaaaga gcaattgatg ctctcaggga atttaatgaa 300gaaggagctc tgtctgtact acagcagttc aaggaaagtg acttatcaca tgttcagaac 360aaaagtgcat ttttatgtgg agttatgaag acctacaggc agagagagaa acaggggagc 420aaggtgcaag agtccacaaa gggacctgat gaagcgaaga tcaaggcctt gcttgagaga 480actggttata ctctggatgt aaccacagga cagaggaagt atggtggtcc tccaccagac 540agtgtgtact ctggcgtgca acctggaatt ggaacggagg tatttgtagg caaaatacca 600agggatttat atgaggatga gttggtgccc ctttttgaga aggccggacc catttgggat 660ctacgtctta tgatggatcc actgtccggt cagaatagag ggtatgcatt tatcaccttc 720tgtggaaagg aagctgcaca ggaagccgtg aaactgtgtg acagctatga aattcgccct 780ggtaaacacc ttggagtgtg catttctgtg gcaaacaaca gactttttgt tggatccatt 840ccgaagaata agactaaaga aaacattttg gaagaattca gtaaagtcac agagggtttg 900gtggacgtta ttctctatca tcaacccgat gacaaaaaga agaatcgggg gttctgcttc 960cttgaatatg aggatcacaa gtcagcagca caagccagac gccggctgat gagtggaaaa 1020gtaaaagtgt ggggaaatgt agttacagtt gaatgggctg accctgtgga agaaccagat 1080ccagaagtca tggctaaggt aaaagttttg tttgtgagaa acttggctac tacggtgaca 1140gaagaaatat tggaaaagtc attttctgaa tttggaaaac tcgaaagagt aaagaagttg 1200aaagattatg catttgttca ttttgaagac agaggagcag ctgttaaggc tatggatgaa 1260atgaatggca aagaaataga aggggaagaa attgaaatag tcttagccaa gccaccagac 1320aagaaaagga aagagcgcca agctgctaga caggcctcca gaagcactgc gtatgaagat 1380tattactacc accctcctcc tcgcatgcca cctccaatta gaggtcgggg tcgtggtggg 1440gggagaggtg gatatggcta ccctccagat tactacggct atgaagatta ctatgatgat 1500tactatggtt atgattatca cgactatcgt ggaggctatg aagatcccta ctacggctat 1560gatgatggct atgcagtaag aggaagagga ggaggaaggg gagggcgagg tgctccacca 1620ccaccaaggg ggaggggagc accacctcca agaggtagag ctggctattc acagaggggg 1680gcacctttgg gaccaccaag aggctctagg ggtggcagag ggggtcctgc tcaacagcag 1740agaggccgtg gttcccgtgg atctcggggc aatcgtgggg gcaatgtagg aggcaagaga 1800aaggcagatg ggtacaacca gcctgattcc aagcgtcgtc agaccaacaa ccaacagaac

1860tggggttccc aacccatcgc tcagcagccg cttcagcaag gtggtgacta ttctggtaac 1920tatggttaca ataatgacaa ccaggaattt tatcaggata cttatgggca acagtggaag 1980tagacaagta agggcttgaa aatgatactg gcaagatacg attggctcta gatctacatt 2040cttcaaaaaa aaaaattggc ttaactgttt catctttaag tagcattttg ctgccatttg 2100tattgggctg aagaaatcac tattgtgtat atactcaagt ctttttattt ttcctctttt 2160cataaatgct cttggacatt attgggcttg cagagttccc ttattctggg gattacaatg 2220cttttatcgt ttcaggcttc attttagctt caaaacaagc tgggcacact gttaaatcat 2280gattttgcag aacctttggt tttggacagt ttcatttttt tggatttggg atagattaca 2340taggagtatg gagtatgctg taaataaaaa tacaagctag tgctttgtct tagtagtttt 2400aagaaattaa agcaaacaaa tttaagtttt cttgtattga aaataaccta tgattgtatg 2460ttttgcattc ctagaagtag gttaactgtg tttttaaatt gttataactt cacacctttt 2520tgaaatctgc cctacaaaat ttgtttggct taaacgtcaa aagccgtgac aatttgttct 2580ttgatgtgat tgtatttcca atttcttgtt catgtaagat ttcaataaaa ctaaaaaatc 2640tattcaaaac aaaaaaaaaa aaaaaaaaaa aaa 2673128633PRTHomo sapiens 128Met Ala Asn Gln Val Asn Gly Asn Ala Val Gln Leu Lys Glu Glu Glu 1 5 10 15Glu Pro Met Asp Thr Ser Ser Val Thr His Thr Glu His Tyr Lys Thr 20 25 30Leu Ile Glu Ala Gly Leu Pro Gln Lys Val Ala Glu Arg Leu Asp Glu 35 40 45Ile Phe Gln Thr Gly Leu Val Ala Tyr Val Asp Leu Asp Glu Arg Ala 50 55 60Ile Asp Ala Leu Arg Glu Phe Asn Glu Glu Gly Ala Leu Ser Val Leu 65 70 75 80Gln Gln Phe Lys Glu Ser Asp Leu Ser His Val Gln Asn Lys Ser Ala 85 90 95Phe Leu Cys Gly Val Met Lys Thr Tyr Arg Gln Arg Glu Lys Gln Gly 100 105 110Ser Lys Val Gln Glu Ser Thr Lys Gly Pro Asp Glu Ala Lys Ile Lys 115 120 125Ala Leu Leu Glu Arg Thr Gly Tyr Thr Leu Asp Val Thr Thr Gly Gln 130 135 140Arg Lys Tyr Gly Gly Pro Pro Pro Asp Ser Val Tyr Ser Gly Val Gln145 150 155 160Pro Gly Ile Gly Thr Glu Val Phe Val Gly Lys Ile Pro Arg Asp Leu 165 170 175Tyr Glu Asp Glu Leu Val Pro Leu Phe Glu Lys Ala Gly Pro Ile Trp 180 185 190Asp Leu Arg Leu Met Met Asp Pro Leu Ser Gly Gln Asn Arg Gly Tyr 195 200 205Ala Phe Ile Thr Phe Cys Gly Lys Glu Ala Ala Gln Glu Ala Val Lys 210 215 220Leu Cys Asp Ser Tyr Glu Ile Arg Pro Gly Lys His Leu Gly Val Cys225 230 235 240Ile Ser Val Ala Asn Asn Arg Leu Phe Val Gly Ser Ile Pro Lys Asn 245 250 255Lys Thr Lys Glu Asn Ile Leu Glu Glu Phe Ser Lys Val Thr Glu Gly 260 265 270Leu Val Asp Val Ile Leu Tyr His Gln Pro Asp Asp Lys Lys Lys Asn 275 280 285Arg Gly Phe Cys Phe Leu Glu Tyr Glu Asp His Lys Ser Ala Ala Gln 290 295 300Ala Arg Arg Arg Leu Met Ser Gly Lys Val Lys Val Trp Gly Asn Val305 310 315 320Val Thr Val Glu Trp Ala Asp Pro Val Glu Glu Pro Asp Pro Glu Val 325 330 335Met Ala Lys Val Lys Val Leu Phe Val Arg Asn Leu Ala Thr Thr Val 340 345 350Thr Glu Glu Ile Leu Glu Lys Ser Phe Ser Glu Phe Gly Lys Leu Glu 355 360 365Arg Val Lys Lys Leu Lys Asp Tyr Ala Phe Val His Phe Glu Asp Arg 370 375 380Gly Ala Ala Val Lys Ala Met Asp Glu Met Asn Gly Lys Glu Ile Glu385 390 395 400Gly Glu Glu Ile Glu Ile Val Leu Ala Lys Pro Pro Asp Lys Lys Arg 405 410 415Lys Glu Arg Gln Ala Ala Arg Gln Ala Ser Arg Ser Thr Ala Tyr Glu 420 425 430Asp Tyr Tyr Tyr His Pro Pro Pro Arg Met Pro Pro Pro Ile Arg Gly 435 440 445Arg Gly Arg Gly Gly Gly Arg Gly Gly Tyr Gly Tyr Pro Pro Asp Tyr 450 455 460Tyr Gly Tyr Glu Asp Tyr Tyr Asp Asp Tyr Tyr Gly Tyr Asp Tyr His465 470 475 480Asp Tyr Arg Gly Gly Tyr Glu Asp Pro Tyr Tyr Gly Tyr Asp Asp Gly 485 490 495Tyr Ala Val Arg Gly Arg Gly Gly Gly Arg Gly Gly Arg Gly Ala Pro 500 505 510Pro Pro Pro Arg Gly Arg Gly Ala Pro Pro Pro Arg Gly Arg Ala Gly 515 520 525Tyr Ser Gln Arg Gly Ala Pro Leu Gly Pro Pro Arg Gly Ser Arg Gly 530 535 540Gly Arg Gly Gly Pro Ala Gln Gln Gln Arg Gly Arg Gly Ser Arg Gly545 550 555 560Ser Arg Gly Asn Arg Gly Gly Asn Val Gly Gly Lys Arg Lys Ala Asp 565 570 575Gly Tyr Asn Gln Pro Asp Ser Lys Arg Arg Gln Thr Asn Asn Gln Gln 580 585 590Asn Trp Gly Ser Gln Pro Ile Ala Gln Gln Pro Leu Gln Gln Gly Gly 595 600 605Asp Tyr Ser Gly Asn Tyr Gly Tyr Asn Asn Asp Asn Gln Glu Phe Tyr 610 615 620Gln Asp Thr Tyr Gly Gln Gln Trp Lys625 630129938DNAHomo sapiens 129gcaagtccat gcctctacca tgagggtgga ggagttaaga tcaacagatc cacatgtacc 60ttgaggtgac agactggctc tgaacaagtt gaaatcatcg cagaaggata aagttcgtca 120gtttatgatc ttcacacaat ctagtgaaaa aacagcagta agttgtcttt ctcaaaatga 180ctggaagtta gatgttgcaa cagataattt tttccaaaat cctgaacttt atatacgaga 240gagtgtaaaa ggatcattgg acaggaagaa gttagaacag ctgtacaata gataccaaga 300ccctcaagat gagaataaaa ttggaataga tggcatacag cagttctgtg atgacctggc 360actcgatcca gccagcatta gtgtgttgat tattgcatgg aagttcagag cagcaacaca 420gtgcgagttc tccaaacagg agttcatgga tggcatgaca gaattaggat gtgacagcat 480agaaaaacta aaggcccaga tacccaagat ggaacaagaa ttgaaagaac caggacgatt 540taaggatttt taccagttta cttttaattt tgcaaagaat ccaggacaaa aaggattaga 600tctagaaatg gccattgcct actggaactt agtgcttaat ggaagattta aattcttaga 660cttatggaat aaatttttgt tggaacatca taaacgatca ataccaaaag acacttggaa 720tcttctttta gacttcagta cgatgattgc agatgacatg tctaattatg atgaagaagg 780agcatggcct gtttttattg atgactttgt ggaatttgca cgccctcaaa ttgctgggac 840aaaaagtaca acagtgtagc actaaaggaa ccttctagaa tgtacatagt ctgtacaata 900aatacaacag aaaattgcaa aaaaaaaaaa aaaaaaaa 938130244PRTHomo sapiens 130Met Ile Phe Thr Gln Ser Ser Glu Lys Thr Ala Val Ser Cys Leu Ser 1 5 10 15Gln Asn Asp Trp Lys Leu Asp Val Ala Thr Asp Asn Phe Phe Gln Asn 20 25 30Pro Glu Leu Tyr Ile Arg Glu Ser Val Lys Gly Ser Leu Asp Arg Lys 35 40 45Lys Leu Glu Gln Leu Tyr Asn Arg Tyr Gln Asp Pro Gln Asp Glu Asn 50 55 60Lys Ile Gly Ile Asp Gly Ile Gln Gln Phe Cys Asp Asp Leu Ala Leu 65 70 75 80Asp Pro Ala Ser Ile Ser Val Leu Ile Ile Ala Trp Lys Phe Arg Ala 85 90 95Ala Thr Gln Cys Glu Phe Ser Lys Gln Glu Phe Met Asp Gly Met Thr 100 105 110Glu Leu Gly Cys Asp Ser Ile Glu Lys Leu Lys Ala Gln Ile Pro Lys 115 120 125Met Glu Gln Glu Leu Lys Glu Pro Gly Arg Phe Lys Asp Phe Tyr Gln 130 135 140Phe Thr Phe Asn Phe Ala Lys Asn Pro Gly Gln Lys Gly Leu Asp Leu145 150 155 160Glu Met Ala Ile Ala Tyr Trp Asn Leu Val Leu Asn Gly Arg Phe Lys 165 170 175Phe Leu Asp Leu Trp Asn Lys Phe Leu Leu Glu His His Lys Arg Ser 180 185 190Ile Pro Lys Asp Thr Trp Asn Leu Leu Leu Asp Phe Ser Thr Met Ile 195 200 205Ala Asp Asp Met Ser Asn Tyr Asp Glu Glu Gly Ala Trp Pro Val Phe 210 215 220Ile Asp Asp Phe Val Glu Phe Ala Arg Pro Gln Ile Ala Gly Thr Lys225 230 235 240Ser Thr Thr Val1315170DNAHomo sapiens 131ccgggtcgac ccacgcgtcc gcgtaattcc gaaagagcag aagaaagaga aggagaacag 60gaaaagaaga gctagtaagc gagagcgaga gcacagaaaa gaaaaaaaaa agccttaaga 120ggaccgaagg ggaggaaagg aaaaggatgg acaaccacaa aacgcagcga ttgcggaaat 180tttccagcgc cattggctgg gcagcgtgag tccttcggtc gggcgtgatt tcagcaccgg 240gggaactgga cagcacctcg gggggacttc tgggcaaccc gcaaccacag caagaactcc 300accagcagcc tcaacaacag aagccgcgga aaaccctgct ttgtatcaga gaggcaaggt 360cagtccgacg cacagccatg cacaggcagt gcgcctgtac tacgctgcaa accctctgct 420tgtttctcta acatgcactt gcttctaatt actagcattg tttcatttct gatcagtgaa 480gatcagtaga tgagattctg taagggtgta cttttaattt atatgtatat atttaacttc 540tttttctgtt atttttaaag tgttgtgggg gagtggggtt tttttcctac tttttttttt 600tttttttttt tctttgcttg ccttgcacta cgtgcctgga tagtttgtgg atataattat 660tgactggcgt ctgggctatt gcagtgcggg ggggttaggg aggaaggaat ccacccccac 720ccccccaaac ccttttcttc tcctttcctg gcttcggaca ttggagcact aaatgaactt 780gaattgtgtc tgtggcgagc aggatggtcg ctgttacttt gtgatgagat cggggatgaa 840ttgctcgctt taaaaatgct gctttggatt ctgttgctgg agacgtctct ttgttttgcc 900gctggaaacg ttacagggga cgtttgcaaa gagaagatct gttcctgcaa tgagatagaa 960ggggacctac acgtagactg tgaaaaaaag ggcttcacaa gtctgcagcg tttcactgcc 1020ccgacttccc agttttacca tttatttctg catggcaatt ccctcactcg acttttccct 1080aatgagttcg ctaactttta taatgcggtt agtttgcaca tggaaaacaa tggcttgcat 1140gaaatcgttc cgggggcttt tctggggctg cagctggtga aaaggctgca catcaacaac 1200aacaagatca agtcttttcg aaagcagact tttctggggc tggacgatct ggaatatctc 1260caggctgatt ttaatttatt acgagatata gacccggggg ccttccagga cttgaacaag 1320ctggaggtgc tcattttaaa tgacaatctc atcagcaccc tacctgccaa cgtgttccag 1380tatgtgccca tcacccacct cgacctccgg ggtaacaggc tgaaacgctg ccctatgagg 1440agtcttggag caaatccctg gtattgcgga gatcctgcta gagataaccc ttgggactgc 1500acctgtgatc tgctctccct gaaagaatgg ctggaaaaca ttcccaagaa tgccctgatc 1560ggccgagtgg tctgcgaagc ccccaccaga ctgcagggta aagacctcaa tgaaaccacc 1620gaacaggact tgtgtccttt gaaaaaccga gtggattcta gtctcccggc gccccctgcc 1680caagaagaga cctttgctcc tggacccctg ccaactcctt tcaagacaaa tgggcaagag 1740gatcatgcca caccagggtc tgctccaaac ggaggtacaa agatcccagg caactggcag 1800atcaaaatca gacccacagc agcgatagcg acgggtagct ccaggaacaa acccttagct 1860aacagtttac cctgccctgg gggctgcagc tgcgaccaca tcccagggtc gggtttaaag 1920atgaactgca acaacaggaa cgtgagcagc ttggctgatt tgaagcccaa gctctctaac 1980gtgcaggagc ttttcctacg agataacaag atccacagca tccgaaaatc gcactttgtg 2040gattacaaga acctcattct gttggatctg ggcaacaata acatcgctac tgtagagaac 2100aacactttca agaacctttt ggacctcagg tggctataca tggatagcaa ttacctggac 2160acgctgtccc gggagaaatt cgcggggctg caaaacctag agtacctgaa cgtggagtac 2220aacgctatcc agctcatcct cccgggcact ttcaatgcca tgcccaaact gaggatcctc 2280attctcaaca acaacctgct gaggtccctg cctgtggacg tgttcgctgg ggtctcgctc 2340tctaaactca gcctgcacaa caattacttc atgtacctcc cggtggcagg ggtgctggac 2400cagttaacct ccatcatcca gatagacctc cacggaaacc cctgggagtg ctcctgcaca 2460attgtgcctt tcaagcagtg ggcagaacgc ttgggttccg aagtgctgat gagcgacctc 2520aagtgtgaga cgccggtgaa cttctttaga aaggatttca tgctcctctc caatgacgag 2580atctgccctc agctgtacgc taggatctcg cccacgttaa cttcgcacag taaaaacagc 2640actgggttgg cggagaccgg gacgcactcc aactcctacc tagacaccag cagggtgtcc 2700atctcggtgt tggtcccggg actgctgctg gtgtttgtca cctccgcctt caccgtggtg 2760ggcatgctcg tgtttatcct gaggaaccga aagcggtcca agagacgaga tgccaactcc 2820tccgcgtccg agattaattc cctacagaca gtctgtgact cttcctactg gcacaatggg 2880ccttacaacg cagatggggc ccacagagtg tatgactgtg gctctcactc gctctcagac 2940taagacccca accccaatag gggagggcag agggaaggcg atacatcctt ccccaccgca 3000ggcaccccgg gggctggagg ggcgtgtacc caaatccccg cgccatcagc ctggatgggc 3060ataagtagat aaataactgt gagctcgcac aaccgaaagg gcctgacccc ttacttagct 3120ccctccttga aacaaagagc agactgtgga gagctgggag agcgcagcca gctcgctctt 3180tgctgagagc cccttttgac agaaagccca gcacgaccct gctggaagaa ctgacagtgc 3240cctcgccctc ggccccgggg cctgtggggt tggatgccgc ggttctatac atatatacat 3300atatccacat ctatatagag agatagatat ctatttttcc cctgtggatt agccccgtga 3360tggctccctg ttggctacgc agggatgggc agttgcacga aggcatgaat gtattgtaaa 3420taagtaactt tgacttctga caaaaaacaa aaagtgctgc atggctcgca tggaatccac 3480gcgctccagg gactctgccc gcccccgcga ctggagacgg catctcgttc acagcaccca 3540ccctcttacc tgataagttc catcgtatca aactttctat aaacaaaata cagtataatc 3600agaaagtgcc atttcgccat tatttgtgat cggtaggcag ttcagagcat aagttaactg 3660tgaaaaaaat gtaaaggttt tatttaggac atttgcatgg ctagtcatca gtccatttta 3720tgagttaaca atgtattttg ttgagggaag tttttagggg ttgttttggg ttcttttatt 3780ttgatggtga tgttttattt tattttattt ttttcagggg gtcttttttt taatacatat 3840ccaataatgc cttccatctg aatgtaaaat aagtacccat gatttctatt atagtatcag 3900tgtaattatt taaaaaatga ttttgaggca gttaagcatg accaattaat gtcactctag 3960tgcttaggct gcgatcctat ggtagcaatt ctgtgctggt ataaatctta cttataaagt 4020aggaaaagag aaccgaggaa gcacgtgaaa cttactaatt ctattcgagg attttataat 4080ggcatatttt ttcagtatta aagcgaaaat gttttcaact ctgggtcctt acctttttcc 4140agcttcatat ttgcaagtgg taaattggat ttgcggtgga agagacaggg gagggaaacg 4200gttggggtta gatcccttcc tgagctacat taaggctctt tctctaatcg ccttacttag 4260ctttttaccc tttaagtagc tcctcttccc tcgcccccac cctctacccc acccccacct 4320tcgctcagac tttaccggct ttccccagtc cataaaggtc ttgccccaac actcacccct 4380tctttttttc ccctctccaa atgcagcagt gaatcccttt attaatactg gaaatccctc 4440tctgctgctt ttgttggtgc tgcccacact gcagatatat taaggatgtt aggagagatt 4500tgatttaatt gactctgcct agataggtct cattaaacag agtggagatt tcattggtca 4560gcactcctca atgaaagaca gacctaatga ctggcatttg agatgctgct ggcattttga 4620attcaacatc tgctgaaaac ggtaaaacta attagtgccc acccaccctc cccgccccag 4680caactgcata ttgaaatttg ttaaagcact catctttatg gaaattaatc attatcctaa 4740agaagtgttt ctctcccatc atccggattt ctggttgtgg cccagcaatt aacaaaaaca 4800gcttcaactg ttcgaatttt attgaaccaa tgtaactctg gcctcaatca tattcctctg 4860ggatttctaa acagcagtta agctacaaaa agcaaacaaa accacacata ttgatggagt 4920ctgcattcca ccacatatcc acccttgaga agtatgtcaa aagactgcag actatagatt 4980tttttttaat ataggattat aaatcagcta gtgaaagacc tcagagcagt tgtaagtaga 5040tctgccatct agaactcata ttctaaaggg aagtgatttc tcagaacagt gatgttctgg 5100aatatgtatt atttatttta acactttttt aataaaatct ttattataaa ccatgaaaaa 5160aaaaaaaaaa 5170132695PRTHomo sapiens 132Met Leu Leu Trp Ile Leu Leu Leu Glu Thr Ser Leu Cys Phe Ala Ala 1 5 10 15Gly Asn Val Thr Gly Asp Val Cys Lys Glu Lys Ile Cys Ser Cys Asn 20 25 30Glu Ile Glu Gly Asp Leu His Val Asp Cys Glu Lys Lys Gly Phe Thr 35 40 45Ser Leu Gln Arg Phe Thr Ala Pro Thr Ser Gln Phe Tyr His Leu Phe 50 55 60Leu His Gly Asn Ser Leu Thr Arg Leu Phe Pro Asn Glu Phe Ala Asn 65 70 75 80Phe Tyr Asn Ala Val Ser Leu His Met Glu Asn Asn Gly Leu His Glu 85 90 95Ile Val Pro Gly Ala Phe Leu Gly Leu Gln Leu Val Lys Arg Leu His 100 105 110Ile Asn Asn Asn Lys Ile Lys Ser Phe Arg Lys Gln Thr Phe Leu Gly 115 120 125Leu Asp Asp Leu Glu Tyr Leu Gln Ala Asp Phe Asn Leu Leu Arg Asp 130 135 140Ile Asp Pro Gly Ala Phe Gln Asp Leu Asn Lys Leu Glu Val Leu Ile145 150 155 160Leu Asn Asp Asn Leu Ile Ser Thr Leu Pro Ala Asn Val Phe Gln Tyr 165 170 175Val Pro Ile Thr His Leu Asp Leu Arg Gly Asn Arg Leu Lys Arg Cys 180 185 190Pro Met Arg Ser Leu Gly Ala Asn Pro Trp Tyr Cys Gly Asp Pro Ala 195 200 205Arg Asp Asn Pro Trp Asp Cys Thr Cys Asp Leu Leu Ser Leu Lys Glu 210 215 220Trp Leu Glu Asn Ile Pro Lys Asn Ala Leu Ile Gly Arg Val Val Cys225 230 235 240Glu Ala Pro Thr Arg Leu Gln Gly Lys Asp Leu Asn Glu Thr Thr Glu 245 250 255Gln Asp Leu Cys Pro Leu Lys Asn Arg Val Asp Ser Ser Leu Pro Ala 260 265 270Pro Pro Ala Gln Glu Glu Thr Phe Ala Pro Gly Pro Leu Pro Thr Pro 275 280 285Phe Lys Thr Asn Gly Gln Glu Asp His Ala Thr Pro Gly Ser Ala Pro 290 295 300Asn Gly Gly Thr Lys Ile Pro Gly Asn Trp Gln Ile Lys Ile Arg Pro305 310 315 320Thr Ala Ala Ile Ala Thr Gly Ser Ser Arg Asn Lys Pro Leu Ala Asn 325 330 335Ser Leu Pro Cys Pro Gly Gly Cys Ser Cys Asp His Ile Pro Gly Ser 340 345 350Gly Leu Lys Met Asn Cys Asn Asn Arg Asn Val Ser Ser Leu Ala Asp 355 360 365Leu Lys Pro Lys Leu Ser Asn Val Gln Glu Leu Phe Leu Arg Asp Asn 370 375 380Lys Ile His Ser Ile Arg Lys Ser His Phe Val Asp Tyr Lys Asn Leu385 390 395 400Ile Leu Leu Asp Leu Gly Asn Asn Asn Ile Ala Thr Val Glu Asn Asn 405 410 415Thr Phe Lys Asn Leu Leu Asp Leu Arg Trp Leu Tyr Met Asp Ser Asn 420

425 430Tyr Leu Asp Thr Leu Ser Arg Glu Lys Phe Ala Gly Leu Gln Asn Leu 435 440 445Glu Tyr Leu Asn Val Glu Tyr Asn Ala Ile Gln Leu Ile Leu Pro Gly 450 455 460Thr Phe Asn Ala Met Pro Lys Leu Arg Ile Leu Ile Leu Asn Asn Asn465 470 475 480Leu Leu Arg Ser Leu Pro Val Asp Val Phe Ala Gly Val Ser Leu Ser 485 490 495Lys Leu Ser Leu His Asn Asn Tyr Phe Met Tyr Leu Pro Val Ala Gly 500 505 510Val Leu Asp Gln Leu Thr Ser Ile Ile Gln Ile Asp Leu His Gly Asn 515 520 525Pro Trp Glu Cys Ser Cys Thr Ile Val Pro Phe Lys Gln Trp Ala Glu 530 535 540Arg Leu Gly Ser Glu Val Leu Met Ser Asp Leu Lys Cys Glu Thr Pro545 550 555 560Val Asn Phe Phe Arg Lys Asp Phe Met Leu Leu Ser Asn Asp Glu Ile 565 570 575Cys Pro Gln Leu Tyr Ala Arg Ile Ser Pro Thr Leu Thr Ser His Ser 580 585 590Lys Asn Ser Thr Gly Leu Ala Glu Thr Gly Thr His Ser Asn Ser Tyr 595 600 605Leu Asp Thr Ser Arg Val Ser Ile Ser Val Leu Val Pro Gly Leu Leu 610 615 620Leu Val Phe Val Thr Ser Ala Phe Thr Val Val Gly Met Leu Val Phe625 630 635 640Ile Leu Arg Asn Arg Lys Arg Ser Lys Arg Arg Asp Ala Asn Ser Ser 645 650 655Ala Ser Glu Ile Asn Ser Leu Gln Thr Val Cys Asp Ser Ser Tyr Trp 660 665 670His Asn Gly Pro Tyr Asn Ala Asp Gly Ala His Arg Val Tyr Asp Cys 675 680 685Gly Ser His Ser Leu Ser Asp 690 6951331564DNAHomo sapiens 133attctagacc tcggcctccc aaagtgctgt gattataggt gtaagccacc gtgtctggcc 60tctgaacaac tttttcagca actaaaaaag ccacaggagt tgaactgcta ggattctgac 120tatgctgtgg tggctagtgc tcctactcct acctacatta aaatctgttt tttgttctct 180tgtaactagc ctttaccttc ctaacacaga ggatctgtca ctgtggctct ggcccaaacc 240tgaccttcac tctggaacga gaacagaggt ttctacccac accgtcccct cgaagccggg 300gacagcctca ccttgctggc ctctcgctgg agcagtgccc tcaccaactg tctcacgtct 360ggaggcactg actcgggcag tgcaggtagc tgagcctctt ggtagctgcg gctttcaagg 420tgggccttgc cctggccgta gaagggattg acaagcccga agatttcata ggcgatggct 480cccactgccc aggcatcagc cttgctgtag tcaatcactg ccctggggcc aggacgggcc 540gtggacacct gctcagaagc agtgggtgag acatcacgct gcccgcccat ctaacctttt 600catgtcctgc acatcacctg atccatgggc taatctgaac tctgtcccaa ggaacccaga 660gcttgagtga gctgtggctc agacccagaa ggggtctgct tagaccacct ggtttatgtg 720acaggacttg cattctcctg gaacatgagg gaacgccgga ggaaagcaaa gtggcaggga 780aggaacttgt gccaaattat gggtcagaaa agatggaggt gttgggttat cacaaggcat 840cgagtctcct gcattcagtg gacatgtggg ggaagggctg ccgatggcgc atgacacact 900cgggactcac ctctggggcc atcagacagc cgtttccgcc ccgatccacg taccagctgc 960tgaagggcaa ctgcaggccg atgctctcat cagccaggca gcagccaaaa tctgcgatca 1020ccagccaggg gcagccgtct gggaaggagc aagcaaagtg accatttctc ctcccctcct 1080tccctctgag aggccctcct atgtccctac taaagccacc agcaagacat agctgacagg 1140ggctaatggc tcagtgttgg cccaggaggt cagcaaggcc tgagagctga tcagaagggc 1200ctgctgtgcg aacacggaaa tgcctccagt aagtacaggc tgcaaaatcc ccaggcaaag 1260gactgtgtgg ctcaatttaa atcatgttct agtaattgga gctgtcccca agaccaaagg 1320agctagagct tggttcaaat gatctccaag ggcccttata ccccaggaga ctttgatttg 1380aatttgaaac cccaaatcca aacctaagaa ccaggtgcat taagaatcag ttattgccgg 1440gtgtggtggc ctgtaatgcc aacattttgg gaggccgagg cgggtagatc acctgaggtc 1500aggagttcaa gaccagcctg gccaacatgg tgaaacccct gtctctacta aaaaaaaaaa 1560aaaa 1564134109PRTHomo sapiens 134Met Leu Trp Trp Leu Val Leu Leu Leu Leu Pro Thr Leu Lys Ser Val 1 5 10 15Phe Cys Ser Leu Val Thr Ser Leu Tyr Leu Pro Asn Thr Glu Asp Leu 20 25 30Ser Leu Trp Leu Trp Pro Lys Pro Asp Leu His Ser Gly Thr Arg Thr 35 40 45Glu Val Ser Thr His Thr Val Pro Ser Lys Pro Gly Thr Ala Ser Pro 50 55 60Cys Trp Pro Leu Ala Gly Ala Val Pro Ser Pro Thr Val Ser Arg Leu 65 70 75 80Glu Ala Leu Thr Arg Ala Val Gln Val Ala Glu Pro Leu Gly Ser Cys 85 90 95Gly Phe Gln Gly Gly Pro Cys Pro Gly Arg Arg Arg Asp 100 105135839DNAHomo sapiens 135aacgcgtttt gccagttatg cgaaaacatg gctgcggccg gtttggccct tctttgtagg 60agagtttcat ccgccctgaa atcttcccga tcgttaataa ctcctcaggt ccctgcctgc 120acagggtttt ttcttagttt gttgcctaag agtacaccaa atgtgacatc ctttcaccaa 180tatagattac ttcataccac attgtcaagg aaaggactag aagaattttt tgatgaccca 240aaaaactggg ggcaagaaaa agtaaaatct ggagcagcat ggacctgtca gcaactaagg 300aacaaaagta atgaagattt acacaaactt tggtatgtct tactgaaaga aagaaacatg 360cttctaaccc tagagcagga ggccaagcgg cagagattgc caatgccaag tccagagcgg 420ttagataagg tagtagattc catggatgca ttagataaag ttgtccagga aagagaagat 480gccctaaggc ttcttcagac tggtcaagaa agagctagac ctggtgcttg gagaagagac 540atctttggaa gaatcatctg gcacaagttc aagcagtggg ttataccttg gcacctaaat 600aaaagataca ataggaaacg attctttgcc ttgccttatg tggaccattt tctcagactg 660gaacgtgaga aacgagcccg catcaaagca cggaaggaaa atttagagag aaagaaagca 720aaaattcttt taaaaaagtt tccacatctt gctgaagccc aaaagtcaag tcttgtctaa 780gatgtctgaa ctattaaatt taccattttg tttttcttga aaaaaaaaaa aaaaaaaaa 839136250PRTHomo sapiens 136Met Ala Ala Ala Gly Leu Ala Leu Leu Cys Arg Arg Val Ser Ser Ala 1 5 10 15Leu Lys Ser Ser Arg Ser Leu Ile Thr Pro Gln Val Pro Ala Cys Thr 20 25 30Gly Phe Phe Leu Ser Leu Leu Pro Lys Ser Thr Pro Asn Val Thr Ser 35 40 45Phe His Gln Tyr Arg Leu Leu His Thr Thr Leu Ser Arg Lys Gly Leu 50 55 60Glu Glu Phe Phe Asp Asp Pro Lys Asn Trp Gly Gln Glu Lys Val Lys 65 70 75 80Ser Gly Ala Ala Trp Thr Cys Gln Gln Leu Arg Asn Lys Ser Asn Glu 85 90 95Asp Leu His Lys Leu Trp Tyr Val Leu Leu Lys Glu Arg Asn Met Leu 100 105 110Leu Thr Leu Glu Gln Glu Ala Lys Arg Gln Arg Leu Pro Met Pro Ser 115 120 125Pro Glu Arg Leu Asp Lys Val Val Asp Ser Met Asp Ala Leu Asp Lys 130 135 140Val Val Gln Glu Arg Glu Asp Ala Leu Arg Leu Leu Gln Thr Gly Gln145 150 155 160Glu Arg Ala Arg Pro Gly Ala Trp Arg Arg Asp Ile Phe Gly Arg Ile 165 170 175Ile Trp His Lys Phe Lys Gln Trp Val Ile Pro Trp His Leu Asn Lys 180 185 190Arg Tyr Asn Arg Lys Arg Phe Phe Ala Leu Pro Tyr Val Asp His Phe 195 200 205Leu Arg Leu Glu Arg Glu Lys Arg Ala Arg Ile Lys Ala Arg Lys Glu 210 215 220Asn Leu Glu Arg Lys Lys Ala Lys Ile Leu Leu Lys Lys Phe Pro His225 230 235 240Leu Ala Glu Ala Gln Lys Ser Ser Leu Val 245 2501371067DNAHomo sapiens 137gacaaaggga gaaaaacaac aggaagcagc ttacaaactc ggtgaacaac tgagggaacc 60aaaccagaga cgcgctgaac agagagaatc aggctcaaag caagtggaag tgggcagaga 120ttccaccagg actggtgcaa ggcgcagagc cagccagatt tgagaagaag gcaaaaagat 180gctggggagc agagctgtaa tgctgctgtt gctgctgccc tggacagctc agggcagagc 240tgtgcctggg ggcagcagcc ctgcctggac tcagtgccag cagctttcac agaagctctg 300cacactggcc tggagtgcac atccactagt gggacacatg gatctaagag aagagggaga 360tgaagagact acaaatgatg ttccccatat ccagtgtgga gatggctgtg acccccaagg 420actcagggac aacagtcagt tctgcttgca aaggatccac cagggtctga ttttttatga 480gaagctgcta ggatcggata ttttcacagg ggagccttct ctgctccctg atagccctgt 540gggccagctt catgcctccc tactgggcct cagccaactc ctgcagcctg agggtcacca 600ctgggagact cagcagattc caagcctcag tcccagccag ccatggcagc gtctccttct 660ccgcttcaaa atccttcgca gcctccaggc ctttgtggct gtagccgccc gggtctttgc 720ccatggagca gcaaccctga gtccctaaag gcagcagctc aaggatggca ctcagatctc 780catggcccag caaggccaag ataaatctac caccccaggc acctgtgagc caacaggtta 840attagtccat taattttagt gggacctgca tatgttgaaa attaccaata ctgactgaca 900tgtgatgctg acctatgata aggttgagta tttattagat gggaagggaa atttggggat 960tatttatcct cctggggaca gtttggggag gattatttat tgtatttata ttgaattatg 1020tacttttttc aataaagtct tatttttgtg gcaaaaaaaa aaaaaaa 1067138189PRTHomo sapiens 138Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Leu Pro Trp Thr 1 5 10 15Ala Gln Gly Arg Ala Val Pro Gly Gly Ser Ser Pro Ala Trp Thr Gln 20 25 30Cys Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His 35 40 45Pro Leu Val Gly His Met Asp Leu Arg Glu Glu Gly Asp Glu Glu Thr 50 55 60Thr Asn Asp Val Pro His Ile Gln Cys Gly Asp Gly Cys Asp Pro Gln 65 70 75 80Gly Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly 85 90 95Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu 100 105 110Pro Ser Leu Leu Pro Asp Ser Pro Val Gly Gln Leu His Ala Ser Leu 115 120 125Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr 130 135 140Gln Gln Ile Pro Ser Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu145 150 155 160Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe Val Ala Val Ala 165 170 175Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro 180 1851391785DNAHomo sapiens 139gcccaggaga ctcccctccc accagcctgg cccccagagt gctgactggc aacaatattc 60caagttaaaa tagtttgcta aatagttata caattagttt acaattcaaa tatatcagag 120gaaaagacag ggaaaaaaat tctaagatac atgaatccca gaccattgct ctccaaatat 180tttcaagtga ttcatctcct ttatttaaaa aatgaattaa ccaccagatg ggacactcat 240acattcctga tggttgtagg aatcagtaga ccctgtatgg aaagcaatag gataatattt 300cataggatca aattaaaatg ttcacagcat tggttccagg aaattggctt ctggagaatt 360tatactccag aaacaattca acaaaagaac acagctctgt gcatgcagat gctcattagc 420ccatcaccta gagtaaggga aagtggagat cccaatgaac aacaatgaga tgggttagcg 480aactgtgacc tatcagccca atggacattt aagcaatcac tgaaaagtag aaacatgaag 540atattacaca acatggaaac tgtttatgga gtatatttag gtaaaaagga aaaaaaggca 600gaactgtata tctgtggttg gatatacttt ttttttttaa tattaagcac caaccaaaag 660aagaaaggag gatagaaaaa ataaaatgga agatgtaggg tgggcagatt agggctgcgt 720ttgttgcttg ctttcatgtt accatcatag cgtttttgcc acttacaaag gaggaaaaaa 780atcaattctg tgccaaccca gacaacagag acctgagtgg gggttgggaa gagagatttt 840tcagcacaga atcagactcc ttctccaaag agctgtgtgg ccttcacctg caaggcgacc 900tcttccacaa gcagaggcca ggacaaaaag aggcacctgt gagcgacaaa gacggtttcc 960ttggtttccc tcacggcgcc aagcggagtg gccgcctccc accacagggc cccctaatgg 1020gcgcttttgt cctgcggggc agagggacct cattagaagg cgctggtgct aaagggaaat 1080gcatttccag aacaggaggt ttcatcattc ctagcgttag cgacagaatg gtgacagaag 1140ctctgtggac gtattttcca gcgttcagtt cacatcaagg atgggtatgc actggcggaa 1200aaggccctca ggaggaagca ctcatcttta acaagacctg ctttctcagg actgcaaaca 1260agagaaaagc ccaataagag gaaagtgaag tgtgaaaatc catttcaaag aactttactg 1320agaactcacc atgtcagaga gcttccatta atacagttgc ttcaaaacca ataggcagaa 1380cccaaagtaa tggatgactc accaggactt ttagcagcta atggagtact ctgagaaatg 1440ctgtaaatcc aatatttttg ctgaaaaatt aatgtgttat gggagggagc ctcttttcta 1500atcacttacc cacccccacc ctctacttct agttcaccat cagcatcttt agctcttcta 1560atttttgcca aagctgaatg cagttctttc ccaattttct tatatcattt taagtattat 1620atatgctatc ttaccaggcc cactcagaga aacagcactt atctttaaaa ttatttttta 1680actactcccc acagcctacg gccaataaaa actctgtaaa ctatgttaaa tataccaaag 1740taaagtttcc agaattcaca gaaaaaaaaa aaaaaaaaaa aaaaa 178514086PRTHomo sapiens 140Met Gly Ala Phe Val Leu Arg Gly Arg Gly Thr Ser Leu Glu Gly Ala 1 5 10 15Gly Ala Lys Gly Lys Cys Ile Ser Arg Thr Gly Gly Phe Ile Ile Pro 20 25 30Ser Val Ser Asp Arg Met Val Thr Glu Ala Leu Trp Thr Tyr Phe Pro 35 40 45Ala Phe Ser Ser His Gln Gly Trp Val Cys Thr Gly Gly Lys Gly Pro 50 55 60Gln Glu Glu Ala Leu Ile Phe Asn Lys Thr Cys Phe Leu Arg Thr Ala 65 70 75 80Asn Lys Arg Lys Ala Gln 85141947DNAHomo sapiens 141caaactgaag gtaggatgtc tatataccct tcatttcagg ggcccctaga gaatatacct 60tagctttccc tcttccggca tcctggaaag tggatacctg tggccttcct ttcactttga 120aagcttacac cctcattttg actacaacta atactaaaag cttggcatct tgcttgagat 180tagtgtttgc tatgccaaac accttctcct ctttctattg aaagcaaaac ataggaaaat 240aatttgaaat acttttaagg catcttaaaa acatgacttt ttcatcttat ggaaaagcag 300accaattttg cttttttttc ccaacttgtt ctccagactg tgccaataaa atgtgttcat 360agcaggaaaa tttggaaaat acagaaaagc actatgaaga aaacaaaatg tacccaaaat 420cccatcactc agataacatc actgttaatg ttttgatatg tatttccagt cttttctatt 480gtgttaattt ttcattttgt ttttgaataa ataactttca ggaaagaaat tgagcctttt 540ctgccacctc tgaagcctga ttactgtgtg aagcaggcca tgaaggccat cctcactgac 600cagcccatga tctgcactcc ccgcctcatg tacatcgtga ccttcatgaa gagcatccta 660ccatttgaag cagttgtgtg catgtatcgg ttcctaggag cggacaagtg tatgtacccc 720tttattgctc aaagaaagca agccacaaac aataatgaag caaaaaatgg aatctaagaa 780tctttttgta tggaatatta cttctatcag aagatgatca agatgtttca gtccagtgca 840catcagcatt gctgacattt tatggattct aaacttgtgt tgtttctttt ttaaatcaac 900tttttaaaaa aataaagtgt aaattaaccg acaaaaaaaa aaaaaaa 94714265PRTHomo sapiens 142Met Lys Ala Ile Leu Thr Asp Gln Pro Met Ile Cys Thr Pro Arg Leu 1 5 10 15Met Tyr Ile Val Thr Phe Met Lys Ser Ile Leu Pro Phe Glu Ala Val 20 25 30Val Cys Met Tyr Arg Phe Leu Gly Ala Asp Lys Cys Met Tyr Pro Phe 35 40 45Ile Ala Gln Arg Lys Gln Ala Thr Asn Asn Asn Glu Ala Lys Asn Gly 50 55 60Ile 651431148DNAHomo sapiens 143gcgagatccc taccgcagta tccgcctctg ccgccgcgga gcttcccgaa cctcttcagc 60cgcccggagc cgctcccgga gcccggccgt agaggctgca atcgcagccg ggagcccgca 120gcccgcgccc cgagcccgcc gccgcccttc gagggcgccc caggccgcgc catggtgaag 180gtgacgttca actccgctct ggcccagaag gaggccaaga aggacgagcc caagagcggc 240gaggaggcgc tcatcatccc ccccgacgcc gtcgcggtgg actgcaagga cccagatgat 300gtggtaccag ttggccaaag aagagcctgg tgttggtgca tgtgctttgg actagcattt 360atgcttgcag gtgttattct aggaggagca tacttgtaca aatattttgc acttcaacca 420gatgacgtgt actactgtgg aataaagtac atcaaagatg atgtcatctt aaatgagccc 480tctgcagatg ccccagctgc tctctaccag acaattgaag aaaatattaa aatctttgaa 540gaagaagaag ttgaatttat cagtgtgcct gtcccagagt ttgcagatag tgatcctgcc 600aacattgttc atgactttaa caagaaactt acagcctatt tagatcttaa cctggataag 660tgctatgtga tccctctgaa cacttccatt gttatgccac ccagaaacct actggagtta 720cttattaaca tcaaggctgg aacctatttg cctcagtcct atctgattca tgagcacatg 780gttattactg atcgcattga aaacattgat cacctgggtt tctttattta tcgactgtgt 840catgacaagg aaacttacaa actgcaacgc agagaaacta ttaaaggtat tcagaaacgt 900gaagccagca attgtttcgc aattcggcat tttgaaaaca aatttgccgt ggaaacttta 960atttgttctt gaacagtcaa gaaaaacatt attgaggaaa attaatatca cagcataacc 1020ccacccttta cattttgtgc agtgattatt ttttaaagtc ttctttcatg taagtagcaa 1080acagggcttt actatcttct catctcatta attcaattaa aaccattacc ttaaaaaaaa 1140aaaaaaaa 1148144266PRTHomo sapiens 144Met Val Lys Val Thr Phe Asn Ser Ala Leu Ala Gln Lys Glu Ala Lys 1 5 10 15Lys Asp Glu Pro Lys Ser Gly Glu Glu Ala Leu Ile Ile Pro Pro Asp 20 25 30Ala Val Ala Val Asp Cys Lys Asp Pro Asp Asp Val Val Pro Val Gly 35 40 45Gln Arg Arg Ala Trp Cys Trp Cys Met Cys Phe Gly Leu Ala Phe Met 50 55 60Leu Ala Gly Val Ile Leu Gly Gly Ala Tyr Leu Tyr Lys Tyr Phe Ala 65 70 75 80Leu Gln Pro Asp Asp Val Tyr Tyr Cys Gly Ile Lys Tyr Ile Lys Asp 85 90 95Asp Val Ile Leu Asn Glu Pro Ser Ala Asp Ala Pro Ala Ala Leu Tyr 100 105 110Gln Thr Ile Glu Glu Asn Ile Lys Ile Phe Glu Glu Glu Glu Val Glu 115 120 125Phe Ile Ser Val Pro Val Pro Glu Phe Ala Asp Ser Asp Pro Ala Asn 130 135 140Ile Val His Asp Phe Asn Lys Lys Leu Thr Ala Tyr Leu Asp Leu Asn145 150 155 160Leu Asp Lys Cys Tyr Val Ile Pro Leu Asn Thr Ser Ile Val Met Pro 165 170 175Pro Arg Asn Leu Leu Glu Leu Leu Ile Asn Ile Lys Ala Gly Thr Tyr 180 185 190Leu Pro Gln Ser Tyr Leu Ile His Glu His Met Val Ile Thr Asp Arg 195 200 205Ile Glu Asn Ile Asp His Leu Gly Phe Phe Ile Tyr Arg Leu Cys His 210 215 220Asp Lys Glu Thr Tyr Lys Leu Gln Arg Arg Glu Thr Ile Lys Gly Ile225 230

235 240Gln Lys Arg Glu Ala Ser Asn Cys Phe Ala Ile Arg His Phe Glu Asn 245 250 255Lys Phe Ala Val Glu Thr Leu Ile Cys Ser 260 2651451353DNAHomo sapiens 145aggtctagaa ttcaatcggc cgcttttttt tttttttttt ttgctaacac ccagttctgc 60ctgctacacc acctgggaat tgaccatcca gctgtgttct ctctgcctct ggcccagtag 120caactgacct gccctattcc tggctgatct catgctgctg aagttcaagg cgctggacac 180actaccctga tttttgttgc acctggccta gcctcattaa cttggcaatt agttggtggt 240tttctttctt tcttcttctt ttttttttta attcatttca tttctgtcac cccttaattt 300tcatctttct tttttaagta gttgttccat gctgttgttt tttgttttat ctttcattgc 360ctttccctct gcagtcaaca ttatgacctg gggactccag catccttcaa gcaagccatt 420tccgaagaag gtgaaaagaa gccaggatga ttggcacctc ctcctcctcc tcctcttctt 480cctcttccct tgcccagccc cctcctgtgc gtgtgtttca gacaacacag gagccagcac 540aggagtggaa aatcctgcag cgcaactcag ctcagcccac agaagccttg ggaatggcct 600cagtttgtgc aataagaaga tttttttttt ctttttaaat cttcattata ttttctttga 660ttgtctgtga gaaagtaccc aggtccgcct ggaattactc tacagtagaa ataactgaac 720acaaacaaac tgatggaaaa aaagagttaa ctattttatt tatttcaata tttaaaagga 780aaaaagtgct gacatggcac agtatttttg tttaaagtac ctcctacttc aaaagttaag 840cgcaattttg tgaagacatg aaatcataag agtacttaat gtaaaataaa agactgcata 900ttaactctaa agaaaaatgc cccacatttt aaataagaaa ataaagatca actctgctct 960ctcaggcttt ttaaaaagcc attcatgtat gtgctttagg tatttttatt tctgcgagtt 1020ggatgtggta agtgaggagt gctcagtttt tttttcctcc ttcaaaagtc tattgaaagt 1080gttggtgatg ttaaatgatt gtgtgttaag atttgactga aataacttag ccacaaatca 1140gcagtttccc ccaccctcat tgccccctca ccccaggcaa gcccctttta tctgaatgtc 1200agaagcagcc tgcctcctag ttatcatgtc tgatgaggtc tagctcagga aggaattcca 1260tctattgatg gaatatatcc cctcaagttc aatagattcg aacacagaga gctttgttta 1320aaataatgca gcaaaaaaaa aaaaaaaaaa aaa 1353146113PRTHomo sapiens 146Met Leu Leu Phe Phe Val Leu Ser Phe Ile Ala Phe Pro Ser Ala Val 1 5 10 15Asn Ile Met Thr Trp Gly Leu Gln His Pro Ser Ser Lys Pro Phe Pro 20 25 30Lys Lys Val Lys Arg Ser Gln Asp Asp Trp His Leu Leu Leu Leu Leu 35 40 45Leu Phe Phe Leu Phe Pro Cys Pro Ala Pro Ser Cys Ala Cys Val Ser 50 55 60Asp Asn Thr Gly Ala Ser Thr Gly Val Glu Asn Pro Ala Ala Gln Leu 65 70 75 80Ser Ser Ala His Arg Ser Leu Gly Asn Gly Leu Ser Leu Cys Asn Lys 85 90 95Lys Ile Phe Phe Phe Phe Leu Asn Leu His Tyr Ile Phe Phe Asp Cys 100 105 110Leu1472312DNAHomo sapiensunsure(2224)unsure(2236) 147gtttcggcct ggcctgggca ggcgcttgtg ctgccagggc gccgggcccg gggaggccgg 60ggtctcgggt ggccgccggc ccaggcgctg gacggcagca ggatggggaa ggcgaaggtc 120cccgcctcca agcgcgcccc gagcagcccc gtggctaagc cgggtcctgt caagacgctc 180actcggaaga aaaacaagaa gaaaaaaagg ttttggaaaa gcaaggcgcg ggaagtaagc 240aagaagccag caagcggccc cggtgctgtg gtgcgacctc caaaggcacc agaagacttt 300tctcaaaact ggaaggcgct gcaagagtgg ctgctgaaac aaaaatctca ggccccagaa 360aagcctcttg tcatctctca gatgggttcc aaaaagaagc ccaaaattat ccagcaaaac 420aaaaaagaga cctcgcctca agtgaaggga gaggagatgc cggcaggaaa agaccaggag 480gccagcaggg gctctgttcc ttcaggttcc aagatggaca ggagggcgcc agtacctcgc 540accaaggcca gtggaacaga gcacaataag aaaggaacca aggaaaggac aaatggtgat 600attgttccag aacgagggga catcgagcat aagaagcgga aagctaagga ggcagcccca 660gccccaccca ccgaggaaga catctggttt gacgacgtgg acccagcgga tatcgaagct 720gccataggtc cagaggcggc caagatagcg aggaaacagt tgggtcagag cgagggcagc 780gtcagcctca gcctcgtgaa agagcaggcc ttcggcggcc tgacaagagc cttagccttg 840gactgtgaga tggtgggcgt gggccctaag ggggaggaga gcatggccgc ccgtgtgtcc 900atcgtgaacc agtatgggaa gtgcgtttat gacaagtacg tcaaaccaac cgagcccgtg 960acggactata ggacagcggt cagtgggatt cggcctgaga acctcaagca gggagaagag 1020cttgaagttg ttcagaagga agtggcagag atgctgaagg gcagaattct agtggggcac 1080gctctgcata atgacctaaa ggtactattt cttgatcatc caaaaaagaa gattcgggac 1140acacagaaat ataaaccttt caagagtcaa gtaaagagtg gaaggccgtc tctgagacta 1200ctttcagaga agatccttgg gctccaggtc cagcaggcgg agcactgttc aattcaggat 1260gcccaggcag caatgaggct gtacgtcatg gtgaagaagg agtgggagag catggcccga 1320gacaggcgcc ccctgctgac tgctccagac cactgcagtg acgacgccta gcagtcctgc 1380cctgctgctg ctgccgcccc gctacagagg caatgtgacc agtcacaggg acagatcaca 1440tctccccaga gtggcaactc tggtgaaacc ttttcagaat catggcagag gggcgtggcg 1500tggtgctact gagaaggtcc tccttcctct tgactttgtg gtctgaaacc tggtcttact 1560gtccatgtgt gtttgggccc ggatggtcag ggtggggagc agggacggcc atgggcacgc 1620ctggccacgc tttaccgact gctgaccccc tgggccaggt gaggttgggg cctgtgggcc 1680gccagtccat acggtgctgt cactgcccat cttcggtgac accctggggt gaggtgctca 1740gcaccttcct ctcgaggagc cacattttcc tcctttgtgt taggggacat aacaagctct 1800gctgggcttg agggacccag accaggtgtc tgcagtcagc tcctgagaca cagctggccg 1860gcacaacagg tgttacatca ggggtttcct gtggccgttt gaactttgag catttatcta 1920aattaaattg gcccagggtt ggctggtggg tcacccagca gaggcttctc cccatagcac 1980gaggatgtgt tgcctgggca cggtgactgc ggttattcct ggaggtcggc agacatgcca 2040accttgggct atttgagctg gagaagctat gtgatgctag ccggtggctt tctgggctag 2100gccccagttt gaggctcccc tgggaactag agccaggaac agccagtggc actgacaagg 2160ggacggagtc caaggcgtta ttgggccacc tgacagctgg acagaaaagg ggcagacaca 2220ccgnggatgc gatttnaaat aaatgcagat gtttacttgg aaaaaaaaaa aaaaaaaaaa 2280aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2312148422PRTHomo sapiens 148Met Gly Lys Ala Lys Val Pro Ala Ser Lys Arg Ala Pro Ser Ser Pro 1 5 10 15Val Ala Lys Pro Gly Pro Val Lys Thr Leu Thr Arg Lys Lys Asn Lys 20 25 30Lys Lys Lys Arg Phe Trp Lys Ser Lys Ala Arg Glu Val Ser Lys Lys 35 40 45Pro Ala Ser Gly Pro Gly Ala Val Val Arg Pro Pro Lys Ala Pro Glu 50 55 60Asp Phe Ser Gln Asn Trp Lys Ala Leu Gln Glu Trp Leu Leu Lys Gln 65 70 75 80Lys Ser Gln Ala Pro Glu Lys Pro Leu Val Ile Ser Gln Met Gly Ser 85 90 95Lys Lys Lys Pro Lys Ile Ile Gln Gln Asn Lys Lys Glu Thr Ser Pro 100 105 110Gln Val Lys Gly Glu Glu Met Pro Ala Gly Lys Asp Gln Glu Ala Ser 115 120 125Arg Gly Ser Val Pro Ser Gly Ser Lys Met Asp Arg Arg Ala Pro Val 130 135 140Pro Arg Thr Lys Ala Ser Gly Thr Glu His Asn Lys Lys Gly Thr Lys145 150 155 160Glu Arg Thr Asn Gly Asp Ile Val Pro Glu Arg Gly Asp Ile Glu His 165 170 175Lys Lys Arg Lys Ala Lys Glu Ala Ala Pro Ala Pro Pro Thr Glu Glu 180 185 190Asp Ile Trp Phe Asp Asp Val Asp Pro Ala Asp Ile Glu Ala Ala Ile 195 200 205Gly Pro Glu Ala Ala Lys Ile Ala Arg Lys Gln Leu Gly Gln Ser Glu 210 215 220Gly Ser Val Ser Leu Ser Leu Val Lys Glu Gln Ala Phe Gly Gly Leu225 230 235 240Thr Arg Ala Leu Ala Leu Asp Cys Glu Met Val Gly Val Gly Pro Lys 245 250 255Gly Glu Glu Ser Met Ala Ala Arg Val Ser Ile Val Asn Gln Tyr Gly 260 265 270Lys Cys Val Tyr Asp Lys Tyr Val Lys Pro Thr Glu Pro Val Thr Asp 275 280 285Tyr Arg Thr Ala Val Ser Gly Ile Arg Pro Glu Asn Leu Lys Gln Gly 290 295 300Glu Glu Leu Glu Val Val Gln Lys Glu Val Ala Glu Met Leu Lys Gly305 310 315 320Arg Ile Leu Val Gly His Ala Leu His Asn Asp Leu Lys Val Leu Phe 325 330 335Leu Asp His Pro Lys Lys Lys Ile Arg Asp Thr Gln Lys Tyr Lys Pro 340 345 350Phe Lys Ser Gln Val Lys Ser Gly Arg Pro Ser Leu Arg Leu Leu Ser 355 360 365Glu Lys Ile Leu Gly Leu Gln Val Gln Gln Ala Glu His Cys Ser Ile 370 375 380Gln Asp Ala Gln Ala Ala Met Arg Leu Tyr Val Met Val Lys Lys Glu385 390 395 400Trp Glu Ser Met Ala Arg Asp Arg Arg Pro Leu Leu Thr Ala Pro Asp 405 410 415His Cys Ser Asp Asp Ala 4201492103DNAHomo sapiens 149gggaggaacg tatcccttct ggaggctgtc tcagggggca gagggaccgg accggaagtg 60acgtgagcgg gttccggttg tctggagccc agctgcgggt gtgagagtcc gtaaggagca 120gcttccagga tcctgagatc cggagcagcc ggggtcggag cggctcctca agagttactg 180atctatgaaa tggcagagaa tggaaaaaat tgtgaccaga gacgtgtagc aatgaacaag 240gaacatcata atggaaattt cacagacccc tcttcagtga atgaaaagaa gaggagggag 300cgggaagaaa ggcagaatat tgtcctgtgg agacagccgc tcattacctt gcagtatttt 360tctctggaaa tccttgtaat cttgaaggaa tggacctcaa aattatggca tcgtcaaagc 420attgtggtgt cttttttact gctgcttgct gtgcttatag ctacgtatta tgttgaagga 480gtgcatcaac agtatgtgca acgtatagag aaacagtttc ttttgtatgc ctactggata 540ggcttaggaa ttttgtcttc tgttgggctt ggaacagggc tgcacacctt tctgctttat 600ctgggtccac atatagcctc agttacatta gctgcttatg aatgcaattc agttaatttt 660cccgaaccac cctatcctga tcagattatt tgtccagatg aagagggcac tgaaggaacc 720atttctttgt ggagtatcat ctcaaaagtt aggattgaag cctgcatgtg gggtatcggt 780acagcaatcg gagagctgcc tccatatttc atggccagag cagctcgcct ctcaggtgct 840gaaccagatg atgaagagta tcaggaattt gaagagatgc tggaacatgc agagtctgca 900caagactttg cctcccgggc caaactggca gttcaaaaac tagtacagaa agttggattt 960tttggaattt tggcctgtgc ttcaattcca aatcctttat ttgatctggc tggaataacg 1020tgtggacact ttctggtacc tttttggacc ttctttggtg caaccctaat tggaaaagca 1080ataataaaaa tgcatatcca gaaaattttt gttataataa cattcagcaa gcacatagtg 1140gagcaaatgg tggctttcat tggtgctgtc cccggcatag gtccatctct gcagaagcca 1200tttcaggagt acctggaggc tcaacggcag aagcttcacc acaaaagcga aatgggcaca 1260ccacagggag aaaactggtt gtcctggatg tttgaaaagt tggtcgttgt catggtgtgt 1320tacttcatcc tatctatcat taactccatg gcacaaagtt atgccaaacg aatccagcag 1380cggttgaact cagaggagaa aactaaataa gtagagaaag ttttaaactg cagaaattgg 1440agtggatggg ttctgcctta aattgggagg actccaagcc gggaaggaaa attccctttt 1500ccaacctgta tcaattttta caactttttt cctgaaagca gtttagtcca tactttgcac 1560tgacatactt tttccttctg tgctaaggta aggtatccac cctcgatgca atccaccttg 1620tgttttctta gggtggaatg tgatgttcag cagcaaactt gcaacagact ggccttctgt 1680ttgttacttt caaaaggccc acatgataca attagagaat tcccaccgca caaaaaaagt 1740tcctaagtat gttaaatatg tcaagctttt taggcttgtc acaaatgatt gctttgtttt 1800cctaagtcat caaaatgtat ataaattatc tagattggat aacagtcttg catgtttatc 1860atgttacaat ttaatattcc atcctgccca acccttcctc tcccatcctc aaaaaagggc 1920cattttatga tgcattgcac accctctggg gaaattgatc tttaaatttt gagacagtat 1980aaggaaaatc tggttggtgt cttacaagtg agctgacacc attttttatt ctgtgtattt 2040agaatgaagt cttgaaaaaa actttataaa gacatcttta atcattccaa aaaaaaaaaa 2100aaa 2103150406PRTHomo sapiens 150Met Ala Glu Asn Gly Lys Asn Cys Asp Gln Arg Arg Val Ala Met Asn 1 5 10 15Lys Glu His His Asn Gly Asn Phe Thr Asp Pro Ser Ser Val Asn Glu 20 25 30Lys Lys Arg Arg Glu Arg Glu Glu Arg Gln Asn Ile Val Leu Trp Arg 35 40 45Gln Pro Leu Ile Thr Leu Gln Tyr Phe Ser Leu Glu Ile Leu Val Ile 50 55 60Leu Lys Glu Trp Thr Ser Lys Leu Trp His Arg Gln Ser Ile Val Val 65 70 75 80Ser Phe Leu Leu Leu Leu Ala Val Leu Ile Ala Thr Tyr Tyr Val Glu 85 90 95Gly Val His Gln Gln Tyr Val Gln Arg Ile Glu Lys Gln Phe Leu Leu 100 105 110Tyr Ala Tyr Trp Ile Gly Leu Gly Ile Leu Ser Ser Val Gly Leu Gly 115 120 125Thr Gly Leu His Thr Phe Leu Leu Tyr Leu Gly Pro His Ile Ala Ser 130 135 140Val Thr Leu Ala Ala Tyr Glu Cys Asn Ser Val Asn Phe Pro Glu Pro145 150 155 160Pro Tyr Pro Asp Gln Ile Ile Cys Pro Asp Glu Glu Gly Thr Glu Gly 165 170 175Thr Ile Ser Leu Trp Ser Ile Ile Ser Lys Val Arg Ile Glu Ala Cys 180 185 190Met Trp Gly Ile Gly Thr Ala Ile Gly Glu Leu Pro Pro Tyr Phe Met 195 200 205Ala Arg Ala Ala Arg Leu Ser Gly Ala Glu Pro Asp Asp Glu Glu Tyr 210 215 220Gln Glu Phe Glu Glu Met Leu Glu His Ala Glu Ser Ala Gln Asp Phe225 230 235 240Ala Ser Arg Ala Lys Leu Ala Val Gln Lys Leu Val Gln Lys Val Gly 245 250 255Phe Phe Gly Ile Leu Ala Cys Ala Ser Ile Pro Asn Pro Leu Phe Asp 260 265 270Leu Ala Gly Ile Thr Cys Gly His Phe Leu Val Pro Phe Trp Thr Phe 275 280 285Phe Gly Ala Thr Leu Ile Gly Lys Ala Ile Ile Lys Met His Ile Gln 290 295 300Lys Ile Phe Val Ile Ile Thr Phe Ser Lys His Ile Val Glu Gln Met305 310 315 320Val Ala Phe Ile Gly Ala Val Pro Gly Ile Gly Pro Ser Leu Gln Lys 325 330 335Pro Phe Gln Glu Tyr Leu Glu Ala Gln Arg Gln Lys Leu His His Lys 340 345 350Ser Glu Met Gly Thr Pro Gln Gly Glu Asn Trp Leu Ser Trp Met Phe 355 360 365Glu Lys Leu Val Val Val Met Val Cys Tyr Phe Ile Leu Ser Ile Ile 370 375 380Asn Ser Met Ala Gln Ser Tyr Ala Lys Arg Ile Gln Gln Arg Leu Asn385 390 395 400Ser Glu Glu Lys Thr Lys 4051511330DNAHomo sapiens 151gatgtgagtc ttgccaaagc tcctggcgga ataaagccct tccttcttta actcggtgtc 60tgaggggttt tgtctgtggc ttgtcctgct acatttcttg gttccctgac caggaaacaa 120ggtgattaat ggatggtcga gacagctcct taggtggctt aggcctgccc tgtggagcat 180acctgagggg gactccagcc agcttgagtg aagcagatcc tgagagcact cccaggtagg 240caattgcccc agtggaatgc ctcatcagag cagtgcacag caggcccctg tggaggatca 300atgcagtggc tgaacaccat gaaggaactg gcacttggag tccggacatc taaaacttgc 360accttttctg ctgccatgac aaccatgcaa ggaatggaac aggccatgcc aggggctggc 420cctggtgtgc cccagctggg aaacatggct gtcatacatt cacatctgtg gaaaggattg 480caagagaagt tcttgaaggg agaacccaaa gtccttgggg ttgtgcagat tctgactgcc 540ctgatgagcc ttagcatggg aataacaatg atgtgtatgg catctaatac ttatggaagt 600aaccctattt ccgtgtatat cgggtacaca atttgggggt cagtaatgtt tattatttca 660ggatccttgt caattgcagc aggaattaga actacaaaag gcctggtccg aggtagtcta 720ggaatgaata tcaccagctc tgtactggct gcatcaggga tcttaatcaa cacatttagc 780ttggcgtttt attcattcca tcacccttac tgtaactact atggcaactc aaataattgt 840catgggacta tgtccatctt aatgggtctg gatggcatgg tgctcctctt aagtgtgctg 900gaattctgca ttgctgtgtc cctctctgcc tttggatgta aagtgctctg ttgtacccct 960ggtggggttg tgttaattct gccatcacat tctcacatgg cagaaacagc atctcccaca 1020ccacttaatg aggtttgagg ccaccaaaag atcaacagac aaatgctcca gaaatctatg 1080ctgactgtga cacaagagcc tcacatgaga aattaccagt atccaacttc gatactgata 1140gacttgttga tattattatt atatgtaatc caattatgaa ctgtgtgtgt atagagagat 1200aataaattca aaattatgtt ctcatttttt tccctggaac tcaataactc atttcactgg 1260ctctttatcg agagtactag aagttaaatt aataaataat gcatttaatg aggcaaaaaa 1320aaaaaaaaaa 1330152245PRTHomo sapiens 152Met Gln Trp Leu Asn Thr Met Lys Glu Leu Ala Leu Gly Val Arg Thr 1 5 10 15Ser Lys Thr Cys Thr Phe Ser Ala Ala Met Thr Thr Met Gln Gly Met 20 25 30Glu Gln Ala Met Pro Gly Ala Gly Pro Gly Val Pro Gln Leu Gly Asn 35 40 45Met Ala Val Ile His Ser His Leu Trp Lys Gly Leu Gln Glu Lys Phe 50 55 60Leu Lys Gly Glu Pro Lys Val Leu Gly Val Val Gln Ile Leu Thr Ala 65 70 75 80Leu Met Ser Leu Ser Met Gly Ile Thr Met Met Cys Met Ala Ser Asn 85 90 95Thr Tyr Gly Ser Asn Pro Ile Ser Val Tyr Ile Gly Tyr Thr Ile Trp 100 105 110Gly Ser Val Met Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala Ala Gly 115 120 125Ile Arg Thr Thr Lys Gly Leu Val Arg Gly Ser Leu Gly Met Asn Ile 130 135 140Thr Ser Ser Val Leu Ala Ala Ser Gly Ile Leu Ile Asn Thr Phe Ser145 150 155 160Leu Ala Phe Tyr Ser Phe His His Pro Tyr Cys Asn Tyr Tyr Gly Asn 165 170 175Ser Asn Asn Cys His Gly Thr Met Ser Ile Leu Met Gly Leu Asp Gly 180 185 190Met Val Leu Leu Leu Ser Val Leu Glu Phe Cys Ile Ala Val Ser Leu 195 200 205Ser Ala Phe Gly Cys Lys Val Leu Cys Cys Thr Pro Gly Gly Val Val 210 215 220Leu Ile Leu Pro Ser His Ser His Met Ala Glu Thr Ala Ser Pro Thr225 230 235 240Pro Leu Asn Glu Val 2451531724DNAHomo sapiens 153cgttctctcc tccttcctcc ccgcctccag ctgccggcag gacctttctc tcgctgccgc 60tgggaccccg tgtcatcgcc caggccgagc acgatgcccc ctaaaaaggg aggtgatgga 120attaaaccac ccccaatcat tggaagattt ggaacctcac tgaaaattgg tattgttgga

180ttgccaaatg ttgggaaatc tactttcttc aatgtgttaa ccaatagtca ggcttcagca 240gaaaacttcc cgttctgcac tattgatcct aatgagagca gagtacctgt gccagatgaa 300aggtttgact ttctttgtca ataccacaaa ccagcaagca aaattcctgc ctttctaaat 360gtggtggata ttgctggcct tgtgaaagga gctcacaatg ggcagggcct ggggaatgct 420tttttatctc atattagtgc ctgtgatggc atctttcatc taacacgtgc ttttgaagat 480gatgatatca cgcacgttga aggaagtgta gatcctattc gagatataga aataatacat 540gaagagcttc agcttaaaga tgaggaaatg attgggccca ttatagataa actagaaaag 600gtggctgtga gaggaggaga taaaaaacta aaacctgaat atgatataat gtgcaaagta 660aaatcctggg ttatagatca aaagacacct gttcgcttct atcatgattg gaatgacaaa 720gagattgaag tgttgaatac acacttattt ttgacttcaa aaccaatggt ctacttggtt 780aatctttctg aaaaagacta cattagaaag aaaaacaaat ggttgataaa aattaaagag 840tgggtggaca agtatgaccc aggtgctttg gtcattcctt ttagtggggc cttggaactc 900aagttgcaag aattgagtgc tgaggagaga cagaagtatc tggaagcgaa catgacacaa 960agtgctttgc caaagatcat taaggctggg tttgcagcac tccaactaga atactttttc 1020actgcaggcc cagatgaagt gcgtgcatgg accatcagga aagggactaa ggctcctcag 1080gctgcaggaa agattcacac agattttgaa aagggattca ttatggctga agtaatgaaa 1140tacgaagatt ttaaagagga aggttctgaa aatgcagtca aggctgctgg aaagtacaga 1200caacaaggca gaaattatat tgttgaagat ggagatatta tcttcttcaa atttaacaca 1260cctcaacaac cgaagaagaa ataaaattta gttattgctc agataaacat acaacttcca 1320aaaggcatct gatttttaaa aaattaaaat ttctgaaaac caatgcgaca aataaagttg 1380gggagatggg aatctttgac aaacaaatta tttttatttg ttttaaaatt aaaatactgt 1440gtaccccccc cccccccatg aaatgcaggt tcactaaatg tgaacagctt tgcttttcac 1500gtgattaaga ccctactcca aattgtagaa gcttttcagg aaccatatta ctctcatgat 1560acttcattaa tctccatcat gtatgccaag cctgacacat ttgacagtga ggacaatgtg 1620gcttgctcct ttttgaatct acagataatg catgttttac agtactccag atgtctacac 1680tcaataaaac atttgacaaa accaaaaaaa aaaaaaaaaa aaaa 1724154396PRTHomo sapiens 154Met Pro Pro Lys Lys Gly Gly Asp Gly Ile Lys Pro Pro Pro Ile Ile 1 5 10 15Gly Arg Phe Gly Thr Ser Leu Lys Ile Gly Ile Val Gly Leu Pro Asn 20 25 30Val Gly Lys Ser Thr Phe Phe Asn Val Leu Thr Asn Ser Gln Ala Ser 35 40 45Ala Glu Asn Phe Pro Phe Cys Thr Ile Asp Pro Asn Glu Ser Arg Val 50 55 60Pro Val Pro Asp Glu Arg Phe Asp Phe Leu Cys Gln Tyr His Lys Pro 65 70 75 80Ala Ser Lys Ile Pro Ala Phe Leu Asn Val Val Asp Ile Ala Gly Leu 85 90 95Val Lys Gly Ala His Asn Gly Gln Gly Leu Gly Asn Ala Phe Leu Ser 100 105 110His Ile Ser Ala Cys Asp Gly Ile Phe His Leu Thr Arg Ala Phe Glu 115 120 125Asp Asp Asp Ile Thr His Val Glu Gly Ser Val Asp Pro Ile Arg Asp 130 135 140Ile Glu Ile Ile His Glu Glu Leu Gln Leu Lys Asp Glu Glu Met Ile145 150 155 160Gly Pro Ile Ile Asp Lys Leu Glu Lys Val Ala Val Arg Gly Gly Asp 165 170 175Lys Lys Leu Lys Pro Glu Tyr Asp Ile Met Cys Lys Val Lys Ser Trp 180 185 190Val Ile Asp Gln Lys Thr Pro Val Arg Phe Tyr His Asp Trp Asn Asp 195 200 205Lys Glu Ile Glu Val Leu Asn Thr His Leu Phe Leu Thr Ser Lys Pro 210 215 220Met Val Tyr Leu Val Asn Leu Ser Glu Lys Asp Tyr Ile Arg Lys Lys225 230 235 240Asn Lys Trp Leu Ile Lys Ile Lys Glu Trp Val Asp Lys Tyr Asp Pro 245 250 255Gly Ala Leu Val Ile Pro Phe Ser Gly Ala Leu Glu Leu Lys Leu Gln 260 265 270Glu Leu Ser Ala Glu Glu Arg Gln Lys Tyr Leu Glu Ala Asn Met Thr 275 280 285Gln Ser Ala Leu Pro Lys Ile Ile Lys Ala Gly Phe Ala Ala Leu Gln 290 295 300Leu Glu Tyr Phe Phe Thr Ala Gly Pro Asp Glu Val Arg Ala Trp Thr305 310 315 320Ile Arg Lys Gly Thr Lys Ala Pro Gln Ala Ala Gly Lys Ile His Thr 325 330 335Asp Phe Glu Lys Gly Phe Ile Met Ala Glu Val Met Lys Tyr Glu Asp 340 345 350Phe Lys Glu Glu Gly Ser Glu Asn Ala Val Lys Ala Ala Gly Lys Tyr 355 360 365Arg Gln Gln Gly Arg Asn Tyr Ile Val Glu Asp Gly Asp Ile Ile Phe 370 375 380Phe Lys Phe Asn Thr Pro Gln Gln Pro Lys Lys Lys385 390 3951552291DNAHomo sapiens 155gaacttgtct gaagcccttg tccgtaagcc ttgaactacg ttcttaaatc tatgaagtcg 60agggaccttt cgctgctttt gtagggactt ctttccttgc ttcagcaaca tgaggctttt 120cttgtggaac gcggtcttga ctctgttcgt cacttctttg attggggctt tgatccctga 180accagaagtg aaaattgaag ttctccagaa gccattcatc tgccatcgca agaccaaagg 240aggggatttg atgttggtcc actatgaagg ctacttagaa aaggacggct ccttatttca 300ctccactcac aaacataaca atggtcagcc catttggttt accctgggca tcctggaggc 360tctcaaaggt tgggaccagg gcttgaaagg aatgtgtgta ggagagaaga gaaagctcat 420cattcctcct gctctgggct atggaaaaga aggaaaaggt aaaattcccc cagaaagtac 480actgatattt aatattgatc tcctggagat tcgaaatgga ccaagatccc atgaatcatt 540ccaagaaatg gatcttaatg atgactggaa actctctaaa gatgaggtta aagcatattt 600aaagaaggag tttgaaaaac atggtgcggt ggtgaatgaa agtcatcatg atgctttggt 660ggaggatatt tttgataaag aagatgaaga caaagatggg tttatatctg ccagagaatt 720tacatataaa cacgatgagt tatagagata catctaccct tttaatatag cactcatctt 780tcaagagagg gcagtcatct ttaaagaaca ttttattttt atacaatgct ctttcttgct 840ttgcttttta tttttatata ttttttctga ctcctattta aagaacccct taggtttcta 900agtacccatt tctttctgat aagttattgg gaagaaaaag ctaattggtc tttgaataga 960agacttctgg acaatttttc actttcacag atatgaagct ttgttttact ttctcactta 1020taaatttaaa atgttgcaac tgggaatata ccacgacatg agaccaggtt atagcacaaa 1080ttagcaccct atatttctgc ttccctctat tttctccaag ttagaggtca acatttgaaa 1140agccttttgc aatagcccaa ggcttgctat tttcatgtta taatgaaata gtttatgtgt 1200aactggctct gagtctctgc ttgaggacca gaggaaaatg gttgttggac ctgacttgtt 1260aatggctact gctttactaa ggagatgtgc aatgctgaag ttagaaacaa ggttaatagc 1320caggcatggt ggctcatgcc tgtaatccca gcactttggg aggctgaggc gggcggatca 1380cctgaggttg ggagttcgag accagcctga ccaacacgga gaaaccctat ctctactaaa 1440aatacaaaag tagccgggcg tggtgatgcg tgcctgtaat cccagctacc caggaaggct 1500gaggcggcag aatcacttga acccggaggc ggaggttgcg gtaagccgag atcacctcca 1560gcctggacac tctgtctcga aaaaaagaaa agaaacacgg ttaataacat ataaatatgt 1620atgcattgag acatgctacc taggacttaa gctgatgaag cttggctcct agtgattggt 1680ggcctattat gataaatagg acaaatcatt tatgtgtgag tttctttgta ataaaatgta 1740tcaatatgtt atagatgagg tagaaagtta tatttatatt caatatttac ttcttaaggc 1800tagcggaata tccttcctgg ttctttaatg ggtagtctat agtatattat actacaataa 1860cattgtatca taagataaag tagtaaacca gtctacattt tcccatttct gtctcatcaa 1920aaactgaagt tagctgggtg tggtggctca tgcctgtaat cccagcactt tgggggccaa 1980ggagggtgga tcacttgaga tcaggagttc aagaccagcc tggccaacat ggtgaaacct 2040tgtctctact aaaaatacaa aaattagcca ggcgtggtgg tgcacacctg tagtcccagc 2100tactcgggag gctgagacag gagatttgct tgaacccggg aggcggaggt tgcagtgagc 2160caagattgtg ccactgcact ccagcctggg tgacagagca agactccatc tcaaaaaaaa 2220aaaaaagaag cagacctaca gcagctacta ttgaataaat acctatcctg gattttaaaa 2280aaaaaaaaaa a 2291156211PRTHomo sapiens 156Met Arg Leu Phe Leu Trp Asn Ala Val Leu Thr Leu Phe Val Thr Ser 1 5 10 15Leu Ile Gly Ala Leu Ile Pro Glu Pro Glu Val Lys Ile Glu Val Leu 20 25 30Gln Lys Pro Phe Ile Cys His Arg Lys Thr Lys Gly Gly Asp Leu Met 35 40 45Leu Val His Tyr Glu Gly Tyr Leu Glu Lys Asp Gly Ser Leu Phe His 50 55 60Ser Thr His Lys His Asn Asn Gly Gln Pro Ile Trp Phe Thr Leu Gly 65 70 75 80Ile Leu Glu Ala Leu Lys Gly Trp Asp Gln Gly Leu Lys Gly Met Cys 85 90 95Val Gly Glu Lys Arg Lys Leu Ile Ile Pro Pro Ala Leu Gly Tyr Gly 100 105 110Lys Glu Gly Lys Gly Lys Ile Pro Pro Glu Ser Thr Leu Ile Phe Asn 115 120 125Ile Asp Leu Leu Glu Ile Arg Asn Gly Pro Arg Ser His Glu Ser Phe 130 135 140Gln Glu Met Asp Leu Asn Asp Asp Trp Lys Leu Ser Lys Asp Glu Val145 150 155 160Lys Ala Tyr Leu Lys Lys Glu Phe Glu Lys His Gly Ala Val Val Asn 165 170 175Glu Ser His His Asp Ala Leu Val Glu Asp Ile Phe Asp Lys Glu Asp 180 185 190Glu Asp Lys Asp Gly Phe Ile Ser Ala Arg Glu Phe Thr Tyr Lys His 195 200 205Asp Glu Leu 2101572229DNAHomo sapiens 157gaagacgttg acacacttgg agccaacaag aacattagtc atgacaagca tgccatctga 60aaagcagaat gtcgtcatcc aggttgtgga taaattgaaa ggcttttcaa ttgcaccaga 120cgtctgtgag accacgactc acgtgctttc cgggaagcca cttcgcaccc tgaatgtgct 180gctgggaatt gcgcgtggct gctgggttct ctcttatgat tgggtgctat ggtctttaga 240attgggtcac tggatttctg aggagccgtt cgaactgtct caccacttcc ctgcagctcc 300cctgtgccga agcgagtgcc acttgtctgc agggccgtac cgcggaaccc tctttgccga 360ccagccagcg atgtttgtct cgcctgccag cagcccccca gtggccaagc tctgtgaact 420agtccacctg tgcggaggcc gggtcagcca agtcccccgc caggccagca tcgtcatcgg 480gccctacagc ggaaagaaga aagccacagt caagtatctg tctgagaaat gggtcttagg 540taagaatcca ggcacacaga cgctgtggtg tggtccagat ctgtggacag gtttccaggg 600agggcggcgt caggctcaca cccccttcca cgcagctggg gcacctgggt tgatgtctca 660gcctccagca tctgccctgg cagcgtcgtg tggtcaccct cggcattccc gctccttgct 720gttagcagac gtacagttca cgaggaaatg ggaactctaa ctggacttcc ccacttgact 780tccctggctc gtgtgaaaaa tccaggctac ccaaagccac cccgggccac ccctgtgggc 840acagactctc cgggcacccc tcttagaccc tccctcccca gtgcctcctt gtcctgcttc 900aggagtccct ggcagcgccc ggcactgggg cccaagcccc cgtccctgtc atctcctctc 960ccaggtacat ctcatgatca ctccgtctgc tcatgtgctc aaagggtgtt aaaagacgtc 1020aaacgactcc atcttttatt tgacaaagtg agcacagtgt gaccgtaatg tcccactctg 1080gcgttcatgg agctgcgcca ggcgccgtgt gcgattctgg ggaggaagag gtggtaggag 1140ctgagctgag atcggaggag gctggaaccc cacgccgtgc taacacacgg gctccaggag 1200acttgcaggt gatccccgga gaagagggtt aaggaagagt gtgaagcaag gacggcctgg 1260ggaatgcgga ggaagcaggg cagcgtctgt gctagaaatt acctgccctg tggtggagtc 1320atatgtggcg ggacaagcct agggctccac tgtggggaaa tcccacaccc tcctccatgg 1380ggttgtgata aacatgttag tttgcttggg ctgccatcgc aaaatactac aggctgggtg 1440gcttcaaaca acacgcattg tctctcagtt ctggaggctg gaagtctaag atggggtatc 1500ggcagcgttg gtttcccctg aggcctctct cctgggcttg cagacagctg ccttcttcct 1560gtgacctcac gtggcctttc ctccatgcac acacatccct ggtatctctg tgtgtgtcca 1620aatgttctct tctctaagga taccagtcag attggattag ggctcaccca gtggcatcat 1680tttaacttgt ctttttcaag gccccatctc caaatacagt ctcatcctga gttactgagg 1740gttaagacat cgacatacga attttgggca gacacaattc agcccataac aatgaatcac 1800tctagtttca gcccctgggg ccaagatcct tacccgactt tagaggtaca tcccctctct 1860ctctctcaat ctctctctct ctctcccgtt ctctcattct ttttctctct ctttgcttcc 1920atctccttcc atgtttccta ttcagtctcc tttcttagta cttttgcatg tctctaaatc 1980ctaaacttct ggcttttctc atcatctgct caacattatc ccttaataga caagtagata 2040ctgtgtttgt tcaagttaca ttcgtatcta actacggaca ttttacaagt atcttttaca 2100tgactgatgg tcatcctttc atatatttta gaagtgtggc aatcaaaagt aattttttac 2160tctggtgcag agtaattcat cttttgcctg gaaaccaact tccaaaaaaa aaaaaaaaaa 2220aaaaaaaaa 2229158239PRTHomo sapiens 158Met Thr Ser Met Pro Ser Glu Lys Gln Asn Val Val Ile Gln Val Val 1 5 10 15Asp Lys Leu Lys Gly Phe Ser Ile Ala Pro Asp Val Cys Glu Thr Thr 20 25 30Thr His Val Leu Ser Gly Lys Pro Leu Arg Thr Leu Asn Val Leu Leu 35 40 45Gly Ile Ala Arg Gly Cys Trp Val Leu Ser Tyr Asp Trp Val Leu Trp 50 55 60Ser Leu Glu Leu Gly His Trp Ile Ser Glu Glu Pro Phe Glu Leu Ser 65 70 75 80His His Phe Pro Ala Ala Pro Leu Cys Arg Ser Glu Cys His Leu Ser 85 90 95Ala Gly Pro Tyr Arg Gly Thr Leu Phe Ala Asp Gln Pro Ala Met Phe 100 105 110Val Ser Pro Ala Ser Ser Pro Pro Val Ala Lys Leu Cys Glu Leu Val 115 120 125His Leu Cys Gly Gly Arg Val Ser Gln Val Pro Arg Gln Ala Ser Ile 130 135 140Val Ile Gly Pro Tyr Ser Gly Lys Lys Lys Ala Thr Val Lys Tyr Leu145 150 155 160Ser Glu Lys Trp Val Leu Gly Lys Asn Pro Gly Thr Gln Thr Leu Trp 165 170 175Cys Gly Pro Asp Leu Trp Thr Gly Phe Gln Gly Gly Arg Arg Gln Ala 180 185 190His Thr Pro Phe His Ala Ala Gly Ala Pro Gly Leu Met Ser Gln Pro 195 200 205Pro Ala Ser Ala Leu Ala Ala Ser Cys Gly His Pro Arg His Ser Arg 210 215 220Ser Leu Leu Leu Ala Asp Val Gln Phe Thr Arg Lys Trp Glu Leu225 230 2351593580DNAHomo sapiens 159aggtctagaa gtgccccaag ccccatcatg gaagagggct tccgagaccg ggcagctttc 60atccgtgggg ccaaagacat tgctaaggaa gtcaaaaagc atgcggccaa gaaggtggtg 120aagggcctgg acagagtcca ggacgaatat tcccgaagat cgtactcccg ctttgaggag 180gaggatgatg atgatgactt ccctgctccc agtgatggtt attacccagg agaagggacc 240caggatgagg aggaaggtgg tgcatccagt gatgctactg agggccatga cgaggatgat 300gacatctatg aaggggaata tcagggcatt ccccgggcag agtctggggg caaaggcgag 360cggatggcag atggggcgcc cctggctgga gtaagggggg gcttgagtga tggggagggt 420ccccctgggg gccgggggga ggcacaacga cggaaagaac gagaagaact ggcccaacag 480tatgaagcca tcctacggga gtgtggccac ggccgcttcc agtggacact gtattttgtg 540cttggtctgg cgctgatggc tgacggtgtg gaggtctttg tggtgggctt cgtgctgccc 600agcgctgaga aagacatgtg cctgtccgac tccaacaaag gcatgctagg cctcatcgtc 660tacctgggca tgatggtggg agccttcctc tggggaggtc tggctgaccg gctgggtcgg 720aggcagtgtc tgctcatctc gctctcagtc aacagcgtct tcgccttctt ctcatctttt 780gtccagggtt acggcacttt cctcttctgc cgcctacttt ctggggttgg gattggaggg 840tccatcccca ttgtcttctc ctatttctcc gagtttctgg cccaggagaa acgaggggag 900catttgagct ggctctgcat gttttggatg attggtggcg tgtacgcagc tgctatggcc 960tgggccatca tcccccacta tgggtggagt tttcagatgg gttctgccta ccagttccac 1020agctggaggg tcttcgtcct cgtctgcgcc tttccttctg tgtttgccat tggggctctg 1080accacgcagc ctgagagccc ccgtttcttc ctagagaatg gaaagcatga tgaggcctgg 1140atggtgctga agcaggtcca tgataccaac atgcgagcca aaggacatcc tgagcgagtg 1200ttctcagtaa cccacattaa gacgattcat caggaggatg aattgattga gatccagtcg 1260gacacaggga cctggtacca gcgctggggg gtccgggcct tgagcctagg ggggcaggtt 1320tgggggaatt ttctctcctg ttttggtccc gaatatcggc gcatcactct gatgatgatg 1380ggtgtgtggt tcaccatgtc attcagctac tatggcctga ccgtctggtt tcctgacatg 1440atccgccatc tccaggcagt ggactacgca tcccgcacca aagtgttccc cggggagcgc 1500gtagagcatg taacttttaa cttcacgttg gagaatcaga tccaccgagg cgggcagtac 1560ttcaatgaca agttcattgg gctgcggctc aagtcagtgt cctttgagga ttccctgttt 1620gaagagtgtt attttgagga tgtcacatcc agcaacacgt ttttccgcaa ctgcacattc 1680atcaacactg tgttctataa cactgacctg ttcgagtaca agtttgtgaa cagccgtctg 1740ataaacagta cattcctgca caacaaggag ggctgcccgc tagacgtgac agggacgggc 1800gaaggtgcct acatggtata ctttgtgagc ttcctgggga cactggcagt gcttcctggg 1860aatatcgtgt ctgccctgct catggacaag atcggcaggc tcagaatgct tgctggctcc 1920agcgtgatgt cctgtgtctc ctgcttcttc ctgtcttttg ggaacagtga gtcggccatg 1980atcgctctgc tctgcctttt tggcggggtc agcattgcat cctggaatgc gctggacgtg 2040ttgactgttg aactttaccc ctcagacaag aggaccacag cttttggctt cctgaatgcc 2100ctgtgtaagc tggcagctgt gctggggatc agcatcttca catccttcgt gggaatcacc 2160aaggctgcac ccatcctctt tgcctcagct gcccttgccc ttggcagctc tctggccctg 2220aagctgcctg agacccgggg gcaggtgctg cagtgaaggg gtctctaggg ctttgggatt 2280ggcaggcaca ctgtgagacc aacaactcct tccttcccct ccctgccctg ccatcctgac 2340ctccagagcc ctcactcccc actccccgtg tttggtgtct tagctgtgtg tgcgtgtgcg 2400tgtgcatgtg tgtaaacccc gtgggcaggg actacaggga aggctccttc atcccagttt 2460tgagatgaag ctgtactccc catttcccac tgcccttgac tttgcacaag agaaggctga 2520gccccatcct tctccccctg ttagagaggg gcccttgctt ccctgttcca ggggttccag 2580aataggcttc ctgccttccc catcattccc tctgcctagg ccctggtgaa accacaggta 2640tgcaattatg ctaggggctg gggctctggt gtagaccatg gaccaaaaga acttcttaga 2700gtctgaagag tgggcctcgg gtgccctctc acatctcctg ttggatgctg ggggagaagc 2760aataaacctc agccctctgg cctccacttt cctctcaatt tgggctgcaa atatgaagcc 2820tgaattttat gaaattagct ttctgattct tatttattaa tagattaagt tctgaggcag 2880ctccgcagga ctgtgtgtga atgtgtatgt atacttacat atgtgtgtgc atgtgccatg 2940gggcgggggg tatcactata ctgtcctcaa atataagcca agggtaattt cagcggatgc 3000acacacaacc ctgcctccca cagttcctcc cctaatctgg tttctgtgtt gagcctggga 3060tggaggagcc ctaggccagc ctgggataag agtcccacag tctagggaga tctgagggca 3120tccgacaagg cccatctcct tccctcctca agaagcagag gcctcctctg gagtgagagg 3180ctccacccac tacagcacag gcgggaatag cacagctgcc ctcccatgct ccctacctgt 3240cccctcacag ggaggggagc aggggaggga aagaaaccag gcatctggtc aaaccagcag 3300atcaaaaagc acaaagagct ggggcagagg caggaagcag gggccctcct ggcagctcct 3360ctgagtgggg agaggttggg cagtgagtga gggaccccta atgcagggac tagaagcctc 3420agtttcccca ttttaccctt ccacacaata gcctctgtag gttaggctgc cccatcccac 3480cctactctgt gtggctgctt tctttggtgc cctcccctca ccccactgta gctgtgacgt 3540gttgtagttt ttagatgttt gtaaaatgtt taaaaaaatg

3580160742PRTHomo sapiens 160Met Glu Glu Gly Phe Arg Asp Arg Ala Ala Phe Ile Arg Gly Ala Lys 1 5 10 15Asp Ile Ala Lys Glu Val Lys Lys His Ala Ala Lys Lys Val Val Lys 20 25 30Gly Leu Asp Arg Val Gln Asp Glu Tyr Ser Arg Arg Ser Tyr Ser Arg 35 40 45Phe Glu Glu Glu Asp Asp Asp Asp Asp Phe Pro Ala Pro Ser Asp Gly 50 55 60Tyr Tyr Pro Gly Glu Gly Thr Gln Asp Glu Glu Glu Gly Gly Ala Ser 65 70 75 80Ser Asp Ala Thr Glu Gly His Asp Glu Asp Asp Asp Ile Tyr Glu Gly 85 90 95Glu Tyr Gln Gly Ile Pro Arg Ala Glu Ser Gly Gly Lys Gly Glu Arg 100 105 110Met Ala Asp Gly Ala Pro Leu Ala Gly Val Arg Gly Gly Leu Ser Asp 115 120 125Gly Glu Gly Pro Pro Gly Gly Arg Gly Glu Ala Gln Arg Arg Lys Glu 130 135 140Arg Glu Glu Leu Ala Gln Gln Tyr Glu Ala Ile Leu Arg Glu Cys Gly145 150 155 160His Gly Arg Phe Gln Trp Thr Leu Tyr Phe Val Leu Gly Leu Ala Leu 165 170 175Met Ala Asp Gly Val Glu Val Phe Val Val Gly Phe Val Leu Pro Ser 180 185 190Ala Glu Lys Asp Met Cys Leu Ser Asp Ser Asn Lys Gly Met Leu Gly 195 200 205Leu Ile Val Tyr Leu Gly Met Met Val Gly Ala Phe Leu Trp Gly Gly 210 215 220Leu Ala Asp Arg Leu Gly Arg Arg Gln Cys Leu Leu Ile Ser Leu Ser225 230 235 240Val Asn Ser Val Phe Ala Phe Phe Ser Ser Phe Val Gln Gly Tyr Gly 245 250 255Thr Phe Leu Phe Cys Arg Leu Leu Ser Gly Val Gly Ile Gly Gly Ser 260 265 270Ile Pro Ile Val Phe Ser Tyr Phe Ser Glu Phe Leu Ala Gln Glu Lys 275 280 285Arg Gly Glu His Leu Ser Trp Leu Cys Met Phe Trp Met Ile Gly Gly 290 295 300Val Tyr Ala Ala Ala Met Ala Trp Ala Ile Ile Pro His Tyr Gly Trp305 310 315 320Ser Phe Gln Met Gly Ser Ala Tyr Gln Phe His Ser Trp Arg Val Phe 325 330 335Val Leu Val Cys Ala Phe Pro Ser Val Phe Ala Ile Gly Ala Leu Thr 340 345 350Thr Gln Pro Glu Ser Pro Arg Phe Phe Leu Glu Asn Gly Lys His Asp 355 360 365Glu Ala Trp Met Val Leu Lys Gln Val His Asp Thr Asn Met Arg Ala 370 375 380Lys Gly His Pro Glu Arg Val Phe Ser Val Thr His Ile Lys Thr Ile385 390 395 400His Gln Glu Asp Glu Leu Ile Glu Ile Gln Ser Asp Thr Gly Thr Trp 405 410 415Tyr Gln Arg Trp Gly Val Arg Ala Leu Ser Leu Gly Gly Gln Val Trp 420 425 430Gly Asn Phe Leu Ser Cys Phe Gly Pro Glu Tyr Arg Arg Ile Thr Leu 435 440 445Met Met Met Gly Val Trp Phe Thr Met Ser Phe Ser Tyr Tyr Gly Leu 450 455 460Thr Val Trp Phe Pro Asp Met Ile Arg His Leu Gln Ala Val Asp Tyr465 470 475 480Ala Ser Arg Thr Lys Val Phe Pro Gly Glu Arg Val Glu His Val Thr 485 490 495Phe Asn Phe Thr Leu Glu Asn Gln Ile His Arg Gly Gly Gln Tyr Phe 500 505 510Asn Asp Lys Phe Ile Gly Leu Arg Leu Lys Ser Val Ser Phe Glu Asp 515 520 525Ser Leu Phe Glu Glu Cys Tyr Phe Glu Asp Val Thr Ser Ser Asn Thr 530 535 540Phe Phe Arg Asn Cys Thr Phe Ile Asn Thr Val Phe Tyr Asn Thr Asp545 550 555 560Leu Phe Glu Tyr Lys Phe Val Asn Ser Arg Leu Ile Asn Ser Thr Phe 565 570 575Leu His Asn Lys Glu Gly Cys Pro Leu Asp Val Thr Gly Thr Gly Glu 580 585 590Gly Ala Tyr Met Val Tyr Phe Val Ser Phe Leu Gly Thr Leu Ala Val 595 600 605Leu Pro Gly Asn Ile Val Ser Ala Leu Leu Met Asp Lys Ile Gly Arg 610 615 620Leu Arg Met Leu Ala Gly Ser Ser Val Met Ser Cys Val Ser Cys Phe625 630 635 640Phe Leu Ser Phe Gly Asn Ser Glu Ser Ala Met Ile Ala Leu Leu Cys 645 650 655Leu Phe Gly Gly Val Ser Ile Ala Ser Trp Asn Ala Leu Asp Val Leu 660 665 670Thr Val Glu Leu Tyr Pro Ser Asp Lys Arg Thr Thr Ala Phe Gly Phe 675 680 685Leu Asn Ala Leu Cys Lys Leu Ala Ala Val Leu Gly Ile Ser Ile Phe 690 695 700Thr Ser Phe Val Gly Ile Thr Lys Ala Ala Pro Ile Leu Phe Ala Ser705 710 715 720Ala Ala Leu Ala Leu Gly Ser Ser Leu Ala Leu Lys Leu Pro Glu Thr 725 730 735Arg Gly Gln Val Leu Gln 74016129DNAArtificial Sequenceoligonucleotide 161cnccaagcag gggaacggtg agagaaaca 2916229DNAArtificial Sequenceoligonucleotide 162cnagcacaaa acacaaagct gcaaaagcc 2916329DNAArtificial Sequenceoligonucleotide 163gntgagttag tgaccacaaa gatgcgctt 2916429DNAArtificial Sequenceoligonucleotide 164gncatcgtcc tcctccttca acatcccag 2916529DNAArtificial Sequenceoligonucleotide 165gngtttcaga aaattccata cagacctca 2916629DNAArtificial Sequenceoligonucleotide 166angacattga gatgttcctt gagtccagc 2916729DNAArtificial Sequenceoligonucleotide 167tngtggttcc aaagtacggg ccatcctga 2916829DNAArtificial Sequenceoligonucleotide 168tncagcatcc gtagcacaaa tctccattg 2916929DNAArtificial Sequenceoligonucleotide 169gngcacagag gccagcacgt taagaagga 2917029DNAArtificial Sequenceoligonucleotide 170cntcatgagg gggaccacac agttggcta 2917129DNAArtificial Sequenceoligonucleotide 171gnattctcta tgtttgcaga tgccgccat 2917229DNAArtificial Sequenceoligonucleotide 172tncgcttgtg acaaggaacc aagcaattt 2917329DNAArtificial Sequenceoligonucleotide 173gngctaaata ccgccatata tccaaagta 2917429DNAArtificial Sequenceoligonucleotide 174tncagagttc taaccaggct ccccaatgc 2917529DNAArtificial Sequenceoligonucleotide 175cnactaaagg gaccataaca accaaaact 2917629DNAArtificial Sequenceoligonucleotide 176cnagacacca acactgctac catgcgcag 2917729DNAArtificial Sequenceoligonucleotide 177gntcacaatg gagaacacac ggagaaggc 2917829DNAArtificial Sequenceoligonucleotide 178cnggctgtcc tcgccgtttt ctaaccatg 2917929DNAArtificial Sequenceoligonucleotide 179tnctgtaggg ctgcctggct cttgtcgct 2918029DNAArtificial Sequenceoligonucleotide 180antcccttag aaagagatga ctggatgtc 2918129DNAArtificial Sequenceoligonucleotide 181gngcataatc ctccagatcc atgtaaacc 2918229DNAArtificial Sequenceoligonucleotide 182tncttccaat cactatatca ccacgctca 2918329DNAArtificial Sequenceoligonucleotide 183gnatagacga agccccctgc cacagatcg 2918429DNAArtificial Sequenceoligonucleotide 184gnccttcctt ccactggact gccacaaca 2918529DNAArtificial Sequenceoligonucleotide 185cnggaacctt cttcgtacac tgcctttgg 2918629DNAArtificial Sequenceoligonucleotide 186gncttgcaat tactgatcca accctctgt 2918729DNAArtificial Sequenceoligonucleotide 187tnctgtctcg tcataaaaca gctctgggg 2918829DNAArtificial Sequenceoligonucleotide 188gngaaacatg tggtgatgat ggcagaagc 2918929DNAArtificial Sequenceoligonucleotide 189angagtccac tgttgaatga tgactaaca 2919029DNAArtificial Sequenceoligonucleotide 190gnccagagat acacaggaga atagacatt 2919129DNAArtificial Sequenceoligonucleotide 191cntgtagcat ctttctcctg actatctaa 2919229DNAArtificial Sequenceoligonucleotide 192gnaacttgaa ttccgcacat ggcatagcc 2919329DNAArtificial Sequenceoligonucleotide 193tnctccacag ggcatacatg gtggttcat 2919429DNAArtificial Sequenceoligonucleotide 194cntctgcatt tttttctgtg atcggtctt 2919529DNAArtificial Sequenceoligonucleotide 195tngtcttttt gtgagtgttt tctgactgc 2919629DNAArtificial Sequenceoligonucleotide 196gncactaact ctaaaatccc accctgcct 2919723DNAArtificial Sequenceoligonucleotide 197cactatgagg tttaattgga aac 2319821DNAArtificial Sequenceoligonucleotide 198tcctgaattg aaagcaactg c 2119921DNAArtificial Sequenceoligonucleotide 199aactccatga ctgaccgaca c 2120020DNAArtificial Sequenceoligonucleotide 200tcagttcccg tcatattcag 2020118DNAArtificial Sequenceoligonucleotide 201gaccaagctg gtgaaccg 1820221DNAArtificial Sequenceoligonucleotide 202gtgctgttta gactcagatt c 2120321DNAArtificial Sequenceoligonucleotide 203agctcacaga gtcaggacat c 2120429DNAArtificial Sequenceoligonucleotide 204cnacgcccag tcctttctcc aagttcttt 2920529DNAArtificial Sequenceoligonucleotide 205tnattctctc cttcaatgcg gatgtctgg 2920629DNAArtificial Sequenceoligonucleotide 206antctatctt ggatgccttt acttcctgc 2920729DNAArtificial Sequenceoligonucleotide 207anagagagag tcaacgtcgg cagagcgag 2920829DNAArtificial Sequenceoligonucleotide 208tngattgaca ccaatccctt cagccttat 2920929DNAArtificial Sequenceoligonucleotide 209anagcgtcat cgttagcgat gccttgtat 2921029DNAArtificial Sequenceoligonucleotide 210gngacacagc agagaacgaa ctgacagga 2921129DNAArtificial Sequenceoligonucleotide 211cnttgtatga atcgtggact tcctgttct 2921229DNAArtificial Sequenceoligonucleotide 212tnggtgttga cagtgaccag atagaggct 2921329DNAArtificial Sequenceoligonucleotide 213antggtgttc ttctatgttc tcaagttcc 2921429DNAArtificial Sequenceoligonucleotide 214gntgggtctg atgtcctgct gtttttgga 2921529DNAArtificial Sequenceoligonucleotide 215angtcaggga ggcaccgtag ttaatgaat 2921629DNAArtificial Sequenceoligonucleotide 216ancggtaact ctgaccagtg tcctggaag 2921729DNAArtificial Sequenceoligonucleotide 217tnctgtggaa caggaggtca ctacgctga 2921829DNAArtificial Sequenceoligonucleotide 218cnctggtcat aagacagtac tccagcgct 2921929DNAArtificial Sequenceoligonucleotide 219tnataatgct acttaaccac cttttgtct 2922029DNAArtificial Sequenceoligonucleotide 220cntgacacaa atccaccttc ttgccacct 2922129DNAArtificial Sequenceoligonucleotide 221tnagtgtctt gtagtgttct gtgtgagtt 2922229DNAArtificial Sequenceoligonucleotide 222gntcatggat ggcatgacag aattaggat 2922329DNAArtificial Sequenceoligonucleotide 223anattgtcat ttaaaatgag cacctccag 2922429DNAArtificial Sequenceoligonucleotide 224cnctagccac cacagcatag tcagaatcc 2922529DNAArtificial Sequenceoligonucleotide 225gngcagcatg gacctgtcag caactaagg 2922629DNAArtificial Sequenceoligonucleotide 226gntcagcgcg tctctggttt ggttccctc 2922729DNAArtificial Sequenceoligonucleotide 227gnacaccatc agatgtatga aatgtgggt 2922829DNAArtificial Sequenceoligonucleotide 228tnccacctct gaagcctgat tactgtgtg 2922929DNAArtificial Sequenceoligonucleotide 229tnttgggctc gtccttcttg gcctccttc 2923029DNAArtificial Sequenceoligonucleotide 230cntaatgttg actgcagagg gaaaggcaa 2923129DNAArtificial Sequenceoligonucleotide 231tngataattt tgggcttctt tttggaacc 2923229DNAArtificial Sequenceoligonucleotide 232tnagcggctg tctccacagg acaatattc 2923329DNAArtificial Sequenceoligonucleotide 233tncccgatat acacggaaat agggttact 2923429DNAArtificial Sequenceoligonucleotide 234tngatttccc aacatttggc aatccaaca 2923529DNAArtificial Sequenceoligonucleotide 235angcagcgaa aggtccctcg acttcatag 2923620DNAArtificial Sequenceoligonucleotide 236cggaaagaag aaagccacag 2023729DNAArtificial Sequenceoligonucleotide 237tngtcagagc cccaatggca aacacagaa 2923886PRTHomo sapiens 238Met Ser Gly His Ser Leu Ala Arg Thr Leu Leu Leu Tyr Leu Arg Asn 1 5 10 15Met Thr Phe Leu Phe Gln Arg Met Met Met Met Met Thr Asn Arg Asn 20 25 30Tyr Arg Lys Glu Lys Ala Leu Thr Glu Glu Met Val Met Leu Ser Val 35 40 45Ser Leu Pro Ser Leu Ser Ala Glu Arg Leu Gly Glu Gly Pro Gln Pro 50 55 60Pro Ser Leu Val Lys Leu Pro Val Trp Ser Met Thr Val Phe His Pro 65 70 75 80Arg Leu Trp Glu Ala Pro 8523948PRTHomo sapiens 239Met Arg Leu Leu Leu Leu Leu Leu Val Ala Ala Ser Ala Met Val Arg 1 5 10 15Ser Glu Ala Ser Ala Asn Leu Gly Gly Val Pro Ser Lys Arg Leu Lys 20 25 30Met Gln Tyr Ala Thr Gly Pro Leu Leu Lys Phe Gln Ile Cys Val Ser 35 40 45240140PRTHomo sapiens 240Met Leu Ser Asn Arg Leu Pro Phe Ser Ala Ala Lys Ser Leu Ile Asn 1 5 10 15Ser Pro Ser Gln Gly Ala Phe Ser Ser Leu Arg Asp Leu Ser Pro Gln 20 25 30Glu Asn Pro Phe Leu Glu Val Ser Ala Pro Ser Glu His Phe Ile Glu 35 40 45Asn Asn Asn Thr Lys Asp Thr Thr Ala Arg Asn Ala Phe Glu Glu Asn 50 55 60Val Phe Met Glu Asn Thr Asn Met Pro Glu Gly Thr Ile Ser Glu Asn 65 70 75 80Thr Asn Tyr Asn His Pro Pro Glu Ala Asp Ser Ala Gly Thr Ala Phe 85 90 95Asn Leu Gly Pro Thr Val Lys Gln Thr Glu Thr Lys Trp Glu Tyr Asn 100 105 110Asn Val Gly Thr Asp Leu Ser Pro Glu Pro Lys Ser Phe Asn Tyr Pro 115 120 125Leu Leu Ser Ser Gln Val Ile Ser Leu Lys Phe Ser 130 135 140

Claims

1.-13. (canceled)

14. A protein encoded by an isolated polynucleotide, said protein being produced by a process comprising: (i) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with said polynucleotide; and (ii) purifying said protein from the culture, wherein said polynucleotide is operably linked to at least one expression control sequence, and wherein said polynucleotide is selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 110 to nucleotide 742; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 170 to nucleotide 742; and (d) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:156.

15. A protein comprising an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:156; (b) a fragment of the amino acid sequence of SEQ ID NO:156, the fragment comprising eight contiguous amino acids of SEQ ID NO:156; and (c) the amino acid sequence encoded by the cDNA insert of clone qv538.sub.--1 deposited under accession number ATCC 207187, the protein being substantially free from other mammalian proteins.

16. The protein of claim 15, wherein said protein comprises the amino acid sequence of SEQ ID NO:156.

17. A composition comprising the protein of claim 15 and a pharmaceutically acceptable carrier.